<SEC-DOCUMENT>0001193125-22-302256.txt : 20221212
<SEC-HEADER>0001193125-22-302256.hdr.sgml : 20221212
<ACCEPTANCE-DATETIME>20221212073239
ACCESSION NUMBER:		0001193125-22-302256
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20221211
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221212
DATE AS OF CHANGE:		20221212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		221456150

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d346985d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20221211" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-12-11_to_2022-12-11">AMGEN INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-12-11_to_2022-12-11">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-12-11_to_2022-12-11">0000318154</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20221211.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-12-11_to_2022-12-11"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-11</xbrli:startDate> <xbrli:endDate>2022-12-11</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-11</xbrli:startDate> <xbrli:endDate>2022-12-11</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-11</xbrli:startDate> <xbrli:endDate>2022-12-11</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:3.00pt solid #000000">&#160;</p> <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-12-11_to_2022-12-11">8-K</ix:nonNumeric></span></p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt:datemonthdayyearen">December&#160;11, 2022</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amgen Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-12-11_to_2022-12-11">001-37702</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-12-11_to_2022-12-11">95-3540776</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-12-11_to_2022-12-11">One Amgen Center Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-12-11_to_2022-12-11">Thousand Oaks</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-12-11_to_2022-12-11">91320-1799</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-12-11_to_2022-12-11">(805)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-12-11_to_2022-12-11">447-1000</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed since Last Report)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Securities Registered under Section&#160;12(b) of the Act:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:1pt; font-family:Times New Roman;text-align:center"><span style="color:#ffffff">Securities registered pursuant to Section 12(b) of the Act: </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">2.000% Senior Notes Due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">AMGN26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter). Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-12-11_to_2022-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Transaction Agreement </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On December&#160;12, 2022, Amgen Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Amgen</span>&#8221;), issued an announcement (the &#8220;<span style="text-decoration:underline">Rule 2.7 Announcement</span>&#8221;) pursuant to Rule 2.7 of the Irish Takeover Panel Act 1997, Takeover Rules, 2022 (the &#8220;<span style="text-decoration:underline">Irish Takeover Rules</span>&#8221;) disclosing that the respective boards of directors of Amgen and Horizon Therapeutics plc, an Irish public limited company (&#8220;<span style="text-decoration:underline">Horizon</span>&#8221;), had reached an agreement on the terms of a cash offer for Horizon by Pillartree Limited, a newly formed private limited company wholly owned by Amgen (&#8220;<span style="text-decoration:underline">Acquirer Sub</span>&#8221;), pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of Horizon (such proposed offer, the &#8220;<span style="text-decoration:underline">Acquisition</span>&#8221;), for $116.50 in cash per ordinary share (the &#8220;<span style="text-decoration:underline">Consideration</span>&#8221;), nominal value $0.0001 per share, of Horizon (each, a &#8220;<span style="text-decoration:underline">Horizon Share</span>&#8221;). The Acquisition has been unanimously recommended by the board of directors of Horizon (the &#8220;<span style="text-decoration:underline">Horizon Board</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">In connection with the Acquisition, Amgen, Acquirer Sub and Horizon entered into a Transaction Agreement, dated as of December&#160;11,&#160;2022 (the &#8220;<span style="text-decoration:underline">Transaction Agreement</span>&#8221;), pursuant to which the Acquisition will be effected by means of a court-sanctioned scheme of arrangement (the &#8220;<span style="text-decoration:underline">Scheme</span>&#8221;) under Irish law. Amgen reserves the right, subject to the terms of the Transaction Agreement, to elect to implement the Acquisition by way of a takeover offer (as such term is defined in the Irish Takeover Rules) rather than the Scheme. As a result of the Scheme, Horizon will become a wholly owned subsidiary of Amgen. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the Transaction Agreement, at the effective time of the Acquisition (the &#8220;<span style="text-decoration:underline">Effective Time</span>&#8221;), each outstanding equity award with respect to Horizon Shares (other than certain restricted stock unit awards denominated in Horizon Shares (&#8220;<span style="text-decoration:underline">Horizon RSUs</span>&#8221;)) will, whether vested or unvested, be cancelled and converted into the right to receive the Consideration (less the applicable exercise price in the case of options). Other than any Horizon RSUs granted to <span style="white-space:nowrap">non-employee</span> directors or former service-providers of Horizon as of the completion date for the Acquisition (which Horizon RSUs will be canceled and converted into the right to receive in cash the product of the Consideration, <span style="font-style:italic">multiplied</span> by the total number of Horizon Shares subject to such Horizon RSU immediately prior to the Effective Time), all Horizon RSUs will be canceled and converted into the a restricted stock unit (each, an &#8220;<span style="text-decoration:underline">Amgen RSU</span>&#8221;) denominated in shares of common stock of Amgen, par value $0.0001 per share (&#8220;<span style="text-decoration:underline">Amgen Common Stock</span>&#8221;), with the number of shares of Amgen Common Stock subject to each such Amgen RSU equal to the product (rounded down to the nearest whole number) of (i)&#160;the number of Horizon Shares subject to such Horizon RSU immediately prior to the Effective Time <span style="font-style:italic">multiplied</span> by (ii)&#160;(x)&#160;the Consideration divided by (y)&#160;the volume weighted average of the per share closing price of Amgen Common Stock on the Nasdaq (as reported in the Eastern Edition of <span style="font-style:italic">The Wall Street Journal</span>, or, if not reported thereby, another authoritative source) for five trading days ending on the second business day prior to the completion of the Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conditions to Completion of the Acquisition </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The completion of the Acquisition is subject to customary conditions, including, among other things, the approval of the Scheme by Horizon shareholders, the sanction of the Scheme by the Irish High Court (the &#8220;<span style="text-decoration:underline">Court</span>&#8221;), the registration of the Court Order (as defined in the Transaction Agreement) with the Registrar of Companies in Dublin, Ireland and the receipt of required antitrust clearances in the United States, Austria and Germany and the receipt of required foreign investment clearances in France, Germany, Denmark and Italy. The conditions to the completion of the Acquisition are set out in full in Appendix 3 to the Rule 2.7 Announcement (the &#8220;<span style="text-decoration:underline">Conditions Appendix</span>&#8221;). Amgen expects that, subject to the satisfaction or waiver of all conditions set forth in the Conditions Appendix, the Acquisition will be completed in the first half of 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Representations and Warranties; Covenants </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Transaction Agreement contains customary representations and warranties with respect to Amgen, Acquirer Sub and Horizon. The Transaction Agreement also contains customary covenants, including, among others, covenants requiring Horizon to use commercially reasonable efforts to conduct its business in the ordinary course during the period between execution of the Transaction Agreement and the completion of the Acquisition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-1- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Transaction Agreement also requires Horizon not to, directly or indirectly, among other things, (i)&#160;solicit, initiate or take any action or knowingly facilitate or knowingly encourage the submission of any Company Alternative Proposal (as defined in the Transaction Agreement), (ii)&#160;enter into, continue or participate in any discussions or negotiations regarding such an offer or proposal with, or furnish any information relating to Horizon or any of its subsidiaries to, or otherwise cooperate in any way with, or knowingly assist, participate in, knowingly facilitate or knowingly encourage any effort by, any person that would reasonably be expected to seek to make, or has made, a Company Alternative Proposal, (iii)&#160;effect a Company Change of Recommendation (as defined in the Transaction Agreement), (iv)&#160;take any action to make anti-takeover laws and regulations inapplicable to third parties or any Company Alternative Proposal, (v)&#160;waive or release third parties from certain standstill agreements or provisions entered into in respect of any Company Alternative Proposal or (vi)&#160;enter into any agreement providing for or relating to a Company Alternative Proposal. The Transaction Agreement contains a customary &#8220;fiduciary out&#8221; provision that allows Horizon, under certain specified circumstances, to furnish information to, or engage in negotiations or discussions with, third parties with respect to a Company Alternative Proposal if Horizon complies with certain notice and other requirements (including affording Amgen certain matching rights) and the Horizon Board determines in good faith (after consultation with its outside legal counsel and financial advisor) that (x)&#160;such Company Alternative Proposal is a Company Superior Proposal (as defined in the Transaction Agreement) and (y)&#160;its failure to take such actions would be inconsistent with its fiduciary duties under applicable law. Subject to certain exceptions, the Transaction Agreement also requires Horizon to hold an extraordinary general meeting of Horizon shareholders and requires the Horizon Board to recommend approval of the Acquisition to the Horizon shareholders at such extraordinary general meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the Transaction Agreement, each of Amgen and Horizon has agreed to use its respective reasonable best efforts to take all actions and do all things necessary, proper or advisable to complete the Acquisition and the other transactions contemplated by the Transaction Agreement. In furtherance of the foregoing, each of Amgen, Acquirer Sub and Horizon has agreed to use its reasonable best efforts to promptly take all actions and steps requested or required by any governmental entity as a condition to grant required regulatory approvals for the Acquisition, subject to the limitation that Amgen is not obligated to take certain specified actions (x)&#160;with respect to any assets, categories of assets or portions of any business of Amgen or any of its affiliates, (y)&#160;with respect to certain items contained in the disclosure schedules to the Transaction Agreement, or (z)&#160;with respect to assets, categories of assets or portions of any business of Horizon or its subsidiaries, if such action, individually or in the aggregate, would reasonably be expected to be material to Horizon and its subsidiaries, taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Termination and Termination Fees </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Transaction Agreement may be terminated and the transactions contemplated by the Transaction Agreement, including the Acquisition, may be abandoned at any time prior to the Effective Time by mutual written consent of Amgen and Horizon. The Transaction Agreement also contains certain customary termination rights, including, among others and subject to certain conditions, the right of either party to terminate the Transaction Agreement if (i)&#160;the requisite Horizon shareholder approvals are not obtained at the extraordinary general meeting of Horizon shareholders, (ii)&#160;the Scheme has not become effective by 5:00 p.m., New York City time, on June&#160;12,&#160;2023, which period will be automatically extended to September&#160;12,&#160;2023 and further to December&#160;12,&#160;2023 (as may be so extended, the &#8220;<span style="text-decoration:underline">End Date</span>&#8221;) if the only condition remaining to be satisfied (other than those conditions that by their nature cannot be satisfied until the completion of the Acquisition) relates to regulatory approvals, (iii)&#160;the other party breaches or fails to perform in any material respect any of its covenants or other agreements or any of the other party&#8217;s representations or warranties are inaccurate and such breach, failure to perform or inaccuracy would result in certain of the conditions set forth in the Conditions Annex not being satisfied, subject to a cure period, (iv)&#160;there is in effect any law or final and <span style="white-space:nowrap">non-appealable</span> order (other than under any antitrust laws or foreign investment laws of any jurisdiction that is not (x)&#160;certain applicable <span style="white-space:nowrap">non-U.S.</span> antitrust laws or foreign investment laws or (y)&#160;under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#8220;<span style="text-decoration:underline">HSR Act</span>&#8221;)) that permanently restrains, enjoins or otherwise prohibits the completion of the Acquisition or (v)&#160;the Court declines or refuses to sanction the Scheme, unless Amgen and Horizon agree in writing to appeal the decision of the Court. Horizon also has the right, prior to the receipt of the requisite Horizon shareholder approvals, to terminate the Transaction Agreement to accept a Company Superior Proposal in certain circumstances, and Amgen also has the right, prior to receipt of the requisite Horizon shareholder approvals, to terminate the Transaction Agreement if a Company Change of Recommendation occurs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-2- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Horizon has agreed to pay to Amgen, in certain circumstances, an amount equal to all documented, specific and quantifiable third-party costs and expenses incurred, directly or indirectly, by Amgen or its subsidiaries, or on their behalf, for the purposes of, in preparation for, or in connection with the Acquisition. The maximum amount payable by Horizon to Amgen in such circumstances is an amount equal to 1% of the aggregate value of the total Consideration to be paid in the Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Transaction Agreement also provides that Amgen will be required to pay Horizon a termination fee of $974,415,054 in connection with the termination of the Transaction Agreement if the Transaction Agreement is terminated (i)&#160;by Amgen or Horizon due to the End Date having occurred if, on the date of such termination, each of the conditions to completion of the Acquisition have been satisfied other than those related to regulatory approvals, the sanctioning of the Scheme or those conditions that may only be satisfied at the completion of the Acquisition, (ii)&#160;by Amgen or Horizon if at the time of such termination there is in effect any law or final and <span style="white-space:nowrap">non-appealable</span> order that permanently restrains, enjoins or otherwise prohibits the completion of the Acquisition pursuant to the HSR Act or certain applicable <span style="white-space:nowrap">non-U.S.</span> antitrust laws or foreign investment laws, or (iii)&#160;by the Company pursuant to Amgen&#8217;s breach of its covenants related to regulatory approvals pursuant to the HSR Act or certain applicable <span style="white-space:nowrap">non-U.S.</span> antitrust laws or foreign investment laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing descriptions of the Transaction Agreement and the Conditions Appendix do not purport to be complete and are subject to, and qualified in their entireties by, the full text of the Transaction Agreement and the Conditions Appendix, copies of which are filed as Exhibit 2.1 and Exhibit 2.2, respectively, hereto and are incorporated by reference into this Item 1.01. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Transaction Agreement has been included herewith pursuant to the applicable rules and regulations of the U.S. Securities and Exchange Commission&#160;the (&#8220;<span style="text-decoration:underline">SEC</span>&#8221;) to provide investors with information regarding its terms. It is not intended to provide any other factual information about Amgen, Acquirer Sub, Horizon or their respective subsidiaries or affiliates or to modify or supplement any factual disclosures about Amgen or Horizon included in their respective public reports filed with the SEC. The representations, warranties and covenants contained in the Transaction Agreement were made only for purposes of the Transaction Agreement and as of the specific dates therein, were solely for the benefit of the parties to the Transaction Agreement, may be subject to limitations, qualifications or other particulars agreed upon by the contracting parties, including being qualified by confidential disclosures, and were made for the purposes of allocating contractual risk among the parties to the Transaction Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Transaction Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of representations and warranties may change after the date of the Transaction Agreement, which subsequent information may or may not be fully reflected in public disclosures. The Transaction Agreement should not be read alone, but should instead be read in conjunction with the other information regarding Amgen, Acquirer Sub and Horizon and the transactions contemplated by the Transaction Agreement that will be contained in, incorporated by reference into or attached as an annex to the proxy statement (the &#8220;<span style="text-decoration:underline">Proxy Statement</span>&#8221;) that Horizon will file in connection with the transactions contemplated by the Transaction Agreement as well as in the other filings that each of Amgen and Horizon will make with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Bridge Credit Facility </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On December&#160;12, 2022 (the &#8220;<span style="text-decoration:underline">Effective Date</span>&#8221;), Amgen, Citibank, N.A. (&#8220;<span style="text-decoration:underline">Citibank</span>&#8221;), as administrative agent, Bank of America, N.A. (&#8220;<span style="text-decoration:underline">Bank of America</span>&#8221;), as syndication agent, and Citibank and Bank of America as lead arrangers and book runners entered into a Bridge Credit Agreement (the &#8220;<span style="text-decoration:underline">Bridge Credit Agreement</span>&#8221;). The Bridge Credit Agreement provides for a $28.5&#160;billion bridge credit facility (the &#8220;<span style="text-decoration:underline">Bridge Credit Facility</span>&#8221;) that is available to finance the payment of the Consideration in connection with the Acquisition, the repayment of certain existing indebtedness of Horizon, and the payment of fees and expenses related to the Acquisition. The commitments under the Bridge Credit Facility will be reduced by the net cash proceeds received by Amgen or its subsidiaries in connection with debt and equity issuances and <span style="white-space:nowrap">non-ordinary</span> course asset dispositions, with certain exceptions specified in the Bridge Credit Agreement. Advances under the Bridge Credit Facility will be available after the Effective Date, subject to the satisfaction of certain conditions set forth in the Bridge Credit Agreement and will mature on the date that is 364 days after the date on which the first advance is made under the Bridge Credit Facility. The commitments under the Bridge Credit Facility, unless previously terminated, terminate on the earlier of (i)&#160;the date on which the Acquisition has been completed and the other purposes of the Bridge Credit Facility have been achieved without the making of any advances under the Bridge Credit Facility and (ii)&#160;the time after certain mandatory cancellation events occur, including the abandonment of the Acquisition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-3- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Advances under the Bridge Credit Agreement will bear interest at an annual rate of, at Amgen&#8217;s option, either (i)&#160;term SOFR plus 0.10%, plus between 0.875% and 2.125%, depending on the rating of our senior long-term unsecured debt and the number of days elapsed between the initial funding day and the day of determination, or (ii)&#160;the highest of (A)&#160;Citibank&#8217;s base commercial lending rate, (B)&#160;the overnight federal funds rate plus <sup style="vertical-align:top">1</sup>&#8260;<sub style="vertical-align:bottom">2</sub> of 1.00% and <span style="white-space:nowrap">(C)&#160;one-month</span> adjusted term SOFR plus 1.00%, plus between 0.000% and 1.125%, depending on the rating of our senior long-term unsecured debt and the number of days elapsed between the initial funding day and the day of determination. We are also required to pay, commencing on the 90th day after the Effective Date, a ticking fee of 0.125% per annum that will accrue on the aggregate undrawn commitments under the Bridge Credit Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Bridge Credit Agreement contains customary affirmative and negative covenants that will apply after the Effective Date, including limitations on mergers, consolidations and sales of assets, limitations on liens and sales and leasebacks, limitations on transactions with affiliates and limitations on subsidiary indebtedness. In addition, the Bridge Credit Agreement requires maintenance of a minimum consolidated interest coverage ratio of EBITDA to total interest expense, each on a consolidated basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing description of the Bridge Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Bridge Credit Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference into this Item 1.01. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Creation of a Direct Financial Obligation or an Obligation under an <span style="white-space:nowrap">Off-Balance</span> Sheet Arrangement of a Registrant. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On December&#160;12, 2022, Amgen entered into the Bridge Credit Agreement as described under Item 1.01 above. The foregoing description of the Bridge Credit Agreement set forth in Item 1.01 and the full text of the Bridge Credit Agreement, a copy of which is filed as Exhibit 10.1 hereto, are incorporated herein by reference into this Item 2.03. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On December&#160;12, 2022, Amgen issued the Rule 2.7 Announcement disclosing that the boards of directors of Amgen and Horizon had reached agreement on the terms of the Acquisition. A copy of the Rule 2.7 Announcement is furnished as Exhibit 99.1 hereto and is incorporated herein by reference into this Item 7.01. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Responsibility</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Statement Required by the Irish Takeover Rules </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The members of Amgen&#8217;s board of directors accept responsibility for the information contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> other than that relating to Horizon, Horizon&#8217;s subsidiaries and the members of Horizon&#8217;s board of directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the members of Amgen&#8217;s board of directors (who have taken all reasonable care to ensure such is the case), the information contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> for which they respectively accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-4- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Offer or Solicitation </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">This Current Report on Form 8-K is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Acquisition will be implemented by means of a Court sanctioned scheme of arrangement on the terms provided for in the scheme document (or, if the Acquisition is implemented by way of a takeover offer, the applicable takeover offer document), which will contain the full terms and conditions of the Acquisition, including details of how Horizon shareholders may vote in respect of the Acquisition. Any decision in respect of, or other response to, the Acquisition, should be made only on the basis of the information contained in the scheme document (or if the Acquisition is implemented by way of a takeover offer, the applicable takeover offer document). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dealing Disclosure Requirements of the Irish Takeover Laws </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the provisions of Rule 8.3(b) of the Irish Takeover Rules, if any person is, or becomes, &#8216;interested&#8217; (directly or indirectly) in 1% or more of any class of &#8216;relevant securities&#8217; of Horizon (including by means of an option in respect of, or a derivative referenced to, any such &#8216;relevant securities&#8217;), that person must publicly disclose all &#8216;dealings&#8217; in any &#8216;relevant securities&#8217; of Horizon during the &#8216;offer period,&#8217; by not later than 3:30 p.m. (E.T.) on the &#8216;business day&#8217; following the date of the relevant transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">If two or more persons co-operate on the basis of any agreement either express or tacit, either oral or written, to acquire an &#8216;interest&#8217; in &#8216;relevant securities&#8217; of Horizon, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">A disclosure table, giving details of the companies in whose &#8216;relevant securities&#8217; and &#8216;dealings&#8217; should be disclosed can be found on the Irish Takeover Panel&#8217;s website at www.irishtakeoverpanel.ie. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">&#8216;Interests&#8217; in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an &#8216;interest&#8217; by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel&#8217;s website. If you are in any doubt as to whether or not you are required to disclose a &#8216;dealing&#8217; under Rule 8, please consult the Irish Takeover Panel&#8217;s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains certain statements about Horizon and Amgen that are or may be forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the Acquisition. These forward-looking statements are subject to the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this Announcement may be forward-looking statements. Without limitation, forward-looking statements often include words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;assume&#8221; and &#8220;continue&#8221; as well as variations of such words and similar expressions are intended to identify such forward-looking statements. Horizon&#8217;s and Amgen&#8217;s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to complete the transactions contemplated by the Transaction Agreement, including the Acquisition, in a timely manner or at all; the satisfaction (or waiver) of conditions to the consummation of the transactions contemplated by the Transaction Agreement, including the Acquisition, including with respect to the approval of Horizon&#8217;s shareholders and required regulatory approvals; potential delays in consummating the transactions contemplated by the Transaction Agreement, including the Acquisition; the ability of Horizon and Amgen to timely and successfully achieve the anticipated strategic benefits, synergies or opportunities expected of the transactions contemplated by the Transaction Agreement, including the Acquisition; the successful integration of Horizon into Amgen subsequent to the consummation of the transactions contemplated by the Transaction Agreement, including the Acquisition and the timing of such integration; the impact of changes in global, political, economic, business, competitive, market and regulatory forces; the impact of health pandemics, including the <span style="white-space:nowrap">COVID-19</span> pandemic, on Horizon&#8217;s or Amgen&#8217;s respective businesses; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Transaction Agreement; adverse effects on the market price of Horizon&#8217;s or Amgen&#8217;s securities and on Horizon&#8217;s or Amgen&#8217;s operating results because of a failure to complete the Acquisition; the effect of the announcement or pendency of the Acquisition on Horizon&#8217;s or Amgen&#8217;s business relationships, operating results and business generally; costs related to the transactions contemplated by the Transaction Agreement, including the Acquisition; and the outcome of any legal proceedings that may be instituted against Horizon, Amgen, Acquirer Sub or any of their respective directors or officers related to the Transaction Agreement or the transactions contemplated by the Transaction Agreement, including the Acquisition. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#8220;Risk Factors&#8221; and elsewhere in Horizon&#8217;s most recent filings with the SEC, including its Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended September&#160;30, 2022, and Amgen&#8217;s most recent filings with the SEC, including its Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended September&#160;30, 2022, and any subsequent reports on Form <span style="white-space:nowrap">10-K,</span> Form <span style="white-space:nowrap">10-Q</span> or Form <span style="white-space:nowrap">8-K</span> filed with the SEC by Horizon or Amgen from time to time and available at www.sec.gov. These documents can be accessed on Horizon&#8217;s web page at <span style="white-space:nowrap">https://ir.horizontherapeutics.com/sec-filings</span> or on Amgen&#8217;s web page at <span style="white-space:nowrap">https://investors.amgen.com/financials/sec-filings.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The forward-looking statements included in this Current Report on Form <span style="white-space:nowrap">8-K</span> are made only as of the date hereof. Neither Amgen nor Horizon assumes any obligation to, and neither Amgen nor Horizon intends to, update these forward-looking statements, except as required by law. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:94%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d346985dex21.htm">Transaction Agreement, dated as of December&#160;11, 2022, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc.* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d346985dex22.htm">Appendix 3 to the Rule 2.7 Announcement, dated as of December&#160;12, 2022 (Conditions Appendix). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d346985dex101.htm">Bridge Credit Agreement, dated as of December&#160;12, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A. and Bank of America, N.A., as lead arrangers and book runners, and the other banks party thereto. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d346985dex991.htm">Rule 2.7 Announcement, dated as of December&#160;12, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">104</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</td></tr>
</table> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Certain schedules have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-5- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">AMGEN INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: December&#160;12, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan P. Graham</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Jonathan P. Graham</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Vice President, General Counsel and Secretary</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-6- </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d346985dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSACTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>dated as of December 11, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>among </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMGEN INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PILLARTREE LIMITED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HORIZON
THERAPEUTICS PLC </B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INTERPRETATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Definitions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Construction</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RULE 2.7 ANNOUNCEMENT AND SCHEME DOCUMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Rule 2.7 Announcement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>The Scheme</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Change in Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Company Equity Award Holder Proposal</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>IMPLEMENTATION OF THE SCHEME</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Responsibilities of the Company in Respect of the Scheme</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Responsibilities of Parent and Acquirer Sub in Respect of the Scheme</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Mutual Responsibilities of the Parties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Dealings with the Irish Takeover Panel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Scheme Amendment by the Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Switching to a Takeover Offer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EQUITY AWARDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>The Company Equity Awards</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Further Actions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Amendment of Articles</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE COMPANY CONDUCT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Conduct of Business by the Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and Company Change of Recommendation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Company Representations and Warranties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Parent Representations and Warranties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADDITIONAL AGREEMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Access to Information; Confidentiality; Notices of Certain Events</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Consents and Regulatory Approvals</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Directors&#146; and Officers&#146; Indemnification and Insurance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Employment and Benefit Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Employee Share Purchase Plan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Financing</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Section&nbsp;16 Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Financing Cooperation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Treatment of Certain Existing Indebtedness</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Transaction Litigation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>State Takeover Statutes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Acquirer Sub</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Tax Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Stock Exchange Delisting; Deregistration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Filing of Form <FONT STYLE="white-space:nowrap">S-8;</FONT> Listing of Additional Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMPLETION OF ACQUISITION AND MERGER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Completion</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Payment of Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Withholding</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Termination</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Certain Effects of Termination</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GENERAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Announcements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Notices</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Assignment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Counterparts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Amendment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Entire Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Inadequacy of Damages</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Disclosure Schedule References and SEC Document References</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Severability</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Partnership and No Agency</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Costs and Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Governing Law and Jurisdiction</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Third Party Beneficiaries</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Waiver of Claims Against Financing Sources</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations, Warranties, Covenants and Agreements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSACTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> T<SMALL>RANSACTION</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL><B></B></SMALL><B> </B>(this
&#147;<B><I>Agreement</I></B>&#148;), dated as of December 11, 2022 is by and among <B>A<SMALL>MGEN</SMALL> I<SMALL>NC</SMALL>.</B>, a Delaware corporation (&#147;<B><I>Parent</I></B>&#148;), <B>P<SMALL>ILLARTREE</SMALL>
L<SMALL>IMITED</SMALL></B><SMALL></SMALL>, a private limited company incorporated under the laws of Ireland (with registration number: 730855) having its registered office at 6th Floor, 2 Grand Canal Square, Dublin 2, Ireland and a wholly owned
Subsidiary of Parent (&#147;<B><I>Acquirer Sub</I></B>&#148;), and <B>H<SMALL>ORIZON</SMALL> T<SMALL>HERAPEUTICS</SMALL> <SMALL>PLC</SMALL></B><SMALL></SMALL>, a public limited company incorporated under the laws of Ireland (with registration number
507678) having its registered office at 70 St. Stephen&#146;s Green, Dublin 2, D02 E2X4, Ireland (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> Parent has agreed to make a proposal to cause Acquirer Sub to acquire the Company on the terms set out in the Rule 2.7 Announcement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> This Agreement sets out certain matters relating to the conduct of the Acquisition that have been agreed by the Parties; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> The Parties intend that the Acquisition will be implemented by way of the Scheme, although this may, subject to the consent
(where required) of the Irish Takeover Panel, be switched to a Takeover Offer in accordance with the terms set out in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing and the representations, warranties,
covenants and agreements contained in this Agreement, the Parties agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;1. INTERPRETATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement the following words and expressions have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acquirer Sub</I></B>&#148; has the meaning ascribed to it in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acquisition</I></B>&#148; means the proposed offer by Acquirer Sub to acquire the entire issued and to be issued, ordinary share
capital of the Company in accordance with the terms of this Agreement, to be effected by means of the Scheme or, should Parent elect, and subject to the terms of this Agreement and the consent of the Irish Takeover Panel (if required), by means of a
Takeover Offer, and, where the context admits, any subsequent revision, variation, extension or renewal thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acting in
Concert</I></B>&#148; has the meaning given to that term in the Irish Takeover Panel Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means, in
relation to any Person, any other Person that, directly or indirectly, controls, is controlled by, or is under common control with, such first person (as used in this definition, &#147;<B><I>control</I></B>&#148; means the possession, directly or
indirectly, of the power to direct or cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by Contract or otherwise and the terms
&#147;<B><I>controlled</I></B>&#148; and &#147;<B><I>controlling</I></B>&#148; shall have correlative meanings). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Agreement</I></B>&#148; has the meaning ascribed to it in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Alternative Financing</I></B><I>&#148; </I>has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.6(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Anti-Corruption Laws</I></B>&#148; means the FCPA; the Anti-Kickback Act of 1986, the UK Bribery Act of 2010, the relevant Laws in
Ireland relating to bribery or corruption including the Criminal Justice (Corruption Offences) Act 2018 of Ireland or any applicable Laws of similar effect, and the related regulations and published interpretations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Antitrust Laws</I></B>&#148; means the Sherman Act of 1890, the Clayton Act of 1914, the Federal Trade Commission Act of 1914, the
HSR Act and all other federal, state and foreign applicable Laws in effect from time to time that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Balance Sheet</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(f)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Benefits Continuation Period</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Burdensome Condition</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.2(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day, other than a Saturday, Sunday or a day on which banks in Ireland or in New York are
authorized or required by applicable Laws to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cap</I></B>&#148; means an amount equal to one percent of the
aggregate value of the total Consideration payable with respect to the Company Shares in connection with the Acquisition (excluding, for clarity, any interest in such share capital of the Company held by Parent or any Concert Parties of Parent) as
ascribed by the terms of the Acquisition as set out in the Rule 2.7 Announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Change of Recommendation
Termination</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;9.1(a)(iii)(B)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Claim
Expenses</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.3(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Clearance
Date</I></B>&#148; means the Business Day next succeeding the date upon which the later occurring of (i)&nbsp;the Irish Takeover Panel confirming that (x)&nbsp;it has no comments on the Proxy Statement and/or the Scheme Document or (y)&nbsp;its
comments on the Proxy Statement and/or the Scheme Document have been adequately responded to or resolved and (ii)&nbsp;in respect of the SEC, (x)&nbsp;the SEC review period has expired with no comments or (y)&nbsp;the SEC confirming that its
comments on the Proxy Statement have been adequately responded to or resolved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Clearances</I></B>&#148; means all consents,
clearances, approvals, permissions, licenses, variances, exemptions, authorizations, acknowledgements, permits, nonactions, Orders and waivers to be obtained from, and all registrations, applications, notices and filings to be made with or provided
to, any Governmental Entity in connection with the implementation of the Scheme or the Acquisition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Code</I></B>&#148; means the United States Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>&#148; has the meaning ascribed to it in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company </I></B><B><I>Alternative Proposal</I></B>&#148; means any bona fide proposal or offer (including <FONT
STYLE="white-space:nowrap">non-binding</FONT> proposals or offers) from any Person or Group, other than Parent, its controlled Affiliates or any of its Concert Parties, relating to any (i)&nbsp;direct or indirect acquisition (whether in a single
transaction or a series of related transactions) of assets of the Company or any of its Subsidiaries (including equity securities of Subsidiaries) equal to 20% or more of the consolidated assets of the Company, or to which 20% or more of the
revenues or earnings of the Company on a consolidated basis are attributable for the most recent fiscal year for which audited financial statements are then available, (ii)&nbsp;direct or indirect acquisition (including by scheme of arrangement or
takeover offer) or issuance (whether in a single transaction or a series of related transactions) of 20% or more of any class of equity or voting securities of the Company, (iii)&nbsp;scheme of arrangement, tender offer, takeover offer or exchange
offer that, if consummated, would result in a Person or Group beneficially owning 20% or more of any class of equity or voting securities of the Company, or (iv)&nbsp;scheme of arrangement, merger, consolidation, share exchange, business
combination, joint venture, reorganization, recapitalization or similar transaction involving the Company or any of its Subsidiaries, under which a Person or Group or, in the case of <U>clause (B)</U>&nbsp;below, the shareholders or equityholders of
any Person or Group would, directly or indirectly, (A)&nbsp;acquire assets equal to 20% or more of the consolidated assets of the Company, or to which 20% or more of the revenues or earnings of the Company on a consolidated basis are attributable
for the most recent fiscal year for which audited financial statements are then available, or (B)&nbsp;immediately after giving effect to such transactions, beneficially own 20% or more of any class of equity or voting securities of the Company or
the surviving or resulting Person (including any parent Person) in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Alternative Proposal
NDA</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;5.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Approval
Time</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;5.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Board</I></B>&#148;
means the board of directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Breach Termination</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;9.1(a)(iii)(A)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Capitalization Date</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;6.1(c)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Change of Recommendation</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;5.2(a)(iii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Contracts</I></B><I>&#148; </I>means a Contract of any member of the
Company Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Credit Agreement</I></B>&#148; means the Credit Agreement, dated as of
May&nbsp;7, 2015, by and among Horizon Therapeutics USA, Inc., a Delaware corporation, the Company, the subsidiary guarantors party thereto, the lenders party thereto from time to time and Citibank, N.A., as Administrative Agent and Collateral Agent
(as amended by Amendment No.&nbsp;1, dated as of October&nbsp;25, 2016, Amendment No.&nbsp;2, dated as of March&nbsp;29, 2017, Amendment No.&nbsp;3, dated as of October&nbsp;23, 2017, Amendment No.&nbsp;4, dated as of October&nbsp;19, 2018,
Amendment No 5., dated as of March&nbsp;11, 2019, Amendment No.&nbsp;6, dated as of May&nbsp;22, 2019, Amendment No.&nbsp;7, dated as of December&nbsp;18, 2019, the Incremental Amendment and Lender Joinder Agreement, dated as of August&nbsp;17, 2020
and Amendment No.&nbsp;9, dated as of March&nbsp;15, 2021). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Deferred Shares</I></B>&#148; means the deferred ordinary
shares of the Company, nominal value &#128;1.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Disclosure Schedule</I></B>&#148; has the meaning ascribed
to it in <U>Section</U><U></U><U>&nbsp;6.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Employees</I></B>&#148; means the employees of the Company or any
Subsidiary of the Company as of immediately prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Equity Award Holder Proposal</I></B>&#148;
means the proposal of Parent to the Company Equity Award Holders to be made in accordance with this Agreement (including <U>Section</U><U></U><U>&nbsp;4</U>), Rule 15 of the Irish Takeover Rules and the terms of the Company Share Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Equity Award Holders</I></B>&#148; means the holders of the Company Equity Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Equity Awards</I></B>&#148; means the Company Options, the Company RSU Awards and the Company PSU Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company ESPP</I></B>&#148;<B> </B>means the Company&#146;s 2020 Employee Share Purchase Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Group</I></B>&#148; means the Company and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Intellectual Property</I></B>&#148; means the Owned Intellectual Property and the Licensed Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Intervening Event</I></B>&#148; means any material event, fact, change, effect, development or occurrence arising or
occurring after the date of this Agreement and prior to the Company Approval Time that (i)&nbsp;was not known or reasonably foreseeable, or the material consequences of which were not known or reasonably foreseeable, in each case to the Company
Board as of or prior to the date of this Agreement, and (ii)&nbsp;does not relate to (a)&nbsp;any Company Alternative Proposal or consequence thereof, (b)&nbsp;Parent or any of its Subsidiaries or (c)&nbsp;any change in the market price or trading
volume of the Company Shares or the fact that the Company meets or exceeds any internal or analysts&#146; expectations or projections of the results of operations of the Company Group (it being understood that the underlying causes of such change or
fact shall not be excluded by this <U>clause (c)</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Irrecoverable VAT</I></B>&#148; has the meaning ascribed to it
in <U>Section</U><U></U><U>&nbsp;9.2(e)(i)(A)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company IT Assets</I></B>&#148; means computers, Software, firmware,
middleware, servers, workstations, routers, hubs, switches, data communications lines, and all other information technology equipment, and all associated documentation, in each case, used or held for use by a member of the Company Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Material Adverse Effect</I></B>&#148; means any event, change, effect,
development or occurrence that, individually or together with any other event, change, effect, development or occurrence, (a)&nbsp;would prevent, materially delay or materially impair the ability of the Company to consummate the Acquisition or
(b)&nbsp;has had or would reasonably be expected to have a material adverse effect on the condition (financial or otherwise), business, assets, liabilities or results of operations of the Company Group, taken as a whole; <I>provided</I> that, solely
for the purposes of <U>clause (b)</U>, no event, change, effect, development or occurrence to the extent resulting from or arising out of any of the following shall be deemed to constitute a Company Material Adverse Effect or shall be taken into
account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect: (i)&nbsp;any decline in the market price or change in trading volume of the Company Shares; (ii)&nbsp;any event, change, effect,
development or occurrence directly resulting from the announcement or pendency of the Transactions (other than for purposes of any representation or warranty contained in <U>Section</U><U></U><U>&nbsp;6.1(u)(ii)</U> and
<U>Section</U><U></U><U>&nbsp;6.1(v)</U> but subject to corresponding disclosures in the Company Disclosure Schedule); (iii) any event, change, effect, development or occurrence in the industries and jurisdictions in which the Company Group operates
or in the U.S. or global economy generally or other general business, financial or market conditions in the U.S. or globally, except in each case to the extent that the Company Group, taken as a whole, is adversely affected disproportionately
relative to the other participants in such industries or the U.S. or the global economy generally, as applicable, and then only to the extent of such disproportionate impact; (iv)&nbsp;any event, change, effect, development or occurrence arising
directly or indirectly from or otherwise relating to fluctuations in the value of any currency, except to the extent that the Company Group, taken as a whole, is adversely affected disproportionately relative to the other participants in such
industries or the economy generally, as applicable, and then only to the extent of such disproportionate impact; (v)&nbsp;any event, change, effect, development or occurrence arising directly or indirectly from or otherwise relating to any act of
terrorism, war, national or international calamity or any other similar event (other than cyberattacks), except to the extent that such event, circumstance, change or effect disproportionately affects the Company Group, taken as a whole, relative to
other participants in the industries in which the Company Group operates or in the U.S or global economy generally, as applicable, and then only to the extent of such disproportionate impact; (vi)&nbsp;any epidemic, pandemic (including <FONT
STYLE="white-space:nowrap">COVID-19),</FONT> disease outbreak or other public health-related event, hurricane, tornado, flood, earthquake, tsunamis, tornadoes, mudslides, fires or other natural disaster or other force majeure event, or the
escalation or worsening thereof, except to the extent that the Company Group, taken as a whole, is adversely affected disproportionately relative to other participants in the industries in which the Company Group operates or in the U.S. or global
economy generally, as applicable, and then only to the extent of such disproportionate impact; (vii)&nbsp;the failure of any member of the Company Group to meet internal or analysts&#146; expectations or projections of the results of operations of
the Company Group; (viii)&nbsp;any adverse effect arising directly from or otherwise directly relating to any action taken by the Company Group at the written direction of Parent or any action specifically required pursuant to the terms of this
Agreement to be taken by the Company (except for any obligation to operate in the ordinary course of business); (ix) any event, change, effect, development or occurrence arising directly or indirectly from or otherwise relating to any change in, or
any compliance with, any applicable Laws or GAAP (or interpretations of any applicable Laws or GAAP), except to the extent that the Company Group, taken as a whole, is adversely affected disproportionately relative to the other participants in such
industries or the U.S. or global economy generally, as applicable, and then only to the extent of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such disproportionate impact; or (x)&nbsp;any FDA or similar (in the U.S. or globally) regulatory, manufacturing, safety or clinical event, change, effect, development or occurrence relating to
any Company Product (but excluding the loss of any manufacturing license or the loss of marketing authorization for any Company Product); it being understood that the exceptions in <U>clauses (i)</U>&nbsp;and (<U>vii)</U> shall not prevent or
otherwise affect a determination that the underlying cause of any such decline or failure referred to therein (if not otherwise expressly excluded under any of the exceptions provided by <U>clauses (ii)</U>&nbsp;through (<U>vi)</U> or
<U>(viii)</U>&nbsp;through <U>(x)</U> hereof) is a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Memorandum and Articles of
Association</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Note Offers and
Consent Solicitations</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.8(b).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company
Notes</I></B>&#148; means the 5.500% Senior Notes of the Company due 2027 issued under the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company
Options</I></B>&#148; means all options to purchase Company Shares granted pursuant to Company Share Plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company
Product</I></B>&#148; means all products or product candidates that are being researched, tested, developed, commercialized, manufactured, sold or distributed by any member of the Company Group and all products or product candidates, if any, with
respect to which any member of the Company Group has royalty rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company PSU Awards</I></B>&#148; means all restricted
stock units payable in Company Shares or whose value is determined with reference to the value of Company Shares with performance-based vesting or delivery requirements granted pursuant to the Company Share Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Related Parties</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;9.2(h)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company RSU Awards</I></B>&#148; means all restricted stock units payable in Company Shares or whose value is determined with
reference to the value of Company Shares granted pursuant to the Company Share Plans other than any Company PSU Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company SEC Documents</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(d)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Share Award</I></B>&#148; means the Company PSU Awards and the Company RSU Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Share Plans</I></B>&#148; means, collectively, the 2011 Equity Incentive Plan, as amended, the Amended and Restated 2014
Equity Incentive Plan, the 2014 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Equity Plan, as amended, the Amended and Restated 2018 Equity Incentive Plan, the 2020 Employee Share Purchase Plan, and the Amended and Restated 2020 Equity
Incentive Plan, as amended, including any <FONT STYLE="white-space:nowrap">sub-plans</FONT> thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Shareholder Approval</I></B>&#148; means (i)&nbsp;the approval of the
Scheme by a majority in number of members of each class of the Company Shareholders (including as may be directed by the Irish High Court pursuant to Section&nbsp;450(5) of the Irish Companies Act) representing, at the relevant voting record time,
at least 75% in value of the Company Shares of that class held by the Company Shareholders who are members of that class and that are present and voting either in person or by proxy, at the Scheme Meeting (or at any adjournment or postponement of
such meeting) and (ii)&nbsp;the Required EGM Resolutions being duly passed by the requisite majorities of the Company Shareholders at the EGM (or at any adjournment or postponement of such meeting). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Shareholders</I></B>&#148; means the registered holders of Company Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Shares</I></B>&#148; means the ordinary shares of the Company, nominal value US$0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Superior Proposal</I></B>&#148; means any bona fide, written Company Alternative Proposal (with all references to
&#147;20%&#148; in the definition of the Company Alternative Proposal being deemed to be references to &#147;50%&#148;) on terms that the Company Board determines in good faith, after consultation with its financial advisor and outside legal
counsel, (a)&nbsp;is more favorable to the Company Shareholders (in their capacity as such) from a financial point of view than the Acquisition and (b)&nbsp;is reasonably expected to be consummated in accordance with its terms, in the case of each
of <U>clauses (a)</U>&nbsp;and <U>(b)</U>, taking into account all the financial, legal, regulatory and other terms and conditions of the Company Alternative Proposal that the Company Board considers to be appropriate (including the expected timing
of consummation, any governmental or other approval requirements, and availability of necessary financing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company
Supplemental Indenture</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.8(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Completion</I></B>&#148; means the completion of the Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Completion Date</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;8.1(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Concert Parties</I></B>&#148; means such Persons as are deemed to be Acting in Concert with Parent pursuant to Rule 3.3 of Part A
of the Irish Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Conditions</I></B>&#148; means the conditions to the Scheme and the Acquisition set out in
Appendix 3 of the Rule 2.7 Announcement attached hereto, and &#147;<B><I>Condition</I></B>&#148; means any one of the Conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Confidentiality Agreement</I></B>&#148; means the confidentiality agreement between the Company and Parent dated November&nbsp;18,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Consent Solicitations</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.8(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Consideration</I></B>&#148; means US$116.50 in cash per each Company Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Continuing Employee</I></B>&#148; means each Company Employee who is employed by the Company as of immediately prior to the
Effective Time and who continues to be employed by Acquirer Sub or Parent (or any Affiliate thereof) following the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Contract</I></B>&#148; means any written or oral contract, agreement, lease,
license or other legally binding obligation, understanding, instrument, commitment or undertaking of any nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Court
Order</I></B>&#148; means the Order or Orders of the Irish High Court sanctioning the Scheme under Section&nbsp;453 of the Irish Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT></I></B>&#148; means <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any variants or evolutions thereof or epidemics, pandemics or disease outbreaks thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</I></B>&#148; means any quarantine, &#147;shelter in place,&#148;
&#147;stay at home,&#148; workforce reduction, social distancing, shutdown, closure, sequester or other Law, order, directive, guideline or recommendation by any Governmental Entity or public health agency in connection with or in response to <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> and all guidelines and requirements, such as social distancing, cleaning, and other similar or related measures of the United States Occupational Safety and Health Administration and the Centers for
Disease Control and Prevention or other similar U.S. or non U.S. Governmental Entity in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>D&amp;O Claim</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;D&amp;O Indemnified Parties</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>D&amp;O Indemnifying Parties</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Data Security Requirements</I></B>&#148; means, to the extent governing the Company&#146;s or any member of the Company
Group&#146;s Processing of Personal Information, as applicable: (i)&nbsp;Privacy and Security Laws (including as and to the extent applicable, the Health Insurance Portability and Accountability Act of 1996 and the EU General Data Protection
Regulation), (ii)&nbsp;externally published policies (including website privacy policies) and other written notices relating to privacy, data transparency or security, and (iii)&nbsp;contractual requirements relating to the privacy or security of
Personal Information by which any member of the Company Group is bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Debt Agreement</I></B>&#148; means that certain
Bridge Credit Agreement, to be dated as of December&nbsp;12,&nbsp;2022, among Parent, Citibank N.A., as administrative agent, Bank of America, N.A., as syndication agent, and Citibank, N.A. and Bank of America, N.A. as lead arrangers and book
runners, and the other banks from time to time party thereto, an executed copy of which has been provided to the Company on the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Debt Offer Documents</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.8(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effective Date</I></B>&#148; means the date on which the Scheme becomes effective in accordance with its terms or, if the
Acquisition is implemented by way of a Takeover Offer, the date on which the Takeover Offer has become (or has been declared) unconditional in all respects in accordance with the provisions of the Takeover Offer Document and the Irish Takeover
Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effective Time</I></B>&#148; means the time on the Effective Date at which the Court Order is delivered to the
Registrar of Companies or, if the Acquisition is implemented by way of a Takeover Offer, the time on the Effective Date at which the Takeover Offer becomes (or is declared) unconditional in all respects in accordance with the provisions of the
Takeover Offer Document and the Irish Takeover Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>EGM</I></B>&#148; means the extraordinary general meeting of the Company
Shareholders (and any adjournment or postponement thereof) to be convened in connection with the Scheme, expected to be held as soon as the preceding Scheme Meeting shall have been concluded (it being understood that if the Scheme Meeting is
adjourned or postponed, the EGM shall be correspondingly adjourned or postponed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>EGM Resolutions</I></B>&#148; means,
collectively, the following resolutions to be proposed at the EGM: (i)&nbsp;an ordinary resolution to approve the Scheme and to authorize the Company Board to take all such action as it considers necessary or appropriate to implement the Scheme; and
(ii)&nbsp;a special resolution amending the Company Memorandum and Articles of Association in accordance with <U>Section</U><U></U><U>&nbsp;4.3</U> of this Agreement (the resolutions described in the foregoing <U>clauses</U> <U>(i)</U>&nbsp;and
<U>(ii)</U>, the &#147;<B><I>Required EGM Resolutions</I></B>&#148;); (iii) an ordinary resolution that any motion by the chairperson of the Company Board to adjourn or postpone the EGM, or any adjournments or postponements thereof, to another time
and place if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the EGM to approve the Scheme or any of the Required EGM Resolutions to be approved; and (iv)&nbsp;any other resolutions as the
Company reasonably determines to be (A)&nbsp;required under applicable Laws or (B)&nbsp;otherwise necessary or desirable for the purposes of implementing the Acquisition as have been approved by Parent (such approval not to be unreasonably withheld,
conditioned or delayed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Employee Agreement</I></B>&#148;<B><I> </I></B>means each employment, equity incentive, severance,
separation, or other written individual agreement or contract that provides for any salary, bonus, commissions, incentive compensation or other compensation, equity, or benefits (including, any offer letter) between the Company or any member of the
Company Group and any individual service provider, and with respect to which a member of the Company Group could reasonably be expected to have any liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Employee Plan</I></B>&#148;<B><I> </I></B>means any bonus, vacation, deferred compensation, incentive compensation, equity plan,
severance pay, termination pay, death and disability benefits, hospitalization, medical, life or other insurance, flexible benefits, supplemental unemployment benefits, profit-sharing, pension or retirement plan, policy, program, contract, agreement
or arrangement and each other employee compensation or benefit plan, policy, program, contract, agreement or arrangement sponsored, maintained, contributed to or required to be contributed to by any member of the Company Group or with respect to
which any member of the Company Group could reasonably be expected to have any liability, whether written or unwritten, excluding, in all cases, any Employee Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>End Date</I></B>&#148; means June&nbsp;12, 2023; <I>provided</I>, <I>however</I>, that in the event that on the original End Date,
one or more of paragraphs 3.1, 3.2 or 3.3 of the Conditions (with respect to paragraph 3.3, only if the failure of such Condition to have been satisfied as of such date is an Order or Law under any Antitrust Law or Foreign Investment Law in
connection with or in respect of any matter involving Antitrust Law or Foreign Investment Law) have not been satisfied, and on such date, all of the other Conditions (other than (a)&nbsp;the paragraphs 2.3 and 2.4 of the Conditions or (b)&nbsp;any
other Condition that by its nature can only be satisfied on the Sanction Date or, in the alternative to (a) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (b)&nbsp;where the Acquisition is implemented by Takeover Offer, any other condition that by its nature can only be satisfied by no later than the latest date upon which the Takeover Offer
may be declared unconditional in all respects) have been satisfied or waived (or remain capable of being satisfied or waived), then the End Date shall be automatically extended without further action by the Parties until September&nbsp;12, 2023 (the
&#147;<B><I>First Extended End Date</I></B>&#148;) (and in the case of such extension, any reference to the End Date in this Agreement shall be a reference to the First Extended End Date); <I>provided</I>, <I>further</I>, that in the event that on
the First Extended End Date, one or more of the paragraphs 3.1, 3.2 or 3.3 of the Conditions (with respect to paragraph 3.3, only if the failure of such Condition to have been satisfied as of such date is an Order or Law under any Antitrust Law or
Foreign Investment Law in connection with or in respect of any matter involving Antitrust Law or Foreign Investment Law) have not been satisfied, and on such date, all of the other Conditions (other than (a)&nbsp;the Conditions set out in paragraphs
2.3 and 2.4 of the Conditions or (b)&nbsp;any other Condition that by its nature can only be satisfied on the Sanction Date or, in the alternative to (a)&nbsp;and (b) where the Acquisition is implemented by Takeover Offer, any other condition that
by its nature can only be satisfied by no later than the latest date upon which the Takeover Offer may be declared unconditional in all respects) have been satisfied or waived (or remain capable of being satisfied or waived), then the First Extended
End Date shall be automatically extended without further action by the Parties until December&nbsp;12, 2023 (the &#147;<B><I>Second Extended End Date</I></B>&#148;) (and in the case of such extension, any reference to the End Date in this Agreement
shall be a reference to the Second Extended End Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>End Date Termination</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;9.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Environmental Law</I></B>&#148; means each applicable Law relating to
(i)&nbsp;pollution, protection of human health or worker health or the protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface land, subsurface land, plant and animal life
or any other natural resource), or (ii)&nbsp;the exposure to, or the use, storage, recycling, treatment, generation, manufacture, distribution, transportation, processing, handling, labeling, production, release, threatened releases, emissions,
discharges or disposal of, Hazardous Substances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Equitable Exceptions</I></B>&#148; means (i)&nbsp;applicable bankruptcy,
insolvency, examinership, reorganization, moratorium or other similar Laws, now or hereafter in effect, relating to creditors&#146; rights generally and (ii)&nbsp;general equitable principles, whether considered in a proceeding at law or equity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Equity Award Exchange Ratio</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;4.1(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Equity Securities</I></B>&#148; means, with respect to any Person, (i)&nbsp;any shares of capital or capital stock (including any
ordinary shares) or other voting securities of, or other ownership interest in, such Person, (ii)&nbsp;any securities of such Person convertible into or exchangeable for cash or shares of capital or capital stock or other voting securities of, or
other ownership interests in, such Person or any of its Subsidiaries, (iii)&nbsp;any warrants, calls, options or other rights to acquire from such Person, or other obligations of such Person to issue, any shares of capital or capital stock or other
voting securities of, or other ownership interests in, or securities convertible into or exchangeable for shares of capital or capital stock or other voting securities of, or other ownership interests in, such Person or any of its Subsidiaries, or
(iv)&nbsp;any restricted shares, stock appreciation rights, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restricted units, performance units, contingent value rights, &#147;phantom&#148; stock or similar securities or rights issued by or with the approval of such Person that are derivative of, or
provide economic benefits based, directly or indirectly, on the value or price of, any shares of capital or capital stock or other voting securities of, other ownership interests in, or any business, products or assets of, such Person or any of its
Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>ERISA</I></B>&#148; means the United States Employee Retirement Income Security Act of 1974. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the United States Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FCPA</I></B>&#148; means the United States Foreign Corrupt Practices Act of 1977. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FDA</I></B>&#148; means the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FDCA</I></B>&#148; means the United States Food, Drug and Cosmetic Act of 1938. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Filing</I></B>&#148; means any registration, petition, statement, application, schedule, form, declaration, notice, notification,
report, submission or other filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Financing</I></B>&#148; means the debt financing provided by the Debt Agreement and any
other third party debt financing that is necessary, or that is otherwise incurred or intended to be incurred by Parent or any of the Subsidiaries of Parent, to refinance or refund any existing Indebtedness for borrowed money of the Company, Parent
or any of their respective Subsidiaries in each case in connection with the Transactions, or to fund the Consideration payable by Acquirer Sub in the Scheme or (as the case may be) the Takeover Offer, including the offering or private placement of
debt securities or the incurrence of credit facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Financing Amounts</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;6.2(g)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Financing Information</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.8(a)(ii).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Financing Sources</I></B>&#148; means (i)&nbsp;the Persons that have committed
to provide or arrange or otherwise entered into agreements in connection with the Financing, including the parties to any joinder agreements, engagement letters, indentures or credit agreements entered into pursuant thereto or relating thereto, but
excluding in each case, for clarity, the Parties and their Subsidiaries, (ii)&nbsp;the Affiliates of the Persons set forth in <U>clause (i)</U>&nbsp;above and (iii)&nbsp;the Representatives and the respective successors and assigns of the Persons
set forth in clauses (i)&nbsp;and (ii) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Foreign Investment Laws</I></B>&#148; means all applicable Laws (other than
Antitrust Laws) in effect from time to time that are designed or intended to prohibit, restrict or regulate actions by foreigners to acquire interests in or control over domestic equities, securities, entities, assets, land or other holdings for
reasons of national security or other public policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GAAP</I></B>&#148; means U.S. generally accepted accounting principles.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GMP Regulations</I></B>&#148; means the applicable Laws and guidances for current Good Manufacturing Practices promulgated by
the FDA under the FDCA or PHS Act, applicable EU or EU Member State Law, or under the European Union guidelines to Good Manufacturing Practice for medicinal products and any other applicable Governmental Entity in each jurisdiction where any member
of the Company Group or a Third Party acting on its behalf is undertaking a clinical trial or any manufacturing activities as of or prior to the Completion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Government Official</I></B>&#148; means (i)&nbsp;any official, officer,
employee, or representative of, or any Person acting in an official capacity for or on behalf of, any Governmental Entity, (ii)&nbsp;any political party, party official or candidate for political office or (iii)&nbsp;any company, business,
enterprise or other entity owned or controlled by any Person described in the foregoing <U>clause (i)</U>&nbsp;or <U>(ii)</U> of this definition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental Authorization</I></B>&#148; means any: (a)&nbsp;permit, license, certificate, franchise, permission, variance,
clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Entity or pursuant to any Law; or (b)&nbsp;right under any Contract with any Governmental
Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental Entity</I></B>&#148; means any United States, Irish or other foreign or supranational, federal, state or
local governmental commission, board, body, division, ministry, political subdivision, bureau or other regulatory authority or agency, including courts and other judicial bodies, or any competition, antitrust, foreign investment or supervisory body,
central bank, public international organization or other governmental, trade or regulatory agency or body, securities exchange or any self-regulatory body or authority, including any instrumentality or entity designed to act for or on behalf of the
foregoing, in each case, in any jurisdiction, including, the Irish Takeover Panel, the Irish High Court and the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Group</I></B>&#148; means a &#147;group&#148; as defined in Section&nbsp;13(d) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Hazardous Substance</I></B>&#148; means any substance, material or waste that is listed, defined, designated or classified as
hazardous, toxic, radioactive, dangerous or a &#147;pollutant&#148; or &#147;contaminant&#148; or words of similar meaning under any Environmental Law or that is otherwise regulated by any Governmental Entity with jurisdiction over the environment
or natural resources, including petroleum or any derivative, byproduct or waste thereof, radon, radioactive material, asbestos or asbestos-containing material, urea formaldehyde, foam insulation or polychlorinated biphenyls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Healthcare Laws</I></B>&#148; means all Laws relating to the research, development, testing, approval, manufacturing, production,
holding, preparation, propagation, compounding, conversion, pricing, marketing, promotion, sale, distribution, import, export, coverage, or reimbursement of Company Products including: Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167;
1395-1395lll (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1396-1396w-5</FONT> (the Medicaid statute); the Federal Health Care Program Anti-Kickback Statute, 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b(b);</FONT> the False Claims Act, 31 U.S.C. &#167;&#167; 3729-3733; the Program Fraud Civil Remedies Act, 31 U.S.C. &#167;&#167; 3801-3812; the Anti-Kickback Act of 1986, 41 U.S.C. &#167;&#167; <FONT
STYLE="white-space:nowrap">51-58;</FONT> the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7a</FONT> and <FONT STYLE="white-space:nowrap">1320a-7b;</FONT> the Exclusion Laws, 42 U.S.C. &#167; 1320a 7;
the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009); the FDCA; the Public Health
Service Act; Directive 2001/83/EC on the Community code relating to medicinal products for human use; Regulation 726/2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and
establishing a European Medicines Agency; any similar international, federal, state and local Laws that address the subject matter of the foregoing; and the Patient Protection and Affordable Care Act of 2010. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Historical Financial Statements</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.8(a)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>HSR Act</I></B>&#148; means the United States Hart-Scott-Rodino Antitrust
Improvements Act of 1976. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B>&#148; has the meaning ascribed to
it in <U>Section</U><U></U><U>&nbsp;6.1(h)(iv)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indebtedness</I></B>&#148; means, with respect to any Person, without
duplication, all outstanding obligations of such Person (a)&nbsp;for borrowed money, (b)&nbsp;as evidenced by bonds, debentures, notes or similar instruments, (c)&nbsp;pursuant to securitization or factoring programs or arrangements, for net cash
payment obligations of such Person under swaps, options, forward sales contracts, derivatives and other hedging Contracts, financial instruments or arrangements that will be payable upon termination thereof (assuming termination on the date of
determination), (d)&nbsp;for letters of credit, bank guarantees, performance bonds and other similar Contracts or arrangements entered into by or on behalf of such Person, to the extent drawn, or (e)&nbsp;pursuant to guarantees and arrangements
having the economic effect of a guarantee of any obligation or undertaking of any other Person contemplated by the foregoing <U>clauses (a)</U>&nbsp;through <U>(d)</U> of this definition, in each case including all interest, premiums, prepayment
fees, penalties, commitment or other fees, reimbursements, expenses and other payments due with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indenture</I></B>&#148; means that certain Indenture, dated July&nbsp;16, 2019, between Horizon Therapeutics USA, Inc. and U.S.
Bank National Association, as supplemented by the First Supplemental Indenture, dated November&nbsp;19, 2019, the Second Supplemental Indenture dated April&nbsp;23, 2020, and the Third Supplemental Indenture dated March&nbsp;15, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Insurance Policies</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(s)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Intellectual Property</I></B>&#148; means any and all rights in or associated with any of the following, whether or not
registered, arising in the United States or any other jurisdiction throughout the world: (i)&nbsp;trademarks, service marks, trade names, trade dress, logos, symbols, brand names, slogans, Internet domain names, Internet account names (including
social networking and media names) and other indicia of origin, together with all common law rights and goodwill associated therewith or symbolized thereby, and all registrations and applications relating to the foregoing; (ii)&nbsp;patents and
pending patent applications, and all divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues and reexaminations, and any extensions thereof; (iii)&nbsp;works of
authorship (whether or not copyrightable), registered and unregistered copyrights (including those in Software), all registrations and applications to register the same, and all renewals, extensions, reversions and restorations thereof, including
moral rights of authors and common law rights thereto, and technical database rights; (iv)&nbsp;trade secrets, rights in technology, confidential or proprietary information and other <FONT STYLE="white-space:nowrap">know-how,</FONT> including
inventions (whether or not patentable or reduced to practice), concepts, methods, processes, protocols, assays, formulations, formulae, technical, research, clinical and other technical data, technical databases, designs, specifications, schematics,
drawings, algorithms, models and methodologies; (v)&nbsp;rights in Software; and (vi)&nbsp;other similar types of proprietary or industrial rights or other intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Ireland</I></B>&#148; or &#147;<B><I>Republic of Ireland</I></B>&#148; means
Ireland, excluding Northern Ireland, and the word &#147;<B><I>Irish</I></B>&#148; shall be construed accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Irish
Companies Act</I></B>&#148; means the Companies Act 2014 of Ireland, all enactments which are to be read as one with, or construed or read together as one with, the Companies Act 2014 and every statutory modification and <FONT
STYLE="white-space:nowrap">re-enactment</FONT> thereof for the time being in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Irish High Court</I></B>&#148; means the
High Court of Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Irish Takeover Panel Act</I></B>&#148; means the Irish Takeover Panel Act 1997. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Irish</I></B><I> </I><B><I>Takeover Rules</I></B>&#148; means the Irish Takeover Panel Act 1997, Irish Takeover Rules, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Irrecoverable VAT</I></B>&#148; means in relation to any Person, any amount in respect of VAT which that Person (or a member of
the same VAT Group as that Person) has incurred and in respect of which neither that Person nor any other member of the same VAT Group as that Person is entitled to a refund (by way of credit or repayment) from any relevant Tax Authority pursuant to
and determined in accordance with applicable VAT Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>knowledge</I></B>&#148; means in relation to the Company, the actual
knowledge, after reasonable inquiry of their direct reports, of the Persons listed in Section&nbsp;1.1(a) of the Company Disclosure Schedule. With respect to matters involving Intellectual Property, reasonable inquiry does not require that the
Persons listed in Section&nbsp;1.1(a) of the Company Disclosure Schedule to conduct or have conducted or obtain or have obtained any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> opinions or
similar opinions of counsel or any Intellectual Property clearance searches, and no knowledge of any Intellectual Property of any other Person that would have been revealed by such inquiries, opinions or searches will be imputed to such Persons.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Law</I></B>&#148; means any federal, state, local, foreign or supranational law, statute, ordinance, rule, regulation,
judgment, order, injunction, decree, executive order or agency requirement of any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Lease</I></B>&#148;
has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(g)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Leased Real Property</I></B>&#148; has the
meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(g)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Legal Proceeding</I></B>&#148;<B><I> </I></B>means any
action, suit, charge, complaint, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding) or hearing commenced, brought, conducted or heard by or before, or otherwise involving, any
court or other Governmental Entity or any arbitrator or arbitration panel that have the applicable jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Licensed Intellectual Property</I></B>&#148; means any and all Intellectual
Property owned by a Third Party and licensed (including sublicensed or granted a covenant not to sue) to any member of the Company Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Lien</I></B>&#148; means, with respect to any property or asset, any mortgage, lien, pledge, charge, security interest or
encumbrance of any kind in respect of such property or asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Marketing Material</I></B>&#148; has the meaning ascribed to it
in <U>Section</U><U></U><U>&nbsp;7.8(a)(i).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Material Contract</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;6.1(j)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Maximum Premium</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.3(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Nasdaq</I></B>&#148; means the Nasdaq Global Select Market, or any successor stock
market or exchange operated by Nasdaq, Inc., or any successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>New Plans</I></B>&#148; has the meaning ascribed to it
in <U>Section</U><U></U><U>&nbsp;7.4(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Non Approval Termination</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;9.1(a)(i)(A)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Northern Ireland</I></B>&#148; means the counties of Antrim, Armagh, Derry,
Down, Fermanagh and Tyrone on the island of Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Offering Document</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Offers to Exchange</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.8(b).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Offers to Purchase</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.8(b).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Old Plans</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.4(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Option Consideration</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;4.1(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Order</I></B>&#148; means any order, writ, decree, judgment, award, injunction,
ruling, settlement or stipulation issued, promulgated, made, rendered or entered into by or with any Governmental Entity or arbitrator (in each case, whether temporary, preliminary or permanent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Organizational Documents</I></B>&#148; means articles of association, articles of incorporation, certificate of incorporation,
constitution, <FONT STYLE="white-space:nowrap">by-laws,</FONT> limited liability company agreement, operating agreement or other equivalent organizational document, as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">&#147;Out-bound</FONT> License</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;6.1(h)(iv)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Owned Intellectual Property</I></B>&#148; means any and all Intellectual
Property owned or purported to be owned by any member of the Company Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Owned Real</I></B> <B><I>Property</I></B>&#148;
has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(g)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent</I></B>&#148; has the meaning ascribed to
it in the Preamble. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Breach Termination</I></B>&#148;<B><I> </I></B>has the meaning ascribed
to it in <U>Section</U><U></U><U>&nbsp;9.1(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Common Stock</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;4.1(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Financing Information</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;3.4(b)(i). </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Group</I></B>&#148; means Parent and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Material Adverse Effect</I></B>&#148; means any effect, change, event or occurrence that would, individually or in the
aggregate, prevent, materially delay or materially impair the ability of Parent or Acquirer Sub to consummate the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Parties</I></B>&#148; means Parent and Acquirer Sub and &#147;<B><I>Parent Party</I></B>&#148; means either Parent or
Acquirer Sub (as the context requires). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Payment Events</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;9.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Related Parties</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;9.2(h)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent RSU</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;4.1(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parties</I></B>&#148; means the Company and the Parent Parties and
&#147;<B><I>Party</I></B>&#148; means either the Company, on the one hand, or Parent or the Parent Parties (whether individually or collectively), on the other hand (as the context requires). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Permitted Liens</I></B>&#148; means (i)&nbsp;any Lien for Taxes (A)&nbsp;not yet due and payable or (B)&nbsp;which are being
contested in good faith by appropriate proceedings and with respect to which adequate reserves have been established in accordance with GAAP, (ii)&nbsp;carriers&#146;, warehousemen&#146;s, mechanics&#146;, materialmen&#146;s, repairmen&#146;s or
other similar Liens, (iii)&nbsp;pledges or deposits in connection with workers&#146; compensation, unemployment insurance and other social security legislation, (iv)&nbsp;gaps in the chain of title that are required to be recorded, evident from the
records of the applicable Governmental Entity maintaining such records, easements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way,</FONT></FONT> covenants, restrictions and other encumbrances of record as of the date
of this Agreement that do not materially detract from the value or the use of the property subject thereto, (v)&nbsp;statutory landlords&#146; liens and liens granted to landlords under any lease, (vi)&nbsp;any purchase money security interests,
equipment leases or similar financing arrangements, (vii)&nbsp;any Liens which are reflected on the Balance Sheet, or the notes thereto, or incurred in connection with the Company Credit Agreement, (viii)&nbsp;any
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses in the ordinary course of business, or (ix)&nbsp;any Liens that are not material to the Company and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any individual, corporation, partnership, limited liability company, association, trust or other entity
or organization, including a government or political subdivision or an agency or instrumentality of such government or political subdivision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Personal Information</I></B>&#148; means any information Processed by or on behalf of any of the Company Group that constitutes
&#147;personal information,&#148; &#147;personal data,&#148; &#147;personally identifiable information,&#148; &#147;protected health information,&#148; or other analogous term as defined under applicable Privacy and Security Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Privacy and Security Laws</I></B>&#148; means applicable Laws that govern the
Processing, privacy or security of Personal Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Process</I></B>&#148; or &#147;<B><I>Processing</I></B>&#148; means,
with respect Personal Information, the use, collection, receipt, processing, aggregation, storage, recording, retention, organization, adaption, alteration, transfer (including cross-border transfer), retrieval, consultation, disclosure,
dissemination, erasure, destruction, anonymization or combination of such Personal Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Proxy Statement</I></B>&#148;
has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;3.1(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>PSU Consideration</I></B>&#148; has the meaning
ascribed to it in <U>Section</U><U></U><U>&nbsp;4.1(b)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Redemption</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;7.9(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registered IP</I></B>&#148; means all Intellectual Property that are registered or
issued under the authority of any Governmental Entity or Internet domain name registrar, including all issued patents, registered copyrights, registered mask works, and registered trademarks, service marks and trade dress, registered domain names,
and all pending applications for patents, trademarks and service marks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registrar of Companies</I></B>&#148; means the
Registrar of Companies in Dublin, Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Agency</I></B>&#148; means any Governmental Entity that is concerned
with the quality, identity, strength, purity, safety, efficacy, testing, manufacturing, labeling, storage, distribution, marketing, sale, pricing, import or export of any of the Company Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Information Service</I></B>&#148; means a regulatory information service as defined in the Irish Takeover Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Permits</I></B>&#148; means authorization (i)&nbsp;under the FDCA or the Public Health Service Act and (ii)&nbsp;of any
applicable Regulatory Agency, in each case, as necessary for the lawful operation of the business of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Reimbursement Amount</I></B>&#148; means an amount equal to the documented, specific, quantifiable Third Party costs and expenses
incurred, directly or indirectly, by Parent or its Subsidiaries, or on their behalf, for the purposes of, in preparation for, or in connection with the Acquisition, including Third Party costs and expenses incurred in connection with exploratory
work carried out in contemplation of and in connection with the Acquisition, legal, financial and commercial due diligence, the arrangement of financing and the engagement of Third Party Representatives to assist in the process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Reimbursement Payment</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;9.2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Remedy Actions</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.2(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Representatives</I></B>&#148; means, in relation to any Person, the directors, officers, employees, agents, investment bankers,
financial advisors, legal advisors, accountants, brokers, finders, consultants or other representatives of such Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Jurisdiction</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.2(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Resolutions</I></B>&#148; means the EGM Resolutions or the Scheme Meeting Resolution, as the context requires, which will be set
out in the Scheme Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restraining Order Termination</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;9.1(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Reverse Termination Payment</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;9.2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>RSU Cash Consideration</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;4.1(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Rule 2.7 Announcement</I></B>&#148; means the announcement to be made by the
Parties pursuant to Rule 2.7 of the Irish Takeover Rules for the purposes of the Acquisition, in the form agreed to by or on behalf of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Sanction Date</I></B>&#148; has the meaning ascribed to it in Appendix 3 of the Rule 2.7 Announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Scheme</I></B>&#148; means the proposed scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act to effect the
Acquisition pursuant to this Agreement, on such terms and in such form as is consistent with the terms agreed to by the Parties as set out in the Rule 2.7 Announcement, including any revision thereof as may be agreed between the Parties in writing,
and, if required, by the Irish High Court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Scheme Barrister</I></B>&#148; has the meaning ascribed to it in
<U>Section</U><U></U><U>&nbsp;3.1(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Scheme Document</I></B>&#148; means a document (or relevant sections of the Proxy
Statement) (including any amendments or supplements thereto) to be distributed to the Company Shareholders and, for information only, to the Company Equity Award Holders containing (i)&nbsp;the Scheme, (ii)&nbsp;the notice or notices of the Scheme
Meeting and EGM, (iii)&nbsp;an explanatory statement as required by Section&nbsp;452 of the Irish Companies Act with respect to the Scheme, (iv)&nbsp;such other information as may be required or necessary pursuant to the Irish Companies Act, the
Exchange Act or the Irish Takeover Rules and (v)&nbsp;such other information as the Company and Parent shall agree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Scheme
Meeting</I></B>&#148; means the meeting or meetings of the Company Shareholders or, if applicable, the meeting or meetings of any class or classes of Company Shareholders (and, in each case, any adjournment or postponement thereof) convened by order
of the Irish High Court pursuant to Section&nbsp;450 of the Irish Companies Act to consider and, if thought fit, approve the Scheme (with or without amendment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Scheme Meeting Resolution</I></B>&#148; means the resolution to be proposed at the Scheme Meeting for the purposes of approving
and implementing the Scheme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Scheme Recommendation</I></B>&#148; means the unanimous recommendation of the Company Board that
Company Shareholders vote in favor of the Resolutions (or, subject to this Agreement, if Acquirer Sub effects the Acquisition as a Takeover Offer, the unanimous recommendation of the Company Board that Company Shareholders accept the Takeover
Offer). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Scheme Record Time</I></B>&#148; means time specified as the scheme record time
in the Scheme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC</I></B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; means the United States Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Security Incident</I></B>&#148; means any breach of security, phishing incident, ransomware, malware attack or any other incident
involving the unauthorized or unlawful Processing of Personal Information that would require notification to any Person under Data Security Requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Severance Arrangements</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Significant Subsidiary</I></B>&#148; means a significant subsidiary as defined in Rule
<FONT STYLE="white-space:nowrap">l-02(w)</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Software</I></B>&#148; means all (i)&nbsp;computer programs and other software including any and all software implementations of
algorithms, models, methodologies, assemblers, applets, compilers, development tools, design tools and user interfaces, whether in source code or object code form, (ii)&nbsp;technical databases and compilations, including all technical data and
collections of technical data, whether machine readable or otherwise, (iii)&nbsp;updates, upgrades, modifications, improvements, enhancements, derivative works, new versions, new releases and corrections to or based on any of the foregoing, and
(iv)&nbsp;all documentation, including development, diagnostic, support, user and training documentation, related to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Specified Termination</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;9.2(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Standard Contracts</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;6.1(h)(iv)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to any Person, any entity of which securities or other ownership interests having
ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are directly or indirectly owned by such Person. For purposes of this Agreement, a Subsidiary shall be considered a &#147;wholly owned
Subsidiary&#148; of a Person if such Person directly or indirectly owns all of the securities or other ownership interests (excluding any securities or other ownership interests held by an individual director or officer required to hold such
securities or other ownership interests pursuant to applicable Laws) of such Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Superior Proposal
Termination</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;9.1(a)(ii)(B)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Takeover
Offer</I></B>&#148; means an offer in accordance with <U>Section</U><U></U><U>&nbsp;3.6</U> for the entire issued share capital of the Company (other than any Company Shares beneficially owned by Parent or Acquirer Sub and any Company Shares held by
any member of the Company Group) including any amendment or revision thereto pursuant to this Agreement, the full terms of which would be set out in the Takeover Offer Document or (as the case may be) any revised offer documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Takeover Offer Document</I></B>&#148; means, if, following the date of this
Agreement, Parent elects to implement the Acquisition by way of the Takeover Offer in accordance with <U>Section</U><U></U><U>&nbsp;3.6</U>, the document to be sent to the Company Shareholders and others jointly by Parent and Acquirer Sub
containing, among other things, the Takeover Offer, the Conditions (except as Parent determines pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;3.6</U> not to be appropriate in the case of a Takeover Offer) and certain information
about Parent, Acquirer Sub and the Company and, where the context so requires, includes any form of acceptance, election, notice or other document reasonably required in connection with the Takeover Offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax</I></B>&#148; or &#147;<B><I>Taxes</I></B>&#148; means any and all taxes imposed by or payable to any federal, state,
provincial, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Authority, and includes all U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> gross or net income, gain, profits, windfall profits, franchise,
gross receipts, estimated, capital, documentary, transfer, ad valorem, premium, customs duty, capital stock, severances, stamp, payroll, sales, employment, unemployment compensation, social security, disability, use, property, withholding or backup
withholding, excise, production, value added and occupancy taxes, together with all interest, penalties and additions imposed with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Authority</I></B>&#148; means any Governmental Entity responsible for the assessment, collection or enforcement of laws
relating to Taxes (including the United States Internal Revenue Service and the Irish Revenue Commissioners and any similar state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> revenue agency). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Return</I></B>&#148; means all returns and reports (including elections, declarations, disclosures, schedules, estimates,
claims for refunds and information returns) filed or required to be filed with a Tax Authority relating to Taxes, including all attachments thereto and any amendments or supplements thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third Party</I></B>&#148; means any Person or Group, other than the Company or any of its Affiliates, in the case of Parent and
Acquirer Sub, or other than Parent or any of its Affiliates, in the case of the Company, and the Representatives of such Persons, in each case, acting in such capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transaction Litigation</I></B>&#148; has the meaning ascribed to it in <U>Section</U><U></U><U>&nbsp;7.10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transactions</I></B>&#148; means the transactions contemplated by this Agreement, including the Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>U.S.</I></B>&#148; or &#147;<B><I>United States</I></B>&#148; means the United States, its territories and possessions, any State
of the United States and the District of Columbia, and all other areas subject to its jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>VAT</I></B>&#148; means
any tax imposed by any member state of the European Union in conformity with the directive of the Council of the European Union on the common system of value added tax (2006/112/EC) and any tax similar to or replacing the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>VAT Group</I></B>&#148; means a group as defined in Section&nbsp;15 of the Value Added Tax Consolidation Act 2010 and any similar
VAT grouping arrangement in any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Willful Breach</I></B>&#148; means a material breach of this Agreement
that is the consequence of an act or omission by a Party with the actual knowledge that the taking of such act or such omission to take action would be a material breach of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>Construction</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The following rules of interpretation shall apply to this Agreement: (i)&nbsp;the words &#147;hereof,&#148; &#147;hereby,&#148;
&#147;herein&#148; and &#147;hereunder&#148; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement; (ii)&nbsp;the table of contents and captions in this
Agreement are included for convenience of reference only and shall be ignored in the construction or interpretation hereof; (iii)&nbsp;references to Sections are to Sections of this Agreement unless otherwise specified; (iv)&nbsp;all schedules
annexed to this Agreement or referred to in this Agreement, including the Company Disclosure Schedule, are incorporated in and made a part of this Agreement as if set out in full in this Agreement; (v)&nbsp;any capitalized term used in any schedule
annexed to this Agreement, including the Company Disclosure Schedule, but not otherwise defined therein shall have the meaning set out in this Agreement; (vi)&nbsp;any singular term in this Agreement shall be deemed to include the plural, and any
plural term the singular, and references to any gender shall include all genders; (vii)&nbsp;whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the
words &#147;without limitation,&#148; whether or not they are in fact followed by those words or words of like import; (viii) &#147;writing,&#148; &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing
words (including electronic media) in a visible form; (ix)&nbsp;references to any applicable Law shall be deemed to refer to such applicable Law as amended from time to time and to any rules or regulations promulgated thereunder; (x)&nbsp;references
to any Contract are to that Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof; (xi)&nbsp;references to any Person include the successors and permitted assigns of that Person;
(xii)&nbsp;references &#147;from&#148; or &#147;through&#148; any date mean, unless otherwise specified, &#147;from and including&#148; or &#147;through and including,&#148; respectively; (xiii)&nbsp;references to &#147;dollars&#148; and
&#147;$&#148; means U.S. dollars; (xiv)&nbsp;the term &#147;made available&#148; and words of similar import mean that the relevant documents, instruments or materials were (A)&nbsp;with respect to Parent, posted and made available to Parent on the
Company due diligence data site (or in any &#147;clean room&#148; or as otherwise provided on an &#147;outside counsel only&#148; basis) at least one day prior to the date of this Agreement; or (B)&nbsp;filed or furnished to the SEC at least one
Business Day prior to the date of this Agreement and not subject to any redactions or omissions; (xv)&nbsp;the word &#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or other theory extends and such
phrase shall not mean &#147;if&#148;; (xvi)&nbsp;any reference to an Irish legal term for any action, remedy, method of judicial proceeding, legal document, legal status, court, official or any legal concept or thing shall, in respect of any
jurisdiction other than Ireland, be deemed to include a reference to what most nearly approximates in that jurisdiction to the Irish legal term, (xvii)&nbsp;references to times are to New York City times unless otherwise specified;
(xviii)&nbsp;unless otherwise indicated, the word &#147;or&#148; shall not be exclusive (<I>i</I>.<I>e</I>., &#147;or&#148; shall be deemed to mean &#147;and/or&#148;); and (xix)&nbsp;the Parties have participated jointly in the negotiation and
drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Parties and no presumption or burden of proof shall arise favoring or disfavoring
any Party by virtue of the authorship of any provision of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;2. RULE 2.7 ANNOUNCEMENT AND SCHEME DOCUMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Rule 2.7 Announcement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Party confirms that its respective board of directors (or a duly authorized committee thereof) has approved the contents and release
of the Rule 2.7 Announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Following the execution of this Agreement, the Company and Parent shall jointly, in accordance with,
and for the purposes of, the Irish Takeover Rules, procure the release of the Rule 2.7 Announcement to a Regulatory Information Service by no later than 11:59 a.m., New York City time, on December&nbsp;12, 2022, or such later time as may be agreed
between the Parties in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The obligations of the Parties under this Agreement, other than the obligations under
<U>Section</U><U></U><U>&nbsp;2.1(a)</U>, shall be conditional on the release of the Rule 2.7 Announcement to a Regulatory Information Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company confirms that, as of the date of this Agreement, the Company Board unanimously considers that the terms of the Scheme as
contemplated by this Agreement are fair and reasonable and that the Company Board has unanimously resolved to recommend to the Company Shareholders that they vote in favor of the Resolutions. The recommendation of the Company Board that the Company
Shareholders vote in favor of the Resolutions, and the related opinion of the financial advisors to the Company Board, are set out in the Rule 2.7 Announcement and, subject to <U>Section</U><U></U><U>&nbsp;5.2</U>, shall be incorporated in the
Scheme Document and to the extent required by the Irish Takeover Rules, any other document sent to the Company Shareholders in connection with the Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Conditions are hereby incorporated in and shall constitute a part of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>The Scheme</B>. Subject to <U>Section</U><U></U><U>&nbsp;3.6</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Company agrees that, unless this Agreement has been terminated in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, it will propose
the Scheme to the Company Shareholders in the manner set out in <U>Section</U><U></U><U>&nbsp;3</U> and, subject to the satisfaction or, in the sole discretion of the applicable Party, waiver (where permissible under the provisions of the Rule 2.7
Announcement or the Scheme Document) of the Conditions (with the exception of paragraphs 2.3 and 2.4 of the Conditions and any other Conditions that by their nature are to be satisfied on the Sanction Date, but subject to the satisfaction or waiver
(where permissible under the provisions of the Rule 2.7 Announcement or the Scheme Document) of such Conditions), will, in the manner set out in <U>Section</U><U></U><U>&nbsp;3</U>, apply to the Irish High Court for the sanction of the Scheme so as
to facilitate the implementation of the Acquisition; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) each of Parent and Acquirer Sub agrees that it will participate in the Scheme
and agrees to be bound by its terms, as proposed by the Company to the Company Shareholders, and that it shall, subject to the satisfaction or, in the sole discretion of the applicable Party, waiver (where permissible under the provisions of the
Rule 2.7 Announcement or the Scheme Document) of the Conditions, effect the Acquisition through the Scheme on the terms set out in this Agreement and the Scheme; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) each of the Parties agrees that it will perform all of the obligations required of it in
respect of the Acquisition on the terms set out in this Agreement or the Scheme, and each will, subject to the terms and conditions of this Agreement, including <U>Section</U><U></U><U>&nbsp;7.2</U>, use its reasonable best efforts to take such
other steps as are within its power and are reasonably required of it for the proper implementation of the Scheme, including those required of it pursuant to this Agreement in connection with the Completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Change in Shares</B>. If at any time during the period between the date of this Agreement and the earlier of (i)&nbsp;the
Effective Time and (ii)&nbsp;the termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, the outstanding Company Shares shall have been changed into, or exchanged for, a different number of shares or a
different class, by reason of any subdivision, reclassification, reorganization, recapitalization, split, combination, contribution or exchange of shares, or a stock dividend or dividend payable in any other securities shall be declared with a
record date within such period, or any similar event shall have occurred, the Consideration and any payments to be made under <U>Section</U><U></U><U>&nbsp;4</U> and any other number or amount contained in this Agreement which is based upon the
price or number of Company Shares shall be correspondingly adjusted to provide the holders of Company Shares the same economic effect as contemplated by this Agreement prior to such event. Nothing in this <U>Section</U><U></U><U>&nbsp;2.3</U> shall
be construed to permit any Party to take any action that is otherwise prohibited or restricted by any other provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Company Equity Award Holder Proposal</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the posting of the Scheme Document to the Company Shareholders in accordance with <U>Section</U><U></U><U>&nbsp;3.1</U>, the
Parties agree that the Company Equity Award Holder Proposal will be made to Company Equity Award Holders in respect of their respective holdings of Company Options or Company Share Awards in accordance with Rule 15 of the Irish Takeover Rules and
the terms of the Company Share Plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company Equity Award Holder Proposal shall be sent as a joint letter from the Company and
Parent and the Parties shall reasonably agree to the final form of the letter to be issued in respect of the Company Equity Award Holder Proposal and all other documentation necessary to effect the Company Equity Award Holder Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as required by applicable Laws, the Irish High Court or the Irish Takeover Panel, no Party shall amend the Company Equity Award
Holder Proposal after it is sent without the consent of each other Party (such consent not to be unreasonably withheld, conditioned or delayed). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;3. IMPLEMENTATION OF THE SCHEME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Responsibilities of the Company in Respect of the Scheme</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) be
responsible for the preparation of the proxy statement to be sent to the Company Shareholders in connection with the matters to be submitted at the Scheme Meeting and the EGM (such proxy statement, as amended or supplemented, the &#147;<B><I>Proxy
Statement</I></B>&#148;) and the Scheme Document (which shall be on terms consistent with the Rule 2.7 Announcement) and all other documentation necessary to effect the Scheme and to convene the EGM and Scheme Meeting, including any materials
required to be filed with the SEC in connection with the foregoing, (ii)&nbsp;provide Parent with drafts of the Proxy Statement and the Scheme Document and afford Parent a reasonable opportunity to review and comment on the Proxy Statement and the
Scheme Document and such other documents and shall consider such comments in good faith and (iii)&nbsp;subject to the foregoing <U>clauses (i)</U>&nbsp;and <U>(ii)</U>, as promptly as reasonably practicable after the date of this Agreement (but in
no event later than December&nbsp;30, 2022), cause the preliminary Proxy Statement and the Scheme Document to be filed with the SEC and the Irish Takeover Panel (in accordance with Rule 41.1(b) of the Irish Takeover Rules). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) for the purpose of implementing the Scheme, instruct an Irish qualified barrister (of senior counsel standing) (the &#147;<B><I>Scheme
Barrister</I></B>&#148;) and provide Parent and its Representatives with the opportunity to attend any meetings with the Scheme Barrister to discuss matters pertaining to the Scheme and any material issues arising in connection with it (except to
the extent the Scheme Barrister is to advise on matters relating to the fiduciary duties of the directors of the Company or their responsibilities under the Irish Takeover Rules, a Company Alternative Proposal or the termination of this Agreement
pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) as promptly as reasonably practicable, notify Parent upon
the receipt of any comments from the Irish Takeover Panel or the SEC on, or any request from the Irish Takeover Panel or the SEC for amendments or supplements to, the Proxy Statement, the Scheme Document, the Company Equity Award Holder Proposal and
the related forms of proxy and provide Parent with copies of all material written correspondence between it and its Representatives and the Irish Takeover Panel or the SEC relating to such documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) use its reasonable best efforts to respond to and resolve all Irish Takeover Panel and SEC comments with respect to the Proxy Statement
and the Scheme Document as promptly as reasonably practicable after receipt thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) as promptly as reasonably practicable, notify
Parent of any other matter of which it becomes aware which would reasonably be expected to materially delay or prevent filing of the Proxy Statement or the Scheme Document with the SEC and the Irish Takeover Panel, as applicable, or implementation
of the Scheme as the case may be; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) prior to filing or sending any amendment or supplement to the Proxy Statement or the Scheme
Document requested by the Irish Takeover Panel or the SEC, or responding in writing to any comments of the Irish Takeover Panel or the SEC with respect thereto, the Company shall provide Parent with a reasonable opportunity to review and comment on
such document or response and consider in good faith such comments; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) cause the Proxy Statement to be mailed as promptly as reasonably practicable after the
date on which the SEC confirms that it will not review the Proxy Statement (which confirmation will be deemed to occur if the SEC has not affirmatively notified the Company on or prior to the 10th calendar day after filing the Proxy Statement) or
that it has no further comments on the Proxy Statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) to the extent that clearance of the Proxy Statement or the Scheme Document by
the Irish Takeover Panel might require that waivers or derogations in respect of the Takeover Rules be sought and obtained from the Irish Takeover Panel, make a submission for (and use reasonable best efforts to have approved) such waiver or
derogation as promptly as reasonably practicable after having provided Parent with a reasonable opportunity to review and comment on such submission and considering in good faith such comments; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) provide Parent with drafts of any and all pleadings, affidavits, orders, originating notices of motion or other originating pleadings or
notices of motion and other filings prepared by the Company for submission to the Irish High Court in connection with the Scheme prior to their filing, and afford Parent reasonable opportunities to review and comment on all such documents and
consider in good faith such comments; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) as promptly as reasonably practicable (taking into account any requirements of the Irish
Takeover Panel with respect to the Scheme Document and the SEC review (if any) with respect to the Proxy Statement, that must be satisfied prior to the release of the Scheme Document), but in any event not later than 4:30 p.m. on the Wednesday in
the week falling immediately after the Clearance Date, the Company shall file the originating notice of motion, the notice of motion for entry to the commercial division of the Irish High Court and any ancillary court papers with the Central Office
of the Irish High Court for the purpose of commencing the court application to seek directions under Section&nbsp;450(5) of the Irish Companies Act as to the appropriate meetings to be held and to order that the Scheme Meeting be convened and,
thereafter, as promptly as reasonably practicable, make all necessary applications to the Irish High Court in connection with the implementation of the Scheme (including the application for directions under Section&nbsp;450(5) of the Irish Companies
Act as to the appropriate meetings to be held and to order that the Scheme Meeting be convened as promptly as is reasonably practicable so as to be held within 35 calendar days of such directions), and to use its reasonable best efforts to ensure
that the hearing of such proceedings occurs as promptly as is reasonably practicable in order to facilitate sending the Scheme Document and seek such directions of the Irish High Court as it considers necessary or desirable in connection with such
Scheme Meeting and thereafter comply with such directions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) procure the publication of the requisite advertisements and sending of the
Scheme Document (in a form acceptable to the Irish Takeover Panel), Proxy Statement and the related forms of proxy for the use at the Scheme Meeting and EGM (the form of which shall be agreed between the Parties, acting reasonably)&nbsp;(i) to the
Company Shareholders on the register of members of the Company on the record date as agreed with the Irish High Court, as promptly as reasonably practicable after securing approval of the Irish High Court to send such documents, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii) to the holders of the Company Options and the Company Share Awards as of such date, for information only, as promptly as reasonably practicable after securing approval of the Irish High
Court to send such documents, and thereafter shall publish or post such other documents and information (the form of which shall be agreed between the Parties, acting reasonably) as the Irish High Court or the Irish Takeover Panel may approve or
direct from time to time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) unless the Company Board has effected a Company Change of Recommendation pursuant to and in accordance with
<U>Section</U><U></U><U>&nbsp;5.2</U>, procure that the Proxy Statement and the Scheme Document include the Scheme Recommendation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)
include in the Scheme Document a notice convening the EGM to be held immediately following the Scheme Meeting to consider and, if thought fit, approve the EGM Resolutions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) prior to the Scheme Meeting, keep Parent reasonably informed on a reasonably current basis (in each case to the extent the Company
reasonably has access to such information) of the number of proxy votes received in respect of the Resolutions, and in any event provide such number promptly upon the request of Parent or its Representatives and, unless the Company Board has
effected a Company Change of Recommendation pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;5.2</U>, use commercially reasonable efforts to solicit proxies as may be necessary to pass the Resolutions at the Scheme Meeting or the
EGM; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) unless this Agreement has been terminated pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9.1</U>, hold the
Scheme Meeting and EGM on the date set out in the Scheme Document, or such later date as may be agreed in writing by the Parties (such agreements not to be unreasonably withheld, conditioned or delayed), and in such a manner as shall be approved, if
necessary, by the Irish High Court or the Irish Takeover Panel, and propose the Resolutions without any amendments, unless such amendments have been agreed to in writing by Parent, such agreement not to be unreasonably withheld, conditioned or
delayed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) subject to the terms of this Agreement, afford all such cooperation and assistance as may reasonably be requested of it by
Parent in respect of the preparation and verification of any document or in connection with any Clearance or confirmation required for the implementation of the Scheme, including the provision to Parent in a timely manner of such information and
confirmations relating to it, its Subsidiaries and any of its or their respective directors or employees as Parent may reasonably request; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) assume responsibility for the information contained in the Scheme Document, the Proxy Statement or any other document sent to the Company
Shareholders or filed with the Irish High Court or in any announcement issued in connection with the Acquisition, other than information contained in any such document or announcement relating to Parent or Acquirer Sub; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) review and provide comments (if any) in a reasonably timely manner on all documentation submitted to it by or on behalf of Parent or
Acquirer Sub; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) following the Scheme Meeting and EGM, assuming the Resolutions are duly passed
(including by the requisite majorities required under Section&nbsp;453 of the Irish Companies Act in the case of the Scheme Meeting) and all other Conditions are satisfied or, in the sole discretion of the applicable Party, waived (where permissible
under the terms of the Rule 2.7 Announcement or the Scheme Document) (with the exception of paragraphs 2.3 and 2.4 of the Conditions and any other Conditions that are by their nature to be satisfied on the Sanction Date, but subject to the
satisfaction or waiver (where permissible under the provisions of the Rule 2.7 Announcement or the Scheme Document) of such Conditions), take all necessary steps on the part of the Company to prepare and issue, serve and lodge all such court
documents as are required to seek the sanction of the Irish High Court to the Scheme as soon as possible thereafter; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) give such
undertakings as are required by the Irish High Court in connection with the Scheme as are reasonably necessary or desirable to implement the Scheme; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) keep Parent reasonably informed as to the performance of the obligations and responsibilities required of the Company pursuant to the
Scheme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Responsibilities of Parent and Acquirer Sub in Respect of the Scheme</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Parent and Acquirer Sub shall: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) either (i)&nbsp;instruct counsel or a solicitor to appear on its behalf at the Scheme Meeting and undertake to the Irish High Court to be
bound by the terms of the Scheme insofar as it relates to Parent or Acquirer Sub, or (ii)&nbsp;provide a written undertaking to the Irish High Court to be bound by the terms of the Scheme insofar as it relates to Parent or Acquirer Sub; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if, and to the extent that, it or any of its Concert Parties owns or is interested in the Company Shares, exercise all of its rights and,
insofar as lies within its powers, procure that each of its Concert Parties shall exercise all of their respective rights, in respect of such Company Shares so as to implement, and otherwise support the implementation of, the Scheme, including by
voting (and, in respect of interests in the Company held via contracts for difference or other derivative instruments, insofar as lies within its powers, procuring that instructions are given to the holder of the underlying Company Shares to vote)
in favor of the Resolutions or, if required by Law, the Irish High Court or the Irish Takeover Rules, refraining from voting, at any Scheme Meeting or EGM as the case may be; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) once the Scheme becomes effective, keep the Company reasonably informed as to the performance of the obligations and responsibilities
required of Parent and Acquirer Sub pursuant to the Scheme; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) subject to the terms of this Agreement (including
<U>Section</U><U></U><U>&nbsp;7.2</U> hereof) and the Scheme, afford all such cooperation and assistance as may reasonably be requested of it by the Company in respect of the preparation and verification of any document or in connection with any
Clearance or confirmation required for the implementation of the Scheme, including the provision to the Company in a timely manner of such information and confirmations relating to it, its Subsidiaries and any of its or their respective directors or
employees as the Company may reasonably request (including for the purposes of preparing the Scheme Document); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) assume responsibility
for the information relating to it or any of its Subsidiaries contained in the Scheme Document, the Proxy Statement or any other document sent to the Company Shareholders or filed with the Irish High Court or in any announcement issued in connection
with the Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) review and provide comments (if any) in a reasonably timely manner on the Scheme
Document, the Proxy Statement or any other document to be sent to the Company Shareholders or filed with the Irish High Court in connection with the Transaction submitted to it by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) to the extent that clearance of the Proxy Statement or the Scheme Document by the Irish Takeover Panel might require that waivers or
derogations in respect of the Takeover Rules be sought and obtained from the Irish Takeover Panel in relation to matters that relate to Parent and/or any of its Concert Parties, make a submission for (and use reasonable best efforts to have
approved) such waiver or derogation as promptly as practicable after having provided the Company with a reasonable opportunity to review and comment on such submission and considering in good faith such comments; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) as promptly as practicable, notify the Company of any other matter of which it becomes aware which would reasonably be expected to
materially delay or prevent filing of the Proxy Statement or the Scheme Document with the SEC and the Irish Takeover Panel, as applicable, or implementation of the Scheme, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Mutual Responsibilities of the Parties</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If any of the Parties becomes aware of any information that, pursuant to the Irish Takeover Rules, the Irish Companies Act, the Securities
Act or the Exchange Act, should be disclosed in an amendment or supplement to the Scheme Document or the Proxy Statement, then such Party shall promptly inform the other Party thereof and the Parties shall cooperate with each other in submitting or
filing such amendment or supplement with the Irish Takeover Panel, the SEC or the Irish High Court, as applicable, and, if required, in sending such amendment or supplement to the Company Shareholders and, for information only, if required, to the
Company Equity Award Holders. Each of the Parties agrees to promptly (i)&nbsp;correct any information provided by it specifically for inclusion or incorporation by reference in the Scheme Document or the Proxy Statement, as applicable, if and to the
extent that such information shall have become false or misleading in any material respect and (ii)&nbsp;supplement the information provided by it specifically for inclusion or incorporation by reference in the Scheme Document or the Proxy
Statement, as applicable, to include any information that shall become necessary in order to make the statements in the Scheme Document or the Proxy Statement, as applicable, in light of the circumstances under which they were made, not misleading.
The Company further agrees to cause the Scheme Document or the Proxy Statement, as applicable, as so corrected or supplemented promptly to be filed with the Irish Takeover Panel and the SEC and to be sent to the Company Shareholders and for
information only, if required, to the Company Equity Award Holders, in each case as and to the extent required by applicable Laws. For purposes of this <U>Section</U><U></U><U>&nbsp;3.3(a)</U>, any information concerning the Company Group will be
deemed to have been provided by the Company, and any information concerning the Parent Group will be deemed to have been provided by Parent or Acquirer Sub. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Party shall provide the other Party with reasonable prior notice of any proposed
material oral communication with the SEC, the Irish Takeover Panel or the Irish High Court and, except to the extent prohibited by the SEC, the Irish Takeover Panel or the Irish High Court, afford the other Party reasonable opportunity to
participate therein, other than with respect to any such communication to the extent related to a Company Alternative Proposal or the termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Party shall promptly provide to each other Party, on request, a copy of any record, memorandum, agreement, contract, notice,
certificate, article, letter, email, written communication, presentation, report, valuation, written consent or other document within the Party&#146;s possession or power of procurement, which that other Party is required to publish on a website
pursuant to the Irish Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Dealings with the Irish Takeover Panel</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Parties will (x)&nbsp;give the other reasonable prior notice of any proposed meeting or material substantive discussion or
correspondence between it or its Representatives with the Irish Takeover Panel, or any amendment to be proposed to the Scheme in connection therewith, and, except to the extent any such correspondence relates to a Company Alternative Proposal or the
termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, afford the other reasonable opportunities to review and make comments and suggestions with respect to the same and consider in good faith such
comments and suggestions, and (y)&nbsp;except to the extent any such meeting, discussion, correspondence or submission relates to a Company Alternative Proposal or the termination of this Agreement pursuant to and in accordance with
<U>Section</U><U></U><U>&nbsp;9</U>, keep the other reasonably informed of all such meetings, discussions or correspondence that it or its Representative(s) have with the Irish Takeover Panel and not participate in any meeting or discussion with the
Irish Takeover Panel concerning this Agreement or the Transactions unless it consults with the other Party in advance, and, unless prohibited by the Irish Takeover Panel, gives such other Party the opportunity to attend and provide copies of all
written submissions it makes to the Irish Takeover Panel and copies (or, where verbal, a verbal or written summary of the substance) of the Irish Takeover Panel responses thereto <I>provided</I> always that any correspondence or other information
required to be provided under this <U>Section</U><U></U><U>&nbsp;3.4</U> may be redacted: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to remove references concerning the
valuation of the businesses of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to prevent the exchange of confidential information as required by applicable Laws
(<I>provided</I> that the redacting Party shall use its reasonable best efforts to cause such information to be provided in a manner that would not result in such confidentiality concerns); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) as necessary to address reasonable privilege concerns (<I>provided</I> that the redacting Party shall use its reasonable best efforts
to cause such information to be provided in a manner that would not result in such privilege concerns). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company undertakes, if so reasonably requested by Parent to, as promptly as
reasonably practicable, provide its written consent to Parent and to the Irish Takeover Panel in respect of any application made by Parent to the Irish Takeover Panel: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to redact any commercially sensitive or confidential information specific to Parent&#146;s financing arrangements for the Acquisition
(&#147;<B><I>Parent Financing Information</I></B>&#148;) from any documents that Parent is required to publish on a website pursuant to Rule 26.3(v)(b)(xi) of the Irish Takeover Rules; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) for a derogation from the requirement under the Irish Takeover Rules to disclose Parent Financing Information in the Scheme Document,
any supplemental document or other document sent to the Company Shareholders or the Company Equity Award Holders pursuant to the Irish Takeover Rules; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) for a derogation from Rule 16.1 or 20.1 of the Irish Takeover Rules to permit Parent to implement, and to pay fees to lenders in
connection with, its Financing and syndication arrangements with respect to its Financing, and to provide information to lenders and prospective lenders on such terms as the Irish Takeover Panel may permit; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) for a derogation from the disclosure requirements of Rule 24.4 of the Irish Takeover Rules, seeking consent to the aggregation of
dealings for purposes of disclosure in the Scheme Document and seeking consent to the aggregation on a <FONT STYLE="white-space:nowrap">bi-weekly</FONT> basis of changes in information announced pursuant to Rule 2.12 of the Irish Takeover Rules.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent undertakes, if so requested by the Company to, as promptly as practicable, provide its written consent to the Company and to
the Irish Takeover Panel in respect of any application made by the Company to the Irish Takeover Panel (i)&nbsp;to permit entering into and effecting the equity, retention, bonus and/or benefit arrangements contemplated by Section&nbsp;5.1 of the
Company Disclosure Schedule, and (ii)&nbsp;with respect to any matter set forth on Section&nbsp;5.1 of the Company Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to the terms and conditions of this Agreement, Parent and the Company undertake, if so requested by the other Party to, as
promptly as reasonably practicable, issue its written consent to the other Party and to the Irish Takeover Panel in respect of any application reasonably requesting any derogation, permission or consent from the Irish Takeover Panel in connection
with the Irish Takeover Rules, which consent shall also constitute consent for all purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the
foregoing provisions of this <U>Section</U><U></U><U>&nbsp;3.4</U>, neither the Company nor Parent shall be required to take any action pursuant to the foregoing provisions (a)&nbsp;through (d) if such action is prohibited by the Irish Takeover
Panel (unless the Irish Takeover Panel decision is successfully appealed by either the Company or Parent). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Nothing in this Agreement
shall in any way limit the Parties&#146; obligations under the Irish Takeover Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>No Scheme Amendment by the Company</B>. Except as required by applicable Laws,
the Irish High Court and/or the Irish Takeover Panel, and, where applicable, with the consent of the Irish High Court and/or the Irish Takeover Panel, the Company shall not take any of the following actions after sending the Scheme Document to the
Company Shareholders, in each case, without the prior written consent of Parent (such consent not to unreasonably withheld, conditioned or delayed): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) amend the Scheme; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
adjourn or postpone (or propose an adjournment or postponement of) the Scheme Meeting or the EGM; <I>provided</I>, <I>however</I>, that the Company may, without the consent of, but after consultation with, Parent, adjourn or postpone (or propose to
adjourn or postpone) the Scheme Meeting or EGM if (i)&nbsp;in the case of adjournment, such adjournment was requested by the Company Shareholders (but only to the extent the proposal for such adjournment was not proposed by the Company or any of its
Affiliates or their respective Representatives), (ii) reasonably necessary to ensure that any required supplement or amendment to the Scheme Document or Proxy Statement is provided to the Company Shareholders or to permit dissemination of
information which is material to the Company Shareholders voting at the Scheme Meeting or the EGM (but only for so long as the Company Board determines in good faith, after having consulted with outside counsel, as is reasonably necessary or
advisable to give the Company Shareholders sufficient time to evaluate any such disclosure or information), or (iii)&nbsp;as of the time the Scheme Meeting or EGM is scheduled (as set out in the Scheme Document or Proxy Statement), there are
insufficient Company Shares represented (either in person or by proxy)&nbsp;(A) to constitute a quorum necessary to conduct the business of the Scheme Meeting or the EGM (but only until a meeting can be held at which there are a sufficient number of
Company Shares represented to constitute a quorum) or (B)&nbsp;voting for the approval of the applicable Resolutions (but only until a meeting can be held at which there are a sufficient number of votes of the Company Shareholders to approve the
applicable Resolutions); <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, other than any adjournments or postponements required by applicable Laws, including adjournments or postponements to the extent reasonably necessary or
advisable to ensure that any required supplement or amendment to the Proxy Statement is provided or made available to the Company Shareholders or to permit dissemination of information which is material to shareholders voting at the Scheme Meeting
and EGM and to give the Company Shareholders sufficient time to evaluate any such supplement or amendment or other information, no such adjournment or postponement pursuant to <U>clause (i)</U>&nbsp;or (<U>iii)</U> shall, without the prior written
consent of Parent (such consent not to be unreasonably withheld, conditioned or delayed), be for a period exceeding 10 Business Days and the Company may not adjourn or postpone the Scheme Meeting or the EGM pursuant to <U>clause (i)</U>&nbsp;or
<U>(iii)</U> more than two times; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) amend the Resolutions (in each case, in the form set out in the Scheme Document). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B> <B>Switching to a Takeover Offer</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms of this <U>Section</U><U></U><U>&nbsp;3.6</U>, in the event that Parent reasonably determines that a competitive
situation (as that term is defined in the Irish Takeover Rules) exists or, based on facts known at the time, may reasonably be expected to arise in connection with the Acquisition, Parent may elect (subject to receiving the Irish Takeover
Panel&#146;s consent, if required) to implement the Acquisition by way of the Takeover Offer (rather than the Scheme), whether or not the Scheme Document has been posted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If Parent elects to implement the Acquisition by way of the Takeover Offer, the Company
undertakes to provide Parent and its Representatives as promptly as reasonably practicable with all such information about the Company Group (including directors and their connected persons) as may reasonably be required for inclusion in the
Takeover Offer Document and to provide all such other assistance as may reasonably be required by the Irish Takeover Rules in connection with the preparation of the Takeover Offer Document, including reasonable access to, and ensuring the provision
of reasonable assistance by, its management and Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If Parent elects to implement the Acquisition by way of a Takeover
Offer, the Company agrees: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) that the Takeover Offer Document will contain provisions consistent with the terms and conditions set out
in the Rule 2.7 Announcement, the relevant Conditions and such other further terms and conditions as agreed (including any modification thereto) between Parent and the Irish Takeover Panel; <I>provided</I>, <I>however</I>, that the terms and
conditions of the Takeover Offer shall be at least as favorable to the Company Shareholders and the Company Equity Award Holders as those which would apply in relation to the Scheme (except for the 80% acceptance condition contemplated by paragraph
9 of the Conditions); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to reasonably <FONT STYLE="white-space:nowrap">co-operate</FONT> and consult with Parent in the preparation
of the Takeover Offer Document or any other document or filing which is required for the purposes of implementing the Acquisition; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) that, subject to the obligations of the Company Board under the Irish Takeover Rules, and unless the Company Board has made a Company
Change of Recommendation pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;5.2</U>, the Takeover Offer shall incorporate a recommendation to the Company Shareholders from the Company Board to accept the Takeover Offer and such
recommendation shall not subsequently be withdrawn, adversely modified or qualified except as contemplated by <U>Section</U><U></U><U>&nbsp;5.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If Parent elects to implement the Acquisition by way of the Takeover Offer in accordance with <U>Section</U><U></U><U>&nbsp;3.6(a)</U>,
the Parties mutually agree: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to prepare and file with, or submit to, the SEC, the Irish Takeover Panel and the Irish High Court, all
documents, amendments and supplements required to be filed therewith or submitted thereto pursuant to the Irish Takeover Rules, the Securities Act, the Exchange Act, or otherwise by applicable Laws in connection with the Takeover Offer and to make
any applications or initiate any appearances as may be required by or desirable to the Irish High Court for the purpose of discontinuing, cancelling or terminating the Irish High Court proceedings initiated in connection with the Scheme and, unless
the Company Board has made a Company Change of Recommendation, each Party shall have reasonable opportunities to review and make comments on all such documents, amendments and supplements and, following good faith consideration of such comments by
the other Party and approval of such documents, amendments and supplements by the other Party, which approval shall not be unreasonably withheld, conditioned or delayed, file or submit, as the case may be, such documents, amendments and supplements
with or to the SEC, the Irish Takeover Panel and the Irish High Court (as applicable); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to provide the other Party with any comments received from the SEC, the Irish Takeover
Panel or the Irish High Court on any documents filed by it with the SEC, the Irish Takeover Panel or the Irish High Court promptly after receipt thereof, other than with respect to any such documents to the extent related to a Company Alternative
Proposal; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to provide the other Party with reasonable prior notice of any proposed material oral communication with the SEC,
the Irish Takeover Panel or the High Court and, except to the extent prohibited by the SEC, the Irish Takeover Panel or the High Court, afford the other Party reasonable opportunity to participate therein, other than with respect to any such
communication to the extent related to a Company Alternative Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If the Takeover Offer is consummated, Parent shall cause
Acquirer Sub (or their respective designees) to effect as promptly as practicable, following it becoming entitled under the Irish Companies Act to do so, a compulsory acquisition of any Company Shares under Section&nbsp;457 of the Irish Companies
Act not acquired in the Takeover Offer for the same consideration per share as provided for in the Takeover Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) For clarity and
except as may be required by the Irish Takeover Rules (and without limiting any other provision of this Agreement), nothing in this <U>Section</U><U></U><U>&nbsp;3.6</U> shall require the Company to provide Parent with any information with respect
to, or to otherwise take or fail to take any action in connection with the Company&#146;s consideration of or response to, any actual or potential Company Alternative Proposal. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;4. EQUITY AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>The Company Equity Awards</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Company Options</B>. Each Company Option that is outstanding as of immediately prior to the Effective Time (whether or not vested)
shall, as of the Effective Time, by virtue of the occurrence of the Effective Time and without any further action on the part of the holder thereof, Parent, or the Company, be canceled and converted into the right to receive cash, without interest,
in an amount equal to the product of (i)&nbsp;the total number of Company Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii)&nbsp;the excess of (A)&nbsp;the Consideration over (B)&nbsp;the exercise
price payable per Share under such Company Option, which amount shall be paid in accordance with <U>Section</U><U></U><U>&nbsp;8.2</U> (the &#147;<B><I>Option Consideration</I></B>&#148;). No holder of a Company Option that has an exercise price per
Share that is equal to or greater than the Consideration shall be entitled to any payment with respect to any such canceled Company Option before or after the Effective Time, and any such Company Option shall be canceled and shall cease to exist as
of the Effective Time and no consideration shall be delivered in exchange therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Company Share Awards</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each Company RSU Award that is outstanding as of immediately prior to the Effective Time (whether or not vested) shall, by virtue of the
occurrence of the Effective Time and without any further action on the part of the holder thereof, Parent, or the Company (A)&nbsp;if granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of the Company Board or held by a person
who, as of the Completion Date, is a former service-provider of the Company, be canceled and converted into the right to receive a cash, without interest, amount equal to (w)&nbsp;the total number of Company Shares subject to such Company RSU Award
immediately prior to the Effective Time <U>multiplied by</U> (x)&nbsp;the Consideration, which amount shall be paid in accordance with <U>Section</U><U></U><U>&nbsp;8.2</U> (the &#147;<B><I>RSU Cash Consideration</I></B>&#148;) and (B)&nbsp;if not
granted to an individual described in <U>clause (A)</U>, be canceled and converted into a restricted stock unit (each, a &#147;<B><I>Parent RSU</I></B>&#148;) denominated in shares of common stock, $0.0001 par value, of Parent (&#147;<B><I>Parent
Common Stock</I></B>&#148;). The number of shares of Parent Common Stock subject to each such Parent RSU shall be equal to the product (rounded down to the nearest whole number) of (y)&nbsp;the number of shares of Company Shares subject to such
Company RSU Award immediately prior to the Effective Time <U>multiplied by</U> (z)&nbsp;the Equity Award Exchange Ratio. Except as specifically provided above, following the Effective Time, each such Parent RSU shall continue to be governed by the
same terms and conditions (including vesting terms) as were applicable to the applicable Company RSU Award immediately prior to the Effective Time. For purposes of this Agreement, the term &#147;<B><I>Equity Award Exchange Ratio</I></B>&#148; means
(1)&nbsp;the Consideration <I>divided by </I>(2)&nbsp;the volume weighted average of the per share closing<B> </B>price of Parent Common Stock on the Nasdaq (as reported in the Eastern Edition of <I>The Wall Street Journal</I> or, if not reported
thereby, another authoritative source) for five (5)&nbsp;trading days ending on the second Business Day prior to the Completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
Each Company PSU Award that is outstanding as of immediately prior to the Effective Time (whether or not vested) shall by virtue of the occurrence of the Effective Time without any further action on the part of the holder thereof, Parent, or the
Company be canceled and converted into the right to receive a cash amount, without interest, equal to (A)&nbsp;the total number of Company Shares issuable in settlement of such Company PSU Award as set forth below (&#147;<B><I>PSU
Achievement</I></B>&#148;) multiplied by (B)&nbsp;the Consideration, which amount shall be paid in accordance with <U>Section</U><U></U><U>&nbsp;8.2</U> (the &#147;<B><I>P</I></B><B><I>SU Consideration</I></B>&#148;). PSU Achievement shall be
determined in accordance with the terms of the applicable Company PSU Award, as determined by the Company Board or the compensation committee of the Company Board prior to the Effective Time, in consultation with, but not subject to the approval of,
Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Further Actions</B>. Prior to the Effective Time, the Company Board (or, if appropriate, any committee thereof
administering the Company Share Plans) shall take all actions, including by adopting any resolutions, obtaining any consents or approvals or otherwise, reasonably necessary to effectuate the transactions contemplated by this
<U>Section</U><U></U><U>&nbsp;4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Amendment of Articles</B>. The Company shall procure that a special resolution be
proposed to the Company Shareholders at the EGM proposing that the Company Memorandum and Articles of Association be amended so that any Company Shares allotted following Scheme Record Time will either be subject to the terms of the Scheme or
acquired by Parent for the same consideration per Company Share as shall be payable to the Company Shareholders under the Scheme (depending upon the timing of such allotment); <I>provided</I>, <I>however</I>, that nothing in such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendment to the Company Memorandum and Articles of Association shall prohibit the sale (whether on a stock exchange or otherwise) of any Company Shares issued on the exercise of Company Options
or vesting or settlement of Company Share Awards, as applicable, following the EGM but prior to the Scheme Record Time approved by the Irish High Court, it being always acknowledged that each and every Company Share will be bound by the terms of the
Scheme. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;5. THE COMPANY CONDUCT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Conduct of Business by the Company</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From the date of this Agreement until the earlier of the Completion and termination of this Agreement pursuant to and in accordance with
<U>Section</U><U></U><U>&nbsp;9</U>, except (w)&nbsp;as prohibited or required by applicable Laws, including Irish Takeover Rules or Nasdaq rules, (x)&nbsp;for any necessary or advisable actions taken in good faith to comply with or implement
applicable local <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures, (y)&nbsp;as set out in Section&nbsp;5.1 or 7.4(f) of the Company Disclosure Schedule, or (z)&nbsp;as otherwise required or expressly contemplated by this Agreement, unless
Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts (1)&nbsp;to conduct its
business in the ordinary course of business and (2)&nbsp;to preserve intact its business organization and relationships with significant customers, suppliers, licensors, licensees and other Third Parties and keep available the services of its
present officers and employees (without any obligation to put in place any retention program); <I>provided</I>, <I>however</I>, that no action taken by the Company or its Subsidiaries with respect to matters explicitly permitted by an exception to
any of <U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U> through <U>(xviii)</U>&nbsp;will be a breach of this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting
the generality of the foregoing, from the date of this Agreement until the earlier of the Completion and termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, except (A)&nbsp;as prohibited or required
by applicable Laws, including Irish Takeover Rules or Nasdaq rules, (B)&nbsp;as set out in Section&nbsp;5.1 of the Company Disclosure Schedule, or (C)&nbsp;as otherwise required or expressly contemplated by this Agreement, without Parent&#146;s
prior written consent (which shall not be unreasonably withheld, conditioned or delayed), the Company shall not, and shall cause each of its Subsidiaries not to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) in the case of the Company and each of its Subsidiaries, amend its Organizational Documents other than, with respect to each Subsidiary,
amendments to Organizational Documents that would not prohibit or hinder, impede or delay or otherwise adversely impact the consummation of the Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) (A) subject to the provisions in<I> </I><U>Section</U><U></U><U>&nbsp;5.2</U>, merge or consolidate with any other Person, or acquire
(including by merger, consolidation, or acquisition of stock or assets), directly or indirectly, any interest in any corporation, partnership, other business organization or any division or business thereof or any assets, securities or property that
(in the case of such assets, securities or property) constitute all or a material portion of such Person or any division or business thereof, other than transactions (x)&nbsp;solely among the Company and one or more of its wholly owned Subsidiaries
or (y)&nbsp;solely among the Company&#146;s direct and indirect wholly owned Subsidiaries, or (B)&nbsp;adopt a plan of complete or partial liquidation, dissolution, recapitalization or restructuring, other than a liquidation or dissolution of any of
the Company&#146;s immaterial wholly owned Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) (A) split, combine or reclassify any shares of its capital stock (other than
transactions (1)&nbsp;solely among the Company and one or more of its wholly owned Subsidiaries or (2)&nbsp;solely among the Company&#146;s wholly owned Subsidiaries), (B) amend any term or alter any rights of any of its outstanding Equity
Securities, (C)&nbsp;declare, set aside or pay any dividend or make any other distribution (whether in cash, stock, property or any combination thereof) in respect of any Equity Securities, other than dividends or distributions by a Subsidiary of
the Company to the Company or a wholly owned Subsidiary of the Company or (D)&nbsp;redeem, repurchase, cancel or otherwise acquire or offer to redeem, repurchase, or otherwise acquire any of its Equity Securities or any Equity Securities of any
Subsidiary of the Company, other than (x)&nbsp;repurchases or withholding of Company Shares in connection with the exercise of Company Options or the vesting or settlement of Company Share Awards (including in satisfaction of any amounts required to
be deducted or withheld under applicable Laws) in accordance with the terms of such Company Equity Awards outstanding as of the date of this Agreement (in accordance with their existing terms as of the date of this Agreement) or granted after the
date of this Agreement (to the extent permitted by Section&nbsp;5.1 of the Company Disclosure Schedule) and (y)&nbsp;transactions among the Company and its wholly owned Subsidiaries or among the Company&#146;s wholly owned Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) issue, deliver or sell, or authorize the issuance, delivery or sale of, any Equity Securities, other than (A)&nbsp;the issuance of
Company Equity Awards permitted by Section&nbsp;5.1 of the Company Disclosure Schedule, the issuance of any Company Shares upon the exercise of Company Options, the issuance of any Company Shares in connection with any offering period in existence
under the Company ESPP, the vesting or settlement of Company Share Awards, or the withholding of Company Shares to satisfy Tax obligations pertaining to the exercise of Company Options or the vesting or settlement of Company Equity Awards or to
satisfy the exercise price, subject to applicable Law, with respect to Company Options or to effectuate an optionee direction upon exercise of Company Options that, in each case, are (x)&nbsp;outstanding as of the date of this Agreement and in
accordance with the terms of the Company ESPP or Company Equity Awards (as applicable) in existence as of the date of this Agreement, or (y)&nbsp;granted after the date of this Agreement (to the extent permitted by Section&nbsp;5.1 of the Company
Disclosure Schedule), or (B)&nbsp;in connection with transactions (1)&nbsp;solely among the Company and one or more of its wholly owned Subsidiaries or (2)&nbsp;solely among the Company&#146;s wholly owned Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) except as otherwise permitted under <U>Section</U><U></U><U>&nbsp;5.1(b)(iv)</U>, (A)&nbsp;establish, adopt, terminate or materially
amend any Employee Agreement or Employee Plan (or any plan, program, or practice that would be an Employee Agreement or an Employee Plan if it were in existence on the date of this Agreement), (B) increase in any manner the compensation or
consulting fees, bonus, pension, welfare, fringe or other benefits, severance or termination pay of any employee of the Company or any of its Subsidiaries, (C)&nbsp;amend or waive any of its rights under, or accelerate the vesting under, any
provision of any Employee Agreement or any of the material Employee Plans (or any plan, program, arrangement, practice or agreement that would be an Employee Agreement or an Employee Plan if it were in existence on the date of this Agreement),
(D)&nbsp;materially change any actuarial or other assumptions used to calculate funding obligations with respect to any Employee Plan or Employee Agreement that is required by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Law to be funded or change the manner in which contributions to such plans are made or the basis on which such contributions are determined or (E)&nbsp;forgive any loans or issue any
loans (other than routine travel advances or other routine business expenses issued or incurred in the ordinary course of business) to any employee of the Company or any of its Subsidiaries, except as may be required by GAAP, except that the Company
Group may: (1)&nbsp;make annual or quarterly bonus or commission payments for completed periods of performance based on actual performance in the ordinary course of business consistent with past practice, including bonus or commission payments
pursuant to existing bonus or commission plans or Contracts and payments to employees; and (2)&nbsp;establish annual or quarterly commission or incentive compensation plans for employee sales force in the ordinary course of business consistent with
past practice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) except as required pursuant to the terms of an existing Employee Plan or Employee Agreement, (A)&nbsp;enter into
(1)&nbsp;any change-of-control agreement with any executive officer, employee, director or independent contractor or (2)&nbsp;any retention agreement with any executive officer, employee, director or independent contractor, (B)&nbsp;enter into any
employment or other agreement providing for severance or termination benefits (1)&nbsp;that are more favorable than the severance or termination benefits provided by the severance plans or agreements in existence as of the date of this Agreement or
(2)&nbsp;to any executive officer, director or <FONT STYLE="white-space:nowrap">non-executive</FONT> employee with an annual base salary greater than $250,000 or any consulting agreement with an independent contractor who is a natural Person with an
annual base compensation greater than $250,000, (C)&nbsp;except to fill vacancies due to a voluntary resignation, hire any executive officer, director or <FONT STYLE="white-space:nowrap">non-executive</FONT> employee with an annual base salary in
excess of $250,000 or (D)&nbsp;terminate the employment of any executive officer or <FONT STYLE="white-space:nowrap">non-executive</FONT> employee with the title of vice president or higher, other than for cause; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) make or authorize any capital expenditure that exceeds the amounts set out for the respective periods set forth in paragraph 19 of
Section&nbsp;5.1 of the Company Disclosure Schedule; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) (A)&nbsp;acquire any assets or properties (including Intellectual Property),
or (B)&nbsp;sell or otherwise dispose of, divest or <FONT STYLE="white-space:nowrap">spin-off,</FONT> transfer, or assign any assets or properties (other than Intellectual Property, which is addressed in
<U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U>), except (1)&nbsp;sale of the Company Group products in the ordinary course of business, (2)&nbsp;assets or properties otherwise permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)(vii)</U>,
(3)&nbsp;pursuant to dispositions of obsolete, surplus or worn out assets that are no longer useful in the conduct of the business of the Company Group, (4)&nbsp;purchases of components, raw materials, drug product, inventory, marketing materials or
equipment or other materials and supplies with respect to the Company&#146;s operations, drug product manufacturing, supply chain, marketing strategy or research and development, in each case, in the ordinary course of business,
(5)&nbsp;intercompany assignment of assets or properties, (6)&nbsp;to the extent not in excess of $20,000,000 in the aggregate, or (7)&nbsp;as permitted under <U>clause (vii)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) sell, divest, transfer, assign, license, sublicense, grant a covenant not to assert with respect to, create or incur any Lien (other
than a Permitted Lien) on, or otherwise abandon, cancel, let lapse or dispose of, any material Company Intellectual Property, except (A)&nbsp;solely between or among the Company Group; (B)&nbsp;with respect to applications of Registered IP, in the
ordinary course of prosecution in the United States Patent and Trademark Office, United States Copyright Office, and foreign equivalents thereof, and (C)&nbsp;entry into (1)&nbsp;Standard Contracts or
<FONT STYLE="white-space:nowrap">(2)&nbsp;non-exclusive</FONT> license agreements, or the creation or incurrence of mortgages, liens, pledges, charges or security interests, in each case, in the ordinary course of business consistent with past
practice; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) except for intercompany loans and capital contributions and sales commission advances
made in the ordinary course of business consistent with past practice, lend money or make capital contributions or advances to or make investments in, any Person, or incur or guarantee any Indebtedness (including the issuance of any debt securities,
warrants or other rights to acquire any debt security but except for short-term borrowings of not more than $15,000,000 in the aggregate, incurred in the ordinary course of business consistent with past practice and advances to employees and
consultants for travel and other business related expenses in the ordinary course of business consistent with past practice); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi)
commence any Legal Proceeding, except with respect to: (A)&nbsp;routine matters in the ordinary course of business (including patent infringement related to generic product filings); (B)&nbsp;such cases where the Company reasonably determines in
good faith that the failure to commence suit would result in a material impairment of a valuable aspect of its business (<I>provided</I> that the Company consults with Parent and considers the views and comments of Parent with respect to such Legal
Proceedings prior to commencement thereof); or (C)&nbsp;a breach of this Agreement or any other agreements contemplated hereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii)
except as set forth in <U>Section</U><U></U><U>&nbsp;7.10</U>, settle, release, waive or compromise, or offer or propose to settle, release, waive or compromise, any Legal Proceeding or other claim (or threatened Legal Proceeding or other claim),
other than (A)&nbsp;any Legal Proceeding relating to a breach of this Agreement or any other agreements contemplated hereby, or (B)&nbsp;a settlement that results solely in a monetary obligation involving only the payment of monies (without the
admission of wrongdoing) by the Company Group of not more than $2,000,000 individually or $10,000,000 in the aggregate (net of insurance proceeds) and that does not involve any license, cross license or similar agreement with respect to rights to
Intellectual Property; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) create or incur any Lien (other than a Permitted Lien) on any material assets or properties (other than
Intellectual Property, which is addressed in <U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U>) other than (A)&nbsp;Liens created or incurred in the ordinary course of business consistent with past practice or (B)&nbsp;Liens that may be discharged at or
prior to the Completion that are not material in amount or effect on the business of the Company Group; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) (A) enter into any
Material Contract other than in the ordinary course of business consistent with past practice (<I>provided</I>, that no Contract of the type described in <U>Sections 6.1(j)(ii)</U>, <U>6.1(j)(v)</U> or <U>6.1(j)(xiv)</U> shall be entered into
without the prior written consent of Parent (which shall not be unreasonably withheld, conditioned or delayed)) or (B)&nbsp;terminate, renew, extend or in any material respect modify or amend (including waiving, releasing or assigning any material
right or claim thereunder) any Material Contract, other than in the ordinary course of business consistent with past practice;<I> provided</I>, that, for purposes of this <U>Section</U><U></U><U>&nbsp;5.1(b)(xiv)</U>, &#147;Material Contracts&#148;
shall include any Company Contract that requires by its terms the payment or delivery of cash or other consideration by or to a member of the Company Group in an amount having an expected value in excess of $25,000,000 in any single fiscal year
after 2022; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) make any material change in any method of financial accounting or financial accounting
principles or practices, except for any such change required by reason of (or, in the reasonable good-faith judgment of the Company, advisable under) a change in GAAP or applicable Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi) (A) make, change or revoke any material Tax election; (B)&nbsp;adopt or change any material method of Tax accounting; (C)&nbsp;enter
into any material &#147;closing agreement&#148; within the meaning of Section&nbsp;7121 of the Code (or any similar provision of state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law) with respect to Taxes; (D)&nbsp;settle,
compromise or surrender any material Tax claim, audit or assessment for an amount in excess of reserves therefor on the financial statements of the Company and its Subsidiaries; (E)&nbsp;file any material amended Tax Return; (F)&nbsp;affirmatively
surrender any right to claim a material Tax refund; or (G)&nbsp;take or cause any action which may reasonably be expected to cause the representations set forth in <U>Section</U><U></U><U>&nbsp;6.1(p)(vi)</U>&nbsp;or
<U>Section</U><U></U><U>&nbsp;6.1(p)(vii)</U> to be untrue; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvii) enter into any collective bargaining agreement or other agreement
with any labor organization or recognize or certify any labor union, works council or other labor organization as the bargaining representative for any employees of any member of the Company Group; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xviii) agree, commit or propose to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, nothing contained herein shall give to Parent or Acquirer Sub, directly or indirectly, rights to control or direct the
operations of the Company Group prior to the Effective Time. Prior to the Effective Time, the Company and each of the members of the Company Group shall exercise, consistent with the terms and conditions hereof, complete control and supervision of
their respective operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and Company Change of
Recommendation</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>No Solicitation or Negotiation</B>. Subject to any actions which the Company is required to take so as to
comply with the requirements of the Irish Takeover Rules, from the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, except as
otherwise set out in this <U>Section</U><U></U><U>&nbsp;5.2</U>, the Company shall not, and it shall cause its Subsidiaries and its and their respective directors, officers and employees not to, and it shall use reasonable best efforts to cause its
and its Subsidiaries&#146; other Representatives not to, directly or indirectly: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) solicit, initiate or take any action to knowingly
facilitate or knowingly encourage (including by way of furnishing information to any Person in connection with) the submission of any Company Alternative Proposal or any indication, proposal or inquiry that would reasonably be expected to lead to a
Company Alternative Proposal; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) enter into, continue or participate in any discussions or negotiations with, furnish any <FONT
STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries to, or afford access to the business, properties, assets, personnel, books or records of the Company or any of its Subsidiaries to, otherwise
cooperate in any way with, or knowingly assist, participate in, knowingly facilitate or knowingly encourage any effort by, any Third Party that would reasonably be expected to seek to make, or has made, a Company Alternative Proposal or any
indication, proposal or inquiry that would reasonably be expected to lead to a Company Alternative Proposal (except to notify such Person as to the existence of the provisions of this <U>Section</U><U></U><U>&nbsp;5.2</U>); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) (A) withdraw or qualify, amend or modify in any manner adverse to Parent, the Scheme
Recommendation or the recommendation contemplated by <U>Section</U><U></U><U>&nbsp;3.6(b)</U>, if applicable, (B)&nbsp;fail to include the Scheme Recommendation in the Scheme Document or the Proxy Statement, (C)&nbsp;recommend, adopt or approve or
publicly propose to recommend, adopt or approve any Company Alternative Proposal or (D)&nbsp;fail to reaffirm the Scheme Recommendation in a statement complying with Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or Rule <FONT
STYLE="white-space:nowrap">14e-2(a)</FONT> under the Exchange Act with regard to a Company Alternative Proposal or in connection with such action by the close of business on the 10th Business Day after the commencement of such Company Alternative
Proposal under Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> (<U>clauses (A)</U>&nbsp;through <U>(D)</U> of the foregoing in this <U>clause (iii)</U>, a <I>&#147;</I><B><I>Company Change
of Recommendation</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) take any action to make any &#147;moratorium,&#148; &#147;control share acquisition,&#148;
&#147;fair price,&#148; &#147;supermajority,&#148; &#147;affiliate transactions&#148; or &#147;business combination statute or regulation&#148; or other similar anti-takeover laws and regulations under applicable Laws inapplicable to any Third Party
or any Company Alternative Proposal; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) waive or release any Person from any standstill agreement or any standstill provisions of any
Contract entered into in respect of a Company Alternative Proposal; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) enter into any agreement in principle, letter of intent,
term sheet, merger agreement, acquisition agreement, option agreement or other agreement providing for or relating to a Company Alternative Proposal (other than a Company Alternative Proposal NDA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing contained herein shall prevent the Company Board from (x)&nbsp;complying with Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> or
Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> under the Exchange Act with regard to a Company Alternative Proposal, so long as any action taken or statement made to so comply is consistent with this <U>Section</U><U></U><U>&nbsp;5.2</U> or
(y)&nbsp;making any required disclosure to the Company Shareholders if the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent
with applicable Laws; <I>provided</I> that any Company Change of Recommendation involving or relating to a Company Alternative Proposal may only be made in accordance with <U>Sections 5.2(b)</U>, <U>5.2(c)</U>, <U>5.2(d)</U> and <U>5.2(e)</U>. For
clarity, a &#147;<I>stop, look and listen</I>&#148; disclosure or similar communication of the type contemplated by Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> under the Exchange Act shall not constitute a Company Change of Recommendation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Company shall, and shall cause its Subsidiaries and its and their respective directors, officers and employees to, and
shall use reasonable best efforts to cause its and its Subsidiaries&#146; other Representatives to, cease immediately and cause to be terminated any and all existing activities, discussions or negotiations, if any, with any Third Party conducted
prior to the date of this Agreement with respect to any Company Alternative Proposal or with respect to any indication, proposal or inquiry that would reasonably be expected to lead to a Company Alternative Proposal. The Company will promptly (and
in each case within 36 hours from the date of this Agreement) request from each Person (and such Person&#146;s Representatives) that has executed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a confidentiality agreement during the past six months in connection with its consideration of a Company Alternative Proposal to return or destroy (as provided in the terms of such applicable
confidentiality agreement) all confidential information concerning the Company or any of its Subsidiaries and shall promptly (and in each case within 36 hours from the date of this Agreement) terminate all physical and electronic data access
previously granted to each such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Responding to Company Alternative Proposals</B>. Notwithstanding
<U>Section</U><U></U><U>&nbsp;5.2(a)</U>, if at any time prior to the receipt of the Company Shareholder Approval (the &#147;<B><I>Company Approval Time</I></B>&#148;) (and in no event after the Company Approval Time), the Company Board receives a
written Company Alternative Proposal made after the date of this Agreement which has not resulted from a breach in any material respect of this <U>Section</U><U></U><U>&nbsp;5.2</U>, the Company Board, directly or indirectly through its
Representatives, may (i)&nbsp;contact the Third Party that has made such Company Alternative Proposal in order to inform such Third Party of the terms of this <U>Section</U><U></U><U>&nbsp;5.2</U> and clarify the terms of such Company Alternative
Proposal for the sole purpose of the Company Board informing itself about such Company Alternative Proposal and such Third Party, and (ii)&nbsp;(x) engage in negotiations or discussions with any such Third Party that has made such an unsolicited
written Company Alternative Proposal, (y)&nbsp;furnish to such Third Party and its Representatives and financing sources nonpublic information relating to the Company or any of its Subsidiaries pursuant to a confidentiality agreement with terms that
are not materially less favorable in the aggregate to the Company than those contained in the Confidentiality Agreement (except that such confidentiality agreement need not contain a standstill or similar provision) and that does not include any
restrictions that prohibits the Company from satisfying its obligations contemplated by this <U>Section</U><U></U><U>&nbsp;5.2(b)</U> (such agreement, a &#147;<B><I>Company Alternative Proposal NDA</I></B>&#148;) <I>provided</I> that all such <FONT
STYLE="white-space:nowrap">non-public</FONT> information (to the extent that such information has not been previously provided or made available to Parent) is provided or made available to Parent, as the case may be, substantially concurrently with
the time it is provided or made available to such Third Party; <I>provided</I>, <I>further</I>, that prior to and as a condition of taking any actions described in this <U>Section</U><U></U><U>&nbsp;5.2(b)</U>, the Company Board determines in good
faith, after consultation with its financial advisor and outside legal counsel, that such Company Alternative Proposal either constitutes or would reasonably be expected to lead to a Company Superior Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B>Notice</B>. The Company shall notify Parent promptly (but in any event within 36 hours) if any Company Alternative Proposal, or any
indication, proposal or inquiry by a Third Party that would reasonably be expected to lead to a Company Alternative Proposal, is received by the Company. Each such notice shall be provided in writing and shall identify the Third Party making, and,
to the extent applicable, the material terms and conditions (including price) of, any such Company Alternative Proposal or any such indication, proposal or inquiry by a Third Party. Following such initial notice, the Company shall keep Parent
reasonably informed, on a reasonably current basis, of any material changes in the status and details of any such Company Alternative Proposal or any such indication, proposal or inquiry and shall promptly (but in no event later than 36 hours after
receipt) provide to Parent copies of all written proposals, offers or draft agreements relating to a Company Alternative Proposal. Neither the Company nor any of its Subsidiaries will enter into any agreement with any Person which prohibits the
Company from providing any information to Parent in accordance with, or otherwise complying with, this <U>Section</U><U></U><U>&nbsp;5.2</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B>Fiduciary Exception to the Company Change of Recommendation Provision</B>.
Notwithstanding anything to the contrary in this Agreement, but subject to <U>Section</U><U></U><U>&nbsp;5.2(e)</U>, prior to the Company Approval Time (and in no event after the Company Approval Time), the Company Board may (A)&nbsp;in response to
the receipt of a written Company Alternative Proposal received after the date hereof that did not result from a material breach of the Company&#146;s obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.2</U>, or in response to the
occurrence of a Company Intervening Event, make a Company Change of Recommendation, or (B)&nbsp;in response to the receipt of a written Company Alternative Proposal received after the date hereof that did not result from a material breach of the
Company&#146;s obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.2</U>, effect a Company Change of Recommendation and terminate this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;9.1(a)(ii)(B)</U> in order to substantially
concurrently enter into a definitive agreement providing for a Company Superior Proposal if, in each case of <U>clause (A)</U>&nbsp;and <U>clause (B)</U>, (x) in the case of such an action taken in connection with a Company Alternative Proposal, the
Company Alternative Proposal has not been withdrawn and the Company Board determines in good faith, after consultation with outside legal counsel and its financial advisor that such Company Alternative Proposal constitutes a Company Superior
Proposal and (y)&nbsp;the Company Board determines in good faith, after consultation with its financial advisor and outside legal counsel, that the failure to take such action would be inconsistent with its directors&#146; fiduciary duties under
applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B>Last Look</B>. The Company Board and the Company, as applicable, shall not take any of the actions contemplated
by <U>Section</U><U></U><U>&nbsp;5.2(d)</U> unless prior to taking such action (i)&nbsp;the Company has notified Parent, in writing at least four Business Days before taking such action, that the Company intends to take such action, which notice
attaches, in the case of a Company Change of Recommendation pursuant to <U>Section</U><U></U><U>&nbsp;5.2(d)(A)</U> in response to a Company Superior Proposal or the termination of this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;5.2(d)(B)</U> and <U>Section</U><U></U><U>&nbsp;9.1(a)(ii)(B)</U>, the most current version of each proposed Contract providing for or related to such Company Superior Proposal (including any Contract relating to
financing or expense reimbursement), the identity of the Third Party(ies) making the Company Superior Proposal or, in the case of a Company Intervening Event, a reasonably detailed description of the facts relating to such Company Intervening Event,
(ii)&nbsp;if requested by Parent, during such four Business Day period, the Company and its Representatives shall have discussed and negotiated in good faith with Parent (to the extent that Parent desires to so discuss or negotiate) regarding any
proposal by Parent to amend the terms of this Agreement in response to such Company Superior Proposal or other potential Company Change of Recommendation and (iii)&nbsp;after such four Business Day period, the Company Board determines in good faith,
after consultation with its financial advisor and outside legal counsel and taking into account any proposal by Parent to amend the terms of this Agreement, that the failure to take such action would be inconsistent with its fiduciary duties under
applicable Laws and, in the case of any such action in connection with a Company Alternative Proposal, such Company Alternative Proposal continues to constitute a Company Superior Proposal (it being understood and agreed that in the event of any
amendment to the financial terms or other material terms of any such Company Superior Proposal, a new written notification from the Company consistent with that described in <U>clause (i)</U>&nbsp;of this <U>Section</U><U></U><U>&nbsp;5.2(e)</U>
shall be required, and a new notice period under <U>clause (i)</U>&nbsp;of this <U>Section</U><U></U><U>&nbsp;5.2(e)</U> shall commence, during which notice period the Company shall be required to comply with the requirements of this
<U>Section</U><U></U><U>&nbsp;5.2(e)</U> anew, except that such new notice period shall be for three Business Days (as opposed to four Business Days)). After delivery of such written notice pursuant to this <U>Section</U><U></U><U>&nbsp;5.2(e)</U>,
the Company shall promptly inform Parent of all material developments affecting the material terms of any such Company Superior Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;6. REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>Company Representations and Warranties</B>. Subject to <U>Section</U><U></U><U>&nbsp;10.8</U> and except as disclosed
(i)&nbsp;in any publicly available Company SEC Document filed on or after January&nbsp;1, 2020 and prior to the date of this Agreement or (ii)&nbsp;in the disclosure schedule delivered by the Company to Parent immediately prior to the execution of
this Agreement (the &#147;<B><I>Company Disclosure Schedule</I></B>&#148;), the Company represents and warrants to Parent and Acquirer Sub as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Qualification, Organization, Subsidiaries, etc</B>. The Company is duly incorporated and validly existing under the Laws of Ireland.
The Company has all requisite corporate power and authority required to own or lease all of its properties or assets and to carry on its business as now conducted. The Company is duly qualified to do business and is in good standing in each
jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified or in good standing has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect. Prior to the date of this Agreement, the Company has made available to Parent true and complete copies of the Memorandum and Articles of Association of the Company as in effect as of the date of this Agreement (the
&#147;<B><I>Company Memorandum and Articles of Association</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Subsidiaries</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each Subsidiary of the Company is a corporation or other entity duly incorporated or organized, validly existing and in good standing
(except to the extent such concept is not applicable under applicable Laws of such Subsidiary&#146;s jurisdiction of incorporation or organization, as applicable) under the Laws of its jurisdiction of incorporation or organization and has all
corporate or other organizational powers and authority, as applicable, required to own, lease and operate its properties and assets and to carry on its business as now conducted, except for those jurisdictions where failure to be so organized,
validly existing and in good standing or to have such power has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. Each such Subsidiary is duly qualified to do business and is
in good standing in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified or in good standing has not had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect. The Company has made available true and correct copies of the Organizational Documents of the Company&#146;s Significant Subsidiaries that, in each case, are in full force and effect as of the date of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) All of the outstanding Equity Securities of each Subsidiary of the Company have been validly issued and are fully
paid and nonassessable (except to the extent such concepts are not applicable under applicable Laws of such Subsidiary&#146;s jurisdiction of incorporation or organization, as applicable) and are owned by the Company or one of its wholly-owned
Subsidiaries, directly or indirectly, free and clear of any Lien (other than Permitted Liens and any restrictions imposed by applicable Laws) and free of preemptive rights, rights of first refusal, subscription rights or similar rights of any Person
and transfer restrictions (other than Permitted Liens and transfer restrictions under applicable Laws or under the Organizational Documents of such Subsidiary). Except for the Equity Securities of its Subsidiaries, the Company does not own, directly
or indirectly, any capital stock or other Equity Securities of any Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B>Capitalization</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The authorized capital of the Company consists of 600,000,000 Company Shares, and 40,000 Company Deferred Shares. As of December&nbsp;9,
2022 (the &#147;<B><I>Company Capitalization Date</I></B>&#148;), there were outstanding (A) 226,962,593 Company Shares, (B) 40,000 Company Deferred Shares, (C)&nbsp;Company Options to purchase an aggregate of 4,997,294 Company Shares,
(D)&nbsp;Company RSU Awards (other than the Company PSU Awards) providing for the issuance of up to an aggregate of 3,581,805 Company Shares and (E)&nbsp;Company PSU Awards providing for the issuance of up to an aggregate of 1,909,313 Company
Shares, determined assuming the maximum number of shares to be issued under the Company PSU Awards. As of December&nbsp;9, 2022, (X) 21,101,438 additional Company Shares were reserved for issuance pursuant to the Company Share Plans (excluding the
Company ESPP), and (Y) 2,046,575 additional Company Shares were reserved for issuance pursuant to the Company ESPP. Except as set out in this <U>Section</U><U></U><U>&nbsp;6.1(c)</U> and for changes since the Company Capitalization Date resulting
from (x)&nbsp;the exercise or vesting and settlement of the Company Equity Awards outstanding on such date (in accordance with their existing terms in effect as of the date of this Agreement) or issued on or after such date to the extent permitted
by <U>Section</U><U></U><U>&nbsp;5.1</U> (as qualified by or permitted under the Company Disclosure Schedule) or (y)&nbsp;the issuance of Equity Securities of the Company on or after the date of this Agreement to the extent permitted by
<U>Section</U><U></U><U>&nbsp;5.1</U> (as qualified by or permitted under the Company Disclosure Schedule) and <U>Section</U><U></U><U>&nbsp;7.5</U> (with respect to an offering period in existence under the Company ESPP), there are no issued,
reserved for issuance or outstanding Equity Securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) All outstanding Company Shares have been, and all Company
Shares that may be issued pursuant to any Company Share Plan, any employee stock option or other compensation plan or arrangement will be, when issued in accordance with the respective terms thereof, duly authorized and validly issued, fully paid
and nonassessable and free of preemptive rights and Liens other than Permitted Liens. No Subsidiary of the Company owns any Equity Securities of the Company. There are no outstanding bonds, debentures, notes or other Indebtedness of the Company
having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which shareholders of the Company have the right to vote. As of the date of this Agreement, other than the Company Shares
underlying the Company RSU Awards or Company PSU Awards, there are no outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any Equity Securities of the Company or its Subsidiaries. Neither the
Company nor any of its Subsidiaries is a party to any agreement with respect to the voting of any Equity Securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Each Company Option (A)&nbsp;was granted in compliance with all applicable Laws and all of the terms and conditions of the Company
Share Plan pursuant to which it was issued, (B)&nbsp;has an exercise price per Company Share equal to or greater than the fair market value of a Company Share on the date of such grant, (C)&nbsp;has a grant date identical to the date on which the
Company Board or the compensation committee thereof actually awarded such Company Option and (D)&nbsp;does not trigger any liability for the holder thereof under Section&nbsp;409A of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B>SEC Filings; Financial Statements</B><B>; Internal Controls and Procedures</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Since January&nbsp;1, 2021, the Company has timely filed or furnished all reports, schedules, forms, statements and other documents
(including exhibits and all other information incorporated therein) required to be filed or furnished by the Company with the SEC (the &#147;<B><I>Company SEC Documents</I></B>&#148;). As of their respective dates, the Company SEC Documents complied
as to form, in all material respects with the requirements of the Securities Act, the Exchange Act or the Sarbanes-Oxley Act, as the case may be, the rules and regulations of the SEC promulgated thereunder applicable to such Company SEC Documents
and the rules and regulations of Nasdaq. Except to the extent that information contained in any Company SEC Document has been revised, amended, modified or superseded (prior to the date of this Agreement) by a later filed Company SEC Document, none
of the Company SEC Documents when filed or furnished contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading; <I>provided</I>, <I>that</I>, any such Company SEC Document that is a registration statement filed pursuant to the Securities Act did not contain any untrue statement of material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading on the date of the effectiveness of such Company SEC Document that is a
registration statement. No member of the Company Group other than the Company is subject to the reporting requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The consolidated financial statements of the Company (including any related notes and schedules) contained or incorporated by reference
in the Company SEC Documents: (A)&nbsp;complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC applicable thereto; (B)&nbsp;were prepared in accordance with GAAP applied
on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or as permitted by Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> or, in the case of unaudited financial statements,
as permitted by Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Form <FONT STYLE="white-space:nowrap">8-K</FONT> or any successor form under the Exchange Act); and (C)&nbsp;fairly present, in all material respects, the consolidated financial
position of the Company and its consolidated Subsidiaries as of the respective dates thereof and the results of operations, shareholders&#146; equity, consolidated income and changes in consolidated financial condition or cash flows of the Company
and its consolidated Subsidiaries for the periods covered thereby (subject, in the case of the unaudited financial statements, to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments that are not, individually or in the
aggregate, material). No financial statements of any Person other than the Subsidiaries of the Company are required by GAAP to be included in the consolidated financial statements of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The Company maintains, and at all times since January&nbsp;1, 2021, has maintained, a system of internal controls over financial
reporting (as required and defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange Act) which is designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that: (A)&nbsp;pertain to the maintenance of records that in reasonable detail accurately
and fairly reflect the transactions and dispositions of the assets of the Company; (B)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with GAAP and that receipts and expenditures are being made only in accordance with authorizations of management and directors of the Company; and (C)&nbsp;provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Company Group that could have a material effect on its financial statements. Except as set out in the Company SEC Documents filed prior to the date
of this Agreement, since January&nbsp;1, 2021, neither the Company nor, to the knowledge of the Company, the Company&#146;s independent registered accountant has identified or been made aware of: (x)&nbsp;any significant deficiency or material
weakness in the design or operation of internal controls over financial reporting utilized by the Company; (y)&nbsp;any illegal act or fraud, whether or not material, that involves the management or other employees of the Company Group; or
(z)&nbsp;any claim or allegation regarding any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) The Company and its Subsidiaries maintain disclosure controls and
procedures required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> or <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act that are designed to provide reasonable assurance that all information required to be disclosed in
the Company&#146;s reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that all such information is accumulated and
communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure and to enable each of the principal executive officer of the Company and the principal financial officer of the Company to make the
certifications required under the Exchange Act and the Sarbanes-Oxley Act with respect to such reports. No executive officer of the Company has failed in any material respect to make the certifications required of them under Rules <FONT
STYLE="white-space:nowrap">13a-14</FONT> and <FONT STYLE="white-space:nowrap">15d-14</FONT> under the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC or Nasdaq with respect
to any Company SEC Document, and the statements contained in any such certifications are true and complete in all material respects as of the date on which they were made. No evidence of a material violation of securities Laws, breach of fiduciary
duty or similar violation by the Company or any of its Representatives has been reported to the Company&#146;s chief legal officer, audit committee (or other committee of the Company Board designated for this purpose) or the Company Board pursuant
to the rules adopted pursuant to Section&nbsp;307 of the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The Company is not a party to nor has any obligation or
other commitment to become a party to any securitization transaction, <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet partnership or any similar Contract (including any Contract relating to any transaction or relationship between or among
the Company, on the one hand, and any unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity, on the other hand, or any <FONT STYLE="white-space:nowrap">&#147;off-balance</FONT> sheet arrangements&#148;
(as defined in Item 303(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act)) where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material
liabilities of, the Company Group in the Company&#146;s published financial statements or other Company SEC Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) As of the
date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the Company SEC Documents. To the knowledge of the Company, none of the Company SEC Documents is the subject of ongoing
SEC review and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened, in each case regarding any accounting practices of the Company. The Company has made available to Parent all material
correspondence with the SEC since January&nbsp;1,&nbsp;2021 through the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) The Company is in compliance in all material respects with all current listing and
corporate governance requirements of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B>Absence of Changes</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Since December&nbsp;31, 2021 through the date of this Agreement, there has not occurred any event, change, effect, development or
occurrence, individually or in the aggregate, that has had or would be reasonably expected to have, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Since the date of the Balance Sheet through the date of this Agreement, (A)&nbsp;the Company Group has operated in all material respects
in the ordinary course of business (except for discussions, negotiations and transactions related to this Agreement or any similar potential strategic transactions) and (B)&nbsp;no Company Group member has taken, or agreed, committed, arranged,
authorized or entered into any written understanding to take any of the following actions: (1) (other than transactions solely among the Company and its wholly owned Subsidiaries) effected any recapitalization, reclassification, distribution, equity
split or like change in its capitalization, amended any term or altered any rights of any of its outstanding Equity Securities, or redeemed, repurchased, canceled or otherwise acquired its Equity Securities or any Equity Securities of the Company;
(2)&nbsp;subjected any material portion of its properties or assets to any material Liens, except for Permitted Liens; (3)&nbsp;sold or otherwise dispose of, divested or <FONT STYLE="white-space:nowrap">spun-off,</FONT> assigned or transferred any
material assets or properties, except in the ordinary course of business (including entering into Standard Contracts and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license agreements, and the sale of obsolete assets, in each case, in the
ordinary course of business); (4) except for intercompany loans and capital contributions and sales commission advances made in the ordinary course of business, made or authorized any capital investment in, or any material loan to, or guarantee any
Indebtedness of any Person other than any Company Group member, except in the ordinary course of business or pursuant to any existing agreement or budget; (5)&nbsp;amended its Organizational Documents; (6)&nbsp;declared, set aside or paid any
dividend or made any other distributions (whether in cash, stock, property or any combination thereof) in respect of any Equity Securities, other than dividends or distributions by a Subsidiary of the Company to the Company or a wholly owned
Subsidiary of the Company; or (7)&nbsp;made any material change in any method of financial accounting or financial accounting principles or practices, except for any such change required by reason of (or, in the reasonable good-faith judgment of the
Company, advisable under) a change in GAAP or applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B>Title to Assets</B>. The Company Group has good and valid title to,
or a valid leasehold interest in, all material tangible properties and assets owned or leased, or purported to be owned or leased, by them, including all material tangible assets and properties reflected on the Company&#146;s unaudited balance sheet
in the most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (the &#147;<B><I>Balance Sheet</I></B>&#148;) filed by the Company with the SEC (but excluding Intellectual Property which is covered by
<U>Section</U><U></U><U>&nbsp;6.1(h)</U>), except for assets sold or otherwise disposed of in the ordinary course of business since the date of such Balance Sheet, and except where such failure has not had and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect. Such tangible assets and properties are, in the aggregate, sufficient to carry on the businesses of the Company Group, except as would not, individually or in the aggregate,
reasonably be expected to result in a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <B>Real Property</B>. Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;the Company Group has good, valid and marketable fee simple title to, or valid leasehold interests in, as the case may be, each parcel of real property owned (the
&#147;<B><I>Owned Real Property</I></B>&#148;) or leased (the &#147;<B><I>Leased Real Property</I></B>&#148;) by the applicable member of the Company Group, free and clear of all Liens, except for Permitted Liens, (ii)&nbsp;each lease, sublease or
license (each, a &#147;<B><I>Lease</I></B>&#148;) under which the applicable member of the Company Group leases, subleases or licenses any real property is, subject to the Equitable Exceptions, a valid and binding obligation of the applicable member
of the Company Group (as the case may be) and, to the knowledge of the Company, each of the other parties thereto, and is in full force and effect and enforceable in accordance with its terms against the applicable member of the Company Group (as
the case may be) and, to the knowledge of the Company, each of the other parties thereto (except for such Leases that are terminated after the date of this Agreement in accordance with their respective terms, other than as a result of a default or
breach by a member of the Company Group of any of the provisions thereof), (iii) no member of the Company Group, nor, to the knowledge of the Company, any of the other parties thereto has violated or committed or failed to perform any act which
(with or without notice, lapse of time or both) would constitute a default under any provision of any Lease, and (iv)&nbsp;no member of the Company Group has received written notice that it has violated or defaulted under any Lease. The Owned Real
Property and the Leased Real Property has been maintained in accordance with normal industry practice and is suitable for the purposes for which it is currently used. No member of the Company Group has received any written notice of any pending or
threatened condemnation of any Owned Real Property or material Leased Real Property by any Governmental Entity, except as has not and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <B>Intellectual Property</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Section 6.1(h)(i) of the Company Disclosure Schedule identifies (A)&nbsp;the name of the applicant/registrant (or the Internet domain
name registrar, as applicable), (B)&nbsp;the jurisdiction of application/registration, (C)&nbsp;the application, patent or registration number and (D)&nbsp;any other <FONT STYLE="white-space:nowrap">co-owners,</FONT> for each material item of
Registered IP included in the Owned Intellectual Property. All material Registered IP included in the Owned Intellectual Property or included in material Licensed Intellectual Property exclusively licensed to the Company Group (collectively, the
(&#147;<B><I>Exclusive Company IP</I></B>&#148;) is subsisting, and, with respect to such material Registered IP that is issued and granted, to the Company&#146;s knowledge, is valid and enforceable. Other than as identified in the Company
Disclosure Schedule, no interference, reissue, reexamination or other proceeding of any nature (other than patent or trademark prosecution activities being conducted before a Governmental Entity in the ordinary course of business) is pending or, to
the knowledge of the Company, threatened, in which the scope, validity, enforceability, inventorship or ownership of any material Registered IP included in the Owned Intellectual Property or, to the knowledge of the Company, in any other Exclusive
Company IP, is contested or challenged. Each member of the Company Group has complied in all material respects with its duty of candor and disclosure to the United States Patent and Trademark Office and any relevant foreign patent office with
respect to all patent and trademark applications included in the Owned Intellectual Property or, to the extent and for the duration any member of the Company Group controls the prosecution and maintenance thereof, any other Exclusive Company IP, in
each case filed by or on behalf of the Company Group and have made no material misrepresentation in such applications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Except as would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect, the Company or any of its Subsidiaries solely owns all right, title and interest in and to all Owned Intellectual Property, free and clear of all Liens other than Permitted Liens, and to the knowledge of the
Company,<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>has the right, pursuant to valid agreements to use all other material Company Intellectual Property used by the Company Group in their businesses as currently conducted. The consummation
of the Transactions will not result in the grant of any Lien with respect to any Intellectual Property owned or controlled by the Parent or any of its Affiliates (other than the Company Group), except as would not be material to the business of
Parent or any of its Affiliates (other than the Company Group). Each Company Employee or independent contractor involved in the creation or development of any material Intellectual Property intended by the Company to be owned by any member of the
Company Group has irrevocably assigned such Company Employee&#146;s or independent contractor&#146;s rights in such Intellectual Property to the Company or its applicable Subsidiary, except in any instance where a failure to do so would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) No funding, facilities or
personnel of any Governmental Entity or any university, college, research institute or other educational institution are being used to create any material Owned Intellectual Property or, to the knowledge of the Company, any other material Company
Intellectual Property, in each case, except for any such funding, facilities or personnel that would not result in such Governmental Entity or institution obtaining ownership rights in or other rights to use or exploit any Company Intellectual
Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Section 6.1(h)(iv) of the Company Disclosure Schedule sets forth each license agreement pursuant to which a member of the
Company Group (A)&nbsp;is granted a license under, covenant not to sue under or option to any of the foregoing under any material Intellectual Property that is incorporated into or distributed or used with any Company Product or that is otherwise
material to the business of the Company Group, taken as a whole (each an &#147;<B><I><FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B>&#148;) or (B)&nbsp;grants to any Third Party a license under, covenant not to sue under or option
to any of the foregoing under any material Company Intellectual Property (each an &#147;<B><I><FONT STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#148;), <I>provided</I> that, <FONT STYLE="white-space:nowrap">In-bound</FONT> Licenses
shall not include any material transfer agreements, sponsored research agreements, clinical trial agreements, nondisclosure agreements, services agreements, commercially available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">software-as-a-service</FONT></FONT></FONT> offerings, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software licenses, <FONT STYLE="white-space:nowrap">non-material</FONT>
trademark <FONT STYLE="white-space:nowrap">co-existence</FONT> agreements or generally available license agreements, in each case, entered into in the ordinary course of business, and <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses shall
not include any material transfer agreements, sponsored research agreements, clinical trial agreements, nondisclosure agreements, services agreements, research agreements, distribution agreements, manufacturing agreements, <FONT
STYLE="white-space:nowrap">non-material</FONT> trademark <FONT STYLE="white-space:nowrap">co-existence</FONT> agreements or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> <FONT STYLE="white-space:nowrap">out-bound</FONT> licenses, in each
case, entered into in the ordinary course of business (collectively, &#147;<B><I>Standard Contracts</I></B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The operation of the business of the Company Group as currently conducted does not
infringe, misappropriate or violate, and has not infringed, misappropriated or violated since January&nbsp;1, 2021, any Intellectual Property owned by any other Person; and, to the knowledge of the Company, no Person is infringing, misappropriating
or otherwise violating, and has not infringed, misappropriated or violated since January&nbsp;1, 2021, any Owned Intellectual Property or Licensed Intellectual Property exclusively licensed to any member of the Company Group. Since January&nbsp;1,
2021, there has been no Legal Proceeding (A)&nbsp;pending (or, to the knowledge of the Company, threatened) against any of the members of the Company Group alleging that the operation of the business of the Company Group as currently conducted
infringes or constitutes the misappropriation or other violation of any Intellectual Property of another Person, or (B)&nbsp;pending (or, to the knowledge of the Company, threatened) by any member of the Company Group that another Person has
infringed, misappropriated or otherwise violated any of the Owned Intellectual Property or Licensed Intellectual Property exclusively licensed to any member of the Company Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) The Company has taken commercially reasonable security, organizational, physical, administrative and technical measures, including
measures designed to protect against unauthorized disclosure and designed to protect the secrecy, confidentiality, and value of its trade secrets and other material confidential technical information, and no such trade secret or other material
confidential technical information has been disclosed by or on behalf of any member of the Company Group to, or, to the knowledge of the Company, has been discovered by, any Person, other than pursuant to valid
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> obligations restricting the disclosure and use thereof, which obligations, to the knowledge of the Company, have not been breached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) As of the date of this Agreement, none of the Owned Intellectual Property or, to the knowledge of the Company, any other Exclusive
Company IP, is subject to any outstanding Order that adversely and materially restricts the use, transfer, validity, enforceability, ownership, registration or licensing by any member of the Company Group of any such Exclusive Company IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <B>Data Protection</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, since
January&nbsp;1, 2021, the members of the Company Group (A)&nbsp;to the knowledge of the Company, are, and have been, in compliance with all Data Security Requirements and (B)&nbsp;have not received, or otherwise been subject to, any written notices,
complaints, notices, audits, proceedings, investigations or claims conducted or asserted by any other Person (including any Governmental Entity) regarding any unauthorized or unlawful Processing of Personal Information or other violation of any Data
Security Requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect, since January&nbsp;1, 2021, the Company Group have maintained and complied with commercially reasonable administrative, technical and physical safeguards that are designed to (A)&nbsp;prevent Security Incidents and (B)&nbsp;protect
the confidentiality, integrity and availability of all Personal Information and Company IT Assets currently used by the Company Group. Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect, and to the knowledge of the Company, since January&nbsp;1, 2021, through the date of this Agreement, none of the members of the Company Group has experienced a Security Incident. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The Company IT Assets (A)&nbsp;operate and perform in all material respects in
accordance with their documentation and functional specifications and otherwise as required by the Company Group in connection with its businesses, (B)&nbsp;have not malfunctioned or failed since January&nbsp;1, 2021 in a manner that has had a
material impact on the businesses of the Company Group, and (C)&nbsp;to the knowledge of the Company,&nbsp;are free from material bugs, material malicious codes or other material defects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <B>Contracts</B>. Section&nbsp;6.1(j) of the Company Disclosure Schedule identifies each Company Contract (other than any Company Contract
that is an Employee Plan identified in Section&nbsp;6.1(q) of the Company Disclosure Schedule) that constitutes a Material Contract as of the date of this Agreement. For purposes of this Agreement, each of the following Company Contracts other than
a Standard Contract shall be deemed to constitute a &#147;<B><I>Material Contract</I></B>&#148;: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Company Contract that requires
by its terms the payment or delivery of cash or other consideration by or to a member of the Company Group in an amount having an expected value in excess of $25,000,000 in the fiscal year ending December&nbsp;31, 2022; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any Company Contract (x)&nbsp;having an expected value in excess of $20,000,000 in the fiscal year ending December&nbsp;31, 2022
(A)&nbsp;containing any exclusivity obligations or otherwise limiting the freedom or right of any member of the Company Group (or upon the Completion by virtue of the consummation of the Acquisition, Parent and its Subsidiaries) in any material
respect, to engage in any line of business, to make use of any material Company Intellectual Property (other than the scope of the rights granted by the terms of any <FONT STYLE="white-space:nowrap">In-bound</FONT> or any <FONT
STYLE="white-space:nowrap">Out-bound</FONT> License to use such material Company Intellectual Property) or to compete with any other Person in any location or line of business, or (B)&nbsp;containing any &#147;most favored nations&#148; terms and
conditions (including with respect to pricing) granted by a member of the Company Group or (y)&nbsp;or containing any exclusivity obligations or otherwise limiting the freedom or right of Parent or any of its Subsidiaries (other than the members of
the Company Group), in any material respect, to engage in any line of business, to make use of any Intellectual Property or to compete with any other Person in any location or line of business, in each case, from and after the Completion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any Company Contract relating to Indebtedness in excess of $30,000,000 (whether incurred, assumed, guaranteed or secured by any asset)
of any member of the Company Group; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any Company Contract that provides for the creation of any Lien, other than a Permitted Lien,
with respect to any tangible asset and Owned Intellectual Property of any Company Group member that is material to the conduct of the business of the Company Group as currently conducted, taken as a whole; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any Company Contract constituting a joint venture, partnership, or limited liability company or the sharing of profits and losses; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any Company Contract that prohibits the payment of dividends or distributions in
respect of the capital stock of the Company or any material Subsidiary, the pledging of the capital stock or other Equity Securities of the Company or any material Subsidiary or prohibits the issuance of any guaranty or the incurrence of any
Indebtedness for borrowed money by the Company or any material Subsidiary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any other Company Contract that is currently in effect
and has been filed (or is required to be filed) by the Company as an exhibit pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act or that would be required to be disclosed under Item 404 of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) any Company Contract with any Affiliate,
director, executive officer, holder of 5% or more of the Company Shares or, to the knowledge of the Company, any of their Affiliates (other than the Company) or immediate family members that would be required to be disclosed under Item 404 of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> that has not been otherwise disclosed in the Company SEC Documents filed prior to the date of this Agreement or with annual payments in the fiscal year ending December&nbsp;31, 2021 in excess of
$1,000,000, other than offer letters or employment agreements that can be terminated at will without severance obligations (or upon only the minimum severance and notice requirements required by applicable Laws) and Company Contracts with respect to
Company Equity Awards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) any Company Contract having an expected payment obligation in excess of $10,000,000 in the fiscal year
ending December&nbsp;31, 2023, for the lease or sublease of any material real property; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any Company Contract that provides for the
acquisition or disposition of any business, or a material amount of stock or assets of any Person, in each case, for consideration in excess of $50,000,000 (whether by merger, sale of stock, sale of assets or otherwise) with material obligations
remaining to be performed or material liabilities continuing after the date of this Agreement (other than indemnification obligations under which there are no pending claims or other provisions that customarily survive such performance); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) any Company Contract with any Governmental Entity under which payments in excess of $20,000,000 were received by any member of the
Company Group in the fiscal year ending December&nbsp;31, 2021; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) any <FONT STYLE="white-space:nowrap">In-bound</FONT> License or <FONT
STYLE="white-space:nowrap">Out-bound</FONT> License; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) any hedging, swap, derivative or similar Company Contract; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) any Company Contract with a sole-source supplier related to Tepezza, Krystexxa or Uplizna such that the inability to maintain supply
from such supplier would materially impact product availability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of the date of this Agreement, the Company has made available to Parent or Parent&#146;s
Representatives a true and correct copy of each Material Contract. Neither the applicable member of the Company Group nor, to the knowledge of the Company, the other party thereto is in material breach of or material default under any Material
Contract and, neither the applicable member of the Company Group, nor, to the knowledge of the Company, the other party thereto has taken or failed to take any action that with or without notice, lapse of time or both would constitute a material
breach of or material default under any Material Contract. To the knowledge of the Company, each Material Contract is enforceable by the applicable member of the Company Group in accordance with its terms, subject to the Equitable Exceptions. Since
January&nbsp;1, 2022 through the date of this Agreement, none of the members of the Company Group has received any written notice (x)&nbsp;regarding any violation or breach or default under any Material Contract that has not since been cured or
(y)&nbsp;from any Person that such Person intends to terminate, or not renew, any Material Contract, in each case, except for such violations or breaches that would not reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect. Since January&nbsp;1, 2021, no member of the Company Group has waived in writing any rights under any Material Contract, except for waivers that would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect. For the purposes of this final paragraph of this <U>Section</U><U></U><U>&nbsp;6.1(j)</U> (other than the first sentence), Material Contracts shall include any Company Contract in effect as of the date of this
Agreement that requires by its terms the payment or delivery of cash or other consideration by or to any member of the Company Group in an amount having an expected value in excess of $25,000,000 in any single fiscal year after 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <B>Liabilities</B>. The Company Group does not have any liabilities of the type required to be disclosed in the liabilities column of a
consolidated balance sheet of the Company and its Subsidiaries prepared in accordance with GAAP, except for: (i)&nbsp;liabilities reflected or reserved in the audited and unaudited financial statements included in the Company SEC Documents;
(ii)&nbsp;liabilities or obligations incurred pursuant to the terms of this Agreement; (iii)&nbsp;liabilities for performance of obligations under Contracts binding upon the applicable member of the Company Group (other than resulting from any
breach or acceleration thereof) made available to Parent or Parent&#146;s Representatives prior to the date of this Agreement or entered into in compliance with <U>Section</U><U></U><U>&nbsp;5.1</U> or in the ordinary course of business, including
Standard Contracts; (iv)&nbsp;liabilities incurred since the date of the Balance Sheet in the ordinary course of business or in connection with the Transactions (none of which would reasonably be expected to be material to the conduct of the
business of the Company Group as currently conducted, taken as a whole); and (v)&nbsp;liabilities that would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <B>Compliance with Law</B>. Each member of the Company Group is, and since January&nbsp;1, 2021, has been, in compliance with all
applicable Laws and all applicable Orders, except where the failure to be in compliance would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect and, since January&nbsp;1, 2021, no member of the
Company Group has been given written notice of, or been charged with, any unresolved violation of, any Law or Order, except, in each case, for any such violation that would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <B>Regulatory Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Since January&nbsp;1, 2021, the Company Group has filed with the applicable regulatory authorities (including the FDA or any other
Governmental Entity performing functions similar to those performed by the FDA) all required material filings, declarations, listings, registrations, reports or submissions, including but not limited to adverse event reports and investigational new
drug safety reports. All such filings, declarations, listings, registrations, reports or submissions were in material compliance with applicable Laws when filed, and no deficiencies that have been asserted by any applicable Governmental Entity with
respect to any such filings, declarations, listing, registrations, reports or submissions remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Except as would not, individually or in the aggregate, reasonably be expected to have
a Company Material Adverse Effect, all nonclinical and clinical investigations sponsored by or on behalf of the Company Group are, to the knowledge of the Company, being or have been conducted in material compliance with applicable Laws and
guidance, including (A)&nbsp;Good Clinical Practices requirements, (B)&nbsp;applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines, (C)&nbsp;approved clinical protocols and informed
consents and (D)&nbsp;applicable Laws restricting the use and disclosure of individually identifiable health information. As of the date of this Agreement, neither the FDA nor any other foreign, federal, state or local governmental or regulatory
authority performing functions similar to those performed by the FDA has sent any written notices or other correspondence to any member of the Company Group with respect to any ongoing clinical or nonclinical studies or tests requiring the
termination, suspension or material modification of such studies or tests, which modification, individually or in the aggregate, would reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the Company&#146;s knowledge, since January&nbsp;1, 2021, neither the members of the Company Group nor any Representative acting on
any member of the Company Group&#146;s behalf has (A)&nbsp;made an untrue statement of a material fact or fraudulent statement to the FDA or any Governmental Entity having applicable jurisdiction over the Company Group under applicable Healthcare
Laws, (B)&nbsp;failed to disclose a material fact required to be disclosed to the FDA or (C)&nbsp;committed any other act, made any statement or failed to make any statement, that (in any such case) establishes a reasonable basis for the FDA to
invoke its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy or for any Governmental Entity having applicable jurisdiction over the Company Group under applicable Healthcare Laws to invoke an equivalent policy.
As of the date of this Agreement, none of any member of the Company Group nor, to the Company&#146;s knowledge, any entity or other Representative acting on any member of the Company Group&#146;s behalf is the subject of any pending or, to the
Company&#146;s knowledge, threatened investigation in writing by the FDA pursuant to its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy or by any Governmental Entity having applicable jurisdiction over the
Company Group under applicable Healthcare Laws on the basis of an equivalent Policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Neither the Company nor, to the knowledge of
the Company, any executive officers, employees, agents or clinical investigators of the Company Group or any entity or individual acting on the Company&#146;s behalf has been (A)&nbsp;debarred under 21 U.S.C. &#167; 335a or any similar Law,
(B)&nbsp;excluded from participation in federal health care programs under 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7,</FONT> <FONT STYLE="white-space:nowrap">1320a-7a</FONT> or any similar Law, (C)&nbsp;disqualified by any
Governmental Entity, (D)&nbsp;suspended or otherwise determined to be or identified as ineligible to participate in any health care contracting program of any Governmental Entity or (E)&nbsp;convicted of, charged with, investigated for or engaged in
any conduct that would reasonably be expected to result in such debarment, exclusion, disqualification, suspension, or ineligibility. No debarment, exclusion or disqualification proceedings or investigations are pending or, to the Company&#146;s
knowledge, threatened against the Company or any officer, director, consultant, employee, manager or agent acting for or on behalf of the Company Group. No Legal Proceedings are pending or, to the Company&#146;s knowledge, threatened that would
reasonably be expected to result in criminal liability, debarment, disqualification, or exclusion by any Governmental Entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Except as, individually or in the aggregate, would not reasonably be expected to have a
Company Material Adverse Effect, the Company Group is in compliance and since January&nbsp;1, 2021, has been in compliance with all Healthcare Laws to the extent applicable to the operation of its business as currently conducted. The Company is not
subject to any enforcement, regulatory or Legal Proceeding against or affecting the Company relating to or arising under any Healthcare Law, and no such enforcement, regulatory or Legal Proceeding has been threatened, including by the issuance of a
warning letter, untitled letter, Form 483 or similar notice of potential violations of Healthcare Laws. To the extent required by applicable Laws, all manufacturing operations conducted for the benefit of any member of the Company Group with respect
to any product or product candidate being used in human clinical trials have been conducted in accordance with GMP Regulations, except where the failure to so comply would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <B>Certain Business Practices</B>. To the Company&#146;s knowledge, neither the Company, nor any
other member of the Company Group, nor any of its or their respective employees, representatives or agents (in each case, acting in the capacity of an employee or representative of any member of the Company Group) has (i)&nbsp;used any funds
(whether of any member of the Company Group or otherwise) for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii)&nbsp;made any unlawful payment to foreign or domestic Government Officials or
employees or to foreign or domestic political parties or campaigns or (iii)&nbsp;violated any provision of any applicable Anti-Corruption Laws or any rules or regulations promulgated thereunder, any applicable anti-money laundering laws and any
rules or regulations promulgated thereunder or any applicable Law of similar effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) <B>Regulatory Permits</B>. The Company Group
holds all Regulatory Permits necessary to enable the Company Group to conduct its business in the manner in which its business is currently being conducted, except where failure to hold such Regulatory Permits would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect. The Regulatory Permits held by the Company Group are, in all material respects, valid and in full force and effect. The Company Group is in compliance with the terms and
requirements of such Regulatory Permits, except where failure to be in compliance would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) <B>Tax Matters</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (A)&nbsp;each of the Tax Returns required to be filed by the Company Group with any Governmental Entity has been filed on or
before the applicable due date (taking into account any extensions of such due date), and all such Tax Returns are accurate and complete, (B)&nbsp;all Taxes required to be paid have been paid, except with respect to matters being contested in good
faith and in accordance with applicable Laws or for which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adequate reserves have been established in accordance with GAAP on the financial statements of the relevant member of the Company Group, (C)&nbsp;the Company Group has made adequate provision for
all unpaid Taxes not yet due, (D)&nbsp;there are no Liens for Taxes upon any property or assets of any member of the Company Group, except for Permitted Liens, (E)&nbsp;during the last three years, no claim has been made in writing by a Tax
Authority in a jurisdiction where a member of the Company Group does not file Tax Returns that such Person is or may be subject to taxation in that jurisdiction, and (F)&nbsp;neither the execution of this Agreement nor the Scheme will result in the
loss, withdrawal or restriction of any applicable Tax holiday or reduced Tax rate granted by a Tax Authority to any member of the Company Group that is not generally available to Persons without specific application therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (A)&nbsp;no
deficiency for any Tax has been asserted or assessed by a Tax Authority in writing against any member of the Company Group which deficiency has not been paid, settled or withdrawn or is not being contested in good faith and in accordance with
applicable Laws, (B)&nbsp;there are no pending or ongoing, audits, examinations, investigations or other proceedings by any Tax Authority with respect to Taxes of or with respect to any member of the Company Group and (C)&nbsp;no member of the
Company Group has received any form of written notice from any Tax Authority communicating an intent to initiate any such audit, examination, investigation or other proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) None of the members of the Company Group (A)&nbsp;is a party to or is bound by any material Tax sharing, allocation or indemnification
agreement or arrangement that would have a continuing effect after the Completion Date (other than such agreements or arrangements (x)&nbsp;exclusively between or among the members of the Company Group or (y)&nbsp;with third parties made in the
ordinary course of business, the principal purpose of which is not Tax) or (B)&nbsp;has any material liability for the Taxes of another Person (other than members of the Company Group) under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local or foreign Law), as a transferee or successor, or otherwise by operation of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) No member of the Company Group has been either a &#147;distributing corporation&#148; or a &#147;controlled corporation&#148; in a
distribution of stock intended to qualify for <FONT STYLE="white-space:nowrap">Tax-free</FONT> treatment under Section&nbsp;355 of the Code in the last two years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) To the knowledge of the Company, no member of the Company Group has entered into any &#147;listed transaction&#148; within the meaning of
Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2)</FONT> or any similar transaction requiring disclosure in accordance with a corresponding provision of state, local or foreign Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) The statements in Section&nbsp;6.1(p)(vi) of the Company Disclosure Schedule, to the extent materially relevant to whether any member of
the Company Group first became a surrogate foreign corporation after November&nbsp;9, 2017, are true in all material respects, and to the knowledge of the Company no member of the Company Group first became a surrogate foreign corporation after
November&nbsp;9, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) With respect to any taxable period or year, neither the Company nor any material member of the Company
Group is, or has been treated as, a U.S. corporation under Section&nbsp;7874(b) of the Code, and to the knowledge of the Company no other member of the Company Group is or has been treated as a U.S. corporation under Section&nbsp;7874(b) of the
Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Notwithstanding anything herein to the contrary, this
<U>Section</U><U></U><U>&nbsp;6.1(p) </U>contains the sole representations concerning Taxes of the Company Group (other than representations concerning Taxes of the Company Group under <U>Section</U><U></U><U>&nbsp;6.1(q)</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) <B>Employee Matters; Benefit Plans</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Except as required by applicable Laws, the employment of each of the Company&#146;s employees located in the United States is terminable
by the Company at will. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) None of the members of the Company Group is a party to, has no duty to bargain for, nor is currently
negotiating in connection with entering into, any collective bargaining agreement or other Contract with a labor organization or works council representing any of its employees and there are no labor organizations or works councils representing,
purporting to represent or, to the knowledge of the Company, seeking to represent any employees of the Company Group. Since January&nbsp;1, 2021, through the date of this Agreement, there has not been any strike, slowdown, work stoppage, lockout,
picketing or labor dispute, or any threat thereof affecting the Company Group or any of its employees. Since January&nbsp;1, 2021, and except for those matters that would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect, the Company Group has complied with all applicable Laws related to employment and employment practices, including any pertaining to payment wages and hours of work, leaves of absence, plant closing notifications,
employment statutes or regulations, workplace health and safety, retaliation, or discrimination matters, including charges of unfair labor practices or harassment complaints, and, as of the date of this Agreement, there is no material Legal
Proceeding pending or, to the knowledge of the Company, threatened in writing relating to such applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the knowledge
of the Company, in the last five years, (A)&nbsp;no allegations of sexual harassment, discrimination or sexual misconduct have been made against any member of the Company Board or any officer of the Company Group subject to the reporting
requirements of Section&nbsp;16(a) of the Exchange Act, (B)&nbsp;no member of the Company Group has entered into any settlement agreement related to allegations of sexual harassment, discrimination or sexual misconduct by any member of the Company
Board or any officer of the Company Group subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act and (C)&nbsp;there have been no, and there are no proceedings currently pending or, to the knowledge of the Company,
threatened, related to any allegations of sexual harassment, discrimination or sexual misconduct by any member of the Company Board or any officer of the Company Group subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Section 6.1(q)(iv) of the Company Disclosure Schedule sets forth a true and complete list of the material Employee Agreements as of
the date of this Agreement (A)&nbsp;the terms of which obligate the Company or any member of the Company Group to provide any severance or termination benefits to any employee, other than as may be required by applicable Laws; or (B)&nbsp;pursuant
to which the Company or any member of the Company Group is obligated to provide any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control,</FONT></FONT> retention, or similar payment or benefits to any employee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Section 6.1(q)(v) of the Company Disclosure Schedule sets forth a true and complete
list of the material Employee Plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) The Company has made available to Parent or Parent&#146;s Representatives prior to the
execution of this Agreement with respect to each material Employee Plan accurate and complete copies of the following (other than equity grant notices, and related documentation, with respect to employees of the Company Group and agreements with
consultants entered into in the ordinary course of business), as relevant: (A)&nbsp;all plan documents and all amendments thereto, and all related trust or other funding documents; (B)&nbsp;any currently effective determination letter or opinion
letter received from the United States Internal Revenue Service; (C)&nbsp;the most recent annual actuarial valuation and the most recent Form 5500; (D)&nbsp;the most recent summary plan descriptions and any material modifications thereto;
(E)&nbsp;the most recent nondiscrimination tests required to be performed under the Code; and (F)&nbsp;copies of any <FONT STYLE="white-space:nowrap">non-routine</FONT> correspondence with any Governmental Entity in the past two years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Neither any member of the Company Group nor any other Person who would be or, at any relevant time, would have been considered a single
employer with the Company under the Code or ERISA has during the past six years maintained, contributed to, or been required to contribute to a plan subject to Title IV of ERISA or Code Section&nbsp;412, including any &#147;single employer&#148;
defined benefit plan or any &#147;multiemployer plan&#148; each as defined in Section&nbsp;4001 of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Neither the Company nor
any Subsidiary has any obligation to provide, and no Employee Plan or other agreement provides any individual with the right to, a gross up, indemnification, reimbursement or other payment for any excise or additional taxes, interest or penalties
incurred pursuant to Section&nbsp;409A or Section&nbsp;4999 of the Code or due to the failure of any payment to be deductible under of Section&nbsp;280G of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) Each of the Employee Plans that is intended to be qualified under Section&nbsp;401(a) of the Code has obtained a favorable determination
letter (or opinion letter, if applicable) as to its qualified status under the Code. Except as would not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect, each of the Employee Plans and Employee
Agreements is now and has been operated in compliance with its terms and all applicable Laws, including ERISA and the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) Each
Employee Plan and Employee Agreement that is a &#147;nonqualified deferred compensation plan&#148; (within the meaning of Section&nbsp;409A of the Code) is in documentary compliance with, and has been operated and administered in all material
respects in compliance with, Section&nbsp;409A of the Code and the guidance issued by the Internal Revenue Service provided thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) Except to the extent required under Section&nbsp;601 <I>et seq</I>. of ERISA or 4980B of the Code (or any other similar state or local
Law), neither any member of the Company Group nor any Employee Plan or Employee Agreement has any obligation to provide post-employment welfare benefits to or make any payment to, or with respect to, any present or former employee, officer or
director of any member of the Company Group pursuant to any retiree medical benefit plan or other retiree welfare plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) The execution and delivery of this Agreement, shareholder or other approval of this
Agreement, or the consummation of the Transactions (including in combination with other events or circumstances) could not, (A)&nbsp;accelerate the time of payment or vesting, or materially increase the amount of, compensation or benefits due to any
such Company Employee under any Employee Agreement or Employee Plan, (B)&nbsp;directly or indirectly cause any of the members of the Company Group to transfer or set aside any material assets to fund any benefits under any Employee Agreement or
Employee Plan, (C)&nbsp;otherwise give rise to any material liability under any Employee Agreement or Employee Plan or (D)&nbsp;limit or restrict the right to merge, materially amend, terminate or transfer the assets of any Employee Agreement or
Employee Plan on or following the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) Neither the execution and delivery of this Agreement, shareholder or other
approval of this Agreement nor the consummation of the Transactions (including in combination with other events or circumstances) could result in the payment of any amount that could, individually or in combination with any other such payment,
constitute an &#147;excess parachute payment&#148; as defined in Section&nbsp;280G(b)(1) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) As of the date of this
Agreement, the Company has made available to Parent a true and complete list, as of the Company Capitalization Date, of all of the Company Share Plans, all outstanding Company Equity Awards, including, the date of grant, the type of the award, the
number of Company Shares subject to such type of award (based on the aggregate number of shares granted on the grant date and vesting on the applicable vesting date), vesting schedule and, for the Company Options, the applicable exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) <B>Environmental Matters</B>. Except for those matters that would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect, (i) (A)&nbsp;the Company Group is, and since January&nbsp;1, 2021 has been, in compliance in with all applicable Environmental Laws, which compliance includes obtaining, maintaining or complying with all Governmental
Authorizations required under Environmental Laws for the operation of their respective business, (B)&nbsp;as of the date of this Agreement, there is no investigation, suit, claim, action or Legal Proceeding relating to or arising under any Company
Group that is pending or, to the knowledge of the Company, threatened in writing against any member of the Company Group or any Owned Real Property or Leased Real Property, and (C)&nbsp;as of the date of this Agreement, since January&nbsp;1, 2021,
none of the members of the Company Group has received any written notice, report, demand, letter, claim or other information of or entered into any legally-binding agreement, Order, settlement, judgment, injunction or decree involving uncompleted,
outstanding or unresolved violations, liabilities or requirements on the part of the respective member of the Company Group relating to or arising under Environmental Laws, and (ii)&nbsp;to the knowledge of the Company (A)&nbsp;no property currently
owned or operated by any member of the Company Group (including soils, groundwater, surface water, buildings and surface and subsurface structures) is contaminated with any Hazardous Substance which could reasonably be expected to require
remediation or other action pursuant to any Environmental Law, (B)&nbsp;no member of the Company Group is subject to obligation or liability for any Hazardous Substance disposal or contamination on any Third Party property, (C)&nbsp;no natural
person has been exposed to any Hazardous Substance at a property or facility of the Company Group at levels in excess of applicable permissible exposure levels or (D)&nbsp;there are no other circumstances or conditions involving any member of the
Company Group that could reasonably be expected to result in any claim, obligation, liability, investigation, cost or restriction on the ownership, use or transfer of any property pursuant to any Environmental Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) <B>Insurance</B>. The Company has made available to Parent an accurate and complete copy
of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets and operations of the Company Group as of the date of this Agreement (collectively, the &#147;<B><I>Insurance
Policies</I></B>&#148;). All Insurance Policies are with reputable insurance carriers, provide reasonably adequate coverage for all normal risks incident to the business of the Company and its Subsidiaries as currently conducted and their respective
properties and assets, and are in character and amount reasonably comparable to that carried by Persons engaged in similar businesses and subject to the same or similar risks to the same or similar extent. Except as would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect, all such insurance policies are in full force and effect (except for any expiration thereof in accordance with its terms), no notice of cancellation or modification has
been received as of the date of this Agreement, and there is no existing default or event which, with the giving of notice or lapse of time or both, would constitute a default by any insured thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) <B>Legal Proceedings; Orders</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) As of the date of this Agreement, there is no Legal Proceeding pending and served (or, to the knowledge of the Company, pending and not
served or threatened) against any member of the Company Group or, to the knowledge of the Company, against any Company Employee in such individual&#146;s capacity as such, other than any Legal Proceedings that would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) As of the date of this Agreement, there is no Order to
which a member of the Company Group or their respective assets is subject that is reasonably likely to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) As of the date of this Agreement, no investigation or review by any Governmental Entity with respect to any member of the Company Group
is pending or, to the knowledge of the Company, is being threatened, other than any investigations or reviews that would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) <B>Corporate Authority Relative to this Agreement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company has all requisite corporate power and authority to enter into this Agreement and, subject to receipt of the Company
Shareholder Approval, to consummate the Transactions, including the Acquisition. The execution and delivery of this Agreement and the consummation of the Transactions (including the Acquisition) have been duly and validly authorized by the Company
Board and, except for (A)&nbsp;the Company Shareholder Approval and (B)&nbsp;the filing of the required documents and other actions in connection with the Scheme with, and to receipt of the required approval of the Scheme by, the Irish High Court,
and registration by the Registrar of Companies of the Court Order and a copy of the minute required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by Section&nbsp;86 of the Irish Companies Act, no other corporate proceedings on the part of the Company are necessary to authorize the consummation of the Transactions (including the
Acquisition). On or prior to the date of this Agreement, the Company Board has determined that the Transactions are fair to and in the best interests of the Company and adopted a resolution to make, subject to <U>Section</U><U></U><U>&nbsp;5.2</U>
and to the obligations of the Company Board under the Irish Takeover Rules, the Scheme Recommendation and the recommendation contemplated by <U>Section</U><U></U><U>&nbsp;3.6(b)</U>. This Agreement has been duly and validly executed and delivered by
the Company and, assuming this Agreement constitutes the valid and binding agreement of the Parent Parties, constitutes the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, subject to the
Equitable Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The execution, delivery and performance by the Company of this Agreement and the consummation by the Company
of the Transactions (including the Acquisition) require no action by or in respect of, Clearances of, or Filings with, any Governmental Entity other than (A)&nbsp;compliance with the provisions of the Irish Companies Act, (B)&nbsp;compliance with
the Irish Takeover Panel Act and the Irish Takeover Rules, (C)&nbsp;compliance with any applicable requirements of the HSR Act, (D)&nbsp;compliance with and Filings under any applicable Antitrust Laws of any
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions or Foreign Investment Laws, (E)&nbsp;compliance with any applicable requirements of the Securities Act, the Exchange Act and any other applicable U.S. state or federal securities laws or
pursuant to the rules of the Nasdaq, and (F)&nbsp;any other actions, Clearances or Filings the absence of which has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <B>No </B><B>Violation</B>. The execution, delivery and performance by the Company of this Agreement and the consummation of the
Transactions (including the Acquisition) and thereby do not and will not (i)&nbsp;contravene, conflict with, or result in any violation or breach of any provision of the Organizational Documents of the Company, (ii)&nbsp;assuming (solely with
respect to the performance under this Agreement by the Company and the consummation of the transactions contemplated by this Agreement) compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;6.1(u)(ii)</U> and receipt of the
Company Shareholder Approval, contravene, conflict with or result in any violation or breach of any provision of any applicable Law, (iii)&nbsp;assuming (solely with respect to the performance under this Agreement by the Company and the consummation
of the transactions contemplated by this Agreement) compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;6.1(u)(ii)</U>, receipt of the Company Shareholder Approval, the Company Notes are discharged at or prior to the Effective
Time, and the Company Credit Agreement is terminated and repaid in full at or prior to the Effective Time, require any Clearance or other action by any Person under, constitute a default, or an event that, with or without notice or lapse of time or
both, would constitute a default under, result in additional payment obligations under or cause or permit the termination, cancellation, acceleration or other change of any right or obligation or the loss of any benefit to which any member of the
Company Group is entitled under, any provision of any Material Contract binding upon any member of the Company Group or affecting, or relating in any way to, the assets or business of the Company and its Subsidiaries, or (iv)&nbsp;result in the
creation or imposition of any Lien (other than Permitted Liens) on any asset or property of the Company or any of its Subsidiaries, except, in the case of each of <U>clauses (ii)</U>&nbsp;through <U>(iv)</U>, as has not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) <B>Information Supplied</B>. The information provided by and relating to the Company and
its Subsidiaries to be contained in the Scheme Document, the Proxy Statement and any other documents filed or furnished with or to the Irish High Court, the SEC or pursuant to the Irish Companies Act and the Irish Takeover Rules in each case in
connection with the Acquisition will not, on the date the Scheme Document and the Proxy Statement (and any amendment or supplement thereto) is first mailed to the Company Shareholders and at the time of the Scheme Meeting, contain any untrue
statement of any material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, at the time and in light of the circumstances under which they were made, not false or misleading.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) <B>Fairness Opinion</B>. The Company Board (in such capacity) has received the opinion of Morgan Stanley&nbsp;&amp; Co LLC, as
financial advisor to the Company, on or prior to the date of this Agreement, to the effect that, as of the date of such opinion and based on and subject to the matters set out therein, including the various assumptions made, procedures followed,
matters considered and qualifications and limitations set out therein, the Consideration to be paid to the holders of Company Shares pursuant to this Agreement is fair, from a financial point of view, to such holders, and as of the date of this
Agreement the foregoing opinion has not been withdrawn, revoked or modified in any respect. It is agreed and understood that such opinion is for the benefit of the Company Board. The Company shall deliver or make available to Parent solely for
informational purposes a copy of the signed opinion as soon as practicable following the Company&#146;s receipt of such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y)
<B>Brokers and Other Advisors</B>. Except for Morgan Stanley&nbsp;&amp; Co LLC and J.P. Morgan LLC, no broker, finder, investment banker, financial advisor or other Person is entitled to any brokerage, finder&#146;s or other similar fee or
commission, or the reimbursement of expenses in connection therewith, in connection with the Transactions based upon arrangements made by or on behalf of the Company. The Company has made available to Parent (on an &#147;outside counsel only&#148;
basis) correct and complete copies of all Contracts pursuant to which any broker, finder, investment banker, financial advisor or other Person is entitled to any fees, rights to indemnification and expenses in connection with any of the
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) <B>No Other Representations or Warranties; Acknowledgment by the Company</B>. Except for the representations and
warranties expressly set out in this <U>Section</U><U></U><U>&nbsp;6.1</U>, none of the members of the Company Group nor any of their Affiliates nor any other Person on behalf of any of them is making or has made any express or implied
representation or warranties of any kind or nature whatsoever, including with respect to the Company Group or its respective businesses or with respect to any other information made available to Parent, Acquirer Sub or their Representatives in
connection with the Transactions, including the accuracy or completeness thereof and the Company hereby expressly disclaims any such other representations and warranties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Parent Representations and Warranties</B>. Subject to <U>Section</U><U></U><U>&nbsp;10.8</U>, each of Parent and Acquirer Sub
jointly and severally represents and warrants to the Company as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Qualification and Organization</B>. Each Parent Party is a legal entity duly
organized, validly existing and in good standing under the laws of its jurisdiction of organization. Each Parent Party has all requisite corporate power and authority required to own or lease all of its properties or assets and to carry on its
business as now conducted. Each Parent Party is duly qualified to do business and is in good standing in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified or in good standing has
not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. Prior to the date of this Agreement, Parent has made available to the Company true and complete copies of the Organizational
Documents of each of Parent and Acquirer Sub, in each case, as in effect on the date of this Agreement. Acquirer Sub was formed solely for the purpose of engaging in the Transactions and activities incidental thereto and has not engaged in any
business activities or conducted any operations other than in connection with the Transactions and those incident to its formation. Either Parent or a wholly owned subsidiary of Parent owns beneficially and of record all of the outstanding capital
stock of Acquirer Sub. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Corporate Authority Relative to this Agreement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each of Parent and Acquirer Sub has all requisite corporate power and authority to enter into this Agreement and, with respect to Parent,
to consummate the Transactions, including the Acquisition. The execution and delivery of this Agreement and the consummation of the Transactions (including the Acquisition) have been duly and validly authorized by the Parent board and, except for
the filing of the required documents in connection with the Scheme with, and to receipt of the required approval of the Scheme by, the Irish High Court, no other corporate proceedings on the part of Parent or Acquirer Sub are necessary to authorize
the consummation of the Transactions (including the Acquisition). This Agreement has been duly and validly executed and delivered by Parent and Acquirer Sub and, assuming this Agreement constitutes the valid and binding agreement of the Company,
constitutes the valid and binding agreement of Parent and Acquirer Sub, enforceable against Parent and Acquirer Sub in accordance with its terms, subject to the Equitable Exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The execution, delivery and performance by Parent and Acquirer Sub of this Agreement (in the case of Parent, and the consummation by
Parent and Acquirer Sub of the Transactions (including the Acquisition)) require no action by or in respect of, Clearances of, or Filings with, any Governmental Entity other than (A)&nbsp;compliance with the provisions of the Irish Companies Act,
(B)&nbsp;compliance with the Irish Takeover Panel Act and the Irish Takeover Rules, (C)&nbsp;compliance with any applicable requirements of the HSR Act, (D)&nbsp;compliance with and Filings under any Antitrust Laws of any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions or any Foreign Investment Laws, (E)&nbsp;compliance with any applicable requirements of the Securities Act, the Exchange Act and any other applicable U.S. state or federal securities laws or
pursuant to the rules of the Nasdaq, and (F)&nbsp;any other actions, Clearances or Filings the absence of which has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B>No Violation</B>. Assuming compliance with the Scheme, the Act and any directions or orders of the Irish High Court, the execution,
delivery and performance by Parent and Acquirer Sub of this Agreement and the consummation of the Transactions (including the Acquisition) do not and will not (A)&nbsp;contravene, conflict with, or result in any violation or breach of any provision
of the Organizational Documents of Parent or Acquirer Sub, (B)&nbsp;assuming compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;6.2(b)(ii),</U> contravene, conflict with or result in any violation or breach of any provision of
any applicable Law, (C)&nbsp;assuming compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;6.2(b)(ii),</U> require any Clearance or other action by any Person under, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constitute a default, or an event that, with or without notice or lapse of time or both, would constitute a default, under, or cause or permit the termination, cancellation, acceleration or other
change of any right or obligation or the loss of any benefit to which Parent or any of its Subsidiaries is entitled under, any provision of any Parent permit or any Contract binding upon Parent or any of its Subsidiaries or affecting, or relating in
any way to, the assets or business of Parent and its Subsidiaries, or (D)&nbsp;result in the creation or imposition of any Lien on any asset of Parent or any of its Subsidiaries, except, in the case of each of <U>clauses (B)</U>&nbsp;through
<U>(D)</U>, as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B>Investigations; Litigation</B>. As of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of Parent,
threatened in writing against or affecting Parent, any of its Subsidiaries, any present or former officers, directors or employees of Parent or any of its Subsidiaries in their respective capacities as such, or any of the respective properties or
assets of Parent or any of its Subsidiaries, before (or, in the case of threatened Legal Proceedings, that would be before) any Governmental Entity (i)&nbsp;that has been or would reasonably be expected to have, individually or in the aggregate, a
Parent Material Adverse Effect or (ii)&nbsp;that would in any manner challenge or seek to prevent, enjoin or alter any of the other Transactions. As of the date of this Agreement, there is no Order outstanding or, to the knowledge of Parent,
threatened in writing against or affecting Parent, any of its Subsidiaries, any present or former officers, directors or employees of Parent or any of its Subsidiaries in their respective capacities as such, or any of the respective properties or
assets of any of Parent or any of its Subsidiaries, that has been or would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B>Ownership of Shares</B>. Neither Parent nor any of Parent&#146;s Affiliates directly or indirectly owns, and at all times for the past
three years, neither Parent nor any of Parent&#146;s controlled Affiliates has owned, beneficially or otherwise, any Company Share or any securities, contracts or obligations convertible into or exercisable or exchangeable for Company Share. Neither
Parent nor Acquirer Sub has enacted or will enact a plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act covering the purchase of any of the shares of the Company&#146;s capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B>Information Supplied</B>. The information provided by and relating to Parent and its Affiliates to be contained in the Scheme Document,
the Proxy Statement and any other documents filed or furnished with or to the Irish High Court, the SEC or pursuant to the Irish Companies Act and the Irish Takeover Rules in each case in connection with the Acquisition will not, on the date the
Scheme Document and the Proxy Statement (and any amendment or supplement thereto) is first proposed to the Company Shareholders and at the time of the Scheme Meeting, contain any untrue statement of any material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements therein, at the time and in light of the circumstances under which they were made, not false or misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <B>Financing</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
From the date of this Agreement to and including the Completion (or if earlier, the termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>), Parent and Acquirer Sub shall have, at all times, sufficient
cash, available lines of credit or other sources of immediately available and cleared funds to enable Parent and Acquirer Sub to make all required payments payable on the Completion in connection with the Transactions, including the payment of
expenses and fees (such amounts, collectively, the &#147;<B><I>Financing Amounts</I></B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) As of the date of this Agreement, Parent has delivered to the Company true, correct
and complete copies, dated as of the date of this Agreement, of the fully executed Debt Agreement, together with all attached exhibits, schedules and annexes, and the fee letters (which may be redacted as described below) associated therewith (but
excluding any side letters or other similar agreements which do not impact the amount or availability of the Financing or amend or, waive any of the terms of the Debt Agreement or expand the conditions to obtaining the Financing on or before the
occurrence of Completion), to provide to Parent the amount of financing set forth in the Debt Agreement, in order to consummate the Transactions. As of the date of this Agreement, a true, correct and complete copy of each fee letter related to the
Debt Agreement as in effect on the date of this Agreement has been provided to the Company, except that the fees and other customary &#147;flex&#148; terms (including provisions in such fee letter related to fees and economic terms) may have been
redacted; <I>provided, however</I>, that no redacted term provides that the aggregate amount or net cash proceeds of the Financing set forth in the unredacted portion of the Debt Agreement could be reduced or adds or modifies any conditions or
contingencies that affect the availability of all or any portion of the Financing. Parent has fully paid (or caused to be paid) all commitment and other fees, if any, required by the Debt Agreement that are due and payable on or before the date of
this Agreement. As of the date of this Agreement and other than as set forth in the Debt Agreement and assuming the satisfaction or waiver of each of the Conditions at Completion, there are no conditions precedent to the funding of the full amount
of the Financing as necessary to consummate the transactions contemplated by this Agreement and to satisfy all of the payment and other obligations of Parent and Acquirer Sub under this Agreement, and there are no contractual contingencies or other
provisions under any agreement (including any side letters) relating to the Transactions to which Parent or Acquirer Sub or any of their respective Affiliates is a party that would permit the Financing Sources to reduce the total amount of the
Financing or impose any additional conditions precedent to the availability of the Financing or that could affect the timing, termination or availability of the Financing necessary to consummate the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) As of the date of this Agreement, the Debt Agreement is a valid and binding obligation of Parent and, to the knowledge of Parent, each
other party thereto, and is enforceable in accordance with its terms, subject, in each case, to Equitable Exceptions, and in full force and effect, and has not been amended, modified, withdrawn, terminated or rescinded in any respect. No such
amendment, modification, withdrawal termination, or rescission is contemplated by Parent or, to the knowledge of Parent, any other party thereto (other than as set forth therein with respect to &#147;flex&#148; rights and/or to add additional
lenders, arrangers, bookrunners, syndication agents and similar entities who had not executed the Debt Agreement as of the date of this Agreement). As of the date of this Agreement, assuming that each of the Conditions are satisfied at Completion,
no event has occurred that (with or without notice, lapse of time or both) constitutes a breach or default under the Debt Agreement on the part of Parent. Other than customary engagement letters, the redacted fee letters provided in accordance with
<U>clause (ii)</U>&nbsp;above or nondisclosure or <FONT STYLE="white-space:nowrap">non-reliance</FONT> agreements which do not impact the conditionality or aggregate amount of the Financing, as of the date of this Agreement, there are no other
contracts or side letters, or arrangements to which Parent or any of its Affiliates is a party related to the Financing, other than as expressly contained in the Debt Agreement or otherwise delivered to the Company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
As of the date of this Agreement, Parent does not have any reason to believe that any of the conditions to the Financing will not be satisfied or, assuming satisfaction or waiver of the
conditions to the Financing, that the Financing will not be available to Parent on the date on which Completion shall occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)
Notwithstanding anything contained in this Agreement to the contrary, the obligations of the Parent Parties under this Agreement, including their obligations to consummate the Completion, are not conditioned in any manner upon the Parent Parties
obtaining the Financing or any other financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <B>No Other Representations or Warranties; Acknowledgment by Parent and Acquirer
Sub</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Except for the representations and warranties expressly set out in this <U>Section</U><U></U><U>&nbsp;6.2</U>, neither
Parent nor Acquirer Sub nor any of their Affiliates nor any other Person on behalf of any of them is making or has made any express or implied representation or warranties of any kind or nature whatsoever, including with respect to Parent, Acquirer
Sub or their respective businesses or with respect to any other information made available to the Company Group or its Representatives in connection with the Transactions, including the accuracy or completeness thereof and Parent and Acquirer Sub
hereby expressly disclaim any such other representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Parent and Acquirer Sub acknowledge and agree that, except
for the representations and warranties made by the Company in this Agreement (as qualified by the Company Disclosure Schedule), none of the members of the Company Group nor any of their Affiliates nor any other Person is making or has made any
representations or warranties, expressed or implied, at law or in equity, with respect to or on behalf of the Company Group, its businesses, operations, assets, liabilities, financial condition, results of operations, future operating or financial
results, estimates, projections, forecasts, plans or prospects (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any information regarding the
Company or any member of the Company Group or any other matter made available to Parent, Acquirer Sub or their Representatives in expectation of, or in connection with, this Agreement or the Transactions. Neither Parent nor Acquirer Sub is relying
upon and each of Parent and Acquirer Sub specifically disclaims that it is relying upon or has relied upon any such other representations or warranties that may have been made by any Person and acknowledges and agrees that the Company and each
member of the Company Group and their Affiliates have specifically disclaimed any such other representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)
Parent and Acquirer Sub have conducted their own independent investigation of the Company and the Company Group and the Transactions and have had an opportunity to discuss and ask questions regarding the Company and the Company Groups&#146;
businesses with the management of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;7. ADDITIONAL AGREEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Access to Information; Confidentiality; Notices of Certain Events</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon reasonable notice, the Company shall, and shall cause its Subsidiaries to, afford to Parent, its Subsidiaries and its and their
respective Representatives and Financing Sources, reasonable access during normal business hours, during the period from the date of this Agreement to the earlier of the Completion and the date, if any, on which this Agreement is validly terminated
pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, to (i)&nbsp;its and its Subsidiaries&#146; properties, contracts, commitments and books and records and (ii)&nbsp;all other information not made available pursuant to <U>clause
(i)</U>&nbsp;of this <U>Section</U><U></U><U>&nbsp;7.1(a)</U> concerning its and its Subsidiaries&#146; businesses, properties and personnel as Parent may reasonably request; <I>provided, however,</I> that any such access shall be conducted at
Parent&#146;s expense, at a reasonable time and in compliance with then-applicable local <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures, under the supervision of appropriate personnel of the Company and in such a manner as not to
unreasonably interfere with the normal operation of the business of the Company and its Subsidiaries; <I>provided, further</I>,<I> </I>that the Company shall be permitted to provide such information electronically or by other remote access where
practicable. Any such access shall be subject to the Company&#146;s reasonable security measures and insurance requirements and shall not include invasive testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of <U>Section</U><U></U><U>&nbsp;7.1(a)</U> (and subject to the limitations set forth therein), during the
period from the date of this Agreement to the earlier of the Completion and the date, if any, on which the Agreement is validly terminated pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, the Company agrees to, and to cause
its Subsidiaries to, subject to applicable Law including Antitrust Law, (i)&nbsp;reasonably assist and reasonably cooperate with Parent and its Subsidiaries (A)&nbsp;to facilitate the post-Completion integration of the Company Group with Parent and
its Subsidiaries (including, at the request of Parent from time to time, reasonably assisting and cooperating with Parent and its Affiliates in the planning and development of a post-Completion integration plan) and (B)&nbsp;by making reasonably
available relevant Third Party advisors and employees on a mutually convenient basis, at the reasonable request of Parent from time to time, for post-Completion Tax planning and other Tax matters related to this Agreement (including any matters
described in <U>Section</U><U></U><U>&nbsp;7.13</U> or any other planning that is aimed at preserving or obtaining a Tax basis step up in the assets of the Company and its Subsidiaries for applicable Tax purposes, it being understood and agreed that
neither the Company nor any of its Subsidiaries makes any representations regarding the availability or effectiveness of such Tax planning); <I>provided</I>, that (1)&nbsp;the Company is not hereby required (before the Completion) to make any Tax
elections, transfers of entities, or take any other action or step that may be requested by Parent that (x)&nbsp;would have a greater than a <I>de minimis</I> effect on the Company or any of its Subsidiaries or shareholders, or (y)&nbsp;would
reasonably be expected to prevent or delay the Completion, (2)&nbsp;Parent shall indemnify the Company for any and all costs and expenses (including any Taxes) that may result from any election or restructuring, or any other action as to which the
Company incurs material costs and expenses, in each case requested by Parent from the Company or its Subsidiaries pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(b)(i)(B)</U>; and (3)&nbsp;that such cooperation shall not require any party to
disclose any information subject to applicable privileges, including the attorney-client privilege, and (ii)&nbsp;provide reasonable access to key personnel identified by Parent to facilitate Parent&#146;s efforts with respect to the post-Completion
retention of such key personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;7.1</U>
or <U>Section</U><U></U><U>&nbsp;7.2</U>, neither the Company nor any of its respective Subsidiaries shall be required to provide access to, disclose information to or assist or cooperate with Parent, its Subsidiaries and its and their respective
Representatives in each case if and to the extent such access, disclosure, assistance or cooperation (i)&nbsp;would jeopardize any attorney-client privilege with respect to such information, or (ii)&nbsp;would, as reasonably determined based on the
advice of outside counsel, contravene any applicable Law or confidentiality obligations in any Contract to which any member of the Company Group is subject or bound; <I>provided</I> that the Company shall, and shall cause its Subsidiaries to, use
reasonable best efforts to make appropriate substitute disclosure arrangements under circumstances in which such restrictions apply (including redacting such information (A)&nbsp;to remove references concerning valuation of the Company Group,
(B)&nbsp;as necessary to comply with any Contract in effect on the date of this Agreement or after the date of this Agreement or with applicable Laws and (C)&nbsp;as necessary to address reasonable attorney-client, work-product or other privilege or
confidentiality concerns, or entering into a joint defense or other arrangement) and to provide such information as to the applicable matter as can be conveyed. Each of the Company and Parent may, as each deems advisable and necessary, reasonably
designate any competitively sensitive material provided to the other under this <U>Section</U><U></U><U>&nbsp;7.1</U> or <U>Section</U><U></U><U>&nbsp;7.2</U> as &#147;Outside Counsel Only Material.&#148; Such materials and the information contained
therein shall be given only to the outside counsel of the recipient and, subject to any additional confidentiality or joint defense agreement the Parties may mutually propose and enter into, will not be disclosed by such outside counsel to
employees, officers or directors of the recipient unless express permission is obtained in advance from the source of the materials (the Company or Parent, as the case may be) or its legal counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each Party shall promptly notify and provide copies to the other Party of the occurrence of any event which would or would reasonably be
expected to (A)&nbsp;prevent or materially delay the consummation of the Scheme, the Acquisition or the other Transactions or (B)&nbsp;result in the failure of any Condition; <I>provided</I> that the delivery of any notice pursuant to this
<U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not in and of itself (i)&nbsp;affect or be deemed to modify any representation, warranty, covenant, right, remedy, or condition to any obligation of any Party hereunder or (ii)&nbsp;update any section
of the Company Disclosure Schedule. A failure of either Party to provide information pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not constitute a breach for purposes of any Condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Parties hereby agree that all information provided to them or their respective Representatives pursuant to this Agreement shall be
subject to the Confidentiality Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Consents and Regulatory Approvals</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The terms of the Acquisition at the date of publication of the Scheme Document shall be set out in the Rule 2.7 Announcement and the
Scheme Document, to the extent required by applicable Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and conditions of this Agreement, each Party shall, and each shall
cause its Subsidiaries to, use its respective reasonable best efforts to take, or cause to be taken, (i)&nbsp;all actions and to do, or cause to be done, all things necessary, proper or advisable, to the extent permitted by applicable Laws, to
achieve satisfaction of the Conditions and to consummate the Acquisition and the other Transactions and (ii)&nbsp;all actions, to file, or cause to be filed, all documents and to do, or cause to be done, and to assist and cooperate with the other
Parties in doing, all things necessary, proper or advisable under applicable Antitrust Laws to consummate and make effective the Transactions as soon as reasonably practicable, including: (A)&nbsp;the obtaining of all necessary Clearances and
expirations or terminations of waiting periods from Governmental Entities and the making of all necessary registrations and filings and the taking of all steps as may be necessary to obtain any such Clearances or expiration or termination of a
waiting period by or from, or to avoid an action or proceeding by, any Governmental Entity in connection with any Antitrust Law, (B)&nbsp;the obtaining of all necessary Clearances from Third Parties, and (C)&nbsp;the execution and delivery of any
additional instruments necessary to consummate the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In furtherance and not in limitation of the foregoing, the Parties
agree to use reasonable best efforts to, and cause their Affiliates to use reasonable best efforts to, promptly take all actions and steps requested or required by any Governmental Entity as a condition to granting any Clearances, and to cause the
prompt expiration or termination of any applicable waiting period and to resolve objections, if any, of the FTC or DOJ, or other Governmental Entities of any Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction so as to obtain such
Clearances under the HSR Act or other Antitrust Laws, and to avoid the commencement of a lawsuit by the FTC, the DOJ or other Governmental Entities under Antitrust Laws, and to avoid the entry of, or to effect the dissolution of, any Order in any
Legal Proceeding which would otherwise have the effect of preventing the Completion or delaying the Completion beyond the End Date, including (i)&nbsp;negotiating, committing to and effecting, by consent decree, hold separate order or otherwise, the
sale, lease, license, divestiture or disposition of any assets, rights, product lines, or businesses of the Company or any of its Subsidiaries, (ii)&nbsp;terminating existing relationships, contractual rights or obligations of the Company or any of
its Subsidiaries, (iii)&nbsp;terminating any venture or other arrangement of the Company or any of its Subsidiaries, (iv)&nbsp;creating any relationship, contractual rights or obligations of the Company or any of its Subsidiaries,
(v)&nbsp;effectuating any other change or restructuring of the Company or any of its Subsidiaries and (vi)&nbsp;otherwise taking or committing to take any actions with respect to the businesses, product lines or assets of the Company or any of its
Subsidiaries (the actions referred to in <U>clauses (i)</U>&nbsp;through <U>(vi)</U>, collectively, &#147;<B><I>Remedy Actions</I></B>&#148;); <I>provided, however</I>, that, notwithstanding anything to the contrary herein (including the
&#147;reasonable best efforts standard&#148; set forth in <U>Section</U><U></U><U>&nbsp;7.2(b)</U>), neither Parent nor any of its Affiliates shall be required to proffer, consent to or agree to or effect any Remedy Action (x)&nbsp;with respect to
any assets, categories of assets or portions of any business of the Company or any of its Subsidiaries if, in each case, any such Remedy Action would, individually or in the aggregate, reasonably be expected to be material to the business, assets or
financial condition of the Company and its Subsidiaries, taken as a whole or (y)&nbsp;with respect to the items listed on Section&nbsp;7.2(c) of the Company Disclosure Schedule or (z)&nbsp;for the avoidance of doubt, with respect to any assets,
categories of assets or portions of any business of Parent or its Affiliates (such effect referred to in <U>clauses (x)</U>, <U>(y)</U>, or <U>(z)</U>, a &#147;<B><I>Burdensome Condition</I></B>&#148;); <I>provided</I>,<I> further</I>, that the
Company shall only be permitted to take or commit to take such Remedy Action with the prior written consent of Parent; provided, further, that Parent may only require the Company to take or commit to take any such Remedy Action if such Remedy Action
is binding on the Company only in the event the Completion occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to the terms and conditions of this Agreement, each of the Parties hereto shall
(and shall cause their respective Affiliates, if applicable, to)&nbsp;(i) promptly, but in no event later than 15 Business Days after the date of this Agreement (or such later date as may be agreed in writing among the Parties), make an appropriate
filing of all Notification and Report forms as required by the HSR Act with respect to the Transactions and (ii)&nbsp;as promptly as reasonably practicable after the date of this Agreement and in any event no later than January&nbsp;16, 2023 (or
such later date as may be agreed in writing among the Parties), make all other filings, notifications or other consents as may be required to be made or obtained by such Party under foreign Antitrust Laws or Foreign Investment Laws in those
jurisdictions identified in Section&nbsp;7.2(d) of the Company Disclosure Schedule, which contains the list of the only non U.S. jurisdictions where filing, notification, expiration of a waiting period or consent or approval is a condition to
Completion as agreed by the Parties (each, a &#147;<B><I>Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Parent shall consult in advance with the Company, and take into account in good faith the views of the Company, regarding the strategy for
all matters with any Governmental Entity; <I>provided, that</I>, in the event of a disagreement regarding such strategy, the determination of Parent shall be final so long as consistent with its obligations hereunder. Notwithstanding anything in
this Agreement to the contrary, neither Party shall commit to or agree with any Governmental Entity to stay, toll or extend any applicable waiting period under the HSR Act, or pull and refile under the HSR Act, or other applicable Antitrust Laws or
Foreign Investment Laws, without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed). Without limiting the generality of anything contained in this
<U>Section</U><U></U><U>&nbsp;7.2</U>, each Party hereto shall use its reasonable best efforts to (i)&nbsp;cooperate in all respects and consult with each other in connection with any filing or submission in connection with any investigation or
other inquiry, including allowing the other Party to have a reasonable opportunity to review in advance and comment on drafts of filings and submissions, in each case, as required under applicable Antitrust Laws, (ii)&nbsp;give the other Parties
prompt notice of the making or commencement of any request, inquiry, investigation or Legal Proceeding brought by a Governmental Entity or brought by a Third Party before any Governmental Entity, in each case, with respect to the Transactions under
applicable Antitrust Laws, (iii)&nbsp;promptly keep the other Parties informed as to the status of any such request, inquiry, investigation, action or Legal Proceeding under applicable Antitrust Laws, (iv)&nbsp;promptly inform the other Parties of
any communication to or from the FTC, DOJ or any other Governmental Entity in connection with any such request, inquiry, investigation or Legal Proceeding under applicable Antitrust Laws, (v)&nbsp;promptly furnish to the other Party, subject to an
appropriate confidentiality agreement to limit disclosure to outside counsel and consultants retained by such counsel, with copies of documents, communications or materials provided to or received from any Governmental Entity in connection with any
such request, inquiry, investigation, action or Legal Proceeding under applicable Antitrust Laws, (vi)&nbsp;subject to an appropriate confidentiality agreement to limit disclosure to counsel and outside consultants retained by such counsel, and to
the extent reasonably practicable, consult in advance and cooperate with the other Parties and consider in good faith the views of the other Parties in connection with any substantive communication, analysis, appearance, presentation, memorandum,
brief, argument, opinion or proposal to be made or submitted in connection with any such request, inquiry, investigation, action or Legal Proceeding under applicable Antitrust laws and (vii)&nbsp;except as may be prohibited by any Governmental
Entity or by any Law, in connection with any such request, inquiry, investigation or Legal Proceeding in respect of the Transactions, each Party shall provide advance notice of and permit authorized Representatives of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the other Party to be present at each meeting or conference relating to such request, inquiry, investigation or Legal Proceeding under applicable Antitrust Laws and to have access to and be
consulted in advance in connection with any argument, opinion or proposal to be made or submitted to any Governmental Entity in connection with such request, inquiry, investigation or Legal Proceeding under applicable Antitrust Laws; <I>provided</I>
that documents and information provided to the other Party pursuant to this paragraph may be redacted (A)&nbsp;to remove references to valuation of the Company or the identity of alternative acquirers, (B)&nbsp;to comply with contractual
arrangements, or (C)&nbsp;to protect privilege, and may be limited to outside counsel and outside consultants retained by such counsel. Each Party shall supply as promptly as practicable such information, documentation, other material or testimony
that may be reasonably requested by any Governmental Entity, including by responding at the earliest reasonably practicable date with any request for additional information, documents or other materials, including any &#147;second request&#148;
under the HSR Act, received by any Party or any of their respective Subsidiaries from any Governmental Entity in connection with such applications or filings for the Transactions under applicable Antitrust Laws. Parent and Acquirer Sub shall pay all
filing fees under the HSR Act and for any filings required under Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdictions, but the Company shall bear its own costs for the preparation of any such filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Parent agrees that it shall not, and shall not permit any of its controlled Affiliates to, directly or indirectly, acquire or agree to
acquire any assets, business or any Person (whether by merger, consolidation, license, purchasing a substantial portion of the assets of or equity in any Person or by any other manner) if the entering into of an agreement relating to or the
consummation of such acquisition, merger, consolidation or purchase, whether individually or in the aggregate, would reasonably be expected to (i)&nbsp;impose any material delay in the expiration or termination of any applicable waiting period or
impose any material delay in the obtaining of, or increase the risk of not obtaining, any Clearance under the HSR Act or any other Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction, (ii)&nbsp;materially increase the risk of any
Governmental Entity entering any permanent, preliminary or temporary injunction or other order, decree, decision, determination or judgment that would materially delay, restrain, prevent, enjoin or otherwise prohibit consummation of the Acquisition
and the other Transactions or (iii)&nbsp;otherwise prevent the consummation of the Acquisition and the Transactions by the End Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
In the event that the latest date on which the Irish High Court or the Irish Takeover Panel would permit Completion to occur is prior to the End Date, the Parties shall use their respective reasonable best efforts to obtain consent of the Irish High
Court or the Irish Takeover Panel, as applicable, to an extension of such latest date (but not beyond the End Date). If (i)&nbsp;the Irish High Court or the Irish Takeover Panel require the lapsing of the Scheme prior to the End Date, or
(ii)&nbsp;the Condition set out in paragraph 1 of the Conditions fails to be satisfied, the Parties shall (unless and until this Agreement is terminated pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>) take all reasonable
actions required in order to <FONT STYLE="white-space:nowrap">re-initiate</FONT> the Scheme process as promptly as practicable (it being understood that no such lapsing described in <U>clause (i)</U>&nbsp;or <U>(ii)</U> shall, in and of itself,
result in a termination of, or otherwise affect any rights or obligations of any Party under, this Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Directors</B><B>&#146;</B><B> and Officers</B><B>&#146;</B><B> Indemnification
and Insurance</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of not less than six years from the Effective Date, Parent shall cause the Company or any applicable
Subsidiary thereof (collectively, the &#147;<B><I>D&amp;O Indemnifying Parties</I></B>&#148;), to the fullest extent each such D&amp;O Indemnifying Party is so authorized or permitted by applicable Laws, as now or hereafter in effect, to:
(i)&nbsp;indemnify and hold harmless, to the fullest extent permitted under the applicable Laws and pursuant to existing arrangements and Organizational Documents of the Company Group (as in effect as of the date of this Agreement) each person who
is at the date of this Agreement, was previously, or during the period from the date of this Agreement through the date of the Effective Time, serving as a director or officer of the Company or any of its Subsidiaries, or at the request or for the
benefit of the Company or any of its Subsidiaries as a director, trustee or officer of any other entity or any benefit plan maintained by the Company or any of its Subsidiaries (collectively, the &#147;<B><I>D&amp;O Indemnified
Parties</I></B>&#148;), as in effect as of the date of this Agreement, in connection with any D&amp;O Claim and any losses, claims, damages, liabilities, Claim Expenses, judgments, fines, penalties and amounts paid in settlement (including all
interest, assessments and other charges paid or payable in connection with or in respect of any thereof) relating to or resulting from a D&amp;O Claim; and (ii)&nbsp;promptly advance to such D&amp;O Indemnified Party any Claim Expenses incurred in
defending, serving as a witness with respect to or otherwise participating with respect to any D&amp;O Claim in advance of the final disposition of such D&amp;O Claim, including payment on behalf of or advancement to the D&amp;O Indemnified Party of
any Claim Expenses incurred by such D&amp;O Indemnified Party in connection with enforcing any rights with respect to such indemnification or advancement, in each case without the requirement of any bond or other security, but subject to the D&amp;O
Indemnifying Party&#146;s receipt of a written undertaking by or on behalf of such D&amp;O Indemnified Party to repay such Claim Expenses if it is ultimately determined under applicable Laws that such D&amp;O Indemnified Party is not entitled to be
indemnified. All rights to indemnification and advancement conferred hereunder shall continue as to a Person who has ceased to be a director or officer of the Company or any of its Subsidiaries after the date of this Agreement and shall inure to the
benefit of such Person&#146;s heirs, successors, executors and personal and legal representatives. As used in this <U>Section</U><U></U><U>&nbsp;7.3</U>: (x) the term &#147;<B><I>D&amp;O Claim</I></B>&#148; means any threatened, asserted, pending or
completed Legal Proceeding, whether instituted by any Governmental Entity or any other Person, arising out of or pertaining to acts or omissions occurring at or prior to the Effective Time that relate to such D&amp;O Indemnified Party&#146;s duties
or service (A)&nbsp;as a director or officer of the Company or the applicable Subsidiary thereof at or prior to the Effective Time (including with respect to any acts, facts, events or omissions occurring in connection with the approval of this
Agreement, the Scheme, the Acquisition and the consummation of the other Transactions (including the Acquisition), including the consideration and approval thereof and the process undertaken in connection therewith) or (B)&nbsp;as a director,
trustee or officer of any other entity or any benefit plan maintained by the Company or any of its Subsidiaries (for which such D&amp;O Indemnified Party is or was serving at the request or for the benefit of the Company or any of its Subsidiaries)
at or prior to the Effective Time; and (y)&nbsp;the term &#147;<B><I>Claim Expenses</I></B>&#148; means reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#146; fees and all other
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, expenses and obligations (including experts&#146; fees, travel expenses, court costs, retainers and transcript fees) paid or incurred in
connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to investigate, defend, be a witness in or participate in any D&amp;O Claim for which indemnification is authorized pursuant to this
<U>Section</U><U></U><U>&nbsp;7.3(a)</U>, including any action relating to a claim for indemnification or advancement brought by a D&amp;O Indemnified Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For a period of not less than six years from the Effective Date, Parent shall cause the
Organizational Documents of the Company and its Subsidiaries to contain provisions no less favorable with respect to indemnification, advancement of expenses and limitations on liability of directors and officers than are set out in the
Organizational Documents of the Company and its Subsidiaries as of the date of this Agreement, which provisions shall not be amended, repealed or otherwise modified for a period of at least six years from the Effective Date in any manner that would
adversely affect the rights thereunder of any D&amp;O Indemnified Party, unless any modification or amendment is required by applicable Laws (but then only to the extent required by applicable Laws). At the Company&#146;s option and expense, prior
to the Effective Time, the Company may purchase (and pay in full the aggregate premium for) a <FONT STYLE="white-space:nowrap">six-year</FONT> prepaid &#147;tail&#148; insurance policy (which policy by its express terms shall survive the
Acquisition) of at least the same coverage and amounts and containing terms and conditions that are no less favorable to the directors and officers of the Company and its Subsidiaries as the Company&#146;s and its Subsidiaries&#146; existing
directors&#146; and officers&#146; insurance policy or policies with a claims period of six years from the Effective Time for D&amp;O Claims arising from facts, acts, events or omissions that occurred on or prior to the Effective Time;
<I>provided</I> that the premium for such tail policy shall not exceed 300% of the annual amount currently paid by the Company and its Subsidiaries for such insurance (such amount being the &#147;<B><I>Maximum Premium</I></B>&#148;). If the Company
fails to obtain such tail policy prior to the Effective Time, Parent shall obtain such a tail policy; <I>provided</I>, <I>however</I>, that the premium for such tail policy shall not be required to exceed the Maximum Premium; <I>provided</I>,
<I>further</I>, that if such tail policy cannot be obtained or can be obtained only by paying a premium in excess of the Maximum Premium, Parent shall only be required to obtain as much coverage as can be obtained by paying a premium equal to the
Maximum Premium. Parent and the Company shall cause any such policy (whether obtained by Parent or the Company) to be maintained in full force and effect, for its full term, and Parent shall, following the Effective Time, cause the Company to honor
all its obligations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If Parent or the Company or any of their respective successors or assigns (i)&nbsp;consolidates with
or merges with or into any other Person and shall not be the continuing or surviving company, partnership or other Person of such consolidation or merger or (ii)&nbsp;liquidates, dissolves or <FONT STYLE="white-space:nowrap">winds-up,</FONT> or
transfers or conveys all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Company, as applicable, assume the obligations
set out in this <U>Section</U><U></U><U>&nbsp;7.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The provisions of this <U>Section</U><U></U><U>&nbsp;7.3</U> are intended to
be for the express benefit of, and shall be enforceable by, each D&amp;O Indemnified Party (who are intended to be third party beneficiaries of this <U>Section</U><U></U><U>&nbsp;7.3</U>), his or her heirs and his or her personal Representatives,
shall be binding on all successors and assigns of Parent, and following the Effective Time, the Company. The exculpation and indemnification provided for by this <U>Section</U><U></U><U>&nbsp;7.3</U> shall not be deemed to be exclusive of any other
rights to which a D&amp;O Indemnified Party is entitled, pursuant to applicable Laws or Contract made available to Parent prior to the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B>Employment and Benefit Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From the date of Completion through the first anniversary of the Effective Time (or, if shorter, the period of employment of the relevant
Continuing Employee) (the &#147;<B><I>Benefits Continuation Period</I></B>&#148;), Parent shall provide or shall cause Acquirer Sub to provide, to (i)&nbsp;each Continuing Employee a base salary or hourly rate that is no less favorable than the base
salary or hourly rate provided to such Continuing Employee immediately prior to the Effective Time, (ii)&nbsp;each Continuing Employee target annual or quarterly cash bonus, incentive compensation (excluding any special, retention or <FONT
STYLE="white-space:nowrap">one-time</FONT> award opportunities) and commissions opportunities (as applicable) that are no less favorable than the target annual or quarterly cash bonus, incentive compensation (excluding any special, retention or <FONT
STYLE="white-space:nowrap">one-time</FONT> award opportunities) and commissions opportunities provided to such Continuing Employee immediately prior to the Effective Time, and (iii)&nbsp;to the Continuing Employees as a group, employee benefits that
are, in the aggregate, no less favorable than the employee benefits provided to similarly-situated employees of Parent and its Subsidiaries; <I>provided</I> that for purposes of determining whether such employee benefits are no less favorable in the
aggregate, any equity, defined benefit pension plan benefits, nonqualified deferred compensation, retiree health or welfare benefits, post-termination health or welfare benefits, and retention or change in control payments or awards shall not be
taken into account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In addition, Acquirer Sub shall provide, and Parent shall cause Acquirer Sub to provide, to each Continuing
Employee who experiences a termination of employment during the Benefits Continuation Period, severance, termination and similar benefits that are no less favorable than the severance, termination and similar benefits to which such Continuing
Employee would have been entitled upon such a termination of employment under any Employee Plan that is a severance plan, policy, program, agreement or arrangement and set out on Section&nbsp;7.4(b) of the Company Disclosure Schedule (collectively,
the &#147;<B><I>Severance Arrangements</I></B>&#148;) and in which such Continuing Employee was eligible to participate as of immediately prior to the Effective Time. For purposes of determining compliance with this
<U>Section</U><U></U><U>&nbsp;7.4(b)</U>, only the existing terms of the Severance Arrangements will be taken into account, and any modifications to the Severance Arrangements that are effective after the date of this Agreement but prior to the
Effective Time (and are made without Parent&#146;s advance written consent) will be disregarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of vesting, eligibility
to participate and determining level of benefits under the employee benefit plans of Parent or any Affiliate providing benefits to any Continuing Employees following the Effective Time (the &#147;<B><I>New Plans</I></B>&#148;), each Continuing
Employee shall be credited with his or her years of service with the Company Group and its predecessors before the Effective Time, to the same extent and for the same purpose as such Continuing Employee was entitled, before the Effective Time, to
credit for such service under the corresponding Employee Plan in which the Continuing Employee participated or was eligible to participate immediately prior to the Effective Time, <I>provided</I> that the foregoing shall not apply with respect to
(i)&nbsp;any defined benefit pension plan or any retiree or post-termination health or welfare benefits, (ii)&nbsp;any benefit plan that is frozen or for which participation is limited to a grandfathered population, (iii)&nbsp;any cash- or
equity-based compensation arrangements, or (iv)&nbsp;to the extent that its application would result in a duplication of benefits or compensation with respect to the same period of service, and <I>provided</I>, <I>further</I>, that such service
shall only be credited to the extent service with Parent is credited for similarly situated employees of the Parent Group under the New Plans. In addition, and without limiting the generality of the foregoing, (A)&nbsp;each Continuing Employee shall
be immediately eligible to participate, without any waiting time, in any and all New Plans to the extent coverage under such New Plan is replacing comparable coverage under an Employee Plan in which such Continuing Employee had already satisfied any
such waiting period and participated immediately before the Effective Time (such plans, collectively, the &#147;<B><I>Old Plans</I></B>&#148;), and (B)&nbsp;for purposes of each New Plan providing medical, dental,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmaceutical or vision benefits to any Continuing Employee, Parent shall use its reasonable best efforts to (1)&nbsp;cause all <FONT STYLE="white-space:nowrap">pre-existing</FONT> condition
exclusions and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">actively-at-work</FONT></FONT> requirements of such New Plan to be waived for such employee and his or her covered dependents, unless and to the extent the individual,
immediately prior to entry in the New Plans, was subject to such conditions under the comparable Old Plans, and (2)&nbsp;to the extent not prohibited by the terms, or by any third party administrator, of any New Plan that is a fully insured medical,
dental, pharmaceutical or vision benefit plan of Parent or any Affiliate, credit each Continuing Employee with all deductible payments, <FONT STYLE="white-space:nowrap">co-payments</FONT> and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by such Continuing Employee and his or her covered dependents under the medical, dental, pharmaceutical or vision benefit plans of the Company prior to the Completion during
the plan year in which the Completion occurs for the purpose of determining the extent to which such Continuing Employee has satisfied the deductible, <FONT STYLE="white-space:nowrap">co-payments</FONT> or maximum <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> requirements applicable to such Continuing Employee and his or her covered dependents for such plan year under any New Plan that is a medical, dental, pharmaceutical or vision benefit plan of
Parent or its Affiliates, as if such amounts had been paid in accordance with such plan (to the extent such credit would have been given under comparable Old Plans prior to the Completion). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Prior to the Effective Time, if requested by Parent in writing, the Company shall cause any United States
<FONT STYLE="white-space:nowrap">Tax-qualified</FONT> defined contribution plan (collectively, the &#147;<B><I>Company 401(k) Plan</I></B>&#148;) to be terminated effective immediately prior to the Effective Time. In the event that Parent requests
that the Company 401(k) Plan be terminated, the Company shall provide Parent with evidence that such Plan has been terminated (the form and substance of which shall be subject to review and approval by Parent) not later than the day immediately
preceding the Effective Time. Upon the distribution of the assets in the accounts under the Company 401(k) Plan to the participants, Parent shall permit the Continuing Employees who are then actively employed by Parent or its Subsidiaries to make
rollover contributions of &#147;eligible rollover distributions&#148; (within the meaning of Section&nbsp;401(a)(31) of the Code), in the form of cash, from the Company 401(k) Plan to the applicable
<FONT STYLE="white-space:nowrap">tax-qualified</FONT> defined contribution plans of Parent or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as permitted
pursuant to <U>Section</U><U></U><U>&nbsp;10.1</U>, prior to making any broad-based communications (written or oral) to the directors, officers or employees of the Company or any of its Subsidiaries pertaining to compensation or benefit matters that
are affected by the transactions contemplated by this Agreement, the Company shall provide Parent with a copy of the intended communication, Parent shall have a reasonable period of time to review and comment on the communication, and the Company
shall consider any such comments in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Nothing contained in this <U>Section</U><U></U><U>&nbsp;7.4</U> (whether express or
implied) shall (i)&nbsp;create or confer any rights, remedies or claims upon any employee of the Company or any of its Affiliates or any right of employment or engagement or continued employment or engagement or any particular term or condition of
employment or engagement for any Company Employee or any other Person, (ii)&nbsp;be considered or deemed to establish, amend, or modify any Employee Plan or any other benefit or compensation plan, program, policy, agreement, arrangement, or
Contract, (iii)&nbsp;prohibit or limit the ability of Parent or any of its Affiliates to amend, modify or terminate any benefit or compensation plan, program, policy, agreement, arrangement, or contract at any time assumed, established, sponsored or
maintained by any of them or (iv)&nbsp;confer any rights or benefits (including any third-party beneficiary rights) on any Person other than the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B>Employee Share Purchase Plan</B>. As promptly as reasonably practicable
following the date of this Agreement, the Company shall take all actions necessary or required under the Company ESPP and applicable Laws to (i)&nbsp;limit participation in the Company ESPP to those employees who participated in the Company ESPP
immediately prior to the execution and delivery of this Agreement, (ii)&nbsp;prevent participants from increasing their payroll deductions or purchase elections from those in effect immediately prior to the execution and delivery of this Agreement,
(iii)&nbsp;ensure that, except for any offering period in existence under the Company ESPP on the date of this Agreement, no offering period shall be authorized or commenced on or after the date of this Agreement, and no existing offering period
shall be extended, and (iv)&nbsp;if the Completion shall occur prior to the end of any offering period in existence under the Company ESPP on the date of this Agreement, cause the rights of participants in the Company ESPP with respect to any such
offering period (and purchase period thereunder) then underway under the Company ESPP to be determined by treating the last Business Day prior to the Effective Time as the last day of such offering period and purchase period. The Company shall
terminate the Company ESPP in its entirety effective as of the Effective Time, contingent upon the Effective Time. Prior to the Effective Time, the Company shall take all actions (including, if appropriate, amending the terms of the Company ESPP)
that are necessary to give effect to the transactions contemplated by this <U>Section</U><U></U><U>&nbsp;7.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B>
<B>Financing</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From and after the date hereof until the earlier of the Completion and the termination of this Agreement pursuant
to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, in a timely manner so as not to delay the Completion, the Parent Parties shall use their reasonable best efforts to (i)&nbsp;take, or cause to be taken, all appropriate action, and to
do, or cause to be done, all things necessary, proper or advisable to consummate, no later than the date the Completion is required to occur pursuant to this Agreement, the Financing on the terms set forth in the Debt Agreement and (ii)&nbsp;satisfy
or cause to be satisfied (or waived) on a timely basis all conditions to funding described in the Debt Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event any
portion of the Financing contemplated by the Debt Agreement becomes unavailable regardless of the reason therefor (as determined by Parent in its reasonable discretion after consulting with the Financing Sources), (i)&nbsp;Parent shall promptly
notify the Company in writing of such unavailability and the reason therefor and (ii)&nbsp;Parent shall use its reasonable best efforts, and shall cause each of its Subsidiaries to use their reasonable best efforts, to obtain as promptly as
practicable following the occurrence of such event, alternative debt financing for any such portion from alternative sources (the &#147;<B><I>Alternative Financing</I></B>&#148;) in an amount sufficient, when taken together with cash of Parent and
its Subsidiaries (but not including the Company and its Subsidiaries) and the other sources of funds immediately available to Parent at the Completion to pay the Financing Amounts and that do not include any conditions to the consummation of such
alternative debt financing that are more onerous than the conditions set forth in the Debt Agreement. In addition to the foregoing, the Parent may also obtain Alternative Financing at its sole discretion which replaces the Financing, so long as the
Parent is able to give the representations set forth in <U>Section</U><U></U><U>&nbsp;6.2(h)</U> with respect to such Alternative Financing as at the date such Alternative Financing becomes effective (with references to &#147;date hereof,&#148; the
&#147;Financing,&#148; &#147;Financing Sources&#148; and &#147;Debt Agreement&#148; (and other like terms) in that section deemed to have been replaced with references to the date such Alternative Financing, the commitments thereunder and the
agreements with respect thereto becomes effective). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent requested in writing by the Company from time to time, the Parent Parties
shall provide the Company with updates on a reasonably current basis on the status of the Financing. The Parent Parties shall, (i)&nbsp;to the extent not publicly filed, provide copies of all executed credit agreements and indentures and any
amendments, modifications, replacements or waivers relating to the Financing or any Indebtedness that is a takeout to the Financing (or notice that such documents have been publicly filed) within one Business Day of execution thereof and
(ii)&nbsp;provide prompt written notice (and in any event, within two Business Days) of (A)&nbsp;the receipt of any written notice or other written communication from any Financing Source with respect to such Financing Source&#146;s failure or
anticipated failure to fund its commitments under any definitive agreements relating to the Financing, (B)&nbsp;any material breach or material default by any party to such definitive agreements of which any Parent Party obtains knowledge,
(C)&nbsp;any actual or, to the knowledge of any Parent Party, threatened in writing, withdrawal, repudiation, or termination of any of such definitive agreements or (D)&nbsp;receipt of written notice or other written communication from any Financing
Source relating to a material dispute or disagreement with respect to the obligation to fund all or any portion of the Financing at Completion (but excluding, for the avoidance of doubt, any ordinary course negotiations with respect to the terms of
the Financing or the Debt Agreement); <I>provided</I> that in no event will the Parent Parties be under any obligation to disclose any information that is subject to attorney-client or similar privilege (<I>provided</I> that the Parent Parties shall
use their respective reasonable best efforts to cause any such information to be disclosed in a manner that would not result in the loss of any such privilege). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything contained in this Agreement to the contrary, the Parent Parties expressly acknowledge and agree that their
obligations under this Agreement, including their obligations to consummate the Completion, are not conditioned in any manner upon the Parent Parties obtaining the Financing or any other financing. To the extent Parent obtains Alternative Financing
pursuant to <U>Section</U><U></U><U>&nbsp;7.6(b)</U> or amends, replaces, supplements, modifies or waives any of the Financing, references to the &#147;Financing,&#148; &#147;Financing Sources&#148; and &#147;Debt Agreement&#148; (and other like
terms in this Agreement) shall be deemed to refer to such Alternative Financing, the commitments thereunder and the agreements with respect thereto, or the Financing as so amended, replaced, supplemented, modified or waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7</B> <B>Section 16 Matters</B>. Prior to the Effective Time, Parent Parties and the Company shall take all such steps as may be required
(to the extent permitted under applicable Laws) to cause any dispositions of the Company Shares (including derivative securities with respect to the Company Shares) resulting from the Transactions by each individual who is subject to the reporting
requirements of Section&nbsp;16(a) of the Exchange Act with respect to the Company, to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.8</B> <B>Financing Cooperation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Until the earlier to occur of the Completion and the termination of this Agreement pursuant to and in accordance with
<U>Section</U><U></U><U>&nbsp;9</U>, the Company shall use its reasonable best efforts, and shall cause each of its Subsidiaries to use its reasonable best efforts, and shall use its reasonable best efforts to cause its and their respective
officers, employees and advisors and other Representatives, including legal and accounting advisors, to use their reasonable best efforts, to provide to Parent and its Subsidiaries such assistance as may be reasonably requested by Parent in writing
that is customary in connection with the offering, arranging, obtaining, syndication, consummation, issuance or sale of the Financing, including using reasonable best efforts with respect to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) participating in and assisting with the due diligence, syndication or other marketing of the Financing, including using reasonable best
efforts with respect to (A)&nbsp;the participation by members of management of the Company with appropriate seniority in a reasonable number of meetings, presentations, road shows, drafting sessions, due diligence sessions and sessions with
prospective lenders, investors and rating agencies, at times and at locations reasonably acceptable to the Company and upon reasonable notice, (B)&nbsp;assisting with Parent&#146;s preparation of customary materials for registration statements,
offering documents, private placement memoranda, bank information memoranda, prospectuses, rating agency presentations, syndication documents and other syndication materials, including information memoranda, lender and investor presentations, bank
books and other marketing documents and similar documents required in connection with any portion of the Financing (collectively, &#147;<B><I>Marketing Material</I></B>&#148;) and due diligence sessions related thereto, (C)&nbsp;delivering and
consenting to the inclusion or incorporation in any SEC filing related to the Financing of the historical audited consolidated financial statements and unaudited consolidated interim financial statements of the Company included or incorporated by
reference into the Company SEC Documents (the &#147;<B><I>Historical Financial Statements</I></B>&#148;) and (D)&nbsp;delivering customary authorization letters, management representation letters, confirmations, and undertakings in connection with
the Marketing Material (in each case, as applicable, subject to customary confidentiality provisions and disclaimers); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) timely
furnishing Parent and its Financing Sources with existing historical financial and other customary information (collectively, the &#147;<B><I>Financing Information</I></B>&#148;) with respect to the Company and its Subsidiaries as is reasonably
requested by Parent or its Financing Sources and customarily required in Marketing Material for Financings of the applicable type, including all Historical Financial Statements and other customary information with respect to the Company and its
Subsidiaries (A)&nbsp;of the type that would be required by Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act if the Financing were incurred by Parent and
registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, including audit reports of annual financial statements to the extent so required, or (B)&nbsp;reasonably necessary to permit Parent to prepare pro forma
financial statements customary for Financings of the applicable type; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) providing to Parent&#146;s legal counsel and its independent
auditors such customary documents and other customary information relating to the Company and its Subsidiaries as may be reasonably requested in connection with their delivery of any customary negative assurance opinions and customary comfort
letters relating to the Financing and use reasonable best efforts to cause the Company&#146;s independent auditors to provide customary cooperation with the respect to the Financing, including by using reasonable best efforts to cause the
Company&#146;s independent auditors to provide customary comfort letters (including &#147;negative assurance&#148; comfort, if customary and appropriate) in connection with any capital markets transaction comprising a part of the Financing or
contemplated as part of any refinancing of the Financing, including at the time of pricing and closing, to the applicable Financing Sources, and by providing customary representation letters to the extent required by such independent auditor in
connection with the foregoing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) obtaining the consents of the Company&#146;s independent auditors to use their audit
reports on the audited Historical Financial Statements of the Company and to references to such independent auditors as experts in any Marketing Material and registration statements and related government filings filed or used in connection with the
Financing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) obtaining the Company&#146;s independent auditors&#146; customary assistance with the accounting due diligence activities
of the Financing Sources, including by participating in a reasonable number of diligence sessions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) provide customary authorization
letters authorizing the distribution of information related to the Company and its Subsidiaries to prospective lenders in connection with a syndicated bank financing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) assist the Parent Parties in obtaining or updating the Parent Parties&#146; corporate and facility credit ratings; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) assist the Parent Parties in the negotiation of and <FONT STYLE="white-space:nowrap">co-operate</FONT> with the Parent Parties&#146;
preparation of any credit agreement, indenture, note, purchase agreement, underwriting agreement, and such other customary closing certificates and schedules as may be reasonably requested by Parent, in each case as contemplated in connection with
the Financing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) cooperate with internal and external counsel of Parent in connection with providing customary <FONT
STYLE="white-space:nowrap">back-up</FONT> certificates and factual information regarding any legal opinion that such counsel may be required to deliver in connection with the Financing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) providing documents reasonably requested by Parent or the Financing Sources relating to the repayment or refinancing of any Indebtedness
for borrowed money of the Company or any of its Subsidiaries to be repaid or refinanced on the Completion Date and the release of related liens or guarantees (if any) effected thereby, including customary payoff letters and (to the extent required)
evidence that notice of any such repayment has been timely delivered to the holders of such Indebtedness, in each case in accordance with the terms of the definitive documents governing such Indebtedness (<I>provided </I>that any such notice or
payoff letter shall be expressly conditioned on the Completion); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) procuring consents to the reasonable use of all of the
Company&#146;s and its Subsidiaries&#146; logos in connection with the Financing (<I>provided</I> that such logos are used solely in a manner that is not intended to and is not reasonably likely to harm or disparage the Company or its Subsidiaries
or the reputation or goodwill of the Company or any of its Subsidiaries); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) providing at least three Business Days in advance of
the Completion Date such documentation and other information about the Company and its Subsidiaries as is reasonably requested in writing by Parent at least 10 Business Days in advance of the Completion Date in connection with the Financing that
relates to applicable &#147;know your customer&#148; and anti-money laundering rules and regulations, including without limitation, the USA PATRIOT ACT, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and, to the extent required by any Financing Source, a beneficial ownership certificate (substantially similar in form and substance to the form of Certification Regarding Beneficial Owners of
Legal Entity Customers published jointly, in May 2018, by the Loan Syndications and Trading Association and Securities Industry and Financial Markets Association) in respect of any of the Company or any of its Subsidiaries that qualifies as a
&#147;legal entity customer&#148; under the Beneficial Ownership Regulation (31 C.F.R. &#167;&nbsp;1010.230). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in connection
with any marketing efforts of the Parent Parties&#146; Financing, the Parent may reasonably request the Company to file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> pursuant to the Exchange Act that contains material <FONT
STYLE="white-space:nowrap">non-public</FONT> information with respect to any member of the Company Group, which Parent, in consultation with the Financing Sources and upon the advice of outside counsel, reasonably determines is necessary to include
in a registration statement, customary offering memorandum or other offering document for the Financing (each an &#147;<B><I>Offering Document</I></B>&#148;) in order to (i)&nbsp;correct any untrue statement of a material fact or an omission of a
material fact necessary in order to make the statements therein not misleading or (ii)&nbsp;to cause such Offering Document to comply with the requirements of the Securities Act. The Company shall consider such request promptly, and if the Company
approves of such request (such approval not be unreasonably withheld), then the Company shall promptly file such Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> in a form reasonably satisfactory to the Company. Notwithstanding
anything to the contrary in this <U>Section</U><U></U><U>&nbsp;7.8</U>, the Company shall not be obligated to effect any such filing of a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> pursuant to this this
<U>Section</U><U></U><U>&nbsp;7.8</U> if in the good faith judgment of the Company Board it would be detrimental to the Company and its shareholders for such Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed at such time
or in the near future, in which case the Company shall not be obligated to file such Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, (A)&nbsp;no member of the Company Group shall be required to take or to permit the taking of
any action pursuant to this <U>Section</U><U></U><U>&nbsp;7.8</U> to (i)&nbsp;pay any commitment or other fee or incur any liability (other than third-party costs and expenses that are to be promptly reimbursed by Parent upon request by the Company
pursuant to <U>Section</U><U></U><U>&nbsp;7.8(c)</U>), (ii) execute or deliver any definitive financing documents or any other agreement, certificate, document or instrument, or agree to any change to or modification of any existing agreement,
certificate, document or instrument, in each case that would be effective prior to the Completion Date or would be effective if the Completion does not occur (except (x)&nbsp;to the extent required by <U>Section</U><U></U><U>&nbsp;7.8(b)</U>,
applicable Company Supplemental Indentures, (y)&nbsp;customary officers&#146; certificates relating to the execution thereof that would not conflict with applicable Law and would be accurate in light of the facts and circumstances at the time
delivered and (z)&nbsp;the authorization letter and management representation letters delivered pursuant to <U>clause (i)(D)</U> above), (iii) provide access to or disclose information that the Company or any of its Subsidiaries reasonably
determines would result in a loss of any attorney-client privilege of the Company or any of its Subsidiaries (<I>provided</I> that the Company shall, and shall cause its Subsidiaries to, use their respective reasonable best efforts to cause any such
information to be disclosed in a manner that would not result in the loss of any such privilege), (iv) deliver or cause its Representatives to deliver any legal opinions, (v)&nbsp;be an issuer or other obligor with respect to the Financing prior to
the Completion, (vi)&nbsp;commence any Company Note Offers and Consent Solicitations that are not conditional on Completion occurring or (vii)&nbsp;prepare any financial statements information (other than the Financing Information) that are not
available to it and prepared in the ordinary course of its financial reporting practice, (B)&nbsp;none of the Company Board, officers of the Company, or directors and officers of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiaries of the Company shall be required to adopt resolutions or consents approving the agreements, documents or instruments pursuant to which the Financing is obtained or the Company Note
Offers and Consent Solicitations is consummated, and (C)&nbsp;neither the Company nor any of its Subsidiaries shall be required to take or permit the taking of any action that would (i)&nbsp;interfere unreasonably with the business or operations of
the Company or its Subsidiaries, (ii)&nbsp;cause any representation or warranty in this Agreement to be breached by the Company or any of its Subsidiaries (unless waived by Parent), (iii) cause any director, officer or employee or shareholder of the
Company or any of its Subsidiaries to incur any personal liability or (iv)&nbsp;result in a material violation or breach of, or a default under, any material Contract to which the Company or any of its Subsidiaries is a party, the Organizational
Documents of the Company or its Subsidiaries or any material applicable Law. Parent shall cause all <FONT STYLE="white-space:nowrap">non-public</FONT> or other confidential information provided by or on behalf of the Company or any of its
Subsidiaries or Representatives pursuant to this <U>Section</U><U></U><U>&nbsp;7.8</U> to be kept confidential in accordance with the Confidentiality Agreement; <I>provided </I>that the Company acknowledges and agrees that the confidentiality
undertakings that will be obtained in connection with syndication of the Financing will be in a form customary for use in the syndication of acquisition-related debt during a takeover offer period in compliance with the requirements of the Irish
Takeover Panel and the Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Cooperation as to Certain Indebtedness</B>. If requested by Parent, the Company shall use
its reasonable best efforts to assist Parent or one or more of its Subsidiaries in (i)&nbsp;commencing any of the following (as requested by Parent): (A) one or more offers to purchase any or all of the outstanding debt issued under the Indenture
for cash (the &#147;<B><I>Offers to Purchase</I></B>&#148;); or (B)&nbsp;one or more offers to exchange any or all of the outstanding debt issued under the Indenture for securities issued by Parent or any of its Affiliates (the &#147;<B><I>Offers to
Exchange</I></B>&#148;); and (ii)&nbsp;soliciting the consent of the holders of debt issued under the Indenture regarding certain proposed amendments to the Indenture (the &#147;<B><I>Consent Solicitations</I></B>&#148; and, together with the Offers
to Purchase and Offers to Exchange, if any, the &#147;<B><I>Company Note Offers and Consent Solicitations</I></B>&#148;); <I>provided</I> that the closing (or effectiveness) of any such transaction shall not be consummated until the Completion and
any such transaction shall be funded using consideration provided by Parent. Company Note Offers and Consent Solicitations shall be made on such terms and conditions (including price to be paid and conditionality) as are proposed by Parent and which
are permitted by the terms of the Indenture and applicable Laws, including SEC rules and regulations. Parent shall consult with the Company regarding the material terms and conditions of any Company Note Offers and Consent Solicitations, including
the timing and commencement of any Company Note Offers and Consent Solicitations and any tender deadlines. Parent shall have provided the Company with the necessary offer to purchase, offer to exchange, consent solicitation statement, letter of
transmittal, press release, if any, in connection therewith, and each other document relevant to the transaction that will be distributed by Parent in the applicable Company Note Offers and Consent Solicitations (collectively, the &#147;<B><I>Debt
Offer Documents</I></B>&#148;) a reasonable period of time in advance of commencing the applicable the Company Note Offers and Consent Solicitations to allow the Company and its counsel to review and comment on such Debt Offer Documents, and Parent
shall give reasonable and good faith consideration to any comments made or input provided by the Company and its legal counsel. Subject to the receipt of the requisite holder consents, in connection with any or all of the Consent Solicitations, the
Company shall execute a supplemental indenture to the Indenture in accordance with the terms thereof amending the terms and provisions of the Indenture as described in the applicable Debt Offer Documents in a form as reasonably requested by Parent
(the &#147;<B><I>Company Supplemental Indenture</I></B>&#148;); <I>provided</I> that the amendments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effected by such supplemental indenture shall not become operative until the Completion. Subject to the second paragraph of <U>Section</U><U></U><U>&nbsp;7.8(a)</U> above, until the earlier of
the Completion and the termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, the Company shall use its reasonable best efforts, and shall cause each of its Subsidiaries to use its reasonable best
efforts, and shall use its reasonable best efforts to cause its and their respective Representatives to use their reasonable best efforts, to provide all reasonable and customary cooperation as may be reasonably requested by Parent in writing to
assist Parent in connection with any Company Note Offers and Consent Solicitations (including upon Parent&#146;s written request, using reasonable best efforts to cause the Company&#146;s independent accountants to provide customary consents for use
of their reports to the extent required in connection with any Company Note Offers and Consent Solicitations). The dealer manager, solicitation agent, information agent, depositary or other agent retained in connection with any Company Note Offers
and Consent Solicitations will be selected and retained by Parent, and their fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses will be paid directly by Parent. If, at any time prior to
the completion of the Company Note Offers and Consent Solicitations, the Company or any of its Subsidiaries, on the one hand, or Parent or any of its Subsidiaries, on the other hand, discovers any information that should be set forth in an amendment
or supplement to the Debt Offer Documents, so that the Debt Offer Documents shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein, in light of circumstances under which they are made, not misleading, such party that discovers such information shall use reasonable best efforts to promptly notify the other Party, and an appropriate amendment or supplement prepared by
Parent describing such information shall be disseminated to the holders of the applicable notes, debentures or other debt securities of the Company or its Subsidiaries outstanding under the Indenture. The consummation of any or all of the Company
Note Offers and Consent Solicitations shall not be a condition to Completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent shall, promptly upon request by the Company,
reimburse the Company for all reasonable and documented third-party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including attorneys&#146; fees) incurred by the Company or its
Subsidiaries in connection with the cooperation, and shall indemnify and hold harmless the Company, its Subsidiaries and their respective Representatives from and against any and all liabilities, losses, damages, claims, expenses (including
attorneys&#146; fees), interest, judgments and penalties suffered or incurred by them, in connection with this <U>Section</U><U></U><U>&nbsp;7.8</U> (other than to the extent resulting from (x)&nbsp;information provided by the Company or its
Subsidiaries in writing in accordance with the terms hereof to the extent such information, as provided, is inaccurate or misleading or (y)&nbsp;the Company&#146;s or its Subsidiaries&#146; or Representatives&#146; willful misconduct or gross
negligence, as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction), in each case whether or not the Completion is consummated or this Agreement is terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.9</B> <B>Treatment of Certain Existing Indebtedness</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall, not later than 11:00 a.m. New York City time three Business Days prior to the expected Completion Date and otherwise
accordance with the terms of the Company Credit Agreement and on a date determined by the Company in consultation with Parent, execute and deliver to the Administrative Agent (as defined in the Company Credit Agreement) the requisite prepayment
notices to repay, in full, all loans outstanding under the Company Credit Agreement, contingent upon consummation of the Acquisition. The Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall prepare such prepayment notice in accordance with the terms of the Company Credit Agreement. The Company will deliver a copy of such notice to Parent promptly after giving such notices to
the Administrative Agent. The Company and its Subsidiaries shall use its reasonable best efforts to cooperate with any back-stop, &#147;roll-over&#148; or termination of any existing letters of credit under the Company Credit Agreement or otherwise,
shall take all actions reasonably requested by Parent to cause the release and discharge of all related Liens and security interests under the Company Credit Agreement, and shall take such other actions as Parent may reasonably request in connection
with such repayment, redemption or prepayment (including providing to Parent at least three Business Days prior to Completion a draft payoff letter or other similar evidence of termination or discharge in respect of the Company Credit Agreement or
any other applicable Company Indebtedness in form and substance customary for transactions of this type in substantially final form, taking into account any final per diem and out of pocket expense calculations that are to be finalized once the
Completion Date is determined). The Company shall deliver to Parent executed payoff letters on the Completion Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Prior to the
expected Completion Date, the Company shall use reasonable best efforts to cooperate with Parent, if Parent shall so request, to effect a redemption of the Company Notes in accordance with their terms (the &#147;<B><I>Redemption</I></B>&#148;);
<I>provided</I> that the consummation of any such Redemption shall be conditional upon the Completion. Such cooperation by the Company shall include:<I> </I>(i)&nbsp;delivery of a notice of redemption, in form reasonably satisfactory to Parent, to
the trustee with respect to the Company Notes, which such notice shall direct such trustee to deliver the notice of conditional redemption to the applicable holders with respect to the Company Notes, in each case, in accordance with the Indenture,
(ii)&nbsp;concurrently with the deposit by Parent with the paying agent under the Company Notes of an amount sufficient to satisfy and discharge the Company Notes, delivery of a notice of satisfaction and discharge, in form reasonably satisfactory
to Parent, to the trustee with respect to the Company Notes, and (iii)&nbsp;use of its best efforts to take all other actions necessary to facilitate the Redemption, other than depositing with the applicable paying agent under the applicable
Indenture the amounts sufficient to pay off, redeem, satisfy, discharge and/or defease the Company Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.10</B> <B>Transaction
Litigation</B>. Subject to the last sentence of this <U>Section</U><U></U><U>&nbsp;7.10</U>, the Company shall promptly notify Parent of any stockholder Legal Proceedings (including derivative claims) commenced against it, its Subsidiaries or its or
its Subsidiaries&#146; respective directors or officers relating to this Agreement or any of the Transactions (collectively, &#147;<B><I>Transaction Litigation</I></B>&#148;) and shall keep Parent informed regarding any Transaction Litigation. The
Company shall reasonably cooperate with Parent in the defense or settlement of any Transaction Litigation, and shall give Parent the opportunity to consult with it regarding the defense and settlement of such Transaction Litigation and shall
consider in good faith Parent&#146;s advice with respect to such Transaction Litigation, and the Company shall give Parent the opportunity to participate in (but not control), at Parent&#146;s expense, the defense and settlement of such Transaction
Litigation. Prior to the Effective Time, neither the Company nor any of its Subsidiaries shall settle or offer to settle any Transaction Litigation without the prior written consent of Parent (which consent shall not be unreasonably withheld,
conditioned or delayed). Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;7.10</U>, in the event of any conflict with any other covenant or agreement contained in <U>Section</U><U></U><U>&nbsp;7.2</U> that expressly
addresses the subject matter of this <U>Section</U><U></U><U>&nbsp;7.10</U>, <U>Section</U><U></U><U>&nbsp;7.2</U> shall govern and control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.11</B> <B>State Takeover Statutes</B>. Each of Parent and the Company shall
(a)&nbsp;take all action necessary so that no &#147;moratorium,&#148; &#147;control share acquisition,&#148; &#147;fair price,&#148; &#147;supermajority,&#148; &#147;affiliate transaction&#148; or &#147;business combination&#148; statute or
regulation or other similar state anti-takeover Law, or any similar provision of the Organizational Documents of the Company or the Organizational Documents of Parent, as applicable, is or becomes applicable to the Scheme, the Acquisition or any of
the other Transactions, and (b)&nbsp;if any such Law or provision is or becomes applicable to the Scheme, the Acquisition or any other Transactions, cooperate and grant such approvals and take such actions as are reasonably necessary so that the
Transactions may be consummated as promptly as practicable on the terms contemplated hereby and otherwise act to eliminate or minimize the effects of such Law on the Scheme, the Acquisition or the other Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.12</B> <B>Acquirer Sub</B>. Until the Effective Time, Parent shall at all times be the direct or indirect owner of all of the outstanding
shares of capital stock of Acquirer Sub. Parent shall take all action necessary to cause Acquirer Sub to perform its obligations under this Agreement and to consummate the Acquisition on the terms and subject to the conditions set out in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.13</B> <B>Tax </B><B>Matters</B>. Parent may, in its sole discretion, cause a timely and irrevocable election under
Section&nbsp;338(g) of the Code (and any corresponding provisions of state or local Tax law) to be made with respect to the Company and any or all of its Subsidiaries that is not a U.S. corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.14</B> <B>Stock Exchange Delisting; Deregistration</B>. Prior to the Completion Date, the Company shall cooperate with Parent and use its
reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Laws and rules and policies of Nasdaq to enable the delisting of the
Company Shares from Nasdaq and the deregistration of the Company Shares under the Exchange Act as promptly as practicable after the Effective Time, and in any event no more than ten days after the Completion Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.15</B> <B>Filing of Form <FONT STYLE="white-space:nowrap">S-8;</FONT> Listing of Additional Shares</B>. Parent agrees to file no later
than the Completion Date a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (or any successor or other appropriate form) with respect to the Parent Common Stock issuable with respect to the Parent RSUs and shall use
reasonable best efforts to: (i)&nbsp;maintain the effectiveness of such registration statement or registration statements (and maintain the current status of the prospectus or prospectuses contained therein) for so long as the Parent RSUs assumed in
accordance with this Agreement remain outstanding and (ii)&nbsp;take any action required to be taken by it under any applicable state securities laws in connection with the conversion of the RSU Awards into Parent RSUs.&nbsp;Parent shall take all
action necessary to cause the Parent Common Stock to be issuable upon the vesting and settlement of the Parent RSUs, to be authorized for listing on Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;8. COMPLETION OF ACQUISITION AND MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>Completion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Completion Date</B>. Completion shall take place remotely at 9:00 a.m., New York City time, on a date to be selected by Parent in
consultation with the Company as promptly as reasonably practicable following, but not later than the third Business Day (or such shorter period of time as remains before 5:00 p.m., New York City time, on the End Date) after, the satisfaction or, in
the sole discretion of the applicable Party, waiver (where applicable) of all of the Conditions (&#147;<B><I>Completion Date</I></B>&#148;) (other than those Conditions that by their nature are to be satisfied at the Completion Date, but subject to
the satisfaction or waiver of such Conditions at the Completion Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On or prior to Completion: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Company shall cause a meeting of the Company Board (or a duly authorized committee thereof) to be held at which resolutions are
passed (conditional only on delivery of the Court Order to the Registrar of Companies occurring and effective as of the Effective Time) approving: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) the removal of the directors of the Company as Parent shall determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) the appointment of such persons as Parent may nominate as the directors of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) the registration of the transfer to Acquirer Sub (and/or its nominee(s)) in accordance with the Scheme of the relevant Company Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Company shall deliver to Parent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) a certified copy of the resolutions referred to in <U>Section</U><U></U><U>&nbsp;8.1(b)(i)</U>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) letters of resignation from the directors who are removed from the Company in accordance with
<U>Section</U><U></U><U>&nbsp;8.1(b)(i)(A)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On or substantially concurrently with the Completion and subject to and in accordance
with the terms and conditions of the Scheme, the Company shall cause a copy of the Court Order to be delivered to the Companies Registration Office and shall cause a copy to be provided to Parent as soon as practicable following the Company&#146;s
receipt thereof: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) in respect of each Company Share subject to the Scheme, subject to <U>Section</U><U></U><U>&nbsp;8.2(a)</U>, Parent
shall pay, or caused to be paid, in respect of each holder of Company Shares at the Scheme Record Time, the Consideration to the applicable Company Shareholder or its nominees (who are intended to be third party beneficiaries of this
<U>Section</U><U></U><U>&nbsp;8.1(c)</U> and <U>Section</U><U></U><U>&nbsp;8.2(a)</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>Payment of Consideration</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Payment</B>. Within 14 days following the Effective Date, in respect of each Company Share subject to the Scheme, Parent shall pay, or
cause to be paid, in respect of each holder of Company Shares at the Scheme Record Time, the Consideration in accordance with the terms and conditions of the Scheme. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Payroll</B>. As soon as reasonably practicable after the Completion (but no later
than 10 Business Days after the Effective Time), Parent shall, or shall cause the Acquirer Sub or the Company to, pay through the Company&#146;s payroll the aggregate Option Consideration, RSU Cash Consideration and PSU Consideration payable with
respect to Company Options or other Company Equity Awards held by current or former employees of any member of the Company Group (net of any withholding Taxes required to be deducted and withheld by applicable Laws); <I>provided, however</I>, that,
notwithstanding the foregoing, with respect to any Company RSU Awards and Company PSU Awards that constitute nonqualified deferred compensation subject to Section&nbsp;409A of the Code and that are not permitted to be paid at the Effective Time
without triggering a Tax or penalty under Section&nbsp;409A of the Code, payment shall be made at the earliest time permitted under the applicable Company Share Plan and award agreement that will not trigger a Tax or penalty under Section&nbsp;409A
of the Code; <I>provided, further</I>, that to the extent the holder of a Company Option, or other Company Equity Award is not, and was not at any time during the vesting period of the Company Option or other Company Equity Award, an employee of the
Company or any other member of the Company Group for employment tax purposes, Parent shall pay, or cause to be paid, the Option Consideration, RSU Cash Consideration or PSU Consideration payable pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U> with
respect to such Company Option or other Company Equity Award in the manner described in <U>Section</U><U></U><U>&nbsp;8.2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Withholding</B>. Notwithstanding anything herein to the contrary, Parent, the Company and their respective Affiliates shall be
entitled to deduct and withhold from any amount payable pursuant to this Agreement to any Person who was a holder of a Company Share subject to the Scheme such amounts as Parent, the Company or such Affiliate is required to deduct and withhold with
respect to the making of such payment under the Code or any other provision of federal, state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax law. To the extent that amounts are so withheld and timely paid over to the appropriate Tax
Authority, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person to whom such consideration would otherwise have been paid. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;9. TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B> <B>Termination</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement may be terminated and the Acquisition and the other Transactions may be abandoned at any time prior to the Effective Time,
notwithstanding receipt of the Company Shareholder Approval (except in the case of <U>Section</U><U></U><U>&nbsp;9.1(a)(iii)(B)</U>): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) by either the Company or Parent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) if the Acquisition is implemented by way of the Scheme, Scheme Meeting or the EGM shall have been completed and the Scheme Meeting
Resolution or the Required EGM Resolutions, as applicable, shall not have been approved by the requisite majorities (an &#147;<B><I>Non Approval Termination</I></B>&#148;); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) if the Effective Time shall not have occurred by 5:00 p.m., New York City time, on the
End Date, <I>provided</I> that the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;9.1(a)(i)(B)</U> shall not be available to a Party whose breach of any provision of this Agreement shall have been the primary cause
of the failure of the Effective Time to have occurred by such time (an &#147;<B><I>End Date Termination</I></B>&#148;); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) if the
Acquisition is implemented by way of the Scheme, the Irish High Court shall decline or refuse to sanction the Scheme, unless both Parties agree in writing that the decision of the Irish High Court shall be appealed (it being agreed that the Company
shall make such an appeal if requested to do so in writing by Parent and the counsel appointed by Parent and by the Company agree that doing so is a reasonable course of action); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D) if there shall be in effect any Law or final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> Order (other than under any
Antitrust Laws or Foreign Investment Laws of any jursidiction that is not (A)&nbsp;a Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction or (B)&nbsp;under the HSR Act) issued, promulgated, made, rendered or entered into by any
court or other tribunal of competent jurisdiction, that permanently restrains, enjoins or otherwise prohibits the consummation of the Acquisition; <I>provided</I> that the right to terminate this Agreement pursuant to this
<U>Section</U><U></U><U>&nbsp;9.1(a)(i)(D)</U> shall not be available to any Party whose breach of any provision of this Agreement shall have been the primary cause of such Law, order, writ, decree, judgment, or injunction (a &#147;<B><I>Restraining
Order Termination</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) by the Company: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) if any Parent Party shall have breached or failed to perform in any material respect any of its covenants or other agreements contained
in this Agreement or if any of its representations or warranties set out in this Agreement are inaccurate, which breach, failure to perform or inaccuracy (1)&nbsp;would result in a failure of the Condition set forth paragraph 5.1 or paragraph 5.2
and (2)&nbsp;is not reasonably capable of being cured by the End Date or, if curable, is not cured by the earlier of (x)&nbsp;the End Date and (y) 45 days following written notice by the Company thereof (a &#147;<B><I>Parent Breach
Termination</I></B>&#148;); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) prior to obtaining the Company Shareholder Approval, if (1)&nbsp;in accordance with
<U>Section</U><U></U><U>&nbsp;5.2</U>, the Company Board shall have authorized the Company to terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;9.1(a)(ii)(B)</U> in response to a Company Superior Proposal and (2)&nbsp;substantially
concurrently with such termination, a Company Change of Recommendation shall have occurred and a definitive agreement providing for the consummation of such Company Superior Proposal is duly executed and delivered by all parties thereto and, the
Company pays Parent the Reimbursement Payments (the &#147;<B><I>Superior Proposal Termination</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) by Parent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) if the Company shall have breached or failed to perform in any material respect any of its covenants or other agreements contained in
this Agreement or if any of its representations or warranties set out in this Agreement are inaccurate, which breach, failure to perform or inaccuracy (1)&nbsp;would result in a failure of the Condition set out in paragraph 4.2 or paragraph 4.3 and
(2)&nbsp;is not reasonably capable of being cured by the End Date or, if curable, is not cured by the earlier of (x)&nbsp;the End Date and (y) 45 days following written notice by Parent thereof (a &#147;<B><I>Company Breach
Termination</I></B>&#148;); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) if, prior to the receipt of the Company Shareholder Approval, (x)&nbsp;a Company Change
of Recommendation shall have occurred, (y)&nbsp;the Company Board shall fail to reaffirm the Scheme Recommendation in a statement complying with Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> under the Exchange Act with regard to a Company
Alternative Proposal or in connection with such action by the close of business on the 10th Business Day after the commencement of such Company Alternative Proposal under Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> (the foregoing a
&#147;<B><I>Change of Recommendation Termination</I></B>&#148;) or (z)&nbsp;the Company has materially breached its obligations under <U>Section</U><U></U><U>&nbsp;5.2</U> that cannot be cured; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) by mutual written consent of the Company and Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The termination of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9.1(a)</U> shall not give rise to any
liability of the Parties except as provided in this <U>Section</U><U></U><U>&nbsp;9.1(b)</U> and in<U> Section</U><U></U><U>&nbsp;7.8(c)</U>, <U>Section</U><U></U><U>&nbsp;9.1(c)</U>, <U>Section</U><U></U><U>&nbsp;9.2</U> and
<U>Section</U><U></U><U>&nbsp;10</U> of this Agreement shall survive, and continue in full force and effect, notwithstanding its termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to the proviso in this <U>Section</U><U></U><U>&nbsp;9.1(c)</U>, upon the termination of this Agreement pursuant to and in
accordance with this <U>Section</U><U></U><U>&nbsp;9</U>, no Party (or any partner, member, manager, stockholder, director, officer, employee, Affiliate, agent or other representative of such Party) shall have any liability in connection with this
Agreement or the Transaction, other than the obligation of the Company (if applicable) to reimburse Parent for the Reimbursement Amount, subject to the Cap and the obligation of Parent (if applicable) to pay the Company (or an entity designated by
the Company) the Reverse Termination Payment; <I>provided</I>, <I>however</I>, that nothing herein shall release any Party from liability (including any monetary damages or other appropriate remedy) for Willful Breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B>Certain Effects of Termination</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event of a Parent Payment Event, the Company shall reimburse Parent for the Reimbursement Amount, subject to the Cap (the
&#147;<B><I>Reimbursement Payment</I></B>&#148;), in immediately available funds within seven Business Days following the Company&#146;s receipt of invoices or written documentation supporting Parent&#146;s request for a Reimbursement Payment. The
Reimbursement Amount will be exclusive of any VAT incurred by Parent or its Subsidiaries attributable to third party costs other than Irrecoverable VAT incurred by Parent or its Subsidiaries. In the event of a Specified Termination, then Parent
shall pay to the Company (or an entity designated by the Company) $974,415,054 (the &#147;<B><I>Reverse Termination Payment</I></B>&#148;) in immediately available funds within seven Business Days thereafter; <I>provided</I> that the Company shall
not be entitled to receive the Reverse Termination Payment if the Company&#146;s breach of this Agreement shall have been the primary cause of such Specified Termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The &#147;<B><I>Parent Payment Events</I></B>&#148; means where the Parties have issued the Rule 2.7 Announcement and this Agreement is
terminated in accordance with <U>Section</U><U></U><U>&nbsp;9.1(a)</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) by Parent pursuant to a Change of Recommendation
Termination; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) by the Company pursuant to a Superior Proposal Termination; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) all of the following occur: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) this Agreement is terminated (x)&nbsp;by Parent pursuant to a Company Breach
Termination as a result of a material breach or failure to perform any covenant or agreement in this Agreement described in <U>Section</U><U></U><U>&nbsp;9.1(a)(iii)(A)</U> that first occurred following the making of a Company Alternative Proposal
of the type referenced in the following <U>clause (B)</U>, (y)&nbsp;by Parent or the Company pursuant to a Non Approval Termination but if such termination is by the Company at such time Parent would be permitted to terminate this Agreement; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) prior to the Scheme Meeting, a Company Alternative Proposal was publicly disclosed or announced and not withdrawn (or, in the case
of a Company Breach Termination as a result of a material breach or failure to perform any covenant or agreement in this Agreement, was made publicly or privately to the Company Board), or any Person shall have publicly announced an intention
(whether or not conditional) to make a Company Alternative Proposal that has not been withdrawn (it being understood that, for purposes of this <U>Section</U><U></U><U>&nbsp;9.2(b)(iii)(B)</U> references to &#147;<I>20%</I>&#148; in the definition
of Company Alternative Proposal shall be deemed to refer to &#147;<I>50</I><I>%</I>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) (x) a Company Alternative Proposal
is consummated within 12 months after such termination, or (y)&nbsp;a definitive agreement providing for a Company Alternative Proposal is entered into within 12 months after such termination and is subsequently consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The &#147;<B><I>Specified Termination</I></B>&#148; means a valid termination of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) by Parent or the Company pursuant to an End Date Termination, if, on the date of such termination, each of the Conditions has been
satisfied or, to the extent permitted by applicable Laws, waived, (other than (X)&nbsp;paragraphs 3.1, 3.2 or 3.3 of the Conditions (only as a result of an Order or injunction under (1)&nbsp;the HSR Act or (2)&nbsp;any other Antitrust Law or Foreign
Investment Laws in any Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction), or (Y)&nbsp;paragraphs 2.3 and 2.4 of the Conditions or (Z)&nbsp;any Condition that by its nature can only be satisfied on the Sanction Date or, in the
alternative to (Y)&nbsp;and (Z) where the Acquisition is implemented by Takeover Offer, any other condition that by its nature can only be satisfied by no later than the latest date upon which the Takeover Offer may be declared unconditional in all
respects); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) by Parent or the Company pursuant to a Restraining Order Termination pursuant to or in connection with (1)&nbsp;the HSR
Act or (2)&nbsp;any other Antitrust Law or Foreign Investment Laws in any Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) by the Company pursuant to a Parent Breach Termination with respect to <U>Section</U><U></U><U>&nbsp;7.2</U> in connection with
(1)&nbsp;the HSR Act or (2)&nbsp;any other Antitrust Law or Foreign Investment Laws in any Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B>Single Payment Only</B>. The Parties acknowledge and agree that in no event will Parent or the Company be required to pay, as
applicable, the Reverse Termination Payment or the Reimbursement Payment on more than one occasion, whether or not the Reverse Termination Payment or the Reimbursement Payment may be payable pursuant to more than one provision of this Agreement at
the same or at different times and upon the occurrence of different events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B>VAT</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <B>VAT on the Reimbursement Payment</B>. Parent and the Company consider that any amounts payable under this
<U>Section</U><U></U><U>&nbsp;9</U> do not represent consideration for a taxable supply for VAT purposes and agree to use all reasonable efforts to secure that any Reimbursement Payment should not represent consideration for a taxable supply for VAT
purposes (including not taking any contrary position in any Tax filing or return or in any correspondence with any Tax Authority). If and to the extent that any relevant Tax Authority determines that any Reimbursement Payment is consideration for a
taxable supply and that the Company (or any member of a VAT Group of which the Company is a member) is liable to account to a Tax Authority for VAT in respect of such supply and such VAT is Irrecoverable VAT: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) the sum of the total amount payable by the Company by way of any Reimbursement Payment, together with any Irrecoverable VAT arising in
respect of the supply for which the Reimbursement Payment is consideration (&#147;<B><I>Company Irrecoverable VAT</I></B>&#148;), shall not exceed the Cap and the total amount of the Reimbursement Payment shall be reduced to ensure such; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) to the extent that the Company has already paid amounts in respect of any Reimbursement Payment the sum of which, when combined with any
Company Irrecoverable VAT, exceeds the Cap, Parent shall repay to Company, by way of a reduction in the amount of the Reimbursement Payment, an amount necessary to ensure that the sum of the total remaining Reimbursement Payment combined with any
Company Irrecoverable VAT arising in connection with such does not exceed the Cap; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) the Company shall (and shall procure that any
applicable member of the Company Group shall) accommodate any reasonable action that Parent requests, in writing and without delay, to avoid, dispute, defend, resist, appeal or compromise any determination of a Tax Authority that any Reimbursement
Payment is consideration for a taxable supply for VAT purposes and/or that Company or any member of a VAT Group of which the Company is a member is liable to account to the relevant Tax Authority for VAT in respect of such supply and/or that all or
any part of such VAT is Irrecoverable VAT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <B>VAT on the Reverse Termination Payment</B>. Parent and the Company consider that any
amounts payable under this <U>Section</U><U></U><U>&nbsp;9</U> do not represent consideration for a taxable supply for VAT purposes and agree to use all reasonable efforts to secure that any Reverse Termination Payment should not represent
consideration for a taxable supply for VAT purposes (including not taking any contrary position in any Tax filing or return or in any correspondence with any Tax Authority). If and to the extent that any relevant Tax Authority determines that any
Reverse Termination Payment is consideration for a taxable supply and that the Company or an entity designated by the Company (or any member of a VAT Group of which the Company or an entity designated by the Company is a member) is liable to account
to a Tax Authority for VAT in respect of such supply, Parent shall pay, in addition to the Reverse Termination Payment, an amount equal to such VAT to the Company or an entity designated by the Company (or any member of a VAT Group of which the
Company or an entity designated by the Company is a member) immediately upon receipt of a valid VAT invoice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B>Recovered VAT</B>. If the Reimbursement Payment is reduced in accordance with
<U>Section</U><U></U><U>&nbsp;9.2(e)(i)(A)</U> and / or (B)&nbsp;and the Company (or any member of a VAT Group of which the Company is a member) subsequently becomes entitled to recover all, or any part, of the Company Irrecoverable VAT amount as
originally applied to the calculation in accordance with <U>Section</U><U></U><U>&nbsp;9.2(e)(i)(A)</U> and / or (B)&nbsp;whether by way of credit or refund from the relevant Tax Authority, the Company shall notify Parent without delay and the
Reimbursement Payment shall be increased to reflect the correct amount of Company Irrecoverable VAT subject to a maximum of the original Reimbursement Payment. However, the increase of the Reimbursement Payment shall be subject to a maximum to
ensure at all times that the sum of the total increased Reimbursement Payment combined with any remaining Company Irrecoverable VAT arising in connection with such does not exceed the Cap. Where there is an increase in the Reimbursement Payment in
accordance with this <U>Section</U><U></U><U>&nbsp;9.2(f)</U>, as soon as practicable (and, in any event, within five (5)&nbsp;Business Days of recovering whether by way of credit or refund any such VAT from the relevant Tax Authority), the Company
(or the relevant member of a VAT Group of which the Company is a member) shall pay to Parent the appropriate amount by way of an increase in the Reimbursement Payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <B>Outside the European Union</B>. Parent confirms that it is established outside of the European Union for VAT purposes and is a taxable
person for VAT purposes within the meaning of applicable VAT Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <B>Sole and Exclusive Remedy</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1</U>, Parent&#146;s receipt of the Reimbursement Payment and
any other amount to the extent owed pursuant to <U>Section</U><U></U><U>&nbsp;9.2</U> and Parent&#146;s right to seek specific performance pursuant to <U>Section</U><U></U><U>&nbsp;10.7</U> will be the sole and exclusive remedies of (x)&nbsp;Parent
and Acquirer Sub and (y)&nbsp;the former, current and future holders of any equity, controlling persons, directors, officers, employees, agents, attorneys, Affiliates (other than Parent or Acquirer Sub), members, managers, general or limited
partners, stockholders and assignees of each of Parent and Acquirer Sub (the Persons in <U>clauses (x)</U>&nbsp;and <U>(y)</U> collectively, the &#147;<B><I>Parent Related Parties</I></B>&#148;) against any of (A)&nbsp;the Company and its
Affiliates; and (B)&nbsp;the former, current and future holders of any equity, controlling persons, directors, officers, employees, agents, attorneys, Affiliates, members, managers, general or limited partners, stockholders and assignees of each of
the Company and its Affiliates (the Persons in <U>clauses (A)</U>&nbsp;and <U>(B)</U> collectively, the &#147;<B><I>Company Related Parties</I></B>&#148;) in respect of this Agreement, the Transactions, any agreement executed in connection herewith
and the transactions contemplated hereby and thereby, the termination of this Agreement, the failure to consummate the Transactions or any claims or actions under applicable Laws arising out of any breach, termination or failure. Parent&#146;s
receipt (or the receipt by such other Person as Parent may designate) of the Reimbursement Payment and any other amount to the extent owed pursuant to <U>Section</U><U></U><U>&nbsp;9.2</U> will be the only monetary damages the Parent Related Parties
may recover from Company Related Parties in respect of this Agreement, any agreement executed in connection herewith and the transactions contemplated hereby and thereby, the termination of this Agreement, the failure to consummate the Transactions
or any claims or actions under applicable Laws arising out of any such breach, termination or failure, and upon payment of such amount, (A)&nbsp;none of the Company Related Parties will have any further liability or obligation to any of the Parent
Related Parties relating to or arising out of this Agreement, any agreement executed in connection herewith or the transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby and thereby or any matters forming the basis of such termination (except that the Parties (or their respective Affiliates) will remain obligated with respect to, and Parent
may be entitled to remedies with respect to, the Confidentiality Agreement and <U>Section</U><U></U><U>&nbsp;9.1(c)</U>, as applicable); and (B)&nbsp;none of Parent, Acquirer Sub or any other Person will be entitled to bring or maintain any Law
against any Company Related Party arising out of this Agreement, the Transactions, any agreement executed in connection herewith or the transactions contemplated hereby and thereby or any matters forming the basis for such termination.
Notwithstanding the foregoing, this <U>Section</U><U></U><U>&nbsp;9.2(h)(i)</U> will not relieve the Company from liability (I)&nbsp;for any Willful Breach of this Agreement or (II)&nbsp;for any breaches of the Confidentiality Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1</U>, the Company&#146;s receipt of the Reverse Termination
Payment and any other amount to the extent owed pursuant to <U>Section</U><U></U><U>&nbsp;9.2</U> and the Company&#146;s right to seek specific performance pursuant to <U>Section</U><U></U><U>&nbsp;10.7</U> will be the sole and exclusive remedies of
the Company Related Parties against any of Parent Related Parties in respect of this Agreement, the Transactions, any agreement executed in connection herewith and the transactions contemplated hereby and thereby, the termination of this Agreement,
the failure to consummate the Transactions or any claims or actions under applicable Laws arising out of any breach, termination or failure. The Company&#146;s receipt (or the receipt by such other Person as the Company may designate) of the Reverse
Termination Payment and any other amount to the extent owed pursuant to <U>Section</U><U></U><U>&nbsp;9.2</U> will be the only monetary damages the Company Related Parties may recover from Parent Related Parties in respect of this Agreement, any
agreement executed in connection herewith and the transactions contemplated hereby and thereby, the termination of this Agreement, the failure to consummate the Transactions or any claims or actions under applicable Laws arising out of any such
breach, termination or failure, and upon payment of such amount, (A)&nbsp;none of the Parent Related Parties will have any further liability or obligation to any of the Company Related Parties relating to or arising out of this Agreement, any
agreement executed in connection herewith or the transactions contemplated hereby and thereby or any matters forming the basis of such termination (except that the Parties (or their respective Affiliates) will remain obligated with respect to, and
the Company may be entitled to remedies with respect to, the Confidentiality Agreement and <U>Section</U><U></U><U>&nbsp;9.1(c)</U>, as applicable); and (B)&nbsp;none of the Company or any other Person will be entitled to bring or maintain any Law
against any Parent Related Party arising out of this Agreement, the Transactions, any agreement executed in connection herewith or the transactions contemplated hereby and thereby or any matters forming the basis for such termination.
Notwithstanding the foregoing, this <U>Section</U><U></U><U>&nbsp;9.2</U> will not relieve Parent from liability (I)&nbsp;for any Willful Breach of this Agreement or (II)&nbsp;for any breaches of the Confidentiality Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Each of the Parties acknowledges that any amount payable by the Company pursuant to this <U>Section</U><U></U><U>&nbsp;9.2</U>,
including the Reimbursement Payment, does not constitute a penalty, but rather shall constitute liquidated damages in a reasonable amount that will compensate Parent Parties for the disposition of its rights under this Agreement in the circumstances
in which such amounts are due and payable, which amounts would otherwise be impossible to calculate with precision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Each of the Parties acknowledges that any amount payable by Parent pursuant to this
<U>Section</U><U></U><U>&nbsp;9.2</U>, including the Reverse Termination Payment, does not constitute a penalty, but rather shall constitute liquidated damages in a reasonable amount that will compensate the Company and the entities designated by
the Company for the operational impact of entering this Agreement and all related consequences on ongoing business activities in the event of a Specified Termination, which amounts would otherwise be impossible to calculate with precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Any amount payable to the Company or its designee, or to Parent or its designee, as applicable, pursuant to this
<U>Section</U><U></U><U>&nbsp;9.2</U> shall be paid in such amounts and to such Persons as the Company or Parent, as applicable, shall designate within seven Business Days of the Specified Termination. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;10. GENERAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B> <B>Announcements</B>. Subject to the requirements of applicable Laws or the applicable rules of any securities exchange or
Governmental Entity (including the Panel), the Parties shall consult with each other as to the terms of, the timing of and the manner of publication of any formal public announcement which either Party may make primarily regarding the Acquisition,
the Scheme or this Agreement. Parent and the Company shall each give the other a reasonable opportunity to review and comment upon any such public announcement and shall not issue any such public announcement prior to such consultation, except as
may be required by applicable Laws or the applicable rules of any securities exchange or Governmental Entity (including the Irish Takeover Panel). For clarity, the provisions of this <U>Section</U><U></U><U>&nbsp;10.1</U> do not apply to a
redemption of the Company Notes, any announcement, document or publication in connection with a Company Alternative Proposal, the Company Superior Proposal or a Company Change of Recommendation or any amendment to the terms of the Scheme proposed by
Parent that would effect an increase in the Consideration whether before or after a Company Change of Recommendation. Notwithstanding the foregoing: (a)&nbsp;each Party may, without such consultation or consent, make any public statement in response
to questions from the press, analysts, investors or those attending industry conferences, make internal announcements to any officer or other employee, or individual who is an individual independent contractor, consultant or director, of or to any
of the Company Group and make disclosures in Company SEC Documents, so long as such statements are consistent in tone and substance with previous press releases, public disclosures, public statements or statements to such Persons made jointly by the
Parties (or individually, if approved by the other Party); and (b)&nbsp;a Party may, without the prior consent of the other Party hereto but subject to giving advance notice to the other Party, issue any such press release or make any such public
announcement or statement as may be required by applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2</B> <B>Notices</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any notice or other document to be served under this Agreement may be delivered by overnight delivery service (with proof of service) or
hand delivery, or sent in writing (including email transmission, the receipt of which is confirmed other than by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-office</FONT></FONT> replies or other automatically generated
responses), to the Party to be served as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) if to Parent or Acquirer Sub, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amgen Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Amgen Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thousand Oaks, CA 91320-1799 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (805) <FONT STYLE="white-space:nowrap">499-6751</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with copy to (which in and of itself shall not constitute notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sullivan&nbsp;&amp; Cromwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">125 Broad Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10004 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Francis J. Aquila </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: aquilaf@sullcrom.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">William Fry LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2 Grand Canal Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dublin 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ireland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Myra Garrett </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mark Talbot </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myra.garrett@williamfry.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
mark.talbot@williamfry.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) if to the Company, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Horizon Therapeutics plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">70 St. Stephen&#146;s Green </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dublin 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">D02 E2X4, Ireland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: legal@horizontherapeutics.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with copy to (which in and of itself shall not constitute notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10265 Science Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Barbara L. Borden </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rama Padmanabhan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rowook Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bborden@cooley.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rama@cooley.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rpark@cooley.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Matheson LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">70 Sir John Rogerson&#146;s Quay </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dublin 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ireland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: David Fitzgibbon </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;David Jones </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; david.fitzgibbon@matheson.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;david.jones@matheson.com
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other postal or email address as it may have notified to the other Party in writing in accordance with the provisions of this
<U>Section</U><U></U><U>&nbsp;10.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All such notices, requests and other communications shall be deemed received on the date of
receipt by the recipient thereof if received prior to 5:00 p.m. (addressee&#146;s local time) on a Business Day. Otherwise, any such notice, request or communication shall be deemed to have been received on the next succeeding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B> <B>Assignment</B>. Neither Party shall assign all or any part of its rights or obligations under this Agreement without the prior
written consent of the other Party; <I>provided</I> that Parent, without the Company&#146;s consent, may assign any or all of its rights and obligations hereunder, in whole or from time to time in part, to one or more of its Subsidiaries and
Acquirer Sub, without the Company&#146;s consent, may assign its rights and obligations hereunder, in whole or from time to time in part, to any other wholly owned Subsidiary of Parent (<I>provided</I> that the prior consent in writing has been
obtained from the Irish Takeover Panel in respect of each such assignment), but no such assignment shall relieve Parent or Acquirer Sub, as applicable, of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B> <B>Counterparts</B>. This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute
one and the same agreement, and each Party may enter into this Agreement by executing a counterpart and delivering it to the other Party (by hand delivery, <FONT STYLE="white-space:nowrap">e-mail</FONT> or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B> <B>Amendment</B>. No amendment of this Agreement shall be binding unless the same shall be evidenced in writing duly executed by
each of the Parties, except that, following approval by the Company Shareholders, there shall be no amendment to the provisions hereof which by applicable Laws would require further approval by the Company Shareholders without such further approval
nor shall there be any amendment or change not permitted under applicable Laws. Notwithstanding anything to the contrary herein, this <U>Section</U><U></U><U>&nbsp;10.5</U>, <U>Sections 10.12(b)</U> and <U>10.12(c)</U>, <U>10.13</U> and <U>10.14</U>
may not be amended, supplemented, waived or otherwise modified in any manner materially adverse to the Financing Sources without the prior written consent of such Financing Sources party to any definitive agreement relating to the Financing (it
being expressly agreed that the Financing Sources in their capacities as such shall be third party beneficiaries of this <U>Section</U><U></U><U>&nbsp;10.5</U> and shall be entitled to the protections of the provisions contained in this
<U>Section</U><U></U><U>&nbsp;10.5</U> as if they were a party to this Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6</B> <B>Entire Agreement</B>. This Agreement, together with the Confidentiality
Agreement, the Rule 2.7 Announcement and any documents delivered by Parent and the Company in connection herewith (including the Company Disclosure Schedule), constitutes the entire agreement and supersedes all prior agreements and understandings,
both written and oral, between Parent and the Company with respect to the subject matter hereof, it being understood that the Confidentiality Agreement shall survive the execution and delivery of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7</B> <B>Inadequacy of Damages</B>. The Parties acknowledge and agree that irreparable harm would occur and that the Parties would not
have any adequate remedy at Law (i)&nbsp;for any breach of any of the provisions of this Agreement or (ii)&nbsp;in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms. It is accordingly
agreed that, except where this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;9.1</U>, the Parties shall be entitled to seek an injunction or injunctions to prevent breaches or threatened breaches of this Agreement and to
specifically enforce the terms and provisions of this Agreement, without proof of actual damages, and each Party further agrees to waive any requirement for the securing or posting of any bond in connection with such remedy. Subject to
<U>Section</U><U></U><U>&nbsp;9.1(b)</U>, the Parties further agree that (x)&nbsp;by seeking the remedies provided for in this <U>Section</U><U></U><U>&nbsp;10.7</U>, a Party shall not in any respect waive its right to seek any other form of relief
that may be available to a Party under this Agreement and (y)&nbsp;nothing contained in this <U>Section</U><U></U><U>&nbsp;10.7</U> shall require any Party to institute any proceeding for (or limit any Party&#146;s right to institute any proceeding
for) specific performance under this <U>Section</U><U></U><U>&nbsp;10.7</U> before exercising any termination right under <U>Section</U><U></U><U>&nbsp;9.1</U> (and pursuing damages after such termination), nor shall the commencement of any action
pursuant to this <U>Section</U><U></U><U>&nbsp;10.7</U> or anything contained in this <U>Section</U><U></U><U>&nbsp;10.7</U> restrict or limit any Party&#146;s right to terminate this Agreement in accordance with the terms of
<U>Section</U><U></U><U>&nbsp;9.1</U> or pursue any other remedies under this Agreement that may be available then or thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.8</B> <B>Disclosure Schedule References and SEC Document References</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Parties agree that each section or subsection of the Company Disclosure Schedule, shall be deemed to qualify the corresponding section
or subsection of this Agreement, irrespective of whether or not any particular section or subsection of this Agreement specifically refers to the Company Disclosure Schedule. The Parties further agree that disclosure of any item, matter or event in
any particular section or subsection of either the Company Disclosure Schedule shall be deemed disclosure with respect to any other section or subsection of the Company Disclosure Schedule, to which the relevance of such disclosure would be
reasonably apparent on its face, notwithstanding the omission of a cross-reference to such other section or subsections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Parties
agree that in no event shall any cautionary, predictive or forward-looking statements contained in any part of any Company SEC Document entitled &#147;Risk Factors,&#148; &#147;Forward-Looking Statements,&#148; &#147;Cautionary Statement Regarding
Forward-Looking Statements,&#148; &#147;Special Note Regarding Forward Looking Statements&#148; or &#147;Note Regarding Forward Looking Statements&#148; be deemed to be an exception to (or a disclosure for purposes of or otherwise qualify) any
representations and warranties of any Party contained in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B>Remedies and Waivers</B>. No delay or omission by either
Party in exercising any right, power or remedy provided by Law or under this Agreement shall affect that right, power or remedy or operate as a waiver of it. The exercise or partial exercise of any right, power or remedy provided by Law or under
this Agreement shall not preclude any other or further exercise of it or the exercise of any other right, power or remedy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.9</B> <B>Severability</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If any term, provision, covenant or condition of this Agreement or the Acquisition is held by a court of competent jurisdiction or other
Governmental Entity to be invalid, void or unenforceable, the Parties shall negotiate in good faith to modify this Agreement or, as appropriate, the terms and conditions of this Agreement and the Acquisition, so as to effect the original intent of
the Parties as closely as possible in an equitable manner in order that the Transactions may be consummated as originally contemplated to the fullest extent possible in accordance with applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If at any time any provision of this Agreement is or becomes illegal, invalid or unenforceable in any respect under the Law of any
jurisdiction, that shall not affect or impair (i)&nbsp;the legality, validity or enforceability in that jurisdiction of any other provision of this Agreement; or (ii)&nbsp;the legality, validity or enforceability under the Law of any other
jurisdiction of that or any other provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.10</B> <B>No Partnership and No Agency</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Nothing in this Agreement and no action taken by the Parties pursuant to this Agreement shall constitute, or be deemed to constitute, a
partnership, association, joint venture or other <FONT STYLE="white-space:nowrap">co-operative</FONT> entity between any of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Nothing in this Agreement and no action taken by the Parties pursuant to this Agreement shall constitute, or be deemed to constitute,
either Party the agent of the other Party for any purpose. No Party has, pursuant to this Agreement, any authority or power to bind or to contract in the name of the other Party to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.11</B> <B>Costs and Expenses</B>. Except as otherwise provided in this Agreement, all costs and expenses incurred in connection with
this Agreement shall be paid by the Party incurring such cost or expense, except that (a)&nbsp;the Irish Takeover Panel&#146;s document review fees shall be borne by Parent, (b)&nbsp;the costs associated with the filing, printing, publication and
proposing of the Rule 2.7 Announcement shall be borne by Parent, (c)&nbsp;the costs associated with the filing, printing, publication and proposing of the Scheme Document, Proxy Statement and any other materials required to be proposed to the
Company Shareholders pursuant SEC rules, the Irish Companies Act or the Irish Takeover Rules shall be borne by the Company, (d)&nbsp;the filing fees incurred in connection with notifications with any Governmental Entities under any Antitrust Laws,
shall be borne by Parent and (e)&nbsp;the cost incurred in connection with soliciting proxies in connection with the Scheme Meeting and the EGM shall be borne by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.12</B> <B>Governing Law and Jurisdiction</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement and all Legal Proceedings based upon, arising out of or related to this Agreement or the Transactions shall be governed by,
and construed in accordance with, the Laws of the State of Delaware; <I>provided</I>, <I>however</I>, that the Acquisition and the Scheme and matters related thereto (including matters related to the Takeover Rules) shall, to the extent required by
the Laws of Ireland, and the interpretation of the duties of directors of the Company shall, be governed by, and construed in accordance with, the Laws of Ireland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the Parties irrevocably agrees that the state and federal courts sitting in the
State of Delaware, and any appellate courts therefrom, are to have exclusive jurisdiction to settle any Legal Proceeding based upon, arising out of or related to this Agreement or the Transactions and, for such purposes, irrevocably submits to the
exclusive jurisdiction of such courts and waives, to the fullest extent permitted by Law, any objection which any of them may now or hereafter have to the laying of venue of, and the defense of an inconvenient forum to the maintenance of, any such
Legal Proceeding in any such court. Any Legal Proceeding based upon, arising out of or related to this Agreement or the Transactions shall therefore be brought in the state and federal courts sitting in the State of Delaware, and any appellate
courts therefrom. Notwithstanding the forgoing, the Scheme and matters related to the sanction thereof shall be subject to the jurisdiction of the Irish High Court and any appellate courts therefrom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of the Parties acknowledges and irrevocably agrees (i)&nbsp;that any Legal Proceeding (whether at Law, in equity, in contract, in
tort or otherwise) arising out of, or in any way relating to, the Financing or the performance of services thereunder or related thereto against or by any Financing Source in its capacity as such shall be subject to the exclusive jurisdiction of any
state or federal court sitting in the Borough of Manhattan, New York, New York, and any appellate court therefrom, and each Party hereto submits for itself and its property with respect to any such Legal Proceeding to the exclusive jurisdiction of
such courts, (ii)&nbsp;not to bring or permit any of its Affiliates to bring or support anyone else in bringing any such Legal Proceeding in any other court, (iii)&nbsp;to waive and hereby waive, to the fullest extent permitted by Law, any objection
which any of them may now or hereafter have to the laying of venue of, and the defense of an inconvenient forum to the maintenance of, any such Legal Proceeding in any such court, (iv)&nbsp;that a final judgment in any such Legal Proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law and (v)&nbsp;that any such Legal Proceeding shall be governed by, and construed in accordance with, the Laws of the State of New
York (it being expressly agreed that the Financing Sources in their capacities as such shall be third party beneficiaries of this <U>Section</U><U></U><U>&nbsp;10.12(c)</U> and shall be entitled to enforce the provisions contained in this
<U>Section</U><U></U><U>&nbsp;10.12(c)</U> as if they were a party to this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) EACH PARTY HERETO HEREBY WAIVES, TO THE
FULLEST EXTENT PERMITTED BY APPLICABLE LAWS, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE FINANCING, OR THE PERFORMANCE OF SERVICES THEREUNDER
OR RELATED THERETO (INCLUDING ANY ACTION, PROCEEDING OR COUNTERCLAIM), INCLUDING IN ANY ACTION AGAINST OR BY ANY FINANCING SOURCE IN ITS CAPACITY AS SUCH, INCLUDING ANY ACTION DESCRIBED IN <U>SECTION 10.12(c)(i)</U> IN ANY SUCH COURT DESCRIBED IN
<U>SECTION 10.12(c)(i)</U> (IT BEING EXPRESSLY AGREED THAT THE FINANCING SOURCES IN THEIR CAPACITIES AS SUCH SHALL BE THIRD PARTY BENEFICIARIES OF THIS <U>SECTION 10.12(d)</U> AND SHALL BE ENTITLED TO ENFORCE THE PROVISIONS CONTAINED IN THIS
<U>SECTION 10.12(d)</U> AS IF THEY WERE A PARTY TO THIS AGREEMENT). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.13</B> <B>Third Party Beneficiaries</B>. Except to the extent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) as expressly provided in <U>Section</U><U></U><U>&nbsp;7.3</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) as expressly provided in <U>Section</U><U></U><U>&nbsp;7.8(b)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) as expressly provided in <U>Section</U><U></U><U>&nbsp;8.1(c)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) as expressly provided in <U>Section</U><U></U><U>&nbsp;10.5</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) as expressly provided in <U>Section</U><U></U><U>&nbsp;10.12(b)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) as expressly provided in <U>Section</U><U></U><U>&nbsp;10.12(c)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) as expressly provided in <U>Section</U><U></U><U>&nbsp;10.12(d)</U>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) as expressly provided in <U>Section</U><U></U><U>&nbsp;10.14</U>, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">this Agreement is not intended to confer upon any Person other than the Company and the Parent Parties any rights or remedies under or by reason of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.14</B> <B>Waiver of Claims Against Financing Sources</B>. Without limiting in any respect the liabilities of the
Financing Sources to Parent or its Affiliates, or the remedies of Parent or its Affiliates against the Financing Sources under any other agreement to which they are both parties, none of the Financing Sources shall have any liability to the Parties
or their Affiliates relating to or arising out of this Agreement, whether at Law or equity, in contract, in tort or otherwise, and neither the Parties nor any of their Affiliates will have any rights or claims against the Financing Sources under
this Agreement. Notwithstanding anything herein to the contrary, in no event shall the Company or its Affiliates be entitled to seek the remedy of specific performance of this Agreement against any of the Financing Sources (it being expressly agreed
that the Financing Sources in their capacities as such shall be third party beneficiaries of this <U>Section</U><U></U><U>&nbsp;10.14</U> and shall be entitled to enforce the provisions contained in this <U>Section</U><U></U><U>&nbsp;10.14</U> as if
they were a party to this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.15</B> <B><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations,
Warranties, Covenants and Agreements</B>. The representations, warranties, covenants and agreements contained in this Agreement and in any certificate or other writing delivered pursuant hereto shall not survive the Effective Time or the termination
of this Agreement pursuant to and in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, except that (i)<U>&nbsp;Section</U><U></U><U>&nbsp;7.3</U> and <U>Section</U><U></U><U>&nbsp;8</U> shall survive the Effective Time, and
(ii)<U>&nbsp;Section</U><U></U><U>&nbsp;7.8(c)</U>, <U>Sections 9.1(b)-(c)</U>, <U>Section</U><U></U><U>&nbsp;9.2</U> and this <U>Section</U><U></U><U>&nbsp;10</U> shall survive the termination of this Agreement pursuant to and in accordance with
<U>Section</U><U></U><U>&nbsp;9</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL> the
Parties have entered into this Agreement on the date specified above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SIGNED</B> for and on behalf of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>HORIZON THERAPEUTICS PLC</B><B> </B>by its authorized signatory:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy P. Walbert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Timothy P. Walbert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chairman, President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> T<SMALL>RANSACTION</SMALL>
A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL> the
Parties have entered into this Agreement on the date specified above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SIGNED</B> for and on behalf of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>AMGEN INC.</B><B> </B>by its authorized signatory:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert A. Bradway</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Robert A. Bradway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chairman of the Board, Chief Executive Officer and President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> T<SMALL>RANSACTION</SMALL>
A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL> the
Parties have entered into this Agreement on the date specified above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SIGNED</B> for and on behalf of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PILLARTREE LIMITED </B>by its authorized signatory:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Griffith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Peter Griffith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> T<SMALL>RANSACTION</SMALL>
A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>3
<FILENAME>d346985dex22.htm
<DESCRIPTION>EX-2.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Exhibit 2.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>APPENDIX 3 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDITIONS OF THE ACQUISITION
AND THE SCHEME </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition and the Scheme will comply with the Irish Takeover Rules and, where relevant, the rules and regulations of the
U.S. Exchange Act, the Irish Companies Act and the Nasdaq, and are subject to the terms and conditions set out in this Announcement and to be set out in the Scheme Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition and the Scheme are, to the extent required by the Laws of Ireland, governed by the Laws of Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition and the Scheme will be subject to the conditions set out in this Appendix 3 (<I>Conditions of the Acquisition</I> <I>and the
Scheme</I>). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Acquisition will be conditional upon the Scheme becoming effective and unconditional by not later than the End
Date (or such earlier date as may be specified by the Irish Takeover Panel, or such later date as the Amgen Parties and the Company may, subject to receiving the consent of the Irish Takeover Panel and the Irish High Court, in each case if required,
agree). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Scheme will be conditional upon: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Scheme having been approved by a majority in number of the Company Shareholders (including as may be directed by
the Irish High Court pursuant to Section&nbsp;450(5) of the Irish Companies Act) present and voting either in person or by proxy at the Scheme Meeting (or at any adjournment or postponement of such meeting) representing, at the Voting Record Time,
at least 75% in value of the Company Shares held by such Company Shareholders present and voting either in person or by proxy at the Scheme Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">each of the Required EGM Resolutions having been duly passed by the requisite majority of Company Shareholders at the
EGM (or at any adjournment or postponement of such meeting); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Irish High Court having sanctioned (without material modification) the Scheme pursuant to Sections 449 to 455 of
the Irish Companies Act (the date on which the condition in this paragraph 2.3 is satisfied, the &#147;<B>Sanction Date</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a copy of the Court Order having been delivered for registration to the Irish Registrar of Companies within 21 days of
the Sanction Date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Amgen Parties and the Company have agreed that, subject to paragraph 6, the Scheme and the Acquisition<B> </B>will
also be conditional upon the following matters having been satisfied or waived on or before the Sanction Date: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the waiting period (and any extension thereof) applicable to the Acquisition under the HSR Act shall have expired or
been earlier terminated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">all applicable waiting periods having expired, lapsed or been terminated or Clearances obtained (as appropriate), in
each case in connection with the Acquisition, under (a)&nbsp;the applicable Antitrust Laws of each of Germany and Austria and (b)&nbsp;the applicable Foreign Investment Laws of France, Germany, Denmark and Italy; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Exhibit 2.2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">there shall not have been issued by any court of competent jurisdiction and remain in effect any temporary restraining
order, preliminary or permanent injunction or other Order preventing the consummation of the Acquisition, nor shall any Law or Order (other than any Antitrust Laws or Foreign Investment Laws of any jurisdiction that is not (a)&nbsp;a Required <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction or (b)&nbsp;under the HSR Act) promulgated, entered, enforced, enacted, issued or deemed applicable to the Acquisition by any Governmental Entity which (i)&nbsp;directly or indirectly prohibits
the consummation of the Acquisition or (ii)&nbsp;imposes any Burdensome Condition; <I>provided however</I>, that Amgen and Acquirer Sub shall not be permitted to invoke this paragraph<I> </I>3.3<I> </I>unless they shall have otherwise taken all
actions required under the Transaction<I> </I>Agreement to have any such Order lifted; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Transaction Agreement not having been terminated in accordance with its terms by the applicable Party or Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Amgen Parties and the Company have agreed that, subject to paragraph 6, the Amgen Parties&#146; obligation to
effect the Scheme and the Acquisition<B> </B>will also be conditional upon the following matters having been satisfied (or, to the extent permitted by applicable Laws, waived by the Amgen Parties) on or before the Sanction Date:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">from the date of the Rule 2.7 Announcement to the Sanction Date, there having not been any event, change, effect,
development or occurrence that has had, or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect and that is continuing; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">(a) each of the representations and warranties of the Company set out in Sections 6.1(a) (<I>Qualification,
Organization, Subsidiaries, etc.</I>), 6.1(b) (<I>Subsidiaries</I>), 6.1(u) (<I>Corporate Authority Relative to the Transaction Agreement</I>) and 6.1(y) (<I>Brokers and Other Advisors</I>) of the Transaction Agreement having been true and correct
in all material respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date (in each case except to extent that any such representation and warranty speaks as of a
particular date, in which case such representation and warranty shall have been true and correct in all material respects as of such particular date), (b) the representations and warranties of the Company set out in Section&nbsp;6.1(c)
(<I>Capitalization</I>) of the Transaction Agreement having been true and correct in all respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date except for de
minimis inaccuracies, (c)&nbsp;the representations and warranties of the Company set out in Section&nbsp;6.1(e)(i) (<I>Absence of Changes</I>) of the Transaction Agreement having been true and correct in all respects at and as of the date of the
Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date and (d)&nbsp;each of the other representations and warranties of the Company having been true and correct (without any qualification as to
materiality or the Company Material Adverse Effect therein) in all respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date (in each case except to the extent that
any such representation and warranty speaks as of a particular date, in which case such representation and warranty shall have been true and correct as of such particular date), except for such failures to be true and correct as have not had and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Exhibit 2.2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Company having performed and complied, in all material respects, with all of the covenants and agreements that the
Transaction Agreement requires the Company to perform or comply with prior to the Sanction Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Amgen having received a certificate from an executive officer of the Company confirming the satisfaction of the
conditions set out in paragraphs 4.2 and 4.3. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Amgen Parties and the Company have agreed that, subject to paragraph 6, the Company&#146;s obligation to effect
the Scheme and the Acquisition will also be conditional upon the following matters having been satisfied (or, to the extent permitted by applicable Laws, waived by the Company) on or before the Sanction Date: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">(a) each of the representations and warranties of the Amgen Parties set out in Sections 6.2(a) (<I>Qualification and
Organization</I>) and 6.2(b) (<I>Corporate Authority Relative to the Transaction Agreement</I>) of the Transaction Agreement having been true and correct in all material respects at and as of the date of the Transaction Agreement and at and as of
the Sanction Date as though made at and as of the Sanction Date (in each case except to the extent that any such representation and warranty speaks as of a particular date, in which case such representation and warranty shall have been true and
correct in all material respects as of such particular date), and (b)&nbsp;each of the other representations and warranties of the Amgen Parties set out in Section&nbsp;6.2 of the Transaction Agreement having been true and correct (read for purposes
of this paragraph 5.1(b) without any qualification as to materiality or Amgen Material Adverse Effect therein) in all respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the
Sanction Date (in each case except to the extent that any such representation and warranty speaks as of a particular date, in which case such representation and warranty shall have been true and correct in all respects as of such particular date),
except for such failures to be true and correct as have not had and would not reasonably be expected to have, individually or in the aggregate, an Amgen Material Adverse Effect; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Amgen Parties having performed and complied, in all material respects, with all of the covenants and agreements
that the Transaction Agreement requires either of the Amgen Parties to perform or comply with prior to the Sanction Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Company having received a certificate from an executive officer of Amgen confirming the satisfaction of the
conditions set out in paragraphs 5.1 and 5.2. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Subject to the requirements of the Irish Takeover Panel: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Amgen Parties, on one hand, and the Company, on the other hand, reserve the right (but in no event shall any Party
be under any obligation) to waive (to the extent permitted by applicable Laws), in whole or in part, all or any of the conditions in paragraph 3 (provided that no such waiver shall be effective unless agreed to by both Parties);
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Amgen reserves the right (but shall be under no obligation) to waive (to the extent permitted by applicable Laws), in
whole or in part, all or any of the conditions in paragraph 4; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Company reserves the right (but shall be under no obligation) to waive (to the extent permitted by applicable
Laws), in whole or in part, all or any of the conditions in paragraph 5. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Exhibit 2.2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Scheme will lapse unless it is effective on or prior to the End Date (or such later date as the Amgen Parties and
the Company may, subject to receiving the consent of the Irish Takeover Panel and the Irish High Court, in each case if required, agree). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If Amgen is required to make an offer for the Company Shares under the provisions of Rule 9 of the Irish Takeover
Rules, Amgen may make such alterations to any of the Conditions set out in paragraphs 1, 2, 3, 4 and 5 above as are necessary to comply with the provisions of that rule. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Amgen reserves the right, subject to the prior written consent of the Irish Takeover Panel, to effect the
Acquisition<B> </B>by way of a Takeover Offer in the circumstances described in and subject to the terms of Section&nbsp;3.6 of the Transaction Agreement. Without limiting Section&nbsp;3.6 of the Transaction Agreement, in the event the
Acquisition<B> </B>is structured as a Takeover Offer, such Takeover Offer will be implemented on terms and conditions that are at least as favorable to the Company Shareholders and the Company Equity Award Holders as those which would apply in
relation to the Scheme (except for an acceptance condition set at 80% of the nominal value of the Company Shares to which such an offer relates (and which are not already in the beneficial ownership of Amgen))<B> </B> </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d346985dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BRIDGE CREDIT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of December 12, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>among </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amgen Inc.,
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Banks Herein Named, </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Citibank, N.A. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as
Administrative Agent, </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bank of America, N.A. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Syndication Agent, </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Citibank, N.A. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bank of America, N.A. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Lead Arrangers and Book Runners </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 1</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">DEFINITIONS AND ACCOUNTING TERMS</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Accounting Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rounding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exhibits and Schedules</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>References to &#147;the Borrower and its Subsidiaries&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Miscellaneous Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Divisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 2</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">LOANS</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Advances - General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Base Rate Advances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term Rate Advances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Voluntary Reduction of Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Voluntary Conversion or Continuation of Advances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Administrative Agent&#146;s Right to Assume Funds Available for Advances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mandatory Commitment Termination or Reduction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prepayments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defaulting Banks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 3</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">PAYMENTS AND FEES</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Principal and Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ticking Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Duration Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capital Adequacy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Increased Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Default Rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Computation of Interest and Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Banking</FONT> Days</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Manner and Treatment of Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Funding Sources</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Failure to Charge Not Subsequent Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Administrative Agent&#146;s Right to Assume Payments Will be Made by Borrower</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fee Determination Detail</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survivability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Dodd-Frank, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Replacement of Banks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES</P></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Existence and Qualification; Power; Compliance With Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Compliance With Other Agreements and Instruments and Government Regulations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Governmental Approvals Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Liabilities; No Material Adverse Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governmental Regulation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Binding Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulation U</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sanctions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Foreign Corrupt Practices Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EEA Financial Institution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Beneficial Ownership Certification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Target Acquisition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AFFIRMATIVE COVENANTS</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(OTHER THAN
INFORMATION AND REPORTING REQUIREMENTS)</P></TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Taxes and Other Potential Liens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preservation of Existence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maintenance of Properties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maintenance of Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance With Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Visitation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Keeping of Records and Books of Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Scheme Undertakings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Takeover Undertakings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Completion of Purchase of Remaining Shares in the Target</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Take Private Procedure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 6</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NEGATIVE COVENANTS</P></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Change in Nature of Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Liens; Sales and Leasebacks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subsidiary Indebtedness</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Covenant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 7</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INFORMATION AND REPORTING REQUIREMENTS</P></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial and Business Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 8</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONDITIONS</P></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Effectiveness</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions Precedent to Each Funding Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Actions by Banks During the Certain Funds Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 9</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EVENTS OF DEFAULT AND REMEDIES UPON EVENT OF DEFAULT</P></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Events of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies Upon Event of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 10</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE ADMINISTRATIVE AGENT</P></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Appointment and Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights as a Bank</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exculpatory Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reliance by Administrative Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delegation of Duties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignation of the Administrative Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Reliance</FONT> on Administrative Agent and Other Banks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right to Indemnity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Duties, etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Bank ERISA Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Erroneous Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 11</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS</P></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cumulative Remedies; No Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendments; Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Costs, Expenses and Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligation to Make Payments in Dollars</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Nature of Banks&#146; Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices and Other Communications; Facsimile Copies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Execution of Loan Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Binding Effect; Assignment; Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Setoff Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sharing of Setoffs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnity by the Borrower</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Parties Benefited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Fiduciary Duties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Integration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability of Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Independent Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Headings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Time of the Essence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consent to Jurisdiction and Service of Process</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acknowledgement and Consent to <FONT STYLE="white-space:nowrap">Bail-In</FONT> of Certain Financial Institutions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.26</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Judgment Currency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.27</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Forms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.28</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Damages</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.29</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patriot Act Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibits</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A - [Reserved]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B - Note</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">C - Compliance Certificate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">D - [Reserved]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E - Request for Loan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">F - Assignment Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedules</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Banks&#146; Commitments</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Disclosure of Subsidiaries</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Litigation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.11(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employee Benefit Plans</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Environmental</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Liens</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">13.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notices</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iv- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>BRIDGE CREDIT AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <B>BRIDGE</B> <B>CREDIT AGREEMENT</B> is dated as of December 12, 2022 and is entered into by and among Amgen Inc., a Delaware corporation (the
&#147;<B><U>Borrower</U></B>&#148;), each financial institution whose name is set forth on the signature pages hereof as a Bank, Citibank, N.A. (&#147;<B><U>Citibank</U></B>&#148;) as the Administrative Agent, and Bank of America, N.A.
(&#147;<B><U>Bank of America</U></B>&#148;), as Syndication Agent. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRELIMINARY STATEMENT: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Borrower intends to consummate the Target Acquisition; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the Target Acquisition, the Borrower intends to finance the Target Acquisition, the repayment of the Refinanced
Existing Target Indebtedness and the payment of fees, premiums, costs and expenses (including the fees, costs and expenses payable hereunder) related to the Transactions from the following sources: (i)&nbsp;(x) the issuance by the Borrower or its
Subsidiaries of unsecured debt securities in a public or private offering (the &#147;<B><U>New Senior Notes</U></B>&#148;) and/or the proceeds from borrowings by the Borrower under a senior unsecured term loan facility subject to conditions
precedent to funding that are no less favorable to the Borrower than the conditions set forth herein to the funding of the Bridge Facility (the &#147;<B><U>New Term Loan Facility</U></B>&#148; and, together with the New Senior Notes, the
&#147;<B><U>New Permanent Financing</U></B>&#148;) or (y)&nbsp;to the extent the New Permanent Financing is not consummated at or prior to the time the Target Acquisition is consummated, the proceeds of up to $28,500,000,000 from the borrowings
hereunder and (ii)&nbsp;cash on hand at the Borrower (the transactions set forth in this paragraph and the preceding paragraph, together with all related transactions consummated in connection therewith, are collectively the
&#147;<B><U>Transactions</U></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the proceeds of the Advances are to be used in accordance with
<U>Section</U><U></U><U>&nbsp;5.8</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the Banks are willing to extend such credit to the Borrower on the terms and
subject to the conditions set forth herein. Accordingly, the parties hereto agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS AND ACCOUNTING TERMS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Defined Terms</U></B>. As used in this Agreement, the following terms shall have the meanings set forth
below: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Adjusted Term SOFR</U></B>&#148; means, for purposes of any calculation, the rate per annum equal to
(a)&nbsp;Term SOFR for such calculation plus (b) 0.10%; provided that if Adjusted Term SOFR as so determined shall ever be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Adjusted Term SOFR Rate Advance</U></B>&#148; means an Advance that bears interest based on Adjusted Term SOFR. All Adjusted Term
SOFR Advances shall be denominated in Dollars. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Administrative Agent</U></B>&#148; means Citibank, when acting in its capacity
as the administrative agent under any of the Loan Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Administrative Agent&#146;s Office</U></B>&#148; means the
Administrative Agent&#146;s address as set forth on the signature pages of this Agreement, or such other address as the Administrative Agent hereafter may designate by written notice to the Borrower and the Banks. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Administrative Questionnaire</U></B>&#148; means an Administrative Questionnaire in a form supplied by the Administrative Agent.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Advance</U></B>&#148; means any Advance made or to be made by any Bank to the
Borrower as provided in Article 2, and includes each Base Rate Advance and each Term Rate Advance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Affiliate</U></B>&#148;
means, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, &#147;control&#148; (and the correlative terms, &#147;<B>controlled
by</B>&#148; and &#147;<B>under common control</B> <B>with</B>&#148;) shall mean possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other
ownership interests, by contract or otherwise). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Agents</U></B>&#148; means, collectively, the Administrative Agent, each
Arranger and the Syndication Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Agent Parties</U></B>&#148; has the meaning set forth in Section&nbsp;11.7(d)(ii). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Agreed Form of Scheme Press Announcement</U></B>&#148; means the Scheme Press Announcement in substantially final form and in a
form agreed by the Borrower and the Administrative Agent prior to the Effective Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Agreement</U></B>&#148; means this
Bridge Credit Agreement, either as originally executed or as it may from time to time be supplemented, modified, amended, restated or extended in accordance with Section&nbsp;11.2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Applicable Lending Office</U></B>&#148; means, as to each Bank, its office or branch so designated by written notice to the
Borrower and the Administrative Agent as its Applicable Lending Office. If no Applicable Lending Office is designated by a Bank, its Applicable Lending Office shall be its office at its address for purposes of notices hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Approved Fund</U></B>&#148; means any Fund that is administered or managed by (a)&nbsp;a Bank, (b)&nbsp;an Affiliate of a Bank or
(c)&nbsp;an entity or an Affiliate of an entity that administers or manages a Bank. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Arranger</U></B>&#148; means each of
Citibank and Bank of America when acting in its capacity as an arranger and a bookrunner under any of the Loan Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Asset Sale</U></B>&#148; means the sale or other disposition of assets by the Borrower or any Subsidiary of the Borrower outside
the ordinary course of business (as determined in good faith by the Borrower), including issuances of Equity Interests by the Borrower&#146;s Subsidiaries (excluding (A)&nbsp;asset sales or other dispositions (including issuances of Equity Interests
by the Borrower&#146;s Subsidiaries) between or among members of the Consolidated Group and their affiliates; (B)&nbsp;the sale or other disposition of cash and cash equivalents or debt investments and instruments; (C)&nbsp;the sale, exchange or
other disposition of accounts receivable in connection with compromise, settlement or collection thereof consistent with past practices; (D)&nbsp;any license of intellectual property or a grant of rights for development, manufacture, production,
commercialization, collaboration, marketing, <FONT STYLE="white-space:nowrap">co-promotion,</FONT> or distribution consistent with past practice, (E)&nbsp;any sale, sale-leaseback, disposition or transfer of property primarily consisting of office
space, (F)&nbsp;dispositions of property or assets no longer used or useful or that are obsolete (as reasonably determined by the Borrower); (G) sale-leasebacks by the Borrower and its Subsidiaries; (H) [reserved]; (I) [reserved]; (J) the sale or
other disposition of assets held by joint ventures; (K)&nbsp;the unwinding of hedge arrangements, (L)&nbsp;factoring and similar arrangements, including dispositions of receivables; in the ordinary course of business; (M)&nbsp;any equipment
financing or leasing transactions; (N)&nbsp;the sale or other disposition of assets in connection with receivable securitization programs; and (O)&nbsp;asset sales and other dispositions (including issuance of Equity Interests by the Borrower&#146;s
Subsidiaries), the Net Cash Proceeds of which do not exceed $250,000,000 in any single transaction or related series of transactions or $500,000,000 in the aggregate (and only any amount in excess of such threshold amounts shall constitute Net Cash
Proceeds)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Assignment Agreement</U></B>&#148; means an Assignment Agreement in
substantially the form of Exhibit F, executed by a Bank and an Eligible Assignee of all or part of that Bank&#146;s interest hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Availability Period</U></B>&#148; means the period from and including the Closing Date to, but excluding, the earlier of
(a)&nbsp;the end of the Certain Funds Period and (b)&nbsp;the date of the termination of the Commitments. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U><FONT
STYLE="white-space:nowrap">Bail-In</FONT> Action</U></B>&#148; has the meaning set forth in Section&nbsp;11.25. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Bank</U></B>&#148; means the Persons identified as &#147;Banks&#148; and listed on the signature pages of this Agreement and each
Eligible Assignee that shall become a party hereto pursuant to Section&nbsp;11.9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Bank Insolvency Event</U></B>&#148; means
that (a)&nbsp;a Bank or its Parent Company is insolvent, or is generally unable to pay its debts as they become due, or admits in writing its inability to pay its debts as they become due, or makes a general assignment for the benefit of its
creditors, or (b)&nbsp;such Bank or its Parent Company is the subject of (i)&nbsp;a <FONT STYLE="white-space:nowrap">Bail-In</FONT> Action or (ii)&nbsp;a bankruptcy, insolvency, reorganization, liquidation or similar proceeding, or a receiver,
trustee, conservator, intervenor or sequestrator or the like has been appointed for such Bank or its Parent Company, or such Bank or its Parent Company has taken any action in furtherance of or indicating its consent to or acquiescence in any such
proceeding or appointment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Bank of America</U></B>&#148; has the meaning set forth in the introductory paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Banking Day</U></B>&#148; means any Monday, Tuesday, Wednesday, Thursday or Friday, other than a day on which banks are authorized
or required to be closed in California or New York. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Base Rate</U></B>&#148;, for any day, means the highest of (i)&nbsp;the
rate of interest in effect on such day as publicly announced by Citibank from time to time as its base commercial lending rate (such base rate is not intended to be the lowest rate of interest charged by Citibank) (the &#147;Prime Rate&#148;), (ii)
the Federal Funds Effective Rate in effect on such day plus <SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">2</SUB> of 1% and (iii)&nbsp;Adjusted Term SOFR for a <FONT STYLE="white-space:nowrap">one-month</FONT>
tenor in effect on such day plus 1.00%. Any change in the Base Rate due to a change in the Prime Rate, the Federal Funds Effective Rate or Adjusted Term SOFR shall be effective on the effective day of such change in the Prime Rate, the Federal Funds
Effective Rate or Adjusted Term SOFR, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Base Rate Advance</U></B>&#148; means an Advance made hereunder that bears
interest as set forth in Section&nbsp;3.1(b) and designated as a Base Rate Advance in accordance with Article 2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Beneficial
Ownership Certification</U></B>&#148; means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Beneficial Ownership Regulation</U></B>&#148; means 31 C.F.R. &#167; 1010.230. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Benefit Plan</U></B>&#148; means any of (a)&nbsp;an &#147;employee benefit plan&#148; (as defined in ERISA) that is subject to
Title I of ERISA, (b)&nbsp;a &#147;plan&#148; as defined in and subject to Section&nbsp;4975 of the Code or (c)&nbsp;any Person whose assets include (for purposes of ERISA Section&nbsp;3(42) or otherwise for purposes of Title I of ERISA or
Section&nbsp;4975 of the Code) the assets of any such &#147;employee benefit plan&#148; or &#147;plan&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Bidco</U></B>&#148; means &#147;Acquirer Sub&#148; under and as defined in the
Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Borrower</U></B>&#148; has the meaning set forth in the introductory paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Bridge Facility</U></B>&#148; means the Commitments and any Advances made thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Cash</U></B>&#148; means, when used in connection with any Person, all monetary and
<FONT STYLE="white-space:nowrap">non-monetary</FONT> items owned by that Person that are treated as cash in accordance with Generally Accepted Accounting Principles, except for amounts held by, or on deposit with, another Person as cash collateral
or other security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Certain Funds Default</U></B>&#148; means an Event of Default which is continuing (and has not been either
remedied or waived) arising from any of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;9.1(a) or Section&nbsp;9.1(b) insofar as relating to <FONT
STYLE="white-space:nowrap">non-payment</FONT> by the Borrower of principal or fees (unless the Event of Default is due solely to an administrative or technical error); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Section&nbsp;9.1(d) as it relates to the failure by the Borrower to perform any of the following covenants: Sections 5.2(a) (only in
respect of the Borrower and not any Subsidiary, and it being understood that failure to maintain any good standing status or similar status in any jurisdiction shall not constitute a breach of this provision), Section&nbsp;6.2, Section&nbsp;6.3,
Section&nbsp;6.5 or Section&nbsp;6.7; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Section&nbsp;9.1(i) (but excluding, in relation to involuntary proceedings, any Event of Default
caused by a frivolous or vexatious (and in either case, lacking in merit) action, proceeding or petition in respect of which no order or decree in respect of such involuntary proceeding shall have been entered); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) Section&nbsp;9.1(g), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">in each
case, for the avoidance of doubt, not with respect to the Target or any Subsidiary of the Target and excluding any procurement obligation with respect to the Target or any Subsidiary of the Target. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Certain Funds Period</U></B>&#148; means the period commencing on the Effective Date and ending at the time immediately after a
Mandatory Cancellation Event has occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Certain Funds Purposes</U></B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) where the Target Acquisition proceeds by way of a Scheme: (i)&nbsp;the payment (directly or indirectly) of the cash component of the Scheme
Consideration pursuant to Section&nbsp;8.2(a) of the Transaction Agreement, including by depositing of funds with an exchange agent appointed for the purpose of disbursement of such cash component; (ii)&nbsp;the repayment of the Refinanced Existing
Target Indebtedness; and (iii)&nbsp;the payment of fees, premiums, costs and expenses in respect of the Transactions; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) where the
Target Acquisition proceeds by way of a Takeover Offer: (i)&nbsp;payment (directly or indirectly) of the cash consideration as set forth in the Offer Documents and the Squeeze Out Notice; (ii)&nbsp;the repayment of the Refinanced Existing Target
Indebtedness; and (iii)&nbsp;the payment of fees, premiums, costs and expenses in respect of the Transactions, in each case whether any such payments for such purposes are made on or after the Initial Funding Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Certain Funds Representations</U></B>&#148; means each of the following
representations: <U>Section</U><U></U><U>&nbsp;4.1(a)</U> (it being understood that failure to maintain any good standing status or similar status in any jurisdiction shall not constitute a breach of this provision), <U>Section</U><U></U>&nbsp;4.2,
Section<U>&nbsp;4.7</U>, <U>Section</U><U></U><U>&nbsp;4.9</U>, <U>Section</U><U></U><U>&nbsp;4.12</U>, <U>Section</U><U></U><U>&nbsp;4.20</U>, <U>Section</U><U></U><U>&nbsp;4.21(b)(A)(ii)</U> and <U>Section</U><U></U><U>&nbsp;4.21(b)(B)(ii)</U>, in
each case, for the avoidance of doubt, not with respect to the Target or any Subsidiary of the Target and excluding any procurement obligation with respect to the Target or any Subsidiary of the Target. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Certificate of a Senior Officer</U></B>&#148; means a certificate signed by a Senior Officer of the Person providing the
certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Citibank</U></B>&#148; has the meaning set forth in the introductory paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U><FONT STYLE="white-space:nowrap">Clean-up</FONT> Date</U></B>&#148; has the meaning set forth in Article 9. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Closing Date</U></B>&#148; means the date on which each of the conditions set forth in Section&nbsp;8.2 have been satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Code</U></B>&#148; means the Internal Revenue Code of 1986, as amended or replaced and as in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Commitment</U></B>&#148; means, as to each Bank, such Bank&#146;s commitment to make Advances pursuant to
<U>Section</U><U></U><U>&nbsp;2.1(a)(i)</U>, as set forth on <U>Schedule 2.1</U> or in the Assignment Agreement pursuant to which such Bank becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with
this Agreement. The aggregate amount of all Commitments as of the Effective Date is $28,500,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Communications</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;11.7(d)(ii)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Compliance Certificate</U></B>&#148; means a certificate in the form of Exhibit C, properly completed and signed by a Senior
Officer of the Borrower. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Consolidated EBITDA</U></B>&#148; means, for any period, Consolidated Net Income for such period
plus, without duplication and to the extent deducted in determining Consolidated Net Income for such period, the sum of (a)&nbsp;interest expense, (b)&nbsp;provision for taxes based on income, (c)&nbsp;depreciation expense, (d)&nbsp;amortization
expense, (e)&nbsp;unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> charges, expenses or losses and (f)&nbsp;other <FONT STYLE="white-space:nowrap">non-cash</FONT> charges, expenses or losses (excluding any such <FONT
STYLE="white-space:nowrap">non-cash</FONT> charge to the extent it represents an accrual or reserve for potential cash charge in any future period or amortization of a prepaid cash charge that was paid in a prior period), minus, to the extent
included in determining Consolidated Net Income for such period, the sum of (i)&nbsp;unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> gains and <FONT STYLE="white-space:nowrap">non-cash</FONT> income, (ii)&nbsp;any other <FONT
STYLE="white-space:nowrap">non-cash</FONT> income or gains increasing Consolidated Net Income for such period (excluding any such <FONT STYLE="white-space:nowrap">non-cash</FONT> gain to the extent it represents the reversal of an accrual or reserve
for potential cash charge in any prior period) and (iii)&nbsp;any gains realized from the disposition of property outside of the ordinary course of business, all as determined on a consolidated basis; provided, that the Consolidated EBITDA for any
entity or business acquired by the Borrower or any Subsidiary pursuant to an acquisition the aggregate consideration for which equals or exceeds $1,000,000,000 during such period shall be included on a pro forma basis for such period (as determined
in good faith by the Borrower, assuming the consummation of such acquisition and the incurrence or assumption of any indebtedness by the Borrower and its Subsidiaries in connection therewith incurred as of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the first day of such period), and provided further that the Consolidated EBITDA for any entity or business sold or otherwise disposed of for aggregate consideration of $1,000,000,000 or more by
the Borrower or any Subsidiary shall be deducted on a pro forma basis for such period (as determined in good faith by the Borrower, assuming the consummation of such sale or other disposition occurred on the first day of such period). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Consolidated Group</U></B>&#148; means the Borrower and its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Consolidated Interest Coverage Ratio</U></B>&#148; means, as of any date of determination, the ratio of (a)&nbsp;Consolidated
EBITDA for the period of the four fiscal quarters most recently ended to (b)&nbsp;Consolidated Interest Expense for such period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Consolidated Interest Expense</U></B>&#148; means, for any period, total interest expense (including that attributable to leases
recorded as Finance Leases in accordance with Generally Accepted Accounting Principles) of the Borrower and its Subsidiaries on a consolidated basis for such period with respect to all outstanding Indebtedness of the Borrower and its Subsidiaries.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Consolidated Net Income</U></B>&#148; means, for any period, the consolidated net income (or loss) of the Borrower and its
Subsidiaries on a consolidated basis; provided that there shall be excluded the income (or deficit) of any Person (other than a Subsidiary of the Borrower) in which the Borrower or any of its Subsidiaries has an ownership interest, except to the
extent that any such income is actually received by the Borrower or such Subsidiary in the form of dividends or similar distributions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Consolidated Net Worth</U></B>&#148; means, as of any date of determination, the Shareholders&#146; Equity of the Borrower and its
Consolidated Subsidiaries on that date as set forth or reflected on the consolidated balance sheet of the Borrower and its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Consolidated Subsidiary</U></B>&#148; means, as of any date of determination and with respect to any Person, any Subsidiary of that
Person whose financial data is, in accordance with Generally Accepted Accounting Principles, reflected in that Person&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Contractual Obligation</U></B>&#148; means, as to any Person, any provision of any outstanding Securities issued by that Person or
of any material agreement, instrument or undertaking to which that Person is a party or by which it or any of its Property is bound. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Convert</U></B>,&#148; &#147;<B><U>Conversion</U></B>&#148; and &#147;<B><U>Converted</U></B>&#148; each refers to a conversion of
Advances of one Type into Advances of another Type pursuant to Section&nbsp;2.5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Court Order</U></B>&#148; means &#147;Court
Order&#148; under and as defined in the Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Current ERISA Affiliate</U></B>&#148;, as applied to any
Person, means (i)&nbsp;any corporation which is a member of a controlled group of corporations within the meaning of Section&nbsp;414(b) of the Code of which that Person is a member; (ii)&nbsp;any trade or business (whether or not incorporated)
which is a member of a group of trades or businesses under common control within the meaning of Section&nbsp;414(c) of the Code of which that Person is a member; and (iii)&nbsp;any member of an affiliated service group within the meaning of
Section&nbsp;414(m) or (o)&nbsp;of the Code of which that Person, any corporation described in clause (i)&nbsp;above or any trade or business described in clause (ii)&nbsp;above is a member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Daily Margin</U></B>&#148; means, for any date of determination, for the designated Level and Type of Advances, the following
interest rates per annum: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base Rate Advance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Term Rate Advance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><U>Time of<BR>Determination</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Initial<BR>Funding<BR>Date<BR>through&nbsp;89<BR>days after<BR>Closing<BR>Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">90 days<BR>after<BR>Initial<BR>Funding<BR>Date<BR>through<BR>179&nbsp;days<BR>after<BR>Initial<BR>Funding<BR>Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">180&nbsp;days<BR>after<BR>Initial<BR>Funding<BR>Date<BR>through<BR>269 days<BR>after<BR>Initial<BR>Funding<BR>Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">270 days<BR>after<BR>Initial<BR>Funding<BR>Date and<BR>thereafter</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Initial<BR>Funding<BR>Date<BR>through&nbsp;89<BR>days after<BR>Initial<BR>Funding<BR>Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">90 days<BR>after<BR>Initial<BR>Funding<BR>Date<BR>through<BR>179&nbsp;days<BR>after<BR>Initial<BR>Funding<BR>Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">180&nbsp;days<BR>after<BR>Initial<BR>Funding<BR>Date<BR>through<BR>269 days<BR>after<BR>Initial<BR>Funding<BR>Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">270&nbsp;days<BR>after<BR>Initial<BR>Funding<BR>Date and<BR>thereafter</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.000</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.125</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.375</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.625</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.875</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.125</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.375</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.625</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.000</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.500</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.000</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.250</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.500</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.125</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.375</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.625</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.875</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.125</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.375</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.625</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.875</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.500</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.000</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.250</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.500</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.000</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.375</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.625</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.875</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.125</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.375</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.625</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.875</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.125</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of this definition, (a)&nbsp;if any change in the rating established by S&amp;P or Moody&#146;s
with respect to Long-Term Debt shall result in a change in the Level, the change in the Daily Margin shall be effective as of the date on which such rating change is publicly announced, and (b)&nbsp;if the ratings established by both of S&amp;P and
Moody&#146;s with respect to Long-Term Debt are unavailable for any reason for any day, then the applicable level for such day shall be deemed to be Level&nbsp;5 (or, if the Majority Banks consent in writing, such other Level as may be reasonably
determined by the Majority Banks from a rating with respect to Long-Term Debt for such day established by another rating agency reasonably acceptable to the Majority Banks). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Debt Issuance</U></B>&#148; means the borrowing, issuance or other incurrence of Indebtedness for borrowed money as described under
clause (a)&nbsp;or (c) of the definition of Indebtedness (including loans, hybrid securities and debt securities convertible into equity), in each case, by the Borrower or any of its Subsidiaries, except (i)&nbsp;Indebtedness owed to the Borrower or
any Subsidiary of the Borrower; (ii)&nbsp;borrowings under the Existing Credit Agreement and any refinancing thereof in an amount up to $3,250,000,000, (iii) any ordinary course working capital facilities, cash management, letter of credit,
factoring, surety or similar bonds, hedging arrangements, cash pooling arrangements, local credit facilities or lines of credit of Foreign Subsidiaries or overdraft facilities; (iv)&nbsp;issuances of commercial paper and refinancings thereof
(excluding any term loan indebtedness or underwritten securities offering to refinance such commercial paper); (v) purchase money indebtedness (including deferred purchase price obligations) or equipment financing in each case incurred in the
ordinary course of business; (vi)&nbsp;indebtedness incurred in connection with leases (including sale-leasebacks), capital leases, financial leases and other similar obligations in each case incurred in the ordinary course of business; (vii)
[reserved]; (viii) [reserved]; (ix) receivables securitization programs and other customary receivables financings; <FONT STYLE="white-space:nowrap">(x)&nbsp;non-recourse</FONT> indebtedness (including any indebtedness for which a pledge of
ownership is required) to finance projects, construction or real property; (xi)&nbsp;other Indebtedness to the extent the Net Cash Proceeds of such Indebtedness are utilized or to be utilized to refinance any Indebtedness for borrowed money as
described under clause (a)&nbsp;or (c) of the definition of Indebtedness of the Borrower or any Subsidiary of the Borrower to the extent the issuance or incurrence of such Indebtedness occurs within 12 months of the maturity of the applicable
Indebtedness being refinanced and pay any fees or other amounts in respect thereof (including any prepayment or redemption premiums and accrued interest thereon) and (xii)&nbsp;Indebtedness (other than the New Permanent Financing) in an outstanding
principal amount not to exceed $750,000,000 in the aggregate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Debtor Relief Laws</U></B>&#148; means the Bankruptcy Code of the United States
of America, as amended from time to time, and all other applicable liquidation, conservatorship, bankruptcy, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws from time to time in effect affecting the
rights of creditors generally. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Default</U></B>&#148; means any Event of Default or any event that, with the giving of any
applicable notice or passage of time specified in <U>Section</U><U></U><U>&nbsp;9.1</U>, or both, would be an Event of Default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Default Rate</U></B>&#148; means the interest rate described in <U>Section</U><U></U><U>&nbsp;3.7</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Defaulting Bank</U></B>&#148; means at any time, subject to <U>Section</U><U></U><U>&nbsp;2.9(c)</U>, (i) any Bank that has failed
for two or more Banking Days to comply with its obligations under this Agreement to make an Advance, or make any other payment due hereunder (each, a &#147;<B><U>funding obligation</U></B>&#148;), unless such Bank has notified the Administrative
Agent and the Borrower in writing that such failure is the result of such Bank&#146;s determination that one or more conditions precedent to funding has not been satisfied (which conditions precedent, together with the applicable default, if any,
will be specifically identified in such writing), (ii) any Bank that has notified the Administrative Agent or the Borrower in writing, or has stated publicly, that it does not intend to comply with its funding obligations hereunder, unless such
writing or statement states that such position is based on such Bank&#146;s determination that one or more conditions precedent to funding cannot be satisfied (which conditions precedent, together with the applicable default, if any, will be
specifically identified in such writing or public statement), (iii) any Bank that has defaulted on its funding obligations under other loan agreements or credit agreements generally under which it has commitments to extend credit or that has
notified, or whose Parent Company has notified, the Administrative Agent or the Borrower in writing, or has stated publicly, that it does not intend to comply with its funding obligations under loan agreements or credit agreements generally,
(iv)&nbsp;any Bank that has, for two or more Banking Days after written request of the Administrative Agent or the Borrower, failed to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding
obligations hereunder (provided that such Bank will cease to be a Defaulting Bank solely pursuant to this clause (iv)&nbsp;upon the Administrative Agent&#146;s and the Borrower&#146;s receipt of such written confirmation), or (v)&nbsp;any Bank with
respect to which a Bank Insolvency Event has occurred and is continuing with respect to such Bank or its Parent Company; <U>provided</U> that a Bank Insolvency Event shall not be deemed to occur with respect to a Bank or its Parent Company solely as
a result of the acquisition or maintenance of an ownership interest in such Bank or Parent Company by a Governmental Agency or instrumentality thereof where such action does not result in or provide such Bank with immunity from the jurisdiction of
courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Bank (or such Governmental Agency or instrumentality) to reject, repudiate, disavow or disaffirm any contracts or agreements
made with such Bank . Any determination by the Administrative Agent that a Bank is a Defaulting Bank under any of clauses (i)&nbsp;through (v) above will be conclusive and binding absent manifest error, and such Bank will be deemed to be a
Defaulting Bank (subject to <U>Section</U><U></U><U>&nbsp;2.9(c)</U>) upon notification of such determination by the Administrative Agent to the Borrower and the Banks. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Designated Deposit Account</U></B>&#148; means a deposit account designated by a Borrower in its Request for Loan submitted with
respect to each Loan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Dollars</U></B>&#148; or &#147;<B><U>$</U></B>&#148; means United States Dollars. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Duration Fee</U></B>&#148; means with respect to any Bank, as of any date of determination, the amount equal to (a)&nbsp;the
Duration Percentage in effect on such date of determination, times (b)&nbsp;the sum of (i)&nbsp;the aggregate principal amount of all outstanding Advances, and (ii)&nbsp;the amount of the Commitment, in each case held by such Bank on such date of
determination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Duration Percentage</U></B>&#148; means as of any day set forth below, the rate
set forth below under the heading &#147;Duration Percentage&#148; opposite such day: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Day after Initial Funding Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Duration&nbsp;Percentage:</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">180<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">270<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Effective Date</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.1</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>EGM</U></B>&#148; means &#147;EGM&#148; under and as defined in the Transaction Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>EGM Resolutions</U></B>&#148; means &#147;EGM Resolutions&#148; under and as defined in the Transaction Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Eligible Assignee</U></B>&#148; means any Person that meets the requirements to be an assignee under
<U>Section</U><U></U><U>&nbsp;11.9(b)(iii)</U>, <U>(v)</U> and <U>(vi)</U> (subject to such consents, if any, as may be required under <U>Section</U><U></U><U>&nbsp;11.9(b)(iii)</U>). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Eligible Subsidiary</U></B>&#148; means any of the wholly-owned Subsidiaries of the Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Employee Benefit Plan</U></B>&#148; means any &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA which is,
or was at any time, maintained or contributed to by the Borrower or with respect to any such plan that is subject to Section&nbsp;302 of ERISA or Title IV of ERISA or Section&nbsp;412 of the Code, any of its ERISA Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Environmental Laws</U></B>&#148; means all plans, policies or decrees binding on the Borrower and its Subsidiaries in accordance
with applicable statutes, ordinances, orders, rules or regulations and all statutes, ordinances, orders, rules or regulations and the like, in each case, relating to (i)&nbsp;environmental matters, including, without limitation, those relating to
fines, injunctions, penalties, damages, contribution, cost recovery compensation, losses or injuries resulting from the release or threatened release of hazardous materials, (ii)&nbsp;the generation, use, storage, transportation or disposal of
hazardous materials, or (iii)&nbsp;occupational safety and health, industrial hygiene, land use or the protection of human, plant or animal health or welfare, in any manner applicable to the Borrower or any of its Subsidiaries or any of their
respective properties, including, without limitation, the Comprehensive Environmental Response, Compensation, and Liability Act (42 U.S.C. &#167; 9601 <U>et</U> <U>seq</U>.), the Hazardous Materials Transportation Act (49 U.S.C. &#167; 1801
<U>et</U> <U>seq</U>.), the Resource Conservation and Recovery Act (42 U.S.C. &#167; 6901 <U>et</U> <U>seq</U>.), the Federal Water Pollution Control Act (33 U.S.C. &#167; 1251 <U>et</U> <U>seq</U>.), the Clean Air Act (42 U.S.C. &#167; 7401
<U>et</U> <U>seq</U>.), the Toxic Substances Control Act (15 U.S.C. &#167; 2601 <U>et</U> <U>seq</U>.), the Federal Insecticide, Fungicide and Rodenticide Act (7 U.S.C. &#167;136 <U>et</U> <U>seq</U>.), the Occupational Safety and Health Act (29
U.S.C. &#167; 651 <U>et</U> <U>seq</U>.) and the Emergency Planning and Community <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-to-Know</FONT></FONT> Act (42 U.S.C. &#167; 11001 <U>et</U> <U>seq</U>.), each as amended or
supplemented, and any analogous future or present local, state and federal statutes and regulations promulgated pursuant thereto, each as in effect as of the date of determination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Equity Interests</U></B>&#148; means shares of capital stock, partnership interests, membership interests in a limited liability
company, beneficial interests in a trust or other equity ownership interests in a Person, and any warrants, options or other rights entitling the holder thereof to purchase or acquire any such equity interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Equity Issuance</U></B>&#148; means the issuance of any Equity Interests
(including equity-linked securities) by the Borrower except (a)&nbsp;issuances intended to be used by the Borrower as consideration for any acquisition (including any increase in the cash consideration for the Target Shares pursuant to the Scheme or
in a Takeover Offer from the cash consideration set forth in the Transaction Agreement as in effect on the Effective Date), (b) issuances pursuant to, or in connection with, any employee compensation plans, equity incentive plans, employee stock
plans, dividend reinvestment plans and retirement plans or issued as compensation to employees and/or <FONT STYLE="white-space:nowrap">non-employee</FONT> directors or upon conversion or exercise of outstanding options or other equity awards,
(c)&nbsp;issuances of directors&#146; qualifying shares and/or other nominal amounts required to be held by Persons other than the Borrower or its Subsidiaries under applicable Law, (d)&nbsp;issuances among the Borrower and its affiliates, and
(e)&nbsp;other equity issuances (including issuances of preferred stock of the Borrower) with aggregate net cash proceeds in amount up to $250,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>ERISA</U></B>&#148; means the Employee Retirement Income Security Act of 1974, and any regulations issued pursuant thereto, as
amended or replaced and as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>ERISA Affiliate</U></B>&#148;, as applied to any Person, means
(i)&nbsp;any corporation which is, or was at any time, a member of a controlled group of corporations within the meaning of Section&nbsp;414(b) of the Code of which that Person is, or was at any time, a member; (ii)&nbsp;any trade or business
(whether or not incorporated) which is, or was at any time, a member of a group of trades or businesses under common control within the meaning of Section&nbsp;414(c) of the Code of which that Person is, or was at any time, a member; and
(iii)&nbsp;any member of an affiliated service group within the meaning of Section&nbsp;414(m) or (o)&nbsp;of the Code of which that Person, any corporation described in clause (i)&nbsp;above or any trade or business described in clause
(ii)&nbsp;above is, or was at any time, a member. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>ERISA Event</U></B>&#148; means (i)&nbsp;a &#147;reportable event&#148;
within the meaning of Section&nbsp;4043 of ERISA and the regulations issued thereunder with respect to any Pension Plan (excluding those for which the provision for <FONT STYLE="white-space:nowrap">30-day</FONT> notice to the PBGC, or the penalty
for failure to provide such notice, has been waived by regulation or by PBGC technical update); (ii) the failure to meet the minimum funding standard of Sections 412 and 430 of the Code with respect to any Pension Plan (whether or not waived in
accordance with Section&nbsp;412(c) of the Code) or the failure to make by its due date a required installment under Section&nbsp;430(j) of the Code with respect to any Pension Plan or the failure to make any required contribution to a Multiemployer
Plan; (iii)&nbsp;the provision by the administrator of any Pension Plan pursuant to Section&nbsp;4041(a)(2) of ERISA of a notice of intent to terminate such plan in a distress termination described in Section&nbsp;4041(c) of ERISA; (iv)&nbsp;the
withdrawal by the Borrower or any of its ERISA Affiliates from any Pension Plan with two or more contributing sponsors or the termination of any such Pension Plan resulting in liability therefor pursuant to Sections 4063 or 4064 of ERISA;
(v)&nbsp;the institution by the PBGC of proceedings to terminate under Section&nbsp;4042 of ERISA any Pension Plan, or the occurrence of any event or condition which might constitute grounds under Section&nbsp;4042 of ERISA for the termination of,
or the appointment of a trustee to administer, any Pension Plan; (vi)&nbsp;the imposition of liability on the Borrower or any of its ERISA Affiliates pursuant to Section&nbsp;4062(e) or 4069 of ERISA or by reason of the application of
Section&nbsp;4212(c) of ERISA; (vii)&nbsp;the withdrawal by the Borrower or any of its ERISA Affiliates in a complete or partial withdrawal (within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential
liability therefor, or the receipt by the Borrower or any of its ERISA Affiliates of notice from any Multiemployer Plan that it is insolvent pursuant to Section&nbsp;4245 of ERISA, or that it intends to terminate or has terminated under
Section&nbsp;4041A or 4042 of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
ERISA; (viii)&nbsp;the imposition on the Borrower or any of its ERISA Affiliates of fines, penalties, taxes or related charges under Chapter 43 of the Code or under Section&nbsp;409 or 502(c),
(i) or (l)&nbsp;or 4071 of ERISA in respect of any Pension Plan; (ix)&nbsp;the assertion of a material claim (other than routine claims for benefits) against any Pension Plan or the assets thereof, or against the Borrower or any of its ERISA
Affiliates in connection with any such Pension Plan; (x)&nbsp;receipt from the Internal Revenue Service of notice of the failure of any Pension Plan (or any other Employee Benefit Plan intended to be qualified under Section&nbsp;401(a) of the Code)
to qualify under Section&nbsp;401(a) of the Code, or the failure of any trust forming part of any Pension Plan to qualify for exemption from taxation under Section&nbsp;501(a) of the Code; or (xi)&nbsp;the conditions for imposition of a Lien under
Section&nbsp;303(k) of ERISA shall have been met with respect to any Pension Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Erroneous Payment</U></B>&#148; has the
meaning assigned to it in <U>Section</U><U></U><U>&nbsp;10.11(a)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Erroneous Payment Deficiency Assignment</U></B>&#148;
has the meaning assigned to it in Section&nbsp;10.11(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Erroneous Payment Impacted Class</U></B>&#148; has the meaning
assigned to it in <U>Section</U><U></U><U>&nbsp;10.11(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Erroneous Payment Return Deficiency</U></B>&#148; has the
meaning assigned to it in <U>Section</U><U></U><U>&nbsp;10.11(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Erroneous Payment Subrogation Rights</U></B>&#148; has
the meaning assigned to it in <U>Section</U><U></U><U>&nbsp;10.11(e)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Event of Default</U></B>&#148; shall have the
meaning provided in <U>Section</U><U></U><U>&nbsp;9.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Excluded Taxes</U></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.10(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Existing Credit Agreement</U></B>&#148; means the second amended and restated
credit agreement dated as of December&nbsp;12, 2019, as amended or supplemented from time to time, among the Borrower, the lenders thereto, Citibank N.A., as the administrative agent and an issuing bank, and JPMorgan Chase Bank, N.A., as syndication
agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>FATCA</U></B>&#148; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or
successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section&nbsp;1471(b)(1) of the Code,
any published intergovernmental agreement entered into in connection with the implementation of such Sections of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to such published intergovernmental agreements.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Federal Funds Effective Rate</U></B>&#148; means for any day, the rate per annum (expressed, as a decimal, rounded upwards, if
necessary, to the next higher 1/100 of 1%) equal to the rate on overnight federal funds transactions with members of the Federal Reserve System, as published by the Federal Reserve Bank of New York on the Banking Day next succeeding such day;
<U>provided</U> that (i)&nbsp;if such day is not a Banking Day, the Federal Funds Effective Rate for such day shall be such rate on such transactions on the next preceding Banking Day as so published on the next succeeding Banking Day, and
(ii)&nbsp;if no such rate is so published on such next succeeding Banking Day, the Federal Funds Effective Rate for such day shall be the average rate charged to Administrative Agent, in its capacity as a Bank, on such day on such transactions as
determined by the Administrative Agent; <U>provided</U> that if the Federal Funds Effective Rate shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Fee Letter</U></B>&#148; means that certain syndication and fee letter, dated as
of the date hereof, between the Arrangers and the Borrower. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Finance Lease</U></B>&#148; means, as to any Person, a lease of
any Property by that Person as lessee that is, or should be recorded as a &#147;finance lease&#148; on the balance sheet of that Person prepared in accordance with Generally Accepted Accounting Principles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Fiscal Quarter</U></B>&#148; means the fiscal quarter of the Borrower consisting of a three month fiscal period ending on each
March&nbsp;31, June&nbsp;30, September&nbsp;30 and December 31. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Fiscal Year</U></B>&#148; means the fiscal year of the
Borrower consisting of a twelve month fiscal period ending on each December 31. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Foreign Bank</U></B>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;11.27(a)(i)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Foreign Subsidiary</U></B>&#148; means any Subsidiary of the Borrower
that is organized under the laws of a jurisdiction other than one of the fifty states of the United States or the District of Columbia. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Fund</U></B>&#148; means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or
otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Funding
Date</U></B>&#148; means each date on which any Advance is made hereunder, including the Initial Funding Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Generally
Accepted Accounting Principles</U></B>&#148; means generally accepted accounting principles in the United States of America. The term &#147;<B><U>Generally Accepted Accounting Principles</U></B>&#148; shall be read in each instance as if the words
&#147;<B><U>consistently applied</U></B>&#148; followed immediately thereafter, meaning that the accounting principles applied are consistent in all material respects (except for changes concurred in by the Borrower&#146;s independent public
accountants) to those applied at prior dates or for prior periods. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Governmental Agency</U></B>&#148; means (a)&nbsp;any
foreign, federal, state, county or municipal government, or political subdivision thereof, (b)&nbsp;any governmental or quasi-governmental agency, authority, board, bureau, commission, department, instrumentality or public body, (c)&nbsp;any court
or administrative tribunal or (d)&nbsp;with respect to any Person, any arbitration tribunal or other nongovernmental authority to whose jurisdiction that Person has consented. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>High Court</U></B>&#148; means the High Court of Ireland. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Indebtedness</U></B>&#148; means, as to any Person, (a)&nbsp;all indebtedness of such Person for borrowed money, (b)&nbsp;that
portion of the obligations of such Person under Finance Leases which is properly recorded as a liability on a balance sheet of that Person prepared in accordance with Generally Accepted Accounting Principles, (c)&nbsp;to the extent of the
outstanding Indebtedness thereunder, any obligation of such Person that is evidenced by a promissory note or other similar instrument representing an extension of credit to such Person, whether or not for borrowed money, (d)&nbsp;any obligation of
such Person for the deferred purchase price of Property or services (<U>other</U> <U>than</U> trade or other accounts payable in the ordinary course of business), (e) any obligation of such Person of the nature described in clauses <U>(a)</U>,
<U>(b)</U>, <U>(c)</U> or <U>(d)</U>&nbsp;above that is secured by a Lien on assets of such Person, whether or not that Person has assumed such obligation or whether or not such obligation is <FONT STYLE="white-space:nowrap">non-recourse</FONT> to
the credit of such Person, but only to the extent of the lesser of the face amount of the obligation or the fair market value of the assets so subject to the Lien, (f)&nbsp;obligations of such Person arising under acceptance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
facilities or under facilities for the discount of accounts receivable of such Person, (g)&nbsp;any obligation of such Person to reimburse the issuer of any letter of credit issued for the
account of such Person upon which and only to the extent a draw has been made and (h)&nbsp;in the case of the Borrower, the net obligations of the Borrower under Swap Agreements. Notwithstanding the provisions listed above, Indebtedness shall not
include any intercompany loans made by the Borrower to a Subsidiary or by any Subsidiary to another Subsidiary or by any Subsidiary to the Borrower. As of any date of determination, the amount of the Borrower&#146;s Indebtedness with respect to
(1)&nbsp;Swap Agreements shall be equal to the net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">marked-to-market</FONT></FONT> value (if negative) for the Borrower for all such Swap Agreements taken as a whole and
(2)&nbsp;obligations under clause (d)&nbsp;shall be the stated balance sheet amount of such obligations, determined on a consolidated basis in accordance with Generally Accepted Accounting Principles, of the Borrower and its Consolidated
Subsidiaries on that date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Indemnified Taxes</U></B>&#148; has the meaning set forth in Section&nbsp;3.10(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Indemnitees</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;11.12</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Initial Funding Date</U></B>&#148; means the date on which the first Advance is made hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Interest Period</U></B>&#148; means, as to each Term Rate Advance, the period commencing on the date specified by the Borrower of
such Advance pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)</U> and ending 1, 3 or 6 months thereafter, as specified by the applicable Borrower in the applicable Request for Loan; <U>provided</U> that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The first day of any Interest Period shall be a Banking Day; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Interest Period that would otherwise end on a day that is not a Banking Day shall be extended to the next
succeeding Banking Day unless such Banking Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Banking Day; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Interest Period shall extend beyond the final Maturity Date. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Ireland</U></B>&#148; means Ireland, excluding Northern Ireland, and the word &#147;Irish&#148; shall be construed accordingly.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Irish Companies Act</U></B>&#148; means the Companies Act 2014 of Ireland. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Laws</U></B>&#148; means, collectively, all foreign, federal, state and local statutes, treaties, rules, regulations, ordinances,
codes and administrative or controlling precedents of any Governmental Agency. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Level</U></B>&#148; means Level&nbsp;1,
Level&nbsp;2, Level&nbsp;3, Level&nbsp;4 or Level&nbsp;5, as the case may be, <U>provided</U>, <U>however</U> that if, as of any date of determination, (a)&nbsp;there is a one Level difference between (x)&nbsp;the Level that would be applicable if
such Level were determined solely by reference to the rating assigned by S&amp;P (the &#147;<B><U>Hypothetical S&amp;P Level</U></B>&#148;) and (y)&nbsp;the Level that would be applicable if such Level were determined solely by reference to the
rating assigned by Moody&#146;s (the &#147;<B><U>Hypothetical Moody&#146;s Level</U></B>&#148;) then the &#147;Level&#148; for such date shall be deemed to be the higher of the Hypothetical S&amp;P Level and the Hypothetical Moody&#146;s Level and
(b)&nbsp;there is a two Level or more difference between the Hypothetical S&amp;P Level and the Hypothetical Moody&#146;s Level, then the &#147;Level&#148; for such date shall be deemed to be the middle Level between the Hypothetical S&amp;P Level
and the Hypothetical Moody&#146;s Level, and if such middle Level does not exist, then the &#147;Level&#148; for such date shall be deemed to be the lower of the middle two Levels between the Hypothetical S&amp;P Level and the Hypothetical
Moody&#146;s Level (for these purposes Level&nbsp;1 being higher than Level&nbsp;2, etc.). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Level</U></B><B><U></U></B><B><U>&nbsp;1</U></B>&#148; means that, as of any
date of determination, the Long-Term Debt carries either of the following ratings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; or higher from S&amp;P </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A2&#148; or higher from Moody&#146;s. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Level</U></B><B><U></U></B><B><U>&nbsp;2</U></B>&#148; means that, as of any date of determination, the criteria of Level&nbsp;1
are not satisfied and the Long-Term Debt carries either of the following ratings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#147;A-&#148;</FONT>
from S&amp;P </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A3&#148; from Moody&#146;s. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Level</U></B><B><U></U></B><B><U>&nbsp;3</U></B>&#148; means that, as of any date of determination, the criteria of neither
Level&nbsp;1 nor Level&nbsp;2 are satisfied and the Long-Term Debt carries either of the following ratings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;BBB+&#148; from S&amp;P
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Baa1&#148; from Moody&#146;s. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Level</U></B><B><U></U></B><B><U>&nbsp;4</U></B>&#148; means that, as of any date of determination, the criteria of none of
Level&nbsp;1, Level&nbsp;2 or Level&nbsp;3 are satisfied and the Long-Term Debt carries either of the following ratings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;BBB&#148;
from S&amp;P </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Baa2&#148; from Moody&#146;s. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Level</U></B><B><U></U></B><B><U>&nbsp;5</U></B>&#148; means that, as of any date of determination, the criteria of none of
Level&nbsp;1, Level&nbsp;2, Level&nbsp;3 or Level&nbsp;4 are satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Lien</U></B>&#148; means any mortgage, deed of trust,
pledge, hypothecation, assignment for security, security interest, encumbrance, lien or charge of any kind, whether voluntarily incurred or arising by operation of Law or otherwise, affecting any Property, <U>including</U> any agreement to grant any
of the foregoing, any conditional sale or other title retention agreement, any lease in the nature of a security interest, and/or the filing of or agreement to give any financing statement (<U>other than</U> a precautionary financing statement with
respect to a lease that is not in the nature of a security interest) under the Uniform Commercial Code or comparable Law of any jurisdiction with respect to any Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Loan</U></B>&#148; means any group of Advances made at any one time by the Banks pursuant to <U>Article 2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Loan Documents</U></B>&#148; means, collectively, this Agreement, the Notes, the Fee Letter, and any Request for Loan, in each case
either as originally executed or as the same may from time to time be supplemented, modified, amended, restated, extended or supplanted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Long Stop Date</U></B>&#148; means the earlier of (a)&nbsp;the first anniversary of the Effective Date and (b)&nbsp;the &#147;End
Date&#148; under and as defined in the Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Long-Term Debt</U></B>&#148; means senior, unsecured,
long-term-debt securities of the Borrower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Majority Banks</U></B>&#148; means, as of any date of determination, Banks to
which more than 50% of the aggregate Total Outstandings is owed or, if Total Outstandings at such time are zero, Banks whose aggregate Commitments are greater than 50% of the Commitments then in effect; <U>provided</U> that if any Bank shall be a
Defaulting Bank at such time, there shall be excluded from the determination of Majority Banks at such time the Total Outstandings owed to such Defaulting Bank at such time or, if the Total Outstandings at such time are zero, the Commitments of such
Bank at such time, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Mandatory Cancellation Event</U></B>&#148; means the occurrence of any of the following
conditions or events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Target Acquisition proceeds by way of a Scheme: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) the Scheme Meeting or the EGM shall have been completed and the Scheme Meeting Resolution or the Required EGM Resolutions, as applicable,
shall not have been approved by the requisite majorities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) the High Court shall decline or refuse to sanction the Scheme, which
decision has become final and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii) either the Scheme lapses or it is withdrawn,
unless the Borrower has elected to convert the Scheme to a Takeover Offer in accordance with Section&nbsp;3.6 of the Transaction Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv) the Scheme Circular is not dispatched within 28 days of the date of the Scheme Press Announcement (or such later date as the Takeover
Panel may permit); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v) a Court Order(s) is issued but not filed with the Registrar within 21 calendar days of its issuance; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vi) the date which is 15 days after the Scheme Effective Date, or such later date permitted by the Takeover Panel; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Target Acquisition proceeds by way of a Takeover Offer: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) such Takeover Offer lapses, terminates or is withdrawn; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) the Takeover Offer Document(s) is not dispatched within 28 days (or such longer period permitted by the Takeover Panel) of the date of
issue of the Offer Press Announcement; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the time at which all payments made or to be made for Certain Funds Purposes have been paid in full in cleared
funds; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Long Stop Date, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U> that, for the avoidance of doubt, a switch from a Scheme to a Takeover Offer or from a Takeover Offer to a Scheme (or, for the
avoidance of doubt, any amendment to the terms or conditions of a Scheme or a Takeover Offer) shall not constitute a lapse, termination or withdrawal for the purposes of this definition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Material Adverse Effect</U></B>&#148; means a circumstance or set of
circumstances or events affecting the business, financial condition or operations of the Borrower and its Subsidiaries, taken as a whole, that have a material adverse effect, individually or in the aggregate, upon the ability (i)&nbsp;of the
Borrower and its Subsidiaries, taken as a whole, to perform under the Loan Documents or (ii)&nbsp;of the Banks to enforce, the Obligations under the Loan Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Maturity Date</U></B>&#148; means the date that is 364 days after the Initial Funding Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;</B><B><U>Moody&#146;s</U></B><B>&#148;</B> means Moody&#146;s Investors Service, Inc. or any successor thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Multiemployer Plan</U></B>&#148; means any employee benefit plan which is a &#147;multiemployer plan&#148; (as defined in
Section&nbsp;4001(a)(3) of ERISA) to which the Borrower or any of its ERISA Affiliates is contributing, or within the preceding six (6)&nbsp;years has contributed, or to which the Borrower or any of its ERISA Affiliates has, or within the preceding
six (6)&nbsp;years has had, an obligation to contribute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Net Cash Proceeds</U></B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to any sale or other disposition of assets by the Borrower or any Subsidiary of the Borrower outside the ordinary course of
business (as determined in good faith by the Borrower), including issuance of Equity Interests by the Borrower&#146;s Subsidiaries, the excess, if any, of (i)&nbsp;the cash received in connection therewith (including any cash received by way of
deferred payment pursuant to, or by monetization of, a note receivable or otherwise, but only as and when so received) over (ii)&nbsp;the sum of (A)&nbsp;payments made to retire any Indebtedness that is secured by such asset and that is required to
be repaid in connection with the sale thereof, (B)&nbsp;the fees and expenses incurred by the Consolidated Group in connection therewith, (C)&nbsp;taxes paid or reasonably estimated to be payable by the Consolidated Group in connection with such
transaction, (D)&nbsp;the funded escrow established pursuant to the documents governing such dispositions to secure indemnification and purchase price adjustments; provided that any amounts released from escrow shall constitute Net Cash Proceeds;
(E)&nbsp;the amount of reserves established by the Consolidated Group in good faith and pursuant to commercially reasonable practices for adjustment in respect of the sale price of such asset or assets in accordance with GAAP; and (F)&nbsp;the pro
rata portion of the cash received in connection therewith attributable to minority interests and not available for distribution to or for the account of the Borrower or any of its wholly-owned subsidiaries as a result thereof; <U>provided</U> that
if the amount of such reserves exceeds the amounts charged against such reserves, then such excess, upon the determination thereof, shall then constitute Net Cash Proceeds; <U>provided</U>, <U>further</U>, that if no Event of Default exists and the
Borrower shall deliver to the Administrative Agent a certificate of a Senior Officer of the Borrower to the Administrative Agent promptly following receipt of any such proceeds setting forth the Consolidated Group&#146;s intention to use any portion
of such proceeds in assets useful in the business of the Consolidated Group within the Reinvestment Period, such portion of such proceeds shall not constitute Net Cash Proceeds except to the extent not, within the Reinvestment Period, so used; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) with respect to the borrowing, issuance or other incurrence of Indebtedness for borrowed money as described under clause (a)&nbsp;or (c) of
Indebtedness (including loans, hybrid securities, and debt securities convertible into equity) by the Borrower or any Subsidiary of the Borrower, the excess, if any, of (i)&nbsp;cash received by the Consolidated Group in connection with such
incurrence, issuance, offering or placement over (ii)&nbsp;the sum of (A)&nbsp;payments made to retire any Indebtedness that is required to be repaid in connection with such issuance, offering or placement (other than the Advances) and (B)&nbsp;the
underwriting discounts and commissions and other fees and expenses incurred by the Borrower and its Subsidiaries in connection with such incurrence, issuance, offering or placement; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) with respect to the issuance of any Equity Interests (including equity-linked
securities) by the Borrower, the excess of (i)&nbsp;the cash received by the Borrower in connection with such issuance over (ii)&nbsp;the underwriting discounts and commissions and other fees and expenses incurred by the Consolidated Group in
connection with such issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>New Permanent Financing</U></B>&#148; has the meaning set forth in the Preliminary Statements.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>New Senior Notes</U></B>&#148; has the meaning set forth in the Preliminary Statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>New Term Loan Facility</U></B>&#148; has the meaning set forth in the Preliminary Statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Bank</U></B>&#148; means, at any time, a Bank that is not a Defaulting Bank
or a Potential Defaulting Bank. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Notes</U></B>&#148; means any of the promissory notes made by the Borrower in favor of a Bank
in accordance with <U>Section</U><U></U><U>&nbsp;2.1(e)</U> to evidence Advances made by that Bank under the Commitments, substantially in the form of <U>Exhibit B</U>, as originally executed or as the same may from time to time be supplemented,
modified, amended, renewed or extended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Notice of Conversion/Continuation</U></B>&#148; has the meaning specified in
Section&nbsp;2.5(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Obligations</U></B>&#148; means all present and future monetary obligations of every kind or nature of
the Borrower at any time and from time to time owed to the Arrangers, the Administrative Agent, the Syndication Agent or the Banks or any one or more of them under any one or more of the Loan Documents, whether due or to become due, matured or
unmatured, liquidated or unliquidated, or contingent or noncontingent, <U>including</U> obligations to pay, discharge and satisfy the Erroneous Payment Subrogation Rights and interest that accrues after the commencement of any proceeding under any
Debtor Relief Law by or against the Borrower or any Subsidiary of the Borrower. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Offer Conversion Notice</U></B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;5.10</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Offer Documents</U></B>&#148; means the Takeover Offer Document
and the Offer Press Announcement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Offer Press Announcement</U></B>&#148; means the formal press announcement of the Takeover
Offer required to be issued in compliance with Rule 2.7 of the Takeover Rules in relation to the Takeover Offer following service of an Offer Conversion Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Original Currency</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.1(a)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Other Connection Taxes</U></B>&#148; means, with respect to the Administrative Agent or any Bank, Taxes imposed as a result of a
present or former connection between the Administrative Agent or such Bank and the jurisdiction imposing such Tax (other than connections arising from the Administrative Agent or such Bank having executed, delivered, become a party to, performed its
obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Other Taxes</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.10(d)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Parent Company</U></B>&#148; means, with respect to a Bank, the bank holding
company (as defined in Federal Reserve Board Regulation Y), if any, of such Bank, or if such Bank does not have a bank holding company, then any corporation, association, partnership or other business entity owning, beneficially or of record,
directly or indirectly, a majority of the shares of such Bank. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Participant</U></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;11.9(c)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Participant Register</U></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;11.9(e)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Patriot Act</U></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;11.29</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Payment Recipient</U></B>&#148; has the meaning assigned to it in
<U>Section</U><U></U><U>&nbsp;10.11(a)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>PBGC</U></B>&#148; means the Pension Benefit Guaranty Corporation (or any
successor thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Pension Plan</U></B>&#148; means any Employee Benefit Plan other than a Multiemployer Plan, that is
subject to Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA or Title IV of ERISA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Permitted
Encumbrances</U></B>&#148; means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">inchoate Liens incident to construction or maintenance of real property, or Liens incident to construction or
maintenance of real property, now or hereafter filed of record for sums not yet delinquent or being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by Generally Accepted Accounting Principles shall
have been made therefor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens for taxes and assessments on real property which are not yet past due, or Liens for taxes and assessments
on real property for which adequate reserves have been set aside and are being contested in good faith by appropriate proceedings and have not proceeded to judgment, <U>provided</U> that, by reason of
<FONT STYLE="white-space:nowrap">non-payment</FONT> of the obligations secured by such Liens, no such material real property is subject to a material risk of loss or forfeiture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">easements, exceptions, reservations, or other agreements granted or entered into for the purpose of pipelines,
conduits, cables, wire communication lines, power lines and substations, streets, trails, walkways, drainage, irrigation, water, and sewerage purposes, dikes, canals, ditches, the removal of oil, gas, coal, or other minerals, and other like purposes
affecting real property which in the aggregate do not materially burden or impair the fair market value or use of such real property for the purposes for which it is or may reasonably be expected to be held; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">rights reserved to or vested in any Governmental Agency by Law to control or regulate, or obligations or duties
under Law to any Governmental Agency with respect to, the use of any real property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">rights reserved to or vested in any Governmental Agency by Law to control or regulate, or obligations or duties
under Law to any Governmental Agency with respect to, any right, power, franchise, grant, license, or permit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">present or future zoning laws and ordinances or other laws and ordinances restricting the occupancy, use, or
enjoyment of real property; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">statutory Liens, other than those described in clauses (a)&nbsp;or (b) above, arising in the ordinary course of
business with respect to obligations which are not delinquent or are being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by Generally Accepted Accounting Principles shall have been made therefor;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens consisting of pledges or deposits to secure obligations under workers&#146; compensation laws or similar
legislation, including Liens of judgments thereunder which are not currently dischargeable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens consisting of pledges or deposits of Property to secure performance in connection with operating leases
made in the ordinary course of business to which the Borrower or a Subsidiary is a party as lessee, <U>provided</U> the aggregate value of all such pledges and deposits in connection with any such lease does not at any time exceed <FONT
STYLE="white-space:nowrap">16-2/3%</FONT> of the annual fixed rentals payable under such lease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens consisting of deposits of Property to secure statutory obligations of the Borrower or a Subsidiary of the
Borrower in the ordinary course of its business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens consisting of deposits of Property to secure (or in lieu of) surety, appeal or customs bonds in
proceedings to which the Borrower or a Subsidiary of the Borrower is a party in the ordinary course of its business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">purchase money Liens or purchase money security interests upon or in any property acquired or held by the
Borrower or any Subsidiary in the ordinary course of business to secure the purchase price of such property or to secure indebtedness incurred solely for the purpose of financing the acquisition of such property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens on an asset to secure all or any part of the cost of development or construction of such asset or
improvements thereon and which shall be released or satisfied within 120 days after completion of such development or construction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens on an asset created in connection with the acquisition, construction or development of additions,
extensions or improvements to such asset which shall be financed by obligations described in Sections 142, 144(a) or 144(c) of the Code, as amended, or by obligations entitled to substantially similar tax benefits under other legislation or
regulations in effect from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens on property subject to escrow or similar arrangements established in connection with litigation
settlements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens on an asset required in connection with any program, law, statute or regulation of any state or local
authority which provides financial or tax benefits not available without such Lien, provided that substantially all of the obligations secured by such Lien are obligations that are in lieu of, or reduce, a property tax or other payment obligation
that itself would have been secured by a Lien permitted hereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens on Property securing any intercompany loans made by the Borrower to a Subsidiary or by any Subsidiary to
another Subsidiary; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens on the Target Shares (or any of them) securing any indebtedness or any obligations whatsoever.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Person</U></B>&#148; means any entity, whether an individual, trustee,
corporation, general partnership, limited partnership, limited liability company, joint stock company, trust, estate, unincorporated organization, business association, tribe, firm, joint venture, Governmental Agency, or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Platform</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;11.7(d)(i)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Potential Defaulting Bank</U></B>&#148; means, at any time, (i)&nbsp;any Bank with respect to which an event of the kind referred
to in the definition of &#147;Bank Insolvency Event&#148; has occurred and is continuing in respect of any financial institution affiliate of such Bank, (ii)&nbsp;any Bank that has notified, or whose Parent Company or a financial institution
affiliate thereof has notified, the Administrative Agent or the Borrower in writing, or has stated publicly, that it does not intend to comply with its funding obligations under any other loan agreement or credit agreement or other similar/other
financing agreement, unless such writing or statement states that such position is based on such Bank&#146;s determination that one or more conditions precedent to funding cannot be satisfied (which conditions precedent, together with the applicable
default, if any, will be specifically identified in such writing or public statement), or (iii)&nbsp;any Bank that has, or whose Parent Company has, a <FONT STYLE="white-space:nowrap">non-investment</FONT> grade rating from Moody&#146;s or S&amp;P
or another nationally recognized rating agency. Any determination by the Administrative Agent that a Bank is a Potential Defaulting Bank under any of clauses (i)&nbsp;through (iii) above will be conclusive and binding absent manifest error, and such
Bank will be deemed a Potential Defaulting Bank (subject to Section&nbsp;2.9(c)) upon notification of such determination by the Administrative Agent to the Borrower and the Banks. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Property</U></B>&#148; means any interest in any kind of property or asset, whether real, personal or mixed, or tangible or
intangible. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Qualifying Revolving Facility</U></B>&#148; means a revolving credit facility entered into by the Borrower, all or
a portion of the proceeds of which will be used for Certain Funds Purposes and the commitments (or a portion thereof) under which are subject to conditions precedent to funding that are no less favorable to the Borrower than the conditions set forth
herein to the funding of the Bridge Facility, as determined by the Borrower in its reasonable discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Qualifying Term Loan
Facility</U></B>&#148; means a term loan facility entered into by the Borrower, the proceeds of which will be used for Certain Funds Purposes and that is subject to conditions precedent to funding that are no less favorable to the Borrower than the
conditions set forth herein to the funding of the Bridge Facility, as determined by the Borrower in its reasonable discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>PTE</U></B>&#148; means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may
be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Reference Rate</U></B>&#148; means (a<U>)</U>&nbsp;the Term SOFR Reference Rate, or (b)&nbsp;the
Adjusted Term SOFR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Refinanced Existing Target Indebtedness</U></B>&#148; means (a)&nbsp;Indebtedness under that certain
Credit Agreement, dated as of May&nbsp;7, 2015, by and among Horizon Therapeutics USA, Inc., Horizon Therapeutics plc (f/k/a Horizon Pharma Public Limited Company), the subsidiary guarantors party thereto, the lenders party thereto from time to time
and Citibank, N.A., as administrative agent and collateral agent, (b)&nbsp;Indebtedness under the 5.5% Senior Notes due 2027 issued pursuant to that certain Indenture dated as of July&nbsp;16, 2019, by and among Horizon Therapeutics USA, Inc., the
guarantors party thereto and U.S. Bank National Association, as trustee, and (c)&nbsp;any other indebtedness of the Target or any of its Subsidiaries required or desirable to be repaid on or about the Initial Funding Date, including <FONT
STYLE="white-space:nowrap">(i)&nbsp;close-out</FONT> or termination costs (if applicable) in connection with any derivative instruments to which the Target or any of its Subsidiaries is party, and (ii)&nbsp;any amounts required to cash collateralize
any letters of credit or similar instruments in respect of which the Target (or any of its Subsidiaries) is the underlying account party or obligor in respect of such instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Register</U></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;11.9(g)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Registrar</U></B>&#148; means the means the Registrar of Companies in Dublin,
Ireland, as defined in Section&nbsp;2 of the Irish Companies Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Regulation D</U></B>&#148; means Regulation D, as at any
time amended, of the Board of Governors of the Federal Reserve System, or any other regulation in substance substituted therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Regulation U</U></B>&#148; means Regulation U, as at any time amended, of the Board of Governors of the Federal Reserve System, or
any other regulation in substance substituted therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Reinvestment Period</U></B>&#148; means, with respect to any Net Cash
Proceeds received in connection with any Asset Sale, the period of 6 months following the receipt of such Net Cash Proceeds; provided that, in the event that, during such 6 month period, a member of the Consolidated Group enters into a binding
commitment to reinvest any Net Cash Proceeds, the Reinvestment Period with respect to such Net Cash Proceeds shall be the period of 6 months following the receipt of such Net Cash Proceeds. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Related Parties</U></B>&#148; means, with respect to any Person, such Person&#146;s Affiliates and the partners, directors,
officers, employees, agents and advisors of such Person and of such Person&#146;s Affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Request for Loan</U></B>&#148;
means a written request for a Loan substantially in the form of Exhibit E, signed by a Senior Officer of the applicable Borrower and properly completed to provide all information required to be included therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Required EGM Resolutions</U></B>&#148; has the meaning under and as defined in the Transaction Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Requirement of Law</U></B>&#148; means, as to any Person, the articles or certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws</FONT> or other organizational or governing documents of such Person, and any Law, or judgment, award, decree, writ or determination of a Governmental Agency, in each case applicable to or binding upon such Person
or any of its Property or to which such Person or any of its Property is subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>S&amp;P</U></B>&#148;<B> </B>means S&amp;P
Global Ratings, or any successor thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme</U></B>&#148; means the &#147;Scheme&#148; under and as defined in the
Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme Circular</U></B>&#148; means the &#147;Scheme Document&#148; under and as defined in the
Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme Consideration</U></B>&#148; means &#147;Consideration&#148; under and as defined in the
Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme Documents</U></B>&#148; means the Scheme Press Announcement and the Scheme Circular. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme Effective Date</U></B>&#148; means the date of delivery to the Registrar of the Court Order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme Meeting</U></B>&#148; means &#147;Scheme Meeting&#148; under and as
defined in the Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme Meeting Resolution</U></B>&#148; means &#147;Scheme Meeting Resolution&#148;
under and as defined in the Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Scheme Press Announcement</U></B>&#148; means the &#147;Rule 2.7
Announcement&#148; under and as defined in the Transaction Agreement, with respect to the Scheme. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Securities</U></B>&#148;
means any capital stock, share, voting trust certificate, bond, debenture, note or other evidence of indebtedness, limited partnership interest, or any warrant, option or other right to purchase or acquire any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Senior Officer</U></B>&#148; means the (a)&nbsp;chief executive officer, (b)&nbsp;chief operating officer, (c)&nbsp;chief financial
officer, (d)&nbsp;chief accounting officer, (e)&nbsp;corporate controller, (f)&nbsp;treasurer, (g) assistant treasurer, (h)&nbsp;any senior vice president, or (i)&nbsp;any executive vice president, in each case whatever the title nomenclature may
be, of the Person designated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Shareholders&#146; Equity</U></B>&#148; means, as of any date of determination,
shareholders&#146; equity as of that date determined in accordance with Generally Accepted Accounting Principles; <U>provided</U> that there shall be excluded from Shareholders&#146; Equity any amount attributable to capital stock that is, directly
or indirectly, required to be redeemed or repurchased by the issuer thereof at a specified date or upon the occurrence of specified events or at the election of the holder thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Significant Subsidiary</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.4</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>SOFR</U></B>&#148; means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>SOFR Administrator</U></B>&#148; means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight
financing rate). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Squeeze Out Notice</U></B>&#148; means a notice given under Chapter 2 of Part 9 of the Irish Companies Act
given by Bidco to a Target Shareholder who has not accepted the Takeover Offer and implementing the Squeeze Out Procedures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Squeeze Out Procedures</U></B>&#148; means the procedures set out in Chapter 2 of Part 9 of the Irish Companies Act for the
compulsory acquisition of any minority shareholders in an Irish company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Subsidiary</U></B>&#148; means, as of any date of
determination and with respect to any Person, any corporation, limited liability company, partnership or joint venture, whether now existing or hereafter organized or acquired: (a)&nbsp;in the case of a corporation or limited liability company, of
which a majority of the securities or other ownership interests having ordinary voting power for the election of directors or other governing body (other than securities or other ownership interests having such power only by reason of the happening
of a contingency) are at the time beneficially owned by such Person and/or one or more Subsidiaries of such Person, or (b)&nbsp;in the case of a partnership or joint venture, of which such Person or a Subsidiary of such Person is a general partner
or joint venturer or of which a majority of the partnership or other ownership interests are at the time beneficially owned by such Person and/or one or more of its Subsidiaries, excluding any partnership or joint venture over which the Person or
Subsidiary of such Person does not exercise actual control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Successor Rate Conforming Changes</U></B>&#148; means, with respect to any
proposed Successor Rate, any conforming changes to the definition of Base Rate, Interest Period, Daily Margin, timing and frequency of determining rates and making payments of interest and other administrative matters as may be appropriate, in the
discretion of the Administrative Agent and the Borrower, to reflect the adoption of such Successor Rate and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the
Administrative Agent and the Borrower determine in good faith and in a commercially reasonable manner that adoption of any portion of such market practice is not administratively feasible or that no market practice for the administration of such
Successor Rate exists, in such other manner of administration as determined in the good faith and commercially reasonable discretion of the Administrative Agent and the Borrower). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Swap Agreement</U></B>&#148; means a written agreement between the Borrower and one or more financial institutions providing for
&#147;<B>swap</B>&#148;, &#147;<B>collar</B>&#148; or other interest rate protection (other than &#147;caps&#148;) with respect to any Indebtedness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Syndication Agent</U></B>&#148; means Bank of America, when acting in its capacity as the syndication agent under any of the Loan
Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Takeover Offer</U></B>&#148; means the &#147;Takeover Offer&#148; under and as defined in the Transaction
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Takeover Offer Document</U></B>&#148; means the &#147;Takeover Offer Document&#148; under and as defined in the
Transaction Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Takeover Panel</U></B>&#148; means the Irish Takeover Panel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Takeover Rules</U></B>&#148; means the Irish Takeover Panel Act 1997, Takeover Rules, 2022 and the Irish Takeover Panel Act, 1997,
Substantial Acquisition Rules, 2022. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Target</U></B>&#148; means Horizon Therapeutics Public Limited Company, a public limited
company incorporated under the laws of Ireland (with registration number 507678) having its registered office at 70 St. Stephen&#146;s Green, Dublin, D02 E2X4, Ireland. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Target Acquisition</U></B>&#148; means the direct or indirect acquisition by the Borrower, pursuant to a Scheme or a Takeover
Offer, of all of the outstanding shares of Target which are subject to the Scheme or Takeover Offer (and, in the case of a Takeover Offer, together with the Squeeze Out Procedures) (as the case may be) for cash consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Target Shares</U></B>&#148; means all of the issued and to be issued share capital of the Target. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Taxes</U></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.10(d)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Term Rate Advanc</U></B>e&#148; means an Adjusted Term SOFR Rate Advance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Term SOFR</U></B>&#148; means, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) for any calculation with respect to an Adjusted Term SOFR Advance, the Term SOFR Reference Rate for a tenor comparable to the applicable
Interest Period on the day (such day, the &#147;<B><U>Periodic Term SOFR Determination Day</U></B>&#148;) that is two (2)&nbsp;U.S. Government Securities Business Days prior to the first day of such Interest Period, as such rate is published by the
Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and this
Agreement has not been amended to implement a Successor Rate, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S.
Government Securities Business Day is not more than three (3)&nbsp;U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) for any calculation with respect to a Base Rate Advance on any day, the Term SOFR Reference Rate for a tenor of one month on the day (such
day, the &#147;<B><U>ABR Term SOFR Determination Day</U></B>&#148;) that is two (2)&nbsp;U.S. Government Securities Business Days prior to such day, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m.
(New York City time) on any ABR Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and this Agreement has not been amended to implement a Successor Rate, then Term
SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR
Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3)&nbsp;U.S. Government Securities Business Days prior to such ABR Term SOFR Determination Day; provided that if Term SOFR determined as
provided under this clause (b)&nbsp;shall ever be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Term SOFR Administrator</U></B>&#148; means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the
Term SOFR Reference Rate selected by the Administrative Agent in its reasonable discretion). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Term SOFR Reference
Rate</U></B>&#148; means the forward-looking term rate based on SOFR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Total Outstandings</U></B>&#148; means, as of any date
of determination, the sum on that date of the aggregate outstanding principal amount of the Advances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Transaction
Agreement</U></B>&#148; means the Transaction Agreement, dated as of December 11, 2022, by and among the Borrower, Bidco and the Target. Any reference herein to a section of, or term defined in, the Transaction Agreement means such section or term
as defined in the Transaction Agreement in the form delivered to the Arrangers on or prior to the Effective Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Transactions</U></B>&#148; has the meaning set forth in the Preliminary Statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Type</U></B>&#148; when used with respect to any Loan or Advance, means the designation of whether such Loan or Advance is a Base
Rate Advance or a Term Rate Advance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>U.S. Government Securities Business Day</U></B>&#148; means any day except for (a)&nbsp;a
Saturday, (b)&nbsp;a Sunday or (c)&nbsp;a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States
government securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Unconditional Date</U></B>&#148; means the date on which the Takeover Offer is declared or becomes
unconditional in all respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Unused Portion</U></B>&#148; means the Commitments, less Total Outstandings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Use of Defined Terms</U></B>. Any defined term used in the plural shall refer to all members of the
relevant class, and any defined term used in the singular shall refer to any one or more of the members of the relevant class. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Accounting Terms</U></B>. Unless otherwise specified herein, all accounting terms used herein shall be
interpreted, all accounting determinations hereunder shall be made and all financial statements required to be delivered hereunder shall be prepared in accordance with Generally Accepted Accounting Principles as in effect from time to time, applied
on a basis consistent (except for changes concurred in by the Borrower&#146;s independent public accountants) with the audited consolidated financial statements of the Borrower and its Consolidated Subsidiaries most recently delivered to the Banks;
<U>provided</U>, that, if the Borrower notifies the Administrative Agent that the Borrower wishes to amend any covenant in <U>Article 6</U> to eliminate the effect of any change in Generally Accepted Accounting Principles on the operation of such
covenant (or if the Administrative Agent notifies the Borrower that the Majority Banks wish to amend <U>Article 6</U> for such purpose), then the Borrower&#146;s compliance with such covenant shall be determined on the basis of Generally Accepted
Accounting Principles in effect immediately before the relevant change in Generally Accepted Accounting Principles became effective, until either such notice is withdrawn or such covenant is amended in a manner satisfactory to the Borrower and the
Majority Banks. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Rounding</U></B>. Any financial ratios required to be maintained by the Borrower pursuant to this
Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed in this Agreement and rounding the result up or down to the
nearest number (with a <FONT STYLE="white-space:nowrap">round-up</FONT> if there is no nearest number) to the number of places by which such ratio is expressed in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Exhibits and Schedules</U></B>. All Exhibits and Schedules to this Agreement, either as originally
existing or as the same may from time to time be supplemented, modified or amended, are incorporated herein by this reference. A matter disclosed on any Schedule shall be deemed disclosed on all Schedules. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>References to </U></B><B><U>&#147;</U></B><B><U>the Borrower and its
Subsidiaries</U></B><B><U>&#148;</U></B>. Any reference herein to &#147;the Borrower and its Subsidiaries&#148; or the like shall refer solely to the Borrower during such times, if any, as the Borrower shall have no Subsidiaries.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous Terms</U></B>. The term &#147;or&#148; is disjunctive; the term &#147;and&#148; is
conjunctive. The term &#147;shall&#148; is mandatory; the term &#147;may&#148; is permissive. Masculine terms also apply to females; feminine terms also apply to males. The term &#147;including&#148; is by way of example and not limitation. An Event
of Default or Certain Funds Default is &#147;continuing&#148; if it has not been remedied or waived. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Divisions</U></B>. For all purposes under this Agreement, in connection with any division or plan of
division under Delaware law (or any comparable event under a different jurisdiction&#146;s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall
be deemed to have been transferred from the original Person to the subsequent Person, and (b)&nbsp;if any new Person comes into existence, such new Person shall be deemed to have been organized and acquired on the first date of its existence by the
holders of its equity interests at such time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Rates</U></B>. The Administrative Agent does not warrant or accept responsibility for, and shall not have
any liability with respect to (a)&nbsp;the continuation of, administration of, submission of, calculation of or any other matter related to the Base Rate, the Term SOFR Reference Rate, Adjusted Term SOFR or Term SOFR, or any component definition
thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Successor Rate), including whether the composition or characteristics of any such alternative, successor or replacement
rate (including any Successor Rate) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Base Rate, the Term SOFR Reference Rate, Adjusted Term SOFR, Term SOFR or any other Successor
Rate prior to its discontinuance or unavailability, or (b)&nbsp;the effect, implementation or composition of any Successor Rate Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in transactions that
affect the calculation of the Base Rate, the Term SOFR Reference Rate, Term SOFR, Adjusted Term SOFR or any alternative, successor or replacement rate (including any Successor Rate) or any relevant adjustments thereto, in each case, in a manner
adverse to the Borrower. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain the Base Rate, the Term SOFR Reference Rate, Term SOFR, Adjusted Term SOFR or any Successor Rate, in each case
pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Bank or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses
or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Advances - General</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions set forth in this Agreement, each Bank shall, severally and not jointly,
make Advances to the Borrower during the Availability Period in an amount equal to its ratable share (based on the Banks&#146; Commitments) of the Loan requested hereunder by the Borrower, which amount in any case shall not exceed such Bank&#146;s
Commitment immediately prior to the making of such Advance; <U>provided</U> that all Loans made pursuant to this Section&nbsp;2.1 shall be made on no more than two (2)&nbsp;Funding Dates. Advances borrowed under this Section&nbsp;2.1(a) and repaid
or prepaid may not be reborrowed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the next sentence, each Loan under this <U>Section</U><U></U><U>&nbsp;2.1</U> shall be made pursuant
to a Request for Loan which shall specify the requested (i)&nbsp;date of such Loan and (ii)&nbsp;Type of Loan, (iii)&nbsp;amount of such Loan and (iv)&nbsp;Interest Period for such Loan. Unless the Administrative Agent has notified, in its sole and
absolute discretion, the Borrower to the contrary, a Loan may be requested by telephone by a Senior Officer of the Borrower, in which case the Borrower shall promptly confirm such request by transmitting a telecopy or other electronic communication
of, or at the Administrative Agent&#146;s request by mailing, a Request for Loan executed by a Senior Officer of the Borrower conforming to the preceding sentence to the Administrative Agent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Promptly following receipt of a Request for Loan (or the receipt of a substitute request permitted under the
second sentence of <U>Section</U><U></U><U>&nbsp;2.1(b)</U>), the Administrative Agent shall notify each Bank by telephone (so long as such notice by telephone is promptly followed by a notice in writing) or telecopier or other electronic
communication (the method of notice shall be at the Administrative Agent&#146;s option) of the date and type of the Loan, the applicable Interest Period and the amount of that Bank&#146;s ratable share (based on the Banks&#146; Commitments) of the
Loan. Not later than 2:00 p.m., New York time, on the date specified for any Loan subject to the provisions of <U>Sections 2.2</U> and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<U>2.3</U>, each Bank shall make its ratable share (based on the Banks&#146; Commitments) of the Loan in immediately available funds available to the Administrative Agent at the Administrative
Agent&#146;s Office. Upon fulfillment of the applicable conditions set forth in <U>Article 8</U> and subject to the provisions of <U>Sections 2.2</U> and <U>2.3</U>, all Advances shall be credited in immediately available funds to the Designated
Deposit Account. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Loan under the Commitments shall be in a minimum amount of $2,000,000 and multiples of $1,000,000 in
excess of that amount. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If so requested by any Bank by written notice to the Borrower (with a copy to the Administrative Agent) at
least two Banking Days prior to the Initial Funding Date or at any time thereafter, the Borrower shall execute and deliver to such Bank (and/or, if applicable and if so specified in such notice, to any Person who is an assignee of such Bank pursuant
to <U>Section</U><U></U><U>&nbsp;11.9</U>) on the Initial Funding Date (or, if such notice is delivered after the Initial Funding Date, promptly after the Borrower&#146;s receipt of such notice) a promissory note or promissory notes to evidence such
Bank&#146;s Advances under its Commitment, substantially in the form of <U>Exhibit B</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Request for Loan shall be irrevocable upon the Administrative Agent&#146;s first notification thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the use, administration, adoption or implementation of Adjusted Term SOFR, the
Administrative Agent and the Borrower will have the right to make Successor Rate Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Successor Rate
Conforming Changes will become effective without any further action or consent of any other party to this Agreement. The Administrative Agent will promptly notify the Banks of the effectiveness of any Successor Rate Conforming Changes in connection
with the use or administration of Adjusted Term SOFR. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Base Rate Advances</U></B>. Each request by a Borrower for a Base Rate Advance shall be made pursuant to
a Request for Loan (or telephonic request for Loan referred to in the second sentence of <U>Section</U><U></U><U>&nbsp;2.1(b)</U>, if applicable) received by the Administrative Agent, at the Administrative Agent&#146;s Office, not later than 12:00
noon, New York time, on the date of a proposed Base Rate Advance. All Advances denominated in Dollars shall constitute Base Rate Advances unless properly designated as Adjusted Term SOFR Rate Advances pursuant to
<U>Section</U><U></U><U>&nbsp;2.3</U>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Term Rate Advances</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each request by the Borrower for an Adjusted Term SOFR Rate Advance shall be made pursuant to a Request for
Loan (or telephonic request for Loan referred to in the second sentence of <U>Section</U><U></U><U>&nbsp;2.1(b)</U>, if applicable) received by the Administrative Agent, at the Administrative Agent&#146;s Office, not later than 1:00 p.m., New York
time, at least three (3)&nbsp;U.S. Government Securities Business Days before the first day of the applicable Interest Period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the second U.S. Government Securities Business Day before the first day of the applicable Interest Period in
the case of Adjusted Term SOFR Rate Advances, the Administrative Agent shall determine the applicable Adjusted Term SOFR (which determination shall be conclusive in the absence of manifest error), and prior to 1:00 p.m., New York time on that same
day shall give notice of the same to the Borrower and the Banks by telephone or telecopier or other electronic communication (the method of notice shall be at the Administrative Agent&#146;s option). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the submission of a Request for Loan with respect to a Term Rate Advance, the Borrower may request the
Administrative Agent to provide a <FONT STYLE="white-space:nowrap">non-binding</FONT> estimate of the Adjusted Term SOFR that would then apply in the event the Borrower submitted a Request for Loan. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Voluntary Reduction of Commitment</U></B><B><U>s</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower shall have the right, at any time and from time to time, without penalty or charge, upon at least
two days prior written notice to the Administrative Agent, to voluntarily reduce, permanently and irrevocably, in a minimum amount of $5,000,000 and multiples of $1,000,000 in excess thereof, or to terminate, all or a portion of the then Unused
Portion of the Commitments; <U>provided</U> that any such reduction or termination shall be accompanied by payment of all accrued and unpaid facility fees with respect to the portion of the Commitments being reduced or terminated. Any such notice of
reduction may be conditioned upon the successful closing of a new financing and the Administrative Agent will promptly notify each Bank thereof and of such Bank&#146;s portion of the Commitments being reduced. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower shall have the right, at any time, upon at least three (3)&nbsp;Banking Days&#146; notice to a
Defaulting Bank (with a copy to the Administrative Agent), to terminate in whole such Defaulting Bank&#146;s Commitments under this <U>Section</U><U></U><U>&nbsp;2.4(b)</U>. The Borrower will pay all principal of, and interest accrued to the date of
such payment on, Advances owing to such Defaulting Bank and pay any accrued facility fee payable to such Defaulting Bank pursuant to <U>Section</U><U></U><U>&nbsp;3.2</U> and all other amounts payable to such Defaulting Bank hereunder (including but
not limited to any increased costs, additional interest or other amounts owing under <U>Sections 3.5</U> and <U>3.6</U> and any indemnification for Taxes under <U>Section</U><U></U><U>&nbsp;3.10</U>) and upon such payments, the obligations of such
Defaulting Bank hereunder shall, by the provisions hereof, be released and discharged; <U>provided</U>, <U>however</U>, that (i)&nbsp;such Defaulting Bank&#146;s rights under <U>Sections 3.5</U> and <U>3.6</U> shall survive such release and
discharge as to matters occurring prior to such date and (ii)&nbsp;no claim that the Borrower may have against such Defaulting Bank arising out of such Defaulting Bank&#146;s default hereunder shall be released or impaired in any way. The aggregate
amount of the Commitments of the Banks once reduced pursuant this <U>Section</U><U></U><U>&nbsp;2.4(b) </U>may not be reinstated; <U>provided</U>, <U>however</U>, that if pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(b)</U>, the Borrower shall
pay to a Defaulting Bank any principal of, or interest accrued on, the Advances owing to such Defaulting Bank, then the Borrower shall either (x)&nbsp;confirm to the Administrative Agent that, except as disclosed by the Borrower and approved in
writing by the Administrative Agent, acting at the direction of the Majority Banks, the representations and warranties contained in <U>Article 4</U>, other than <U>Sections 4.4</U>, <U>4.6</U> and <U>4.8</U>, are true and correct in all material
respects (except that to the extent any representation or warranty is qualified by materiality, it is true and correct in all respects) on and as of such date of payment as though made on that date (except to the extent such representations and
warranties specifically relate to an earlier date in which case they are true and correct in all material respects (except that to the extent any representation or warranty is qualified by materiality, it is true and correct in all respects) as of
such earlier date) and no Default has occurred and is continuing or (y)&nbsp;pay or cause to be paid a ratable payment of principal and interest to all Banks who are not Defaulting Banks. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Voluntary Conversion or Continuation of Advances</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower may on any Banking Day upon notice given to the Administrative Agent not later than 12:00 noon
(New York City time) on the third U.S. Government Securities Business Day prior to the date of the proposed Conversion or continuance (a &#147;<B><U>Notice of Conversion/Continuation</U></B>&#148;) and subject to the provisions of
<U>Section</U><U></U><U>&nbsp;2.3</U>, (1) Convert all or any portion of Advances of one Type into Advances made to the Borrower of another Type and (2)&nbsp;upon the expiration of any Interest Period applicable to Advances which are Term Rate
Advances, continue all (or, subject to <U>Section</U><U></U><U>&nbsp;2.3</U>, any portion of) such Advances as Term Rate Advances and the succeeding Interest Period(s) of such continued Advances shall commence on the last day of the Interest Period
of the Advances to be continued; <U>provided</U>, <U>however</U>, that any Conversion of any Term Rate Advances into Base Rate Advances shall be made on, and only on, the last day of an Interest Period for such Term Rate Advances. Each such Notice
of Conversion/Continuation shall, within the restrictions specified above, specify (i)&nbsp;the date of such continuation or Conversion, (ii)&nbsp;the Advances (or, subject to <U>Section</U><U></U><U>&nbsp;2.3</U>, any portion thereof) to be
continued or Converted, (iii)&nbsp;if such continuation is of, or such Conversion is into, Term Rate Advances, the duration of the Interest Period of each such Advance, and (iv)&nbsp;in the case of a continuation of or a Conversion into a Term Rate
Advance, that no Event of Default has occurred and is continuing. Each Conversion or continuation shall be in a minimum amount of $2,000,000, and multiples of $1,000,000. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If upon the expiration of the then existing Interest Period applicable to any Advance which is a Term Rate
Advance, the Borrower thereof shall not have delivered a Notice of Conversion/Continuation in accordance with this <U>Section</U><U></U><U>&nbsp;2.5</U>, then such Advance if it is an Advance of Dollars shall upon such expiration automatically be
continued as a Term Rate Advance with an Interest Period of one month. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the occurrence of and during the continuation of an Event of Default, the Borrower may not elect to have
an Advance be made or continued as, or Converted into, a Term Rate Advance after the expiration of any Interest Period then in effect for that Advance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Administrative Agent</U></B><B><U>&#146;</U></B><B><U>s Right to Assume Funds Available for
Advances</U></B>. Unless the Administrative Agent shall have been notified by any Bank no later than the time of the funding by the Administrative Agent of any Loan that such Bank does not intend to make available to the Administrative Agent such
Bank&#146;s its ratable share (based on the Banks&#146; Commitments) of the total amount of such Loan, the Administrative Agent may assume that such Bank has made such amount available to the Administrative Agent on the date of the Loan and the
Administrative Agent may, in reliance upon such assumption, make available to the applicable Borrower a corresponding amount. If the Administrative Agent has made funds available to the Borrower based on such assumptions and such corresponding
amount is not in fact made available to the Administrative Agent by such Bank, the Administrative Agent shall be entitled to recover such corresponding amount on demand from such Bank, which demand shall be made in a reasonably prompt manner. If
such Bank does not pay such corresponding amount forthwith upon the Administrative Agent&#146;s demand therefor, the Administrative Agent promptly shall notify the applicable Borrower and the Borrower shall pay such corresponding amount to the
Administrative Agent. The Administrative Agent also shall be entitled to recover from such Bank interest on such corresponding amount in respect of each day from the date such corresponding amount was made available by the Administrative Agent to
the Borrower to the date such corresponding amount is recovered by the Administrative Agent, at a rate per annum equal to the average overnight federal funds rate. Nothing herein shall be deemed to relieve any Bank from its obligation to fulfill its
Commitment or to prejudice any rights that the Administrative Agent or the Borrower may have against any Bank as a result of any default by such Bank hereunder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Mandatory Commitment Termination or Reduction</U></B><B><U>.</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Borrower actually receives any Net Cash Proceeds arising from any Equity Issuance or the
Borrower or any of its Subsidiaries actually receives any Net Cash Proceeds arising from any Debt Issuance (other than a Debt Issuance under any committed term loan or revolving facility that has reduced the Commitments hereunder pursuant to clause
(b)&nbsp;below) or Asset Sale, in each case which Net Cash Proceeds are received during the period commencing on the Effective Date and ending on the last day of the Availability Period, then the Commitments then outstanding shall be automatically
reduced in an amount equal to (x) 100% of such Net Cash Proceeds on the date of receipt by the Borrower or, as applicable, any Subsidiary of the Borrower of such Net Cash Proceeds, less (y)&nbsp;if such Net Cash Proceeds are received by the Borrower
after the Initial Funding Date, the amount of such Net Cash Proceeds applied to prepay the Advances pursuant to <U>Section</U><U></U><U>&nbsp;2.8(a)</U>. The Borrower shall promptly notify the Administrative Agent of the receipt by the Borrower, or,
as applicable, any other member of the Consolidated Group, of such Net Cash Proceeds from any Equity Issuance, Debt Issuance or Asset Sale, and such notice shall be accompanied by a reasonably detailed calculation of the Net Cash Proceeds received.
Notwithstanding the foregoing, mandatory commitment reductions with respect to Net Cash Proceeds from Debt Issuances or Asset Sales received by a Foreign Subsidiary shall not be required if and for so long as the Borrower has determined in good
faith (which determination shall be conclusive) that repatriation to the Borrower of such Net Cash Proceeds (x)&nbsp;would have adverse tax consequences (and, in the case of Debt Issuances, such adverse tax consequences are material), (y) would be
prohibited, delayed or restricted under applicable local law or (z)&nbsp;would violate the applicable organizational documents of such Subsidiary. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Borrower or any of its Subsidiaries enters into any committed term loan facility for the
purpose of financing the Transactions (including any New Term Loan Facility), automatically upon the effectiveness of the definitive documentation for such term loan facility (including any New Term Loan Facility) and, other than in respect of any
New Term Loan Facility, receipt by the Administrative Agent of a notice from the Borrower that such term loan facility constitutes a Qualifying Term Loan Facility, the Commitments then outstanding shall be reduced in an amount equal to 100% of the
committed amount under such New Term Loan Facility or other Qualifying Term Loan Facility on the date of receipt by the Administrative Agent of such notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Borrower or any of its Subsidiaries enters into any committed revolving facility, the use
of proceeds of which includes financing a portion of the Transactions, automatically upon the effectiveness of the definitive documentation for such revolving facility and receipt by the Administrative Agent of a notice from the Borrower that such
revolving facility constitutes a Qualifying Revolving Facility, the Commitments then outstanding shall be reduced in an amount equal to 100% of the commitments under such Qualifying Revolving Facility that are subject to conditions precedent to
funding that are no less favorable to the Borrower than the conditions set forth herein to the funding of the Bridge Facility (as determined by the Borrower in its reasonable discretion) on the date of receipt by the Administrative Agent of such
notice. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless previously terminated, the Commitments shall automatically terminate at 5:00 p.m. (New York time) on the
earlier of (i)&nbsp;the date on which all of the Certain Funds Purposes have been achieved without the making of any Advances and (ii)&nbsp;the time immediately after a Mandatory Cancellation Event occurs; <U>provided</U> that (x)&nbsp;upon a
Bank&#146;s making of an Advance hereunder, such Bank&#146;s Commitment shall be automatically reduced by the principal amount of such Advance and (y)&nbsp;in any event the Commitments shall terminate in full on the earlier of the last day of the
Availability Period and the second Funding Date after the proceeds of the Advances have been made available to the Borrower. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Prepayments</U></B><B>.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Mandatory Prepayments</U>. In the event that the Borrower actually receives any Net Cash Proceeds arising
from any Equity Issuance or the Borrower or any other member of the Consolidated Group actually receives any Net Cash Proceeds arising from any Debt Issuance (other than a Debt Issuance under any committed term loan facility that has reduced the
Commitments hereunder pursuant to <U>Section</U><U></U><U>&nbsp;2.7(b)</U> above) or Asset Sale, in each case which Net Cash Proceeds are received after the Initial Funding Date, then the Borrower shall prepay the Advances in an amount equal to 100%
of such Net Cash Proceeds not later than three Banking Days following the receipt by the Borrower or any such Subsidiary of such Net Cash Proceeds. The Borrower shall promptly (and not later than the date of receipt thereof) notify the
Administrative Agent of the receipt by the Borrower or, as applicable, any other member of the Consolidated Group, of such Net Cash Proceeds from any Equity Issuance, Debt Issuance or Asset Sale, and such notice shall be accompanied by a reasonably
detailed calculation of the Net Cash Proceeds. Each prepayment of Advances shall be applied ratably and shall be accompanied by accrued interest and fees on the amount prepaid to the date fixed for prepayment, plus, in the case of any Term Rate
Advances, any amounts due to the Banks under <U>Section</U><U></U><U>&nbsp;3.6(c)</U>. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing,
mandatory repayments with respect to Net Cash Proceeds from Debt Issuances or Asset Sales received by a Foreign Subsidiary shall not be required if and for so long as the Borrower has determined in good faith (which determination shall be
conclusive) that repatriation to the Borrower of such Net Cash Proceeds (x)&nbsp;would have adverse tax consequences (and, in the case of Debt Issuances, such adverse tax consequences are material), (y) would be prohibited, delayed or restricted
under applicable local law or (z)&nbsp;would violate the applicable organizational documents of such Subsidiary. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Defaulting Banks</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Bank becomes, and during the period it remains, a Defaulting Bank, then any amounts paid by the Borrower
or otherwise received by the Administrative Agent for the account of a Defaulting Bank under this Agreement (whether on account of principal, interest, fees, indemnity payments or other amounts) will not be paid or distributed to such Defaulting
Bank, but will instead be retained by the Administrative Agent in a segregated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account until (subject to <U>Section</U><U></U><U>&nbsp;2.9(c)</U>) the termination of the Commitments and
payment in full of all obligations of the Borrower hereunder and will be applied by the Administrative Agent, to the fullest extent permitted by law, to the making of payments from time to time in the following order of priority: <U>first</U> to the
payment of any amounts owing by such Defaulting Bank to the Administrative Agent under this Agreement, <U>second</U> to the payment of post-default </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
interest and then current interest due and payable to the Banks hereunder other than Defaulting Banks, ratably among them in accordance with the amounts of such interest then due and payable to
them, <U>third</U> to the payment of fees then due and payable to the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Banks hereunder, ratably among them in accordance with the amounts of such fees then due and payable to them, <U>fourth</U>
to pay principal then due and payable to the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Banks hereunder ratably in accordance with the amounts thereof then due and payable to them, <U>fifth</U> to the ratable payment of other amounts
then due and payable to the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Banks, and <U>sixth</U> after the termination of the Commitments and payment in full of all obligations of the Borrower hereunder, to pay amounts owing under this
Agreement to such Defaulting Bank or as a court of competent jurisdiction may otherwise direct. Any payments, prepayments or other amounts paid or payable to a Defaulting Bank that are applied (or held) to pay amounts owed by a Defaulting Bank or to
post cash collateral pursuant to this <U>Section</U><U></U><U>&nbsp;2.9(a)</U> shall be deemed paid to and redirected by such Defaulting Bank, and each Bank irrevocably consents hereto. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Commitment of any Bank shall be increased or, except as otherwise expressly provided in
<U>Section</U><U></U><U>&nbsp;2.9(a)</U>, otherwise affected, and performance by the Borrower of its obligations shall not be excused or otherwise modified as a result of the operation of <U>Section</U><U></U><U>&nbsp;2.9(a)</U>. The rights and
remedies against a Defaulting Bank under <U>Section</U><U></U><U>&nbsp;2.9(a)</U> are in addition to any other rights and remedies which the Borrower, the Administrative Agent or any Bank may have against such Defaulting Bank. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Borrower and the Administrative Agent agree in writing in their reasonable determination that a
Defaulting Bank or a Potential Defaulting Bank should no longer be deemed to be a Defaulting Bank or a Potential Defaulting Bank, as the case may be, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date
specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any cash collateral), that Bank will, to the extent applicable, purchase that portion of outstanding Advances of the other Banks
or take such other actions as the Administrative Agent may determine to be necessary to cause the Advances to be funded and held on a pro rata basis by the Banks in accordance with their respective Commitments and Advances, whereupon such Bank will
cease to be a Defaulting Bank or Potential Defaulting Bank; <U>provided</U> that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Bank was a Defaulting Bank; and
<U>provided</U>, <U>further</U>, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Bank or Potential Defaulting Bank to Bank will constitute a waiver or release of any claim of any
party hereunder arising from such Bank&#146;s having been a Defaulting Bank or Potential Defaulting Bank. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Payments and Fees </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Principal and Interest</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest shall be payable on the outstanding daily unpaid principal amount of each Loan from the date thereof
until payment in full is made and shall accrue and be payable at the rates set forth herein before and after default, before and after maturity, before and after judgment, and before and after the commencement of any proceeding under any Debtor
Relief Law, with interest on overdue interest to bear interest at the Default Rate to the fullest extent permitted by applicable Laws. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest accrued on each Base Rate Advance shall be payable quarterly in arrears on the last day of each March,
June, September and December commencing on the first such date to occur after the Initial Funding Date. <U>Except</U> as otherwise provided in <U>Section</U><U></U><U>&nbsp;3.7</U>, the unpaid principal amount of any Base Rate Advance shall bear
interest at a fluctuating rate per annum equal to the Base Rate <U>plus</U> the Daily Margin for such Base Rate Advance for each day during the applicable period. Each change in the interest rate hereunder shall take effect simultaneously with the
corresponding change in the Base Rate. Each change in the Base Rate shall be effective as of 12:01 a.m., New York time, on the Banking Day on which the change in the Base Rate is announced, unless otherwise specified in such announcement, in which
case the change shall be effective as so specified. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest accrued on each Term Rate Advance, the Interest Period for which is three months or less, shall be due
and payable on the last day of the applicable Interest Period. Interest accrued on each other Term Rate Advance shall be due and payable on every three month anniversary of the date which is three months after the date such Term Rate Advance was
made, converted or continued pursuant to <U>Section</U><U></U><U>&nbsp;2.5</U> and on the last day of the Interest Period. <U>Except</U> as otherwise provided in <U>Section</U><U></U><U>&nbsp;3.7</U>, (i) the unpaid principal amount of any Term Rate
Advance shall bear interest at a rate per annum equal to Adjusted Term SOFR for such Term Rate Advance <U>plus</U> the Daily Margin for such Term Rate Advance for each day during the applicable period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If not sooner paid, the principal amount of each Advance shall be payable to each Bank on the Maturity Date
applicable to such Advance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Loans may, at any time and from time to time, voluntarily be paid or prepaid in whole or in part without
premium or penalty, <U>except</U> that with respect to any voluntary prepayment under this subsection, (i)&nbsp;any partial prepayment shall be in minimum amount of $2,000,000 and multiples of $1,000,000 in excess thereof, (ii)&nbsp;the
Administrative Agent shall have received written notice of any prepayment by (x) 11:00 a.m. (New York time) on the date of prepayment (which shall be a Banking Day), in the case of a Base Rate Advance, and (y)&nbsp;by 1:00 p.m. (New York time) three
(3)&nbsp;U.S. Government Securities Business Days before the date of prepayment, in the case of a Term Rate Advance, which notice shall identify the date and amount of the prepayment and the Loan(s) being prepaid, (iii)&nbsp;each prepayment of
principal shall be accompanied by payment of interest accrued through the date of payment on the amount of principal paid and (iv)&nbsp;in any event, any payment or prepayment of all or any part of any Term Rate Advance on a day other than the last
day of the applicable Interest Period shall be subject to <U>Section</U><U></U><U>&nbsp;3.6(c)</U>. Any such notice of prepayment may be conditioned upon the successful closing of a new financing and the Administrative Agent will promptly notify
each Bank thereof and of such Bank&#146;s portion of the outstanding Loans being prepaid; <U>provided</U> that, to the extent such notice of prepayment is rescinded and/or the prepayment is not made, the Borrower shall pay any amounts required to be
made under <U>Section</U><U></U><U>&nbsp;3.6(c)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Ticking Fee</U></B>. The Borrower shall pay, or cause to be paid, to the Administrative Agent, for the
account of each Bank (other than a Defaulting Bank for such time as such Bank is a Defaulting Bank), a <FONT STYLE="white-space:nowrap">non-refundable</FONT> ticking fee calculated (in accordance with Section&nbsp;3.8) on a daily basis at 0.125% per
annum on the aggregate outstanding Commitments of each Bank under the Bridge Facility as of such date, accruing commencing on the 90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day after the Effective Date and payable in arrears (with
respect to all amounts accrued to such date) (A)(i) on the Initial Funding Date, (ii)&nbsp;thereafter quarterly on the last day of each March, June, September and December until the Commitments are terminated in full, and (iii)&nbsp;on the second
Funding Date, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
or (B)&nbsp;the earlier termination of the Commitments in full. For the avoidance of doubt, with respect to the definition of &#147;Mandatory Cancellation Event&#148; and the ability thereunder
for the Borrower to provide notices and issue documents to facilitate a switch from a Scheme to a Takeover Offer and vice versa, the Commitments shall be deemed to be in effect until the end of the day on which the applicable notice or issuance is
required to but does not occur for the purposes of calculating any fees under this Agreement or any fee letters related hereto. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Duration Fee</U></B>.<B><U> </U></B>On each of the 90th, 180th and 270th days after the Initial Funding
Date, the Borrower agrees to pay to the Administrative Agent for the account of each Bank a Duration Fee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Fees</U></B>. On the Effective Date, the Borrower shall pay to the Arrangers fees in the amounts agreed
upon in the Fee Letter. On the dates set forth in the Fee Letter, the Borrower shall pay fees to the Administrative Agent for the account of each Bank in the amounts agreed upon in the Fee Letter. The Borrower shall pay to the Administrative Agent
agency fees in the amounts agreed upon by letter agreement dated on or about the date hereof between the Borrower and the Administrative Agent. Such agency fees shall be payable annually in advance as set forth in such letter agreements. The agency
fees are for the sole account of the Administrative Agent and are fully earned upon receipt and <FONT STYLE="white-space:nowrap">non-refundable;</FONT> provided, however that in the event the facilities hereunder are terminated, the agency fees
deemed earned shall be pro rated over the number of days from the last quarterly date on which the agency fees were paid to the termination date of the facilities. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Capital Adequacy</U></B> If any Bank determines in good faith that compliance with any Law or regulation
or with any guideline or request (excluding any published as of the date hereof or currently scheduled to take effect) from any central bank or other Governmental Agency (whether or not having the force of Law), in each case adopted or effective
after the date hereof has or would have the effect of reducing the rate of return on the capital of such Bank or any corporation controlling such Bank as a consequence of, or with reference to, such Bank&#146;s Commitment or its making or
maintaining of Advances, below the rate which such Bank or such other corporation could have achieved but for such compliance (taking into account the policies of such Bank or corporation with regard to capital), then the Borrower shall from time to
time, upon demand by such Bank (following the expiry of the Certain Funds Period and with a copy of such demand to the Administrative Agent), immediately pay to such Bank additional amounts sufficient to compensate such Bank or other corporation for
such reduction. A certificate as to such amounts, setting forth in reasonable detail the basis for such calculations, submitted to the Borrower and the Administrative Agent by such Bank, shall be conclusive and binding for all purposes, absent
manifest error. Each Bank agrees promptly to notify the Borrower and the Administrative Agent of any circumstances that would cause the Borrower to pay additional amounts pursuant to this <U>Section</U><U></U><U>&nbsp;3.5</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Increased Costs</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, after the date hereof, by reason of (i)&nbsp;any change in the interpretation or administration of any
existing Law by any Governmental Agency, central bank or comparable authority charged with the interpretation or administration thereof, or (ii)&nbsp;compliance by any Bank or its Applicable Lending Office with any request or directive (whether or
not having the force of Law) of any such Governmental Agency, central bank or comparable authority: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) any reserve (<U>including</U>, without limitation, any reserve imposed by the Board of Governors of the
Federal Reserve System), liquidity, special deposit, compulsory loan, insurance charge or similar requirements shall be imposed, modified or deemed applicable against assets of, deposits with or for the account of, or credit extended by, any Bank or
its Applicable Lending Office; or (B)&nbsp;any Bank or its Applicable Lending Office shall have imposed on it any other condition, cost or expense affecting any Advance, any of its Notes, its obligation to make Advances or this Agreement, or its
obligation to make or any of the same shall otherwise be adversely affected; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">and the result of any of the foregoing, as
determined by such Bank, increases the cost to such Bank or its Applicable Lending Office of making, converting to, continuing or maintaining any Advance or in respect of any Advance, any of its Notes or its obligation to make Advances or reduces
the amount of any sum received or receivable by such Bank or its Applicable Lending Office with respect to any Advance, any of its Notes or its obligation to make Advances or its participation therein, then, upon demand by such Bank (with a copy to
the Administrative Agent), the Borrower shall (following the expiry of the Certain Funds Period) pay to such Bank, as the case may be, such additional amount or amounts as will compensate such Bank, as the case may be, for such increased cost or
reduction; <U>provided</U>, <U>however</U>, that this <U>Section</U><U></U><U>&nbsp;3.6</U> shall not apply to any increased cost resulting from Indemnified Taxes, which are covered by <U>Section</U><U></U><U>&nbsp;3.10</U> or Excluded Taxes. A
statement of any Bank claiming compensation under this subsection and setting forth the additional amount or amounts to be paid to it hereunder shall be conclusive in the absence of manifest error. Each Bank agrees to endeavor promptly to notify the
Borrower of any event of which it has actual knowledge (and, in any event, within 90 days from the date on which it obtained such knowledge), occurring after the Effective Date, which will entitle such Bank to compensation pursuant to this
<U>Section</U><U></U><U>&nbsp;3.6</U>, and agrees to designate a different Applicable Lending Office if such designation will avoid the need for or reduce the amount of such compensation and will not, in the judgment of such Bank, otherwise be
disadvantageous to such Bank. If any Bank claims compensation under this <U>Section</U><U></U><U>&nbsp;3.6</U>, the Borrower may at any time, upon at least four (4)&nbsp;Banking Days&#146; prior notice to the Administrative Agent and Banks and upon
payment in full of the amounts provided for in this <U>Section</U><U></U><U>&nbsp;3.6</U> through the date of such payment plus any fee required by <U>Section</U><U></U><U>&nbsp;3.6(c)</U>, pay in full all Advances or request that all Term Rate
Advances be converted to Base Rate Advances or all Base Rate Advances be converted to Term Rate Advances. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any Bank shall have reasonably determined that it shall be unlawful for such Bank or its Applicable Lending
Office to make, maintain or fund its portion of any Term Rate Advance, or to determine or charge interest rates based upon the Adjusted Term SOFR has become unlawful, then such Bank shall so notify the Administrative Agent and the other Banks, and
such Bank&#146;s obligation to make Term Rate Advances shall be suspended for the duration of such illegality and the Administrative Agent forthwith shall give notice thereof to the Borrower and such Bank shall make a Base Rate Advance as part of
any successive Term Rate Advance. Upon receipt of such notice, the outstanding principal amount of all Term Rate Advances made by such Bank automatically shall be converted to Base Rate Advances on either (A)&nbsp;the last day of the Interest
Period(s) applicable to such Term Rate Advances if the affected Bank may lawfully continue to maintain and fund such Term Rate Advances to such day(s) or (B)&nbsp;immediately if the affected Bank may not lawfully continue to fund and maintain such
Term Rate Advances to such day(s), <U>provided</U> that in such event the conversion shall not be subject to payment of a fee under <U>Section</U><U></U><U>&nbsp;3.6(c)</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, with respect to any proposed Term Rate Advance, the Majority Banks advise the Administrative Agent that the
Adjusted Term SOFR, as determined by the Administrative Agent (1)&nbsp;does not represent the effective pricing to such Banks for deposits in Dollars in the interbank market in the relevant amount for the applicable Interest Period, or (2)&nbsp;will
not adequately and fairly reflect the cost to such Banks of making the applicable Term Rate Advances, then the Administrative Agent forthwith shall give notice thereof to the Borrower and the Banks, whereupon until the Administrative Agent notifies
the Borrower that the circumstances giving rise to such suspension no longer exist, the obligation of the Banks to make any future Term Rate Advances shall be suspended. If at the time of such notice there is then pending a Request for Loan that
specifies a Term Rate Advance, such Request for Loan shall be deemed to specify a Base Rate Advance in Dollars. If at the time of such notice there are any Term Rate Advances outstanding, all such Term Rate Advances automatically shall be converted
to Base Rate Advances on the last day of the Interest Period(s) applicable to such Term Rate Advances. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower shall compensate each Bank for any loss sustained by that Bank in connection with the liquidation
or <FONT STYLE="white-space:nowrap">re-employment</FONT> of funds, excluding any loss of margin, and, without duplication, all actual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (excluding
allocations of any expense internal to such Bank) reasonably attributable thereto that such Bank may sustain: (i)&nbsp;if for any reason (other than a default by that Bank) a borrowing of any Term Rate Advance does not occur on a date or in the
amount specified therefor in a Request for Loan or a telephonic request for loan or a Conversion to or continuation of any Term Rate Advance does not occur on a date specified therefor in a Notice of Conversion/Continuation or a telephone request
for Conversion or continuation; (ii)&nbsp;if any prepayment or other principal payment or any conversion (other than as a result of a conversion required under <U>Section</U><U></U><U>&nbsp;3.6(a)(2)</U>) or assignment in accordance with
Section&nbsp;3.17 of any of its Term Rate Advances occurs on a date prior to the last day of an Interest Period applicable to that Loan, or (iii)&nbsp;if any prepayment of any of its Term Rate Advances is not made on any date specified in a notice
of prepayment given by the Borrower. Each Bank&#146;s determination of any amount payable under this <U>Section</U><U></U><U>&nbsp;3.6(c)</U> shall be conclusive in the absence of manifest error. Each Bank shall submit an invoice to the
Administrative Agent of the amount payable by the Borrower under this <U>Section</U><U></U><U>&nbsp;3.6(c)</U> setting forth in reasonable detail the basis for such amount and the Administrative Agent shall notify the Borrower of such amount. The
Borrower shall pay such amount to the Administrative Agent for the account of the relevant Bank, and the Administrative Agent shall promptly pay each relevant Bank the portion of the amount owed to it. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Anything in this Agreement to the contrary notwithstanding, to the extent any notice under
<U>Section</U><U></U><U>&nbsp;3.5,</U> <U>3.6</U> or <U>3.10</U> is given by any Bank more than 180 days after such Bank has knowledge (or should have had knowledge) of the occurrence of the event (or, in the case of a claim under
<U>Section</U><U></U><U>&nbsp;3.10</U>, of the amount of such claim) giving rise to the additional cost, reduction in amounts, loss, Tax or other additional amounts described in such <U>Section</U><U></U><U>&nbsp;3.5,</U> <U>3.6</U> or <U>3.10</U>,
as the case may be, such Bank shall not be entitled to compensation under such Section for any such amounts incurred or accruing prior to the giving of such notice (except that, if such event giving rise to the cost, reduction in amounts, loss, Tax
or other amounts described in such <U>Section</U><U></U><U>&nbsp;3.5,</U> <U>3.6</U> or <U>3.10</U> is retroactive, then the 180 day period referred to above shall be extended to include the period of retroactivity effective thereof).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Administrative
Agent determines (which determination shall be conclusive absent manifest error) that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adequate and reasonable means do not exist for ascertaining the applicable Reference Rate for any requested
Interest Period, including, without limitation, because the applicable Reference Rate is not available or published on a current basis and such circumstances are unlikely to be temporary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the supervisor for the administrator of the applicable Reference Rate or a governmental authority having
jurisdiction over the Administrative Agent has made a public statement identifying a specific date after which the applicable Reference Rate shall no longer be used for determining the interest rate of loans (such specific date, the
&#147;<B><U>Scheduled Unavailability Date</U></B>&#148;), </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">then, after such determination by the
Administrative Agent, the Administrative Agent and the Borrower may amend this Agreement (i)&nbsp;to replace the applicable Reference Rate with an alternate benchmark rate (including any mathematical or other adjustments to the benchmark (if any)
incorporated therein) that gives due consideration to the then prevailing market convention for determining a rate of interest for syndicated loans in the United States at such time in lieu of the applicable Reference Rate (any such proposed rate, a
&#147;<B><U>Successor Rate</U></B>&#148;;<U> provided</U> that if the Successor Rate shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement), and (ii)&nbsp;to make any Successor Rate Conforming Changes (as
defined below) and, notwithstanding anything to the contrary in <U>Section</U><U></U><U>&nbsp;11.2</U>, any such amendment shall become effective without any further action or consent of any other party to this Agreement at 5:00 p.m. (New York time)
on the fifth Banking Day after the Administrative Agent shall have posted such proposed amendment to all Banks and the Borrower unless, prior to such time, Banks comprising the Majority Banks have delivered to the Administrative Agent notice that
such Majority Banks do not accept such amendment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no Successor Rate has been determined and the circumstances under
clause (i)&nbsp;above exist or the Scheduled Unavailability Date has occurred, the obligation of the Banks to make or maintain Term Rate Advances shall be suspended (to the extent of the affected Term Rate Advances or Interest Periods). Upon receipt
of notice from the Administrative Agent regarding its determination, the Borrower may revoke any pending request for a Borrowing of, conversion to, or continuation of, Term Rate Advances (to the extent of the affected Term Rate Advances or Interest
Periods) or, failing that, will be deemed to have converted such request into a request for a Borrowing of Base Rate Advances at the end of the then Interest Period in the amount specified therein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Default Rate</U></B>. Upon the occurrence and during the continuation of any Event of Default under
<U>Section</U><U></U><U>&nbsp;9.1(a)</U> or <U>(b)</U>, the outstanding principal amount of all Advances and, to the extent permitted by applicable Law, any interest payments thereon not paid when due and any fees and other amounts then due and
payable hereunder, shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to 2% in excess of the interest rate otherwise payable under this Agreement with respect to the applicable Advances (or, in the case of any
such fees and other amounts, at a rate which is 2% per annum in excess of the interest rate otherwise payable under this Agreement for Base Rate Advances), to the fullest extent permitted by applicable Laws; <U>provided</U> that, in the case of Term
Rate Advances, upon the expiration of the Interest Period in effect at the time any such increase in interest rate is effective such Term Rate </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Advances shall thereupon become Base Rate Advances and shall thereafter bear interest payable upon demand at a rate which is 2% per annum in excess of the interest rate otherwise payable under
this Agreement for Base Rate Advances. Accrued and unpaid interest on past due amounts (<U>including</U>, without limitation, interest on past due interest) shall be compounded daily and shall be payable on demand, to the fullest extent permitted by
applicable Laws. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Computation of Interest and Fees</U></B>. Computation of interest on Base Rate Advances when the Base
Rate is calculated by reference to Citibank&#146;s base commercial lending rate shall be calculated on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. Computation of all fees and other interest (including in the
case of interest on Base Rate Advances determined by reference to Adjusted Term SOFR or the Federal Funds Effective Rate and Adjusted Term SOFR Rate Advances) shall be calculated on the basis of a year of 360 days and the actual number of days
elapsed. Any Advance that is repaid on the same day on which it is made shall bear interest for one day. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U><FONT STYLE="white-space:nowrap">Non-Banking</FONT> Days</U></B>. If any payment to be made by a Borrower
or any other party under any Loan Document shall come due on a day other than a Banking Day, payment shall instead be considered due on the next succeeding Banking Day and the extension of time shall be reflected in computing the amount of such
payment. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Manner and Treatment of Payments</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as set forth in the next sentence, each payment hereunder or on the Notes or under any other Loan
Document shall be made to the Administrative Agent, at the Administrative Agent&#146;s Office, for the account of each of the appropriate Banks in immediately available funds, without any <FONT STYLE="white-space:nowrap">set-off</FONT> or
counterclaim, not later than 2:00 p.m., New York time, on the day of payment (which must be a Banking Day). All payments received after 2:00 p.m., New York time or local time (as the case may be), on any particular Banking Day, shall be deemed
received on the next succeeding Banking Day. The amount of all payments received by the Administrative Agent for the account of each Bank shall be promptly paid by the Administrative Agent to the applicable Bank in immediately available funds. All
payments of principal, interest and all other amounts payable under this Agreement shall be made in Dollars. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the occurrence of any Event of Default, each payment or prepayment received by the Administrative
Agent on account of any Loan shall be applied: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Loans, pro rata in accordance with the aggregate principal amount thereof owed to each Bank,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any mandatory prepayment of Loans shall be applied first to Base Rate Advances to the full extent thereof
before application to Term Rate Advances as determined by Administrative Agent, in each case in a manner which minimizes the amount of any payments required to be made by Borrower pursuant to <U>Section</U><U></U><U>&nbsp;3.6(c)</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Bank shall use its best efforts to keep a record of Advances made by it and payments received by it with
respect to its Loans and, subject to <U>Section</U><U></U><U>&nbsp;11.9(g)</U>, such record shall be presumptive evidence of the amounts owing. Notwithstanding the foregoing sentence, no Bank shall be liable to any party for any failure to keep such
a record. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any and all payments by the Borrower to or for the account of the Administrative Agent or any Bank under this
Agreement or any other Loan Document shall be made free and clear of and without deduction for any and all present or future taxes, duties, levies, imposts, deductions, assessments, fees, withholdings or similar charges imposed by any Governmental
Agency, and all liabilities with respect thereto (collectively, &#147;<B>Taxes</B>&#148;), <U>except</U> as required by Law, <U>excluding</U>, in the case of the Administrative Agent and each Bank, (A)&nbsp;any Taxes imposed on or measured by its
net income (however denominated), franchise taxes imposed on it and branch profits Taxes, in each case, (1)&nbsp;imposed by the jurisdiction (or any political subdivision thereof) under the Laws of which the Administrative Agent or such Bank, as the
case may be, is organized or maintains a lending office or (2)&nbsp;that are Other Connection Taxes, (B)&nbsp;any Taxes attributable to the Administrative Agent&#146;s or such Bank&#146;s failure or inability to provide the forms set forth in
<U>Section</U><U></U><U>&nbsp;11.27</U>, other than as a result of a change in applicable Law after the date such Person became a party to this Agreement, (C)&nbsp;United States withholding Taxes imposed on amounts payable to or for the account of a
Bank with respect to an applicable interest in a Loan or Commitment pursuant to a Law in effect on the date on which (1)&nbsp;such Bank acquires such interest in the Loan or Commitment or (2)&nbsp;such Bank changes its lending office; except in each
case to the extent that, if at the date of the Assignment Agreement pursuant to which a Bank assignee becomes a party to this Agreement or at the date of such Bank changing its lending office, the assignor or such Bank was entitled to payments under
this <U>Section</U><U></U><U>&nbsp;3.10(d)(i)</U> or <U>(iii)</U>&nbsp;in respect of such United States withholding Tax paid at such date and (D)&nbsp;Taxes imposed under FATCA (all such <FONT STYLE="white-space:nowrap">non-excluded</FONT> Taxes
being hereinafter referred to as &#147;<B><U>Indemnified</U></B><U> </U><B><U>Taxes</U></B>&#148; and all such excluded Taxes being hereinafter referred to as &#147;<B><U>Excluded Taxes</U></B>&#148;). If the Borrower or the Administrative Agent
shall be required by any Laws to deduct any Taxes from or in respect of any sum payable under any Loan Document to the Administrative Agent or any Bank, as applicable, (i)&nbsp;if such Taxes are Indemnified Taxes, then the sum payable by the
Borrower shall be increased as necessary so that after all such required deductions are made (including deductions applicable to additional sums payable under this <U>Section</U><U></U><U>&nbsp;3.10(d)</U>), each of the Administrative Agent and such
Bank receives an amount equal to the sum it would have received had no such deductions been made, (ii)&nbsp;the Borrower or the Administrative Agent, as applicable, shall make such deductions, (iii)&nbsp;the Borrower or the Administrative Agent, as
applicable, shall pay the full amount deducted to the relevant Governmental Agency in accordance with applicable Laws, and (iv)&nbsp;as soon as practicable after the date of such payment, the Borrower shall furnish to the Administrative Agent (which
shall forward the same to such Bank) the original or a certified copy of a receipt evidencing payment thereof (to the extent available). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition, the Borrower agrees to pay any and all present or future stamp, court or documentary Taxes and any
other excise or property Taxes or charges or similar levies which arise from any payment made under any Loan Document or from the execution, delivery, performance, enforcement or registration of, or otherwise with respect to, any Loan Document,
except any such Taxes imposed as a result of a grant of a participation, designation of a new lending office, transfer or assignment (other than an assignment pursuant to a request by a Borrower under <U>Section</U><U></U><U>&nbsp;3.17</U>)
(hereinafter referred to as &#147;<B><U>Other Taxes</U></B>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-39- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower agrees to indemnify the Administrative Agent and each Bank for (A)&nbsp;the full amount of
Indemnified Taxes and Other Taxes (including any Indemnified Taxes or Other Taxes imposed or asserted by any jurisdiction on amounts payable under this <U>Section</U><U></U><U>&nbsp;3.10</U>) payable or paid by the Administrative Agent and such Bank
and (B)&nbsp;any interest, penalties or additions to tax arising therefrom or with respect thereto, in each case whether or not such Indemnified Taxes or Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Agency.
Payment under this <U>Section</U><U></U><U>&nbsp;3.10(d)(iii)</U> shall be made within 30 days after the date the Bank or the Administrative Agent makes a written demand therefor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Borrower is required to pay additional amounts to or for the account of any Bank pursuant to this
<U>Section</U><U></U><U>&nbsp;3.10</U>, then such Bank will change the jurisdiction of its applicable lending office if, in the judgment of such Bank, such change (A)&nbsp;will eliminate or reduce any such additional payment that may thereafter
accrue and (B)&nbsp;is not otherwise disadvantageous to such Bank. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Bank shall severally indemnify the Administrative Agent, within 10 days after demand therefor, for
(i)&nbsp;any Indemnified Taxes attributable to such Bank (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (ii)
any Taxes attributable to such Bank&#146;s failure to comply with the provisions of Section&nbsp;11.9(e) relating to the maintenance of a Participant Register and (iii)&nbsp;any Excluded Taxes attributable to such Bank, in each case, that are
payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant
Governmental Agency. A certificate as to the amount of such payment or liability delivered to any Bank by the Administrative Agent shall be conclusive absent manifest error. Each Bank hereby authorizes the Administrative Agent to set off and apply
any and all amounts at any time owing to such Bank under any Loan Document or otherwise payable by the Administrative Agent to the Bank from any other source against any amount due to the Administrative Agent under this paragraph (v).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any
Taxes as to which it has been indemnified or reimbursed pursuant to this Section&nbsp;3.10(d) or with respect to which the indemnifying party has paid an additional or indemnification amount hereunder, it shall pay to the indemnifying party (within
thirty (30)&nbsp;days after such Person became aware it received such refund) an amount equal to such refund (but only to the extent of indemnity payments made under this Section&nbsp;3.10(d) with respect to the Taxes giving rise to such refund),
net of all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Agency with
respect to such refund). In the event such indemnified party is required by the relevant Governmental Agency to repay any portion of such refund, then such indemnifying party, upon the request of such indemnified party, shall repay to such
indemnified party such portion of any refund previously paid over to such indemnifying party (plus any penalties, interest or other charges imposed by such Governmental Agency with respect to such portion of such refund). Notwithstanding anything to
the contrary in this <U>Section</U><U></U><U>&nbsp;3.10(d)(vi)</U>, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-40- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in no event will the indemnified party be required to pay any amount to the indemnifying party pursuant to this <U>Section</U><U></U><U>&nbsp;3.10(d)(vi)</U> to the extent such payment would
place the indemnified party in a less favorable net <FONT STYLE="white-space:nowrap">after-Tax</FONT> position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted,
withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other
information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of this <U>Section</U><U></U><U>&nbsp;3.10(d)</U>, the term &#147;Law&#148; includes FATCA.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party&#146;s obligations under this Section&nbsp;3.10(d) shall survive the resignation or replacement of
the Administrative Agent or any assignment of rights by, or the replacement of, a Bank, the termination of the Commitments, and the repayment, satisfaction or discharge of all obligations under any Loan Document. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Funding Sources</U></B>. Nothing in this Agreement shall be deemed to obligate any Bank to obtain the
funds for any Loan or Advance in any particular place or manner or to constitute a representation by any Bank that it has obtained or will obtain the funds for any Loan or Advance in any particular place or manner. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Failure to Charge Not Subsequent Waiver</U></B>. Any decision by any Bank not to require payment of any
interest (<U>including</U> interest arising under <U>Section</U><U></U><U>&nbsp;3.7</U>), fee, cost or other amount payable under any Loan Document, or to calculate any amount payable by a particular method, on any occasion shall in no way limit or
be deemed a waiver of such Bank&#146;s right to require full payment of any interest (<U>including</U> interest arising under <U>Section</U><U></U><U>&nbsp;3.7</U>), fee, cost or other amount payable under any Loan Document, or to calculate an
amount payable by another method, on any other or subsequent occasion. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Administrative Agent</U></B><B><U>&#146;</U></B><B><U>s Right to Assume Payments Will be Made by
Borrower</U></B>. Unless the Administrative Agent shall have been notified by the Borrower prior to the date on which any payment to be made by that Borrower hereunder is due that the Borrower does not intend to remit such payment, the
Administrative Agent may, in its discretion, assume that the Borrower has remitted such payment when so due and the Administrative Agent may, in its discretion and in reliance upon such assumption, make available to each Bank on such payment date an
amount equal to such Bank&#146;s share of such assumed payment. If a Borrower has not in fact remitted such payment to the Administrative Agent, each Bank shall forthwith on demand repay to the Administrative Agent the amount of such assumed payment
made available to such Bank, together with interest thereon in respect of each day from and including the date such amount was made available by the Administrative Agent to such Bank to the date such amount is repaid to the Administrative Agent at a
rate per annum equal to the average overnight federal funds rate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Fee Determination Detail</U></B>. The Administrative Agent and any Bank, shall provide reasonable detail
to the Borrower regarding the manner in which the amount of any payment to the Banks, or that Bank, under <U>Article 3</U> has been determined. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-41- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Survivability</U></B>. All of the Borrower&#146;s obligations under <U>Sections 3.5</U> and <U>3.6</U>
shall survive for thirty (30)&nbsp;days following the termination of this Agreement; <U>provided</U>, <U>however</U>, that such obligations shall not, from and after the termination of this Agreement, be deemed Obligations for any purpose under the
Loan Documents. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Dodd-Frank, Etc</U></B>. For the avoidance of doubt and notwithstanding anything herein to the contrary,
for the purposes of <U>Sections 3.5</U> and <U>3.6</U>, (a) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, regulations, guidelines, interpretations or directives thereunder or issued in connection therewith
(whether or not having the force of law) and (b)&nbsp;all requests, rules, regulations, guidelines, interpretations or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or
similar authority ) or the United States or foreign regulatory authorities (whether or not having the force of law), in case for this clause (b)&nbsp;pursuant to Basel III, shall in each case be deemed to be a change in Law regardless of the date
enacted, adopted, issued, promulgated or implemented. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Replacement of Banks</U></B>. If (a)&nbsp;any Bank requests compensation under <U>Sections 3.5</U> and
<U>3.6</U>, (b) the Borrower is required to pay additional amounts to any Bank or any Governmental Agency for the account of any Bank pursuant to Section&nbsp;3.10, (c) any Bank is a Defaulting Bank or (d)&nbsp;any Bank fails to consent to a
requested amendment, waiver or modification to any Loan Document in which the Majority Banks have already consented to such amendment, waiver or modification but the consent of each Bank (or each Bank directly affected thereby, as applicable) is
required with respect thereto, then the Borrower may, at its sole expense and effort, upon notice to such Bank and the Administrative Agent, require such Bank to assign and delegate, without recourse (in accordance with and subject to the
restrictions contained in, and consents required by, <U>Section</U><U></U><U>&nbsp;11.9(b)</U>), all of its interests, rights and obligations under this Agreement to an Eligible Assignee that shall assume such obligations (which assignee may be
another Bank that is not a Defaulting Bank, if such Bank accepts such assignment); <U>provided</U> that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Administrative Agent shall have received the assignment fee (if any) specified in
<U>Section</U><U></U><U>&nbsp;11.9(b)</U>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such Bank shall have received payment of an amount equal to the outstanding principal of its Advances, accrued
interest thereon, accrued fees and all other amounts payable to it hereunder (including any amounts under <U>Section</U><U></U><U>&nbsp;3.6(c)</U>) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the
Borrower (in the case of all other amounts); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any such assignment resulting from a claim for compensation under
<U>Section</U><U></U><U>&nbsp;3.6(c)</U> or payments required to be made pursuant to <U>Section</U><U></U><U>&nbsp;3.10</U>, such assignment will result in a reduction in such compensation or payments thereafter; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such assignment does not conflict with applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any assignment pursuant to clause (d)&nbsp;of this Section&nbsp;3.17, the applicable assignee
shall have consented to the applicable amendment, waiver or consent. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A Bank shall not be required to make any such
assignment or delegation if, prior thereto, as a result of the designation of a different lending office in accordance with Section&nbsp;3.6(a) or Section&nbsp;3.10(d) by the Bank, as applicable, a waiver by such Bank or otherwise, the circumstances
entitling the Borrower to require such assignment and delegation cease to apply. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-42- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Borrower represents and warrants to the Banks on the Effective Date, on the Closing Date and on each Funding Date, that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Existence and Qualification; Power; Compliance With Laws</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower is an organization duly formed, validly existing and in good standing under the Laws of the
jurisdiction of its incorporation. The Borrower has all requisite corporate power and authority to execute and deliver each Loan Document to which it is a party and to perform its Obligations. The Borrower is duly qualified to transact business, and
is in good standing, in any jurisdiction in which the conduct of its business or the ownership or leasing of its Properties makes such qualification or registration necessary, except where the failure so to qualify or register and to be in good
standing would not constitute a Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower has all requisite corporate power and authority to conduct its business and to own and lease its
Properties. The Borrower has obtained all authorizations, consents, approvals, orders, licenses and permits from, and has accomplished all filings, registrations and qualifications with, or obtained exemptions from any of the foregoing from, any
Governmental Agency that are necessary for the transaction of its business, except where the failure so to comply, file, register, qualify or obtain exemptions does not constitute a Material Adverse Effect. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Authority; Compliance With Other Agreements and Instruments and Government Regulations</U></B>. The
execution, delivery and performance of the Loan Documents by the Borrower have been duly authorized by all necessary corporate action, and do not: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Require any consent or approval not heretofore obtained of any partner, director, stockholder, security holder
or creditor of the Borrower; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Result in or require the creation or imposition of any Lien upon or with respect to any Property now owned or
leased or hereafter acquired by the Borrower; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Violate, to the best knowledge of the Borrower, any Requirement of Law applicable to the Borrower; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Result (or, with the giving of notice or passage of time or both, would result) in a breach of or default
under, or cause or permit the acceleration of any obligation owed under any Contractual Obligation to which the Borrower is a party or by which the Borrower or any of its Property is bound or affected; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">except where failure to receive such consent or approval or creation of such Lien or violation of, or default under, any such Requirement of
Law or Contractual Obligation would not constitute a Material Adverse Effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Governmental Approvals Required</U></B>. No authorization, consent, approval, order, license or permit
from, or filing, registration or qualification with, any Governmental Agency is required to authorize or permit under applicable Laws the execution, delivery and performance of the Loan Documents by the Borrower. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-43- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Subsidiaries</U></B>. <U>Schedule 4.4</U> hereto correctly sets forth as of December&nbsp;31, 2021 the
names of each Subsidiary of the Borrower that would constitute a Significant Subsidiary (&#147;<B><U>Significant Subsidiary</U></B>&#148;) under Rule <FONT STYLE="white-space:nowrap">1-02(w)</FONT> of Regulation
<FONT STYLE="white-space:nowrap">S-X</FONT> as adopted by the Securities and Exchange Commission under the provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934 as in force on the date of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Financial Statements</U></B>. The Borrower has made available to the Banks the audited consolidated
financial statements of the Borrower and its Consolidated Subsidiaries as of December&nbsp;31, 2021. Such financial statements (including the footnotes thereto) fairly present in all material respects the consolidated financial condition and the
consolidated results of operations of the Borrower as of such date and for such period in accordance with Generally Accepted Accounting Principles. Also, the Borrower has made available the unaudited condensed consolidated financial statements of
the Borrower and its Consolidated Subsidiaries as of September&nbsp;30, 2022 and for the nine months then ended (the &#147;<B><U>interim financial statements</U></B>&#148;). The interim financial statements (including the footnotes thereto) were
prepared in accordance with applicable Securities and Exchange Commission regulations and include all adjustments (consisting of normal recurring accruals, unless otherwise indicated) the Borrower considers necessary for the fair presentation, in
all material respects, of the results of operations for those periods. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Other Liabilities; No Material Adverse Effect</U></B>. As of the Effective Date, the Borrower and its
Consolidated Subsidiaries do not have any material liability or material contingent liability not reflected or disclosed in the consolidated balance sheet or notes thereto described in <U>Section</U><U></U><U>&nbsp;4.5</U>, other than liabilities
and contingent liabilities: (i)&nbsp;arising in the ordinary course of business subsequent to December&nbsp;31, 2021, (ii) described in materials filed with or furnished to the Securities and Exchange Commission and available to the public, or
(iii)&nbsp;set forth on <U>Schedule 4.8</U>. Except for matters described in documents filed with or furnished to Governmental Agencies and available to the public or in materials delivered to the Banks prior to the Effective Date, there has been no
event or circumstance that constitutes, a Material Adverse Effect with respect to the Borrower and its Subsidiaries taken as a whole since December&nbsp;31, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Governmental Regulation</U></B>. The Borrower is not subject to regulation under the Investment Company
Act of 1940. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Litigation</U></B>. <U>Except</U> for (a)&nbsp;any matter fully covered (subject to applicable
deductibles and retentions) by insurance for which the insurance carrier has assumed full responsibility, (b)&nbsp;matters described in documents filed with or furnished to Governmental Agencies and available to the public or in materials delivered
to the Banks prior to the Effective Date, and (c)&nbsp;matters disclosed on <U>Schedule 4.8</U> hereto, there are no actions, suits, proceedings or investigations pending as to which the Borrower or any of its Subsidiaries have been served or have
received written notice or, to the best knowledge of the Borrower, threatened against or affecting the Borrower or any of its Subsidiaries or any Property of any of them before any Governmental Agency which could reasonably be expected to constitute
a Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Binding Obligations</U></B>. (a)&nbsp;This Agreement has been duly executed and delivered by the Borrower
and constitutes the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms and (b)&nbsp;each of the other Loan Documents will, when executed and delivered by the Borrower, constitute the
legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, <U>except</U> (in each of case (a)&nbsp;and (b)), as enforcement may be limited by Debtor Relief Laws or equitable principles
relating to the granting of specific performance and other equitable remedies as a matter of judicial discretion. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-44- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Default</U></B>. No event has occurred and is continuing that is a Default or Event of Default.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Employee Benefit Plans</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower and, to the knowledge of the Borrower, each of its ERISA Affiliates are in compliance with all
applicable provisions and requirements of ERISA and the regulations and published interpretations thereunder with respect to each Employee Benefit Plan, and have performed all of their obligations under each Employee Benefit Plan, except where the
failure to be in such compliance or to perform such obligation would not constitute a Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No ERISA Event that would constitute a Material Adverse Effect has occurred or is reasonably expected to occur.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as set forth on Schedule 4.11(c) and to the extent required under Section&nbsp;4980B of the Code, no
Employee Benefit Plan maintained by the Borrower or any of its Current ERISA Affiliates provides health or welfare benefits (through the purchase of insurance or otherwise) for any retired or former employees of the Borrower or any of its Current
ERISA Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the most recent valuation date for any Pension Plan with respect to which the Borrower or a Subsidiary
has any financial liability (including potential joint and several liability) in the event any such Pension Plan were to terminate, the &#147;amount of unfunded benefit liabilities&#148; (as defined in Section&nbsp;4001(a)(18) of ERISA),
individually or in the aggregate for all Pension Plans (excluding for purposes of such computation any Pension Plans with respect to which assets exceed benefit liabilities), does not exceed $60,000,000. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Regulation U</U></B>. No part of the proceeds of any Advance hereunder will be used to purchase or carry,
or to extend credit to others for the purpose of purchasing or carrying, any &#147;margin stock&#148; (as such term is defined in Regulation U) in violation of Regulation U. Neither the Borrower nor any of its Subsidiaries is engaged principally, or
as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying any such &#147;margin stock.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Disclosure</U></B>. All written information heretofore supplied by the Borrower to the Administrative
Agent for the purposes of this Agreement (either directly or as documents filed with or furnished to Governmental Agencies and available to the public) is true and accurate in all material respects on the date as of which such information is stated.
The Borrower has disclosed to the Administrative Agent (either directly or as documents filed with or furnished to Governmental Agencies and available to the public) all facts which could reasonably be expected to, in the good faith opinion of the
Borrower, materially and adversely affect (to the extent the Borrower can reasonably foresee) the financial condition of the Borrower and its Subsidiaries, taken as a whole, or the ability of the Borrower to perform its obligations under this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Tax Liability</U></B>. Each of the Borrower and its Subsidiaries has filed or caused to be filed all tax
returns which are required to have been filed by it, and has paid or caused to be paid, or made provision for the payment of, all taxes with respect to the periods, Property or transactions covered by said returns, or pursuant to any assessment
received by the Borrower or any of its Subsidiaries, <U>except</U> (a)&nbsp;taxes for which the Borrower has been fully indemnified, (b)&nbsp;such taxes, if any, as are being contested in good faith by appropriate proceedings and as to which
adequate reserves have been established and maintained or (c)&nbsp;where the failure to so file or pay would not reasonably be expected to have a Material Adverse Effect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-45- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Environmental Matters</U></B>. As of the Effective Date, except as set forth in the Borrower&#146;s
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 to the Securities and Exchange Commission, or as disclosed in <U>Schedule 4.15</U> annexed hereto, (a)&nbsp;the Borrower and each Subsidiary
have complied with all Environmental Laws, except to the extent that the failure to so comply would not be reasonably expected to result in a Material Adverse Effect, (b)&nbsp;the Borrower&#146;s and its Subsidiaries&#146; facilities do not manage
any hazardous wastes, hazardous substances, hazardous materials, toxic substances or toxic pollutants in any manner that would result in a violation of any Environmental Law, except for violations that would not be reasonably expected to result in a
Material Adverse Effect and (c)&nbsp;the Borrower is aware of no events, conditions or circumstances involving environmental pollution or contamination or public or employee health or safety, in each case applicable to it or its Subsidiaries, that
has resulted or would be reasonably expected to result in a Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Sanctions</U></B>. Neither the Borrower nor any of its Subsidiaries nor, to the knowledge of the
Borrower, any director, officer, employee or agent of the Borrower or any of its Subsidiaries is (i)&nbsp;a Person whose name appears on the list of Specially Designated Nationals and Blocked Persons published by the Office of Foreign Assets Control
of the U.S. Department of the Treasury (&#147;<B><U>OFAC</U></B>&#148;), the Consolidated List of Financial Sanctions Targets in the UK maintained by His Majesty&#146;s Treasury or the Consolidated List of Persons, Groups and Entities Subject to EU
Financial Sanctions maintained by the European Union (a &#147;<B><U>Sanctioned Person</U></B>&#148;); (ii) a Person who is engaged in a transaction with any Person who is a Sanctioned Person; (iii)&nbsp;a department, agency or instrumentality of, or
is otherwise owned or controlled by or acting on behalf of, directly or indirectly, (x)&nbsp;one or more Sanctioned Persons, or (y)&nbsp;the government of a country or territory that is the target of comprehensive economic sanctions administered by
OFAC, the European Union or His Majesty&#146;s Treasury (as of the date of this Agreement, Iran, Cuba, Syria, North Korea, the Crimea, <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, and <FONT
STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic regions of Ukraine, and <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Kherson and Zaporizhzhia regions of Ukraine) (collectively,
&#147;<B><U>Sanctioned Countries</U></B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Foreign Corrupt Practices Act</U></B>. The Borrower has implemented and maintains in effect policies and
procedures reasonably designed to promote reasonable compliance by the Borrower, its Subsidiaries and their respective directors, officers and employees with the Foreign Corrupt Practices Act of 1977 (the &#147;<B><U>FCPA</U></B>&#148;), and is in
compliance with the FCPA in all material respects. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>EEA Financial Institution</U></B>. The Borrower is not an EEA Financial Institution.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Beneficial Ownership Certification</U></B>. In respect of the Borrower that is a &#147;legal entity
customer&#148; under the Beneficial Ownership Regulation, the information included in the Beneficial Ownership Certification delivered in respect of the Borrower, as of the date such Beneficial Ownership Certification is delivered, is true and
correct in all respects. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Use of Proceeds</U></B>. The proceeds of the Advances will be used in accordance with Section&nbsp;5.8.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Target Acquisition</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Closing Date, (a)&nbsp;the release of the Scheme Press Announcement (if the Target Acquisition is
consummated by way of a Scheme), and the posting of the Scheme Circular (if the Target Acquisition is consummated by way of a Scheme) or the Takeover Offer Document (if the Target Acquisition is consummated by way of a Takeover Offer), as
applicable, has been duly authorized or ratified by the Borrower and Bidco (as applicable) and (b)&nbsp;each of the obligations of the Borrower and Bidco </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-46- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
under the Takeover Offer Document or Scheme Circular (as applicable) constitutes the legal, valid and binding obligation of the Borrower and Bidco (as applicable), <U>except</U> as enforcement
may be limited by Debtor Relief Laws or equitable principles relating to the granting of specific performance and other equitable remedies as a matter of judicial discretion. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Closing Date, (A)&nbsp;if the Target Acquisition is consummated by way of a Scheme, (i)&nbsp;to the
best of the knowledge and belief of the directors of the Borrower and/or Bidco (having taken all reasonable care to ensure that such is the case) the information contained in the Scheme Documents for which the directors of the Borrower and/or Bidco
take responsibility under the Irish Takeover Code is in accordance with the facts and, where appropriate, does not omit anything likely to affect the import of such information, and (ii)&nbsp;the Scheme Documents, taken as a whole, contain all the
material terms of the Scheme and (B)&nbsp;if the Target Acquisition is consummated by way of a Takeover Offer, (i)&nbsp;to the best of the knowledge and belief of the directors of the Borrower and/or Bidco (having taken all reasonable care to ensure
that such is the case) the information contained in the Offer Documents for which the directors of the Borrower and/or Bidco take responsibility under the Irish Takeover Code is in accordance with the facts and, where appropriate, does not omit
anything likely to affect the import of such information, and (ii)&nbsp;the Offer Documents taken as a whole, contain all the material terms of the Takeover Offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Affirmative
Covenants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Other than Information and Reporting Requirements) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as any Advance remains unpaid, or any other Obligation (other than indemnity obligations for which no claim has been made) remains unpaid or
unperformed, or any portion of the Commitments remains in force, the Borrower shall, and shall cause each of its Subsidiaries to, unless the Administrative Agent (acting with the approval of the Majority Banks) otherwise consents in writing: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Payment of Taxes and Other Potential Liens</U></B>. Pay and discharge promptly all taxes, assessments and
governmental charges or levies imposed upon any of them, upon their respective Property or any part thereof, or upon their respective income or profits or any part thereof, <U>except</U> that the Borrower and its Subsidiaries shall not be required
to pay or cause to be paid any tax, assessment, charge or levy (a)&nbsp;that is not yet past due, or is being contested in good faith by appropriate proceedings, so long as the relevant entity has established and maintains adequate reserves for the
payment of the same and by reason of such nonpayment and contest no material item or portion of Property of the Borrower and its Subsidiaries, taken as a whole, is in jeopardy of being seized, levied upon or forfeited or (b)&nbsp;the nonpayment of
which in the aggregate could not reasonably be expected to have a Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Preservation of Existence</U></B>. Preserve and maintain their respective (a)&nbsp;existences in the
jurisdiction of their formation and (b)&nbsp;all authorizations, rights, franchises, privileges, consents, approvals, orders, licenses, permits, or registrations from any Governmental Agency that are necessary for the transaction of their respective
business, and qualify and remain qualified to transact business in each jurisdiction in which such qualification is necessary in view of their respective business or the ownership or leasing of their respective Properties except where the failure to
maintain such preservation or maintenance of existence, authorizations, rights, franchises, privileges, consents, approvals, orders, licenses, permits or registration or to do so qualify would not constitute a Material Adverse Effect and;
<U>provided</U> that a merger permitted under <U>Section</U><U></U><U>&nbsp;6.2</U> shall not constitute a violation of this covenant. Nothing herein contained </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-47- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shall prevent the termination of the business or corporate existence of any Subsidiary (other than a Borrower) that, in the judgment of the Borrower, is no longer necessary or desirable, as long
as immediately after giving effect to any such transaction, no Default shall have occurred and be continuing. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Maintenance of Properties</U></B>. Maintain, preserve and protect all of their respective depreciable
Properties in good order and condition, subject to wear and tear in the ordinary course of business, and not permit any waste of their respective Properties, <U>except</U> that any failure to so maintain, preserve or protect such Properties that
does not constitute a Material Adverse Effect shall not constitute a violation of this covenant. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Maintenance of Insurance</U></B>. Maintain liability, casualty and other insurance (subject to customary
deductibles and retentions), with responsible insurance companies in such amounts and against such risks as is carried by responsible companies engaged in similar businesses and owning similar assets in the general areas in which the Borrower and
its Subsidiaries operate; <U>provided</U> <U>that</U>, notwithstanding the foregoing, the Borrower may self-insure if reasonable and consistent with sound business practice. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Compliance With Laws</U></B>. Comply with all Requirements of Law noncompliance with which constitutes a
Material Adverse Effect, <U>except</U> that the Borrower and its Subsidiaries need not comply with a Requirement of Law then being contested by any of them in good faith by appropriate proceedings. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Visitation</U></B>. Upon reasonable notice permit the Administrative Agent or representatives of any Bank
at the Administrative Agent&#146;s or such Bank&#146;s expense to visit any of its major properties, during normal business hours, to inspect and make abstracts from its financial and accounting records (other than materials protected by the
attorney-client privilege and materials which are proprietary in nature or which may not be disclosed without violation of a binding confidentiality obligation), and to discuss its affairs and finances with its officers and independent public
accountants, all at such reasonable times and as often as may reasonably be requested; <U>provided</U> that so long as no Default or Event of Default has occurred and is continuing, visitation by representatives of the Banks shall be limited to not
more than one visit in any calendar year for each Bank. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Keeping of Records and Books of Account</U></B>. Keep adequate records and books of account reflecting
all financial transactions in conformity with Generally Accepted Accounting Principles, and in material conformity with all applicable requirements of any Governmental Agency having regulatory jurisdiction over the Borrower or any of its
Subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Use of Proceeds</U></B>. Use the proceeds of Advances only for Certain Funds Purposes.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Scheme Undertakings</U></B>. From the Effective Date to the Closing Date, or, if earlier, until the
Borrower has elected to switch to a Takeover Offer pursuant to Section&nbsp;3.6 of the Transaction Agreement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Terms of the Scheme</U>. The Borrower will ensure that (A)&nbsp;any variation of the terms and conditions of
either the Transaction Agreement or the Scheme Circular from the terms and conditions of the Agreed Form of Scheme Press Announcement (or Transaction Agreement) delivered to the Administrative Agent on the Effective Date and (B)&nbsp;any amendment
or waiver of any terms and conditions in the Scheme or any Scheme Document or the Transaction Agreement shall not, in each case of clauses (A)&nbsp;and (B), be materially adverse to the interests of the Banks in their capacities as such, taken as a
whole, unless </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-48- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Administrative Agent (but not any Bank) has approved such variation, amendment or waiver in writing (which approval may be in the form of an email confirmation from the Administrative Agent
(or its counsel on its behalf) and shall not be unreasonably withheld, delayed or conditioned) or such variations, amendments or waivers are required by the Takeover Panel, the Takeover Rules, the Securities and Exchange Commission or the High Court
or under any applicable law or regulation; provided that the Borrower shall not increase the cash consideration for the Target Shares pursuant to the Scheme from the cash consideration set forth in the Transaction Agreement as in effect on the
Effective Date; except that (x)&nbsp;an increase of cash consideration by less than 10% shall be permitted (and any increase in the cash consideration for the Target Shares by 10% or more shall require the consent of the Administrative Agent (but
not any Bank)), (y) any increase in cash consideration is permitted to the extent such increase is funded entirely (directly or indirectly) by the subscription for Equity Interests in the Borrower, or by the incurrence of any Indebtedness that would
not constitute a Debt Issuance, or cash on hand at the Borrower or any member of the Consolidated Group and any increase in any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration shall be deemed not to be adverse to the interests of the
Banks, and (z)&nbsp;any extension to the End Date (as defined in the Transaction Agreement) to a date falling not later than the Long Stop Date shall be deemed not to be adverse to the interests of the Banks. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dispatch of Scheme Circular</U>. The Borrower will use reasonable endeavors to procure that the Scheme
Circular is dispatched to the holders of the Target Shares as soon as reasonably practicable after approval by the Takeover Panel (to the extent such approval is required) and the High Court and after the Borrower is satisfied that it has obtained
all confirmations necessary or desirable from the Securities and Exchange Commission. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Progress of Scheme</U>. The Borrower will use commercially reasonable efforts to keep the Administrative
Agent reasonably informed as to any material developments in relation to the Scheme and promptly on request provide the Administrative Agent with material information as to the progress of the Scheme and with any material information (subject to
applicable legal and regulatory restrictions on disclosure thereof) in relation to the Scheme and will notify the Administrative Agent promptly following it becoming aware that the Court Order has been issued. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Implementation of the Scheme</U>. The Borrower shall, and shall procure that Bidco shall:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) not take any action (and procure, so far as it is legally able to do so, that no person, acting in
concert with it takes any action) which would compel it (or any person acting in concert with it) to make a mandatory offer to shareholders of the Target under Rule 9 of the Takeover Rules; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) comply in all material respects with their obligations under the Scheme and the Scheme Documents (in each case subject to
(i)&nbsp;waivers granted by or requirements of the Takeover Panel or the requirements of the High Court and (ii)&nbsp;all relevant authorizations, laws and regulations and the requirements, rules and regulations of all applicable regulatory
authorities and bodies relating to the Target Acquisition); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-49- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) comply in all material respects with their obligations under the Irish
Companies Act and the Takeover Rules, subject to any applicable waivers by the Takeover Panel (in each case subject to (i)&nbsp;waivers granted by or requirements of the Takeover Panel or the requirements of the High Court and (ii)&nbsp;all relevant
authorizations, laws and regulations and the requirements, rules and regulations of all applicable regulatory authorities and bodies relating to the Target Acquisition). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Takeover Undertakings</U></B>. At any time after the Borrower has elected to convert the Scheme to a
Takeover Offer pursuant to Section&nbsp;3.6 of the Transaction Agreement, which election shall be notified as soon as reasonably practicable to the Administrative Agent by a written notice (&#147;<B><U>Offer Conversion Notice</U></B>&#148;):
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Terms of the Takeover Offer Document</U>: The Borrower will ensure that (A)&nbsp;any variation of the terms
and conditions of either the Transaction Agreement or the Takeover Offer Document from the terms and conditions of the Agreed Form of Scheme Press Announcement (or Transaction Agreement) delivered to the Administrative Agent on the Effective Date
and (B)&nbsp;any amendment or waiver of any terms and conditions in the Takeover Offer or the Takeover Offer Document or the Transaction Agreement shall not, in each case of clauses (A)&nbsp;and (B), be materially adverse to the interests of the
Banks in their capacities as such, taken as a whole, unless the Administrative Agent (but not any Bank) has approved such variation, amendment or waiver in writing (which approval may be in the form of an email confirmation from the Administrative
Agent (or its counsel on its behalf) and shall not be unreasonably withheld, delayed or conditioned) or such variations, amendments or waivers are required by the Takeover Panel, the Takeover Rules, the Securities and Exchange Commission or the High
Court or under any applicable law or regulation; provided that (1)&nbsp;the Borrower shall not increase the cash consideration for the Target Shares in a Takeover Offer from the cash consideration set forth in the Transaction Agreement as in effect
on the Effective Date; except that (x)&nbsp;an increase of cash consideration for the Target Shares in a Takeover Offer by less than 10% shall be permitted (and any increase in the cash consideration for the Target Shares in a Takeover Offer by 10%
or more shall require the consent of the Administrative Agent (but not any Bank)), (y) any increase in cash consideration in a Takeover Offer shall be permitted to the extent such increase is funded entirely (directly or indirectly) by the
subscription for Equity Interests in the Borrower, or by the incurrence of any Indebtedness that would not constitute a Debt Issuance or cash on hand at the Borrower or any member of the Consolidated Group and any increase in any <FONT
STYLE="white-space:nowrap">non-cash</FONT> consideration or any decrease in the cash consideration in a Takeover Offer shall be deemed not to be adverse to the interests of the Banks to the extent, in the case of any decrease, that any such
reduction in the cash consideration shall have been allocated to a reduction of the commitments under the Bridge Facility, and (z)&nbsp;any extension to the End Date (as defined in the Transaction Agreement) to a date falling not later than the Long
Stop Date shall be deemed not to be adverse to the interests of the Banks and (2)&nbsp;any change to the Takeover Offer that would reduce the minimum acceptance level of Target Shares to which the Takeover Offer relates to less than 80% shall be
deemed materially adverse to the interests of the Banks and the Administrative Agent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-50- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Issue of the Takeover Offer Document</U>: The Borrower shall use commercially reasonable efforts to dispatch
the Takeover Offer Document as soon as reasonably practicable after approval by the Takeover Panel (to the extent such approval is required) and after the Borrower is satisfied that it has obtained all confirmations necessary or desirable from the
Securities and Exchange Commission. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Progress of the Takeover Offer</U>: The Borrower shall keep the Administrative Agent reasonably informed as
to the progress of the Takeover Offer and any market purchases of Target Shares made, and provide the Administrative Agent with such material information (subject to applicable legal and regulatory restrictions on disclosure thereof) in respect of
the Takeover Offer as the Administrative Agent may reasonably request. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Implementation of the Takeover Offer</U>: The Borrower shall, and shall procure that Bidco shall:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) not take any action (and procure, so far as it is legally able to do so, that no person acting in
concert with it takes any action) which would compel it to make a mandatory offer to the holders of the Target Shares under Rule 9 of the Takeover Rules; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) comply in all material respects with their obligations under the Takeover Offer and the Takeover Offer Document (in each
case subject to (i)&nbsp;waivers granted by or requirements of the Takeover Panel and (ii)&nbsp;all relevant authorizations, laws and regulations and the requirements, rules and regulations of all applicable regulatory authorities and bodies
relating to the Target Acquisition); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) comply in all material respects with their obligations under the Irish Companies
Act and the Takeover Rules, subject to any applicable waivers by the Takeover Panel (in each case subject to (i)&nbsp;waivers granted by or requirements of the Takeover Panel and (ii)&nbsp;all relevant authorizations, laws and regulations and the
requirements, rules and regulations of all applicable regulatory authorities and bodies relating to the Target Acquisition); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) not declare the Takeover Offer unconditional unless (i)&nbsp;it has achieved an acceptance level of at least 80% of each
class of Target Shares to which the Takeover Offer relates and (ii)&nbsp;the Borrower has become entitled under the Squeeze Out Procedures to issue a Squeeze Out Notice; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) not (unless the Unconditional Date shall have occurred) extend the Takeover Offer beyond 81 days from the date on which
the Takeover Offer Document are published, unless required to do so by the Takeover Rules, the Takeover Panel, any applicable law or regulation, any applicable stock exchange or any applicable governmental or other regulatory authority. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Completion of Purchase of Remaining Shares in the Target</U></B>. Within 14 days of the date on which the
Borrower or Bidco (as applicable) has (i)&nbsp;by virtue of the Takeover Offer acquired, or unconditionally contracted to acquire, not less than 80% in value of the Target Shares and (ii)&nbsp;become entitled under the Squeeze Out Procedures to
issue a Squeeze Out Notice, the Borrower shall, or shall procure that Bidco shall: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-51- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give notice to all the remaining holders of the Target Shares that it intends to acquire their shares pursuant
to the Squeeze Out Procedures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subsequently purchase such shares as soon as reasonably possible; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with the provisions of the Squeeze Out Procedures in all material respects. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Take Private Procedure</U></B>. To the extent the Target Acquisition is consummated by way of a Scheme,
the Borrower shall, or shall procure that Bidco shall, submit all required documents to the Registrar to procure the <FONT STYLE="white-space:nowrap">re-registration</FONT> of the Target as a private company pursuant to Part 20 of the Irish
Companies Act within 30 days after the Closing Date (or such longer period reasonably acceptable to the Administrative Agent). To the extent the Target Acquisition is consummated by way of a Takeover Offer, the Borrower shall, or shall procure that
Bidco shall, submit all required documents to the Registrar to procure the <FONT STYLE="white-space:nowrap">re-registration</FONT> of the Target as a private company pursuant to Part 20 of the Irish Companies Act within 30 days after it has acquired
all shares of the Target (or such longer period reasonably acceptable to the Administrative Agent). </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Negative Covenants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as
any Advance remains unpaid, or any other Obligation (other than indemnity obligations for which no claim has been made) remains unpaid or unperformed, or any portion of the Commitments remains in force, the Borrower shall not, and shall not permit
any of its Subsidiaries to, unless the Administrative Agent (acting with the approval of the Majority Banks) otherwise consents in writing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Change in Nature of Business</U></B>. Make any material change in the nature of the business of the
Borrower and its Subsidiaries, taken as a whole, as at present conducted. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Mergers</U></B>. Merge, consolidate or amalgamate with or into any Person, or convey substantially all of
its Properties and assets to another Person, <U>unless</U> each of the following conditions are met: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no Default or Event of Default exists or would exist immediately following the consummation of such merger,
consolidation, amalgamation or conveyance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in a merger, consolidation or amalgamation of the Borrower with another Person or Persons, the Borrower is the
surviving entity; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a conveyance of Properties and assets, the Properties and assets conveyed do not consist of
substantially all of the Properties and assets of the Borrower and its Subsidiaries taken as a whole. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Liens; Sales and Leasebacks</U></B>. Create, incur, assume or suffer to exist any Lien of any nature upon
or with respect to any of their respective Properties, whether now owned or hereafter acquired, or engage in any sale and leaseback transaction with respect to its Property, <U>except</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Permitted Encumbrances; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens in favor of the Administrative Agent or the Banks under the Loan Documents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-52- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens existing on the date hereof and listed on <U>Schedule 6.3</U> and Liens on the same Property which secure
Indebtedness or obligations which replaces or refinances the Indebtedness (or commitment) or obligations originally secured by those Liens; <U>provided</U> that the Indebtedness or obligations secured thereby are not increased;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">pre-existing</FONT> Liens on assets acquired by the Borrower or any of its
Subsidiaries after the Effective Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">additional Liens securing Indebtedness or obligations (including sale and leaseback transactions to which the
Borrower or any Subsidiary is a party as vendor and lessee), the outstanding amount of which Indebtedness or obligation together with Indebtedness of the Borrower&#146;s Subsidiaries permitted under <U>Section</U><U></U><U>&nbsp;6.5</U>, does not in
the aggregate exceed 35% of Consolidated Net Worth (measured as of the last day of the most recently ended Fiscal Quarter). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Transactions with Affiliates</U></B>. Enter into any transaction of any kind which is material to the
Borrower and its Subsidiaries taken as a whole with any Affiliate of the Borrower <U>other than</U> (a)&nbsp;transactions between or among the Borrower and its Subsidiaries or between or among its Subsidiaries; provided that, for the purposes of
this <U>Section</U><U></U><U>&nbsp;6.4</U> the term &#147;Subsidiary&#148; shall include any partnership and joint venture that is excluded from the definition of the term &#147;Subsidiary&#148; but as to which the Borrower or Subsidiary owns 50% or
more of the ownership interests, (b)&nbsp;transactions on terms at least as favorable to the Borrower or its Subsidiaries as would be the case in an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction between unrelated parties of
equal bargaining power, and (c)&nbsp;transactions approved by a majority of the disinterested members of the Board of Directors of Borrower or the applicable Subsidiary. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Subsidiary Indebtedness</U></B>. Permit Indebtedness of the Borrower&#146;s Subsidiaries (other than
under this Agreement) at any time that, when aggregated (without duplication) with Indebtedness permitted to be secured by Liens in accordance with <U>Section</U><U></U><U>&nbsp;6.3(e)</U>, exceeds 35% of Consolidated Net Worth (measured as of the
last day of the most recently ended Fiscal Quarter). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Financial Covenant</U></B>. Permit the Consolidated Interest Coverage Ratio as of the end of any Fiscal
Quarter ended on or after the Initial Funding Date to be less than 3.50 to 1.00. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Use of Proceeds</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Use the proceeds of any Advance for the purpose of funding any activity or business in any Sanctioned Countries
or for the purpose of funding any prohibited activity or business of any Person located, organized or residing in any Sanctioned Country or who is a Sanctioned Person or, to the Borrower&#146;s knowledge, any person owned by or controlled by, or
acting for or on behalf of a Sanctioned Person, in any case, absent valid and effective licenses and permits issued by the relevant government sanctioning authorities described in <U>Section</U><U></U><U>&nbsp;4.16</U> (collectively, the
&#147;<B><U>Sanctioning Authorities</U></B>&#148;) or otherwise in accordance with applicable laws, or in any other manner that will result in any violation by any Bank or the Agent of the sanctions administered or enforced by the Sanctioning
Authorities; nor </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Use the proceeds of any Advance for the purpose of funding an offer, payment, promise to pay, or authorization
of the payment or giving of money, or anything else of value, to any Person, in violation of the FCPA (as defined in Section&nbsp;4.17). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-53- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information and Reporting Requirements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Financial and Business Information</U></B>. So long as any Advance remains unpaid, or any other
Obligation (other than indemnity obligations for which no claim has been made) remains unpaid or unperformed, or any portion of the Commitments remains in force, the Borrower shall, unless the Administrative Agent (with the approval of the Majority
Banks) otherwise consents in writing, deliver to the Banks and the Administrative Agent, at the Borrower&#146;s sole expense: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as practicable, and in any event within 45 days after the end of each Fiscal Quarter (other than the
fourth Fiscal Quarter in any Fiscal Year), (i) the consolidated balance sheets of the Borrower and its Subsidiaries as at the end of such Fiscal Quarter, (ii)&nbsp;consolidated statements of income and (iii)&nbsp;consolidated statements of cash
flow, in each case described in clauses (ii)&nbsp;and (iii) of this <U>Section</U><U></U><U>&nbsp;7.1(a)</U> of the Borrower and its Subsidiaries for such Fiscal Quarter and for the portion of the Fiscal Year ended with such Fiscal Quarter, all in
reasonable detail. Such financial statements shall be certified by a Senior Officer of the Borrower as fairly presenting the financial condition, results of operations and changes in financial position of the Borrower and its Subsidiaries in
accordance with Generally Accepted Accounting Principles (other than any requirement for footnote disclosures), as at such date and for such periods, subject only to normal <FONT STYLE="white-space:nowrap">year-end</FONT> accruals and audit
adjustments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as practicable, and in any event within 90 days after the end of each Fiscal Year, (i)&nbsp;the
consolidated balance sheets of the Borrower and its Subsidiaries as at the end of such Fiscal Year, (ii)&nbsp;consolidated statements of income of the Borrower and its Subsidiaries for such Fiscal Year and (iii)&nbsp;consolidated statements of cash
flow of the Borrower and its Subsidiaries for such Fiscal Year, all in reasonable detail. Such financial statements shall be prepared in accordance with Generally Accepted Accounting Principles, and such consolidated balance sheet and consolidated
statements shall be accompanied by a report and opinion of Ernst&nbsp;&amp; Young or other independent public accountants of recognized national standing selected by the Borrower, which report and opinion shall be prepared in accordance with
generally accepted auditing standards as at such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Promptly after the same are available, copies of each annual report, proxy or financial statement or other
report or communication sent to the shareholders of the Borrower generally, and copies of all annual, regular, periodic, current and special reports and registration statements which the Borrower or a Subsidiary of the Borrower may file or be
required to file under Sections 13 or 15(d) of the Securities Exchange Act of 1934; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Promptly, and in any event within five (5)&nbsp;Banking Days after a Senior Officer of the Borrower obtains
actual knowledge of the existence of any condition or event which constitutes a Default or Event of Default, written notice specifying the nature and period of existence thereof and specifying what action the Borrower or any of its Subsidiaries is
taking or proposes to take with respect thereto; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Promptly upon becoming aware of the occurrence of any ERISA Event defined in clauses (i)&nbsp;through (vii) or
(xi)&nbsp;of the definition thereof involving Title IV of ERISA that could reasonably be expected to result in material liability to the Borrower or its Subsidiaries or any ERISA Event that could reasonably be expected to result in a Material
Adverse Effect, a written notice specifying the nature thereof, what action the Borrower or any of its ERISA Affiliates has taken, is taking or proposes to take with respect thereto and, when known, any action taken or threatened by the Internal
Revenue Service, the Department of Labor or the PBGC with respect thereto; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-54- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With reasonable promptness, copies of (a)&nbsp;each Schedule SB (Actuarial Information) to the annual report,
if any (Form 5500 Series), filed by the Borrower or any of its Current ERISA Affiliates with the Internal Revenue Service with respect to each Pension Plan following the Administrative Agent&#146;s request; (b)&nbsp;all notices received by the
Borrower or any of its Current ERISA Affiliates from the sponsor of a Multiemployer Plan concerning an ERISA Event defined in clauses (i)&nbsp;through (vii) or (xi)&nbsp;of the definition thereof following the receipt thereof; and (c)&nbsp;such
other documents or governmental reports or filings relating to any Employee Benefit Plan as the Administrative Agent shall reasonably request; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promptly following any reasonable request therefor, provide information and documentation reasonably requested
by the Administrative Agent or any Bank for purposes of compliance with applicable &#147;know your customer&#148; and anti-money-laundering rules and regulations, including, without limitation, the Patriot Act and the Beneficial Ownership
Regulation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such other material information related to the Borrower&#146;s ability to meet its Obligations hereunder as
from time to time may be reasonably requested by the Administrative Agent or the Majority Banks. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Documents required to
be delivered pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> (to the extent any such documents are included in materials otherwise filed with or furnished to the Securities and Exchange Commission and available to the public may be delivered
electronically and if so delivered), shall be deemed to have been delivered for all purposes of this Agreement on the date (i)&nbsp;on which the Borrower posts such documents, or provides a link thereto on the Borrower&#146;s website on the Internet
at the website address listed on <U>Schedule 13.7</U>; or (ii)&nbsp;on which such documents are posted on the Borrower&#146;s behalf on IntraLinks/IntraAgency or another relevant website (including, without limitation, the EDGAR System), if any, to
which each Bank and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent). The Administrative Agent shall have no obligation to request the delivery or to maintain copies of
the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Borrower with any such request for delivery, and each Bank shall be solely responsible for requesting delivery to it or maintaining its
copies of such documents. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Compliance Certificates</U></B>. So long as any Advance remains unpaid, or any other Obligation (other
than indemnity obligations for which no claim has been made) remains unpaid or unperformed, or any portion of the Commitments remains outstanding, the Borrower shall, unless the Majority Banks otherwise consent, deliver to the Administrative Agent,
at the Borrower&#146;s sole expense, concurrently with the financial statements required pursuant to <U>Sections 7.1(a)</U> and 7.1(b), a Compliance Certificate signed by a Senior Officer of the Borrower, including calculations as set forth therein.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Conditions </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Conditions to Effectiveness</U></B>. This Agreement shall be effective on the first date (the
&#147;<B><U>Effective Date</U></B>&#148;) on which each of the following conditions precedent (unless the Administrative Agent, acting at the direction of the Banks, otherwise consents in writing) shall have been satisfied: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-55- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent shall have received all of the following, each of which shall be originals unless
otherwise specified, each in form and substance satisfactory to the Administrative Agent and the Banks: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">executed counterparts of this Agreement and the Fee Letter; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certified copy of the Certificate of Incorporation of the Borrower, together with a good standing certificate
from the Secretary of State of the State of incorporation of the Borrower and, to the extent generally available, a certificate or other evidence of good standing as to payment of any applicable franchise or similar taxes from the appropriate taxing
authority of such state, each dated a recent date on or prior to the Effective Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">copies of the Borrower&#146;s Bylaws, certified as of a recent date on or prior to the Effective Date by the
corporate secretary or an assistant secretary of the Borrower; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resolutions of the Board of Directors of the Borrower approving and authorizing the execution, delivery and
performance of this Agreement and the other Loan Documents to which the Borrower is a party, certified as of a recent date on or prior to the Effective Date by the corporate secretary or an assistant secretary of the Borrower as being in full force
and effect without modification or amendment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">signature and incumbency certificates of the officers of the Borrower executing this Agreement and the other
Loan Documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the favorable written opinion of Sullivan&nbsp;&amp; Cromwell LLP, counsel to the Borrower; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Certificate of a Senior Officer of the Borrower certifying that the conditions specified in <U>Sections
8.1(b)</U>, <U>8.1(c)</U>, and <U>8.1(d)</U> have been satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Effective Date, the representations and warranties of the Borrower contained in <U>Article 4</U>
(other than Sections 4.20 and 4.21) shall be true and correct. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Default shall have occurred and would be continuing on the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Senior Officer of the Borrower shall have certified to the Administrative Agent in a Certificate that the
Borrower will pay, during ordinary business hours in Los Angeles on the Effective Date, to the Arrangers and the Administrative Agent the fees payable on the Effective Date referred to in <U>Section</U><U></U><U>&nbsp;3.4</U> and the fees, costs and
expenses referred to in <U>Section</U><U></U><U>&nbsp;11.3</U> to the extent invoiced (if applicable) by the relevant person at least one day prior to the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent shall have a copy, certified by the Borrower and signed by a Senior Officer of the
Borrower as true and complete, of (i)&nbsp;the Agreed Form of Scheme Press Announcement and (ii)&nbsp;the executed Transaction Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-56- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent shall have received, so long as requested no less than 4 Banking Days prior to the
Effective Date, all documentation and other information required by regulatory authorities under applicable &#147;know your customer&#148; and anti-money laundering rules and regulations, including the Patriot Act, in each case relating to the
Borrower. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Administrative Agent shall notify the Borrower and the Banks of the Effective Date in writing promptly
upon such conditions precedent being satisfied, and such notice shall be conclusive and binding. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Conditions Precedent</U></B><B><U> to Each Funding Date</U></B>. Subject to <U>Sections 2.2</U> and
<U>2.3</U>, the obligation of each Bank to make an Advance on any Funding Date is subject to the receipt or satisfaction (or waiver in accordance with <U>Section</U><U></U><U>&nbsp;11.2</U>), as applicable, of the following conditions:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Effective Date shall have occurred. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Closing Date, if the Target Acquisition is effected by way of a Scheme, the Administrative Agent
shall have received: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Certificate of a Senior Officer of the Borrower certifying: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which the Scheme Circular was posted to the shareholders of the Target; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which the Scheme Press Announcement was issued; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which the High Court has sanctioned the Scheme; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the Scheme Circular, certified by a Senior Officer of the Borrower as a correct and complete copy;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the Scheme Press Announcement, certified by a Senior Officer of the Borrower as a correct and
complete copy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Closing Date, if the Target Acquisition is effected by way of a Takeover Offer, the Administrative
Agent shall have received: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Certificate of a Senior Officer of the Borrower certifying: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which the Takeover Offer Document was posted to the holders of the Target Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which the Offer Press Announcement was issued; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which the Takeover Offer became or was declared to be wholly unconditional; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the Takeover Offer Document, certified by a Senior Officer of the Borrower as a correct and complete
copy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the Offer Press Announcement, certified by a Senior Officer of the Borrower as a correct and complete
copy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On each Funding Date (A)&nbsp;(x) no Certain Funds Default is continuing and (y)&nbsp;the Certain Funds
Representations are true and correct (or, if a Certain Funds Representation does not include a materiality concept, true and correct in all material respects) as of such date and (B)&nbsp;the Administrative Agent shall have received a certificate of
the Borrower signed by a Senior Officer certifying as to the satisfaction of the condition set forth in the foregoing clause (A). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-57- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where (i)(A) the Target Acquisition is effected by way of a Scheme, the Target Acquisition shall have been, or
substantially concurrently with the occurrence of the Initial Funding Date shall be consummated in all material respects in accordance with the terms and conditions of both the Transaction Agreement and the Scheme Documents (it being understood that
substantially concurrently shall permit the payment of cash component of the Scheme Consideration being made within 14 days after the Scheme Effective Date) without giving effect to any amendment to the Scheme Documents or waiver thereof (except as
permitted by Section&nbsp;5.9(i)) and (B)&nbsp;the Administrative Agent shall have received a certificate of the Borrower signed by a Senior Officer certifying (1)&nbsp;as to the satisfaction of the condition set forth in the preceding clause (i)(A)
and (2)&nbsp;attaching a copy of the Court Order, a copy of the Required EGM Resolutions, certified as a true and correct copy received from Target or (ii)(A) the Target Acquisition is effected by way of a Takeover Offer, the Takeover Offer has
been, or substantially concurrently with the occurrence of the Initial Funding Date shall be consummated in all material respects in accordance with the terms and conditions of the Transaction Agreement and the Takeover Offer Document and shall have
become unconditional in all respects in accordance with the terms of the Transaction Agreement and the Takeover Offer Document (it being understood that substantially concurrently shall permit the payment of cash consideration for the tendered
Target Shares being made within 14 days of the Unconditional Date) without giving effect to any amendment to the Takeover Offer Document or waiver thereof (except as permitted by Section&nbsp;5.10(i)) and (B)&nbsp;the Administrative Agent shall have
received a certificate of the Borrower signed by a Senior Officer certifying as to the satisfaction of the condition set forth in the preceding clause (ii)(A). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent shall have received a Request for Loan in accordance with
<U>Section</U><U></U><U>&nbsp;2.2</U> or <U>2.3</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All fees then due and payable by the Borrower to the Administrative Agent, the Arrangers and the Banks under
the Loan Documents or pursuant to the Fee Letter shall be paid (either in advance of the Closing Date or out of the proceeds of the Advance on such Funding Date, at the Borrower&#146;s option) to the extent invoiced (if applicable) by the relevant
person at least three Banking Days prior to the Closing Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of each Funding Date, as applicable, solely with respect to the applicable Bank (without affecting the
condition to any other Bank&#146;s funding obligation hereunder), there shall not be in effect any applicable law or order in any jurisdiction of competent authority that permanently enjoins, prevents or prohibits the performance of its funding
obligation under <U>Section</U><U></U><U>&nbsp;2.1</U> (and the Bank agrees that as soon as reasonably practicable following becoming aware that any such event is pending or threatened, it shall notify the Borrower and as soon as reasonably
practicable consult with the Borrower about possible mitigants, as well as use commercially reasonable efforts to assign (prior to the expiry of the Certain Funds Period, with the prior written consent of the Borrower, not to be unreasonably
withheld or delayed) its Commitments to an Affiliate of such Bank that is not subject to such enjoinment, prevention or prohibition (to the extent not, in such Bank&#146;s good faith judgment, otherwise disadvantageous to such Bank), and provided
that such Bank shall, within 1 Banking Days&#146; notice from the Borrower, and subject to any applicable &#147;know your customer&#148; requirements, transfer its Commitment to any bank designated by the Borrower at par, together with fees accrued
up to the date of such transfer but at no other cost or expense to the Borrower, and with no entitlement to any fees that may be payable under the Loan Documents at any time after the date of such transfer). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-58- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Administrative Agent shall notify the Borrower and the Banks as soon as practicable upon
the satisfaction of the further conditions precedent in this <U>Section</U><U></U><U>&nbsp;8.2</U>, and such notice shall be conclusive and binding. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Actions by Banks During the Certain Funds Period</U></B>. During the Certain Funds Period and
notwithstanding (i)&nbsp;any provision to the contrary in the Loan Documents or (ii)&nbsp;that any condition set out in <U>Section</U><U></U><U>&nbsp;8.1</U> may subsequently be determined to not have been satisfied or any representation or warranty
given on the Effective Date was incorrect in any respect, none of the Banks nor the Agents shall, unless a Certain Funds Default has occurred and is continuing (neither remedied nor waived), be entitled to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cancel any of its Commitments (subject to any Commitment reductions made pursuant to
<U>Section</U><U></U><U>&nbsp;2.7</U>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(x) rescind, terminate, claim invalidity of or cancel the Loan Documents or the Commitments (subject to any
Commitment reductions made pursuant to <U>Section</U><U></U><U>&nbsp;2.7</U>), (y) exercise any similar right or remedy or (z)&nbsp;make or enforce any claim under the Loan Documents it may have to the extent, in this <U>clause (z)</U>, to do so
would prevent, delay, limit or adversely impact the making of an Advance for Certain Funds Purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">refuse to participate in the making of an Advance for Certain Funds Purposes unless the applicable conditions
set forth in <U>Section</U><U></U><U>&nbsp;8.2</U> have not been satisfied (or waived by the Majority Banks) as of the applicable date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise any right of <FONT STYLE="white-space:nowrap">set-off</FONT> or counterclaim in respect of an Advance
to the extent to do so would prevent, delay, limit or adversely impact the making of an Advance for Certain Funds Purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cancel, accelerate or cause repayment or prepayment of any amounts owing under any Loan Document;
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U> that immediately upon the expiry of the Certain Funds Period, but subject to any limitations set forth
herein, including with respect to the Borrower&#146;s remedies prior to the <FONT STYLE="white-space:nowrap">Clean-up</FONT> Date, all such rights, remedies and entitlements shall be available to the Banks and the Agents notwithstanding that they
may not have been used or been available for use during the Certain Funds Period. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Events of Default and Remedies upon Event of Default </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Events of Default</U></B>. The existence or occurrence of any one or more of the following events,
whatever the reason therefor and under any circumstances whatsoever, shall constitute an &#147;<B><U>Event of Default</U></B>&#148;: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower fails to pay any principal of any of the Loans, or any portion thereof, on the date when due; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower (i)&nbsp;fails to pay any interest on any of the Loans, or any portion thereof, or (ii)&nbsp;fails
to pay any other fee or amount payable to the Administrative Agent, the Banks under any Loan Document, or any portion thereof, in each case within five (5)&nbsp;Banking Days after demand therefor; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-59- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any failure to comply with <U>Section</U><U></U><U>&nbsp;7.1(d)</U>; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower fails to perform or observe any other covenant or agreement contained in any Loan Document on its
part to be performed or observed within thirty (30)&nbsp;days after the giving of notice by the Administrative Agent or the Majority Banks of such Default; <U>provided</U>, <U>however</U>, that (x)&nbsp;any failure to observe any of the covenants
contained in <U>Sections 5.2</U> (as it relates to the Borrower&#146;s existence) and <U>6.2</U> shall constitute an immediate Event of Default hereunder and (y)&nbsp;any failure to observe any of the covenants contained in
<U>Section</U><U></U><U>&nbsp;5.9</U>, <U>5.10</U>, <U>5.11</U> or <U>5.12</U> shall constitute an Event of Default upon a written notice in respect thereof on or prior to the Closing Date from the Administrative Agent to the Borrower;
<U>provided</U>, <U>further</U>, that any failure to observe any of the covenants contained in <U>Section</U><U></U><U>&nbsp;6.3</U> shall constitute an Event of Default upon notice from the Administrative Agent (acting on the direction of the
Majority Banks) to the Borrower; and <U>provided</U> <U>further</U> that any failure to observe any of the covenants contained in <U>Section</U><U></U><U>&nbsp;6.5 </U>shall constitute an Event of Default five (5)&nbsp;Banking Days after knowledge
by the Borrower of such Default (other than as a result of the giving of notice by the Administrative Agent or the Majority Banks as hereinafter provided) or, if earlier, the giving of notice by the Administrative Agent or the Majority Banks of such
Default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any representation or warranty made in this Agreement, any Notes, or any Request for Loan was incorrect in any
material respect when made or reaffirmed; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower or any of its Subsidiaries (i)&nbsp;fails to pay the principal, or any principal installment, or
any interest or fees or any other amount of any present or future Indebtedness (<U>other than</U> under the Loan Documents) in an amount in excess of $200,000,000, or any guaranty of present or future Indebtedness in an aggregate amount in excess of
$200,000,000, on its part to be paid, when due (and after expiration of any stated grace or notice period), whether at the stated maturity, upon acceleration, by reason of required prepayment or otherwise or (ii)&nbsp;fails to perform or observe any
other material term, covenant or agreement on its part to be performed or observed, or suffers any event to occur, and such failure or event continues after the applicable grace period, if any, and is not waived, in connection with any present or
future Indebtedness in an amount in excess of $200,000,000, or of any guaranty of present or future Indebtedness in excess of $200,000,000, if as a result of such failure or sufferance any holder or holders thereof (or an agent or trustee on its or
their behalf) has the right to declare such Indebtedness or guaranty due before the date on which it otherwise would become due; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Loan Document, at any time after its execution and delivery and for any reason other than the agreement of
the Banks or satisfaction in full of all the Obligations, ceases to be in full force and effect or is declared by a court of competent jurisdiction to be null and void, invalid or unenforceable in any respect which, in any such event in the
reasonable opinion of the Majority Banks, is materially adverse to the interests of the Banks; or the Borrower denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind same
(during the Certain Funds Period, in each case, in writing); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A judgment against the Borrower or any of its Subsidiaries is entered for the payment of money in excess of
$200,000,000 (to the extent not adequately covered by insurance as to which a solvent and unaffiliated insurance company has acknowledged coverage) and, absent procurement of a stay of execution, such judgment remains unstayed, unbonded or
unsatisfied for sixty (60)&nbsp;calendar days after the date of entry of judgment; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-60- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Borrower, Bidco or any Subsidiary of the Borrower, the Shareholders&#146; Equity of which, as shown on the
most recent consolidated balance sheet, equals or exceeds 10% of the Shareholders&#146; Equity of the Borrower and its Consolidated Subsidiaries as shown on such consolidated balance sheet, institutes or consents to any proceeding under a Debtor
Relief Law relating to it or to all or any substantial part of its Property, or is unable or admits in writing its inability to pay its debts as they mature, or makes an assignment for the benefit of creditors; or applies for or consents to the
appointment of any receiver, trustee, custodian, conservator, liquidator (or in the case of Bidco, an examiner), rehabilitator or similar officer for it or for all or any substantial part of its Property; or any receiver, trustee, custodian,
conservator, liquidator (or in the case of Bidco, an examiner), rehabilitator or similar officer is appointed without the application or consent of that Person and the appointment continues undischarged or unstayed for sixty (60)&nbsp;calendar days;
or any proceeding under a Debtor Relief Law relating to any such Person or to all or any part of its Property is instituted without the consent of that Person and continues undismissed or unstayed for sixty (60)&nbsp;calendar days; or any judgment,
writ, warrant of attachment or execution or similar process is issued or levied against all or any material part of the Property of any such Person and is not released, vacated or fully bonded within sixty (60)&nbsp;calendar days after its issue or
levy; or any order for relief shall be entered in respect of the Borrower or any such Subsidiary; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) Any Person or two or more Persons acting in concert shall acquire beneficial ownership (within the meaning
of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Securities and Exchange Commission under the Securities Exchange Act of 1934) directly or indirectly, of securities of the Borrower (or other securities convertible into such securities)
representing 30% or more of the combined voting power of all securities of the Borrower entitled to vote in the election of directors, other than securities having such power only by reason of the happening of a contingency; or (ii)&nbsp;during any
period of up to 12 consecutive months, commencing before or after the date of this Agreement, individuals who at the beginning of such <FONT STYLE="white-space:nowrap">12-month</FONT> period were directors of the Borrower, or whose nomination for
election to the Board of Directors of the Borrower was recommended or approved by a vote of at least a majority of the directors then still in office who were directors of the Borrower on the first day of such period, shall cease for any reason to
constitute a majority of the Board of Directors of the Borrower; <U>provided</U>, <U>however</U>, that there shall not be an Event of Default pursuant to subsection (i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;9.1(j)</U> with respect to any
Persons who on the date hereof meet the requirements set forth in said subsection (i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;9.1(j)</U>; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there shall occur one or more ERISA Events which individually or in the aggregate results in or might
reasonably be expected to result in liability of the Borrower, a Subsidiary or any of their ERISA Affiliates in excess of $200,000,000 during the term of this Agreement; or there shall exist an &#147;amount of unfunded benefit liabilities&#148; (as
defined in Section&nbsp;4001(a)(18) of ERISA), individually or in the aggregate for all Pension Plans with respect to which the Borrower or a Subsidiary has any financial liability, including potential joint and several liability in the event any
such Pension Plan were to terminate (excluding for purposes of such computation any Pension Plans with respect to which assets exceed benefit liabilities), which exceeds $200,000,000 and Majority Banks determine that such event could reasonably be
expected to have a Material Adverse Effect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-61- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Remedies Upon Event of Default</U></B>. Without limiting any other rights or remedies of the
Administrative Agent or the Banks provided for elsewhere in this Agreement, or the Loan Documents, or by applicable Law, or in equity, or otherwise (but subject in all respects to Section&nbsp;8.3): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the occurrence, and during the continuance, of any Event of Default other than an Event of Default
described in <U>Section</U><U></U><U>&nbsp;9.1(i) </U>with respect to the Borrower: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the commitment to make Advances and all other obligations of the Administrative Agent, the Banks and all rights
of the Borrower and any other parties under the Loan Documents shall be suspended without notice to or demand upon the Borrower, which are expressly waived by the Borrower, except, subject to <U>Section</U><U></U><U>&nbsp;9.2(a)(2)</U>, that the
Majority Banks (or all of the Banks to the extent required by <U>Section</U><U></U><U>&nbsp;11.2</U>) may waive the Event of Default or, without waiving, determine, upon terms and conditions satisfactory to the Majority Banks (or all of the Banks,
as the case may be), to reinstate the Commitments and make further Advances, which waiver or determination shall apply equally to, and shall be binding upon, all the Banks; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Majority Banks may request the Administrative Agent to, and the Administrative Agent thereupon shall,
terminate the Commitments and declare, by notice to the Borrower, all or any part of the unpaid principal of all Loans, all interest accrued and unpaid thereon and all other amounts payable under the Loan Documents to be forthwith due and payable,
whereupon the same shall become and be forthwith due and payable, without protest, presentment, notice of dishonor, demand or further notice of any kind, all of which are expressly waived by the Borrower. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the occurrence of any Event of Default described in <U>Section</U><U></U><U>&nbsp;9.1(i) </U>with respect
to the Borrower (but for the avoidance of doubt, subject to Section&nbsp;8.3): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the commitment to make Advances and all other obligations of the Administrative Agent or the Banks and all
rights of the Borrower and any other parties under the Loan Documents shall terminate without notice to or demand upon the Borrower, which are expressly waived by the Borrower; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the unpaid principal of all Loans, all interest accrued and unpaid thereon and all other amounts payable under
the Loan Documents shall be forthwith due and payable, without protest, presentment, notice of dishonor, demand or further notice of any kind, all of which are expressly waived by the Borrower. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the occurrence of any Event of Default, subject to clause (d)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;9.2</U>, the Banks and the Administrative Agent, or any of them, without notice to or demand upon the Borrower, which are expressly waived by the Borrower, may proceed to protect, exercise and enforce their rights and
remedies under the Loan Documents against the Borrower and any other party and such other rights and remedies as are provided by Law or equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The order and manner in which the Banks&#146; rights and remedies are to be exercised shall be determined by
the Majority Banks in their sole discretion, and all payments received by the Administrative Agent and the Banks, or any of them, shall be applied first to the costs and expenses (including attorneys&#146; fees and disbursements covered by
<U>Section</U><U></U><U>&nbsp;11.3</U>) of the Administrative Agent, acting as Administrative Agent, and of the Banks </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-62- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(to the extent covered by <U>Section</U><U></U><U>&nbsp;11.3)</U>, and thereafter paid pro rata to the Banks in the same proportions that the aggregate Obligations owed to each Bank under the
Loan Documents bear to the aggregate Obligations owed under the Loan Documents to all the Banks, without priority or preference among the Banks. Regardless of how each Bank may treat payments for the purpose of its own accounting, for the purpose of
computing the Borrower&#146;s Obligations hereunder and under the Notes, payments shall be applied <U>first</U>, to the costs and expenses of the Administrative Agent, acting as Administrative Agent, and the Banks, as set forth above, <U>second</U>,
to the payment of accrued and unpaid interest due under any Loan Documents to and including the date of such application (ratably, and without duplication, according to the accrued and unpaid interest due under each of the Loan Documents), and
<U>third</U>, to the payment of all other amounts (including principal and fees) then owing to the Administrative Agent or the Banks under the Loan Documents. No application of payments will cure any Event of Default, or prevent acceleration, or
continued acceleration, of amounts payable under the Loan Documents, or prevent the exercise, or continued exercise, of rights or remedies of the Banks hereunder or thereunder or at law or in equity. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the occurrence of an Event of Default resulting from or resulting in the default by the Borrower in the
repayment of its Term Rate Advances when required by the terms of this Agreement, the Borrower shall compensate each Bank in accordance with <U>Section</U><U></U><U>&nbsp;3.6(c)</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this Agreement to the contrary, for a period commencing on the Initial Funding Date and ending on the date falling
120 days after the Initial Funding Date (the &#147;<B><U><FONT STYLE="white-space:nowrap">Clean-up</FONT> Date</U></B>&#148;), notwithstanding any other provision of any Loan Document, any breach of covenants, misrepresentation or other default
which arises with respect to the Target and its Subsidiaries will be deemed not to be a breach of representation or warranty, a breach of covenant or an Event of Default, as the case may be, if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is capable of remedy and reasonable steps are being taken to remedy it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the circumstances giving rise to it have not knowingly been procured by the Borrower (and the Borrower&#146;s
knowledge of such circumstances does not of itself constitute procurement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is not reasonably likely to have a Material Adverse Effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the relevant circumstances are continuing on or after the <FONT STYLE="white-space:nowrap">Clean-up</FONT> Date, there shall be a breach of
representation or warranty, breach of covenant or Event of Default, as the case may be, notwithstanding the above. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Administrative Agent </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Appointment and Authority</U></B>. Each of the Banks hereby irrevocably appoints Citibank to act on its
behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof
or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this <U>Article 10</U> are solely for the benefit of the Administrative Agent and the Banks, and the Borrower shall have no rights as a third
party beneficiary of any of such provisions (except for the consents specifically required in Section&nbsp;10.6). It is understood and agreed that the use of the term &#147;agent&#148; herein or in any other Loan Document (or any other similar term)
with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead such term is used as a matter of market custom, and is
intended to create or reflect only an administrative relationship between contracting parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-63- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Rights as a Bank</U></B>. The Person serving as the Administrative Agent hereunder shall have the same
rights and powers in its capacity as a Bank as any other Bank and may exercise the same as though it were not the Administrative Agent and the term &#147;Bank&#148; or &#147;Banks&#148; shall, unless otherwise expressly indicated or unless the
context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in
any other advisory capacity for and generally engage in any kind of business with the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the
Banks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Exculpatory Provisions</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and
in the other Loan Documents, and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and
is continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall not have any duty to take any discretionary action or exercise any discretionary powers, except
discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Majority Banks (or such other number or percentage of the Banks as shall
be expressly provided for herein or in the other Loan Documents); <U>provided</U> that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to
liability or that is contrary to any Loan Document or applicable Law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or
termination of property of a Defaulting Bank in violation of any Debtor Relief Law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and
shall not be liable for the failure to disclose, any information relating to the Borrower or any of their Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent shall not be liable for any action taken or not taken by it (i)&nbsp;with the consent
or at the request of the Majority Banks (or such other number or percentage of the Banks as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in
<U>Section</U><U></U><U>&nbsp;11.2</U> and <U>Article 9</U>), or (ii)&nbsp;in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Administrative
Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent in writing by the Borrower or a Bank. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-64- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into
(i)&nbsp;any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii)&nbsp;the contents of any certificate, report or other document delivered hereunder or thereunder or in connection
herewith or therewith, (iii)&nbsp;the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv)&nbsp;the validity, enforceability, effectiveness or
genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or (v)&nbsp;the satisfaction of any condition set forth in <U>Article 8</U> or elsewhere herein, other than to confirm receipt of items expressly
required to be delivered to the Administrative Agent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Reliance by Administrative Agent</U></B>. The Administrative Agent shall be entitled to rely upon, and
shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it
to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and
shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, that by its terms must be fulfilled to the satisfaction of a Bank, the Administrative Agent may presume that such
condition is satisfactory to such Bank unless the Administrative Agent shall have received notice to the contrary from such Bank prior to the making of such Loan. The Administrative Agent may consult with legal counsel (who may be counsel for the
Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Delegation of Duties</U></B>. The Administrative Agent may perform any and all of its duties and exercise
its rights and powers hereunder or under any other Loan Document by or through any one or more <FONT STYLE="white-space:nowrap">sub-agents</FONT> appointed by the Administrative Agent. The Administrative Agent and any such <FONT
STYLE="white-space:nowrap">sub-agent</FONT> may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such <FONT
STYLE="white-space:nowrap">sub-agent</FONT> and to the Related Parties of the Administrative Agent and each such <FONT STYLE="white-space:nowrap">sub-agent,</FONT> and shall apply to their respective activities in connection with the syndication of
the Loans as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any <FONT STYLE="white-space:nowrap">sub-agents</FONT> except to the extent that a court of competent
jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such <FONT STYLE="white-space:nowrap">sub-agents.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Resignation of the Administrative Agent</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrative Agent may at any time, following the expiry of the Certain Funds Period, give notice of its
resignation to the Banks and the Borrower. Upon receipt of any such notice of resignation, the Majority Banks shall have the right, with the written consent of the Borrower (such consent not to be unreasonably withheld and not to be required if an
Event of Default has occurred and is continuing), to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such successor shall have been so
appointed by the Majority Banks and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Majority Banks) (the
&#147;<B><U>Resignation Effective Date</U></B>&#148;), then the retiring Administrative Agent may (but shall not be obligated to), on behalf of the Banks, appoint a successor Administrative Agent meeting the qualifications set forth above. Whether
or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-65- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Person serving as Administrative Agent is a Defaulting Bank pursuant to clause (v)&nbsp;of the
definition thereof, the Majority Banks may, to the extent permitted by applicable Law, by notice in writing to the Borrower (and, prior to the expiry of the Certain Funds Period, with the prior written consent of the Borrower, such consent not to be
unreasonably withheld or delayed) and such Person remove such Person as Administrative Agent and, with the written consent of the Borrower (such consent not to be unreasonably withheld and (following the expiry of the Certain Funds Period) not to be
required if an Event of Default has occurred and is continuing), appoint a successor. If no such successor shall have been so appointed by the Majority Banks and shall have accepted such appointment within 30 days (or such earlier day as shall be
agreed by the Majority Banks ) (the &#147;<B><U>Removal Effective Date</U></B>&#148;), then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Resignation Effective Date or the Removal Effective Date (as applicable)&nbsp;(1) the
retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (2)&nbsp;except for any indemnity payments owed to the retiring or removed Administrative Agent, all
payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Bank directly, until such time, if any, as the Majority Banks appoint a successor Administrative Agent as
provided for above. Upon the acceptance of a successor&#146;s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed
Administrative Agent (other than any rights to indemnity payments owed to the retiring or removed Administrative Agent, as of the Resignation Effective Date or the Removal Effective Date, as applicable) and the retiring or removed Administrative
Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this <U>Section</U><U></U><U>&nbsp;10.6</U>). The fees payable by the Borrower to
a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring or removed Administrative Agent&#146;s resignation or removal hereunder and
under the other Loan Documents, the provisions of this <U>Article 10</U> and <U>Sections 11.3</U> and <U>11.12</U> shall continue in effect for the benefit of such retiring or removed Administrative Agent, its
<FONT STYLE="white-space:nowrap">sub-agents</FONT> and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring or removed Administrative Agent was acting as Administrative Agent.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U><FONT STYLE="white-space:nowrap">Non-Reliance</FONT> on Administrative Agent and Other Banks</U></B>.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Bank acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Banks
or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Bank also acknowledges that it will, independently and without
reliance upon the Administrative Agent or any other Bank or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action
under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-66- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Right to Indemnity</U></B>. To the extent that the Borrower for any reason fails to indefeasibly pay any
amount required under Section&nbsp;11.12 to be paid by it to the Administrative Agent, its directors, officers, agents, employees, attorneys and Affiliates, each Bank shall, ratably in accordance with its ratable share (based on the Commitments and
Loans held by each Bank), indemnify and hold the Administrative Agent, its directors, officers, agents, employees, attorneys and Affiliates harmless against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits,
costs, expenses or disbursements of any kind or nature whatsoever (including, without limitation, reasonable attorneys&#146; fees and disbursements) that may be imposed on, incurred by or asserted against them in any way relating to or arising out
of the Loan Documents (other than losses incurred by reason of the failure of the Borrower to pay the Obligations represented by the Loan Documents) or any action taken or not taken by it as Administrative Agent thereunder, except such as result
from its own gross negligence or willful misconduct. Without limitation on the foregoing, each Bank shall reimburse the Administrative Agent upon demand for that Bank&#146;s ratable share of any cost or expense incurred by the Administrative Agent
in connection with the negotiation, preparation, execution, delivery, amendment, waiver, restructuring, reorganization (including a bankruptcy reorganization), enforcement or attempted enforcement of the Loan Documents, to the extent that the
Borrower or any other party is required by <U>Section</U><U></U><U>&nbsp;11.3</U> to pay that cost or expense but fails to do so upon demand. Nothing in this Section shall entitle the Administrative Agent to recover any amount from the Banks if and
to the extent that such amount has theretofore been recovered from the Borrower or any of its Subsidiaries. The undertaking in this Section shall survive termination of the Commitments, the payment of all other Obligations and the resignation of the
Administrative Agent. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Other Duties, etc</U></B>. Anything herein to the contrary notwithstanding, none of the Persons acting
as Arrangers or Syndication Agent listed on the cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent or as a
Bank hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Bank ERISA Matters</U></B>. (a)&nbsp;Each Bank (x)&nbsp;represents and warrants, as of the date such
Person became a Bank party hereto, to, and (y)&nbsp;covenants, from the date such Person became a Bank party hereto to the date such Person ceases being a Bank party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of
doubt, to or for the benefit of the Borrower or any other Borrower, that at least one of the following is and will be true: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such Bank is not using &#147;plan assets&#148; (within the meaning of Section&nbsp;3(42) of ERISA or otherwise)
of one or more Benefit Plans with respect to such Bank&#146;s entrance into, participation in, administration of and performance of the Loans, the Commitments or this Agreement, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transaction exemption set forth in one or more PTEs, such as PTE
<FONT STYLE="white-space:nowrap">84-14</FONT> (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE <FONT STYLE="white-space:nowrap">95-60</FONT> (a class exemption for certain transactions
involving insurance company general accounts), PTE <FONT STYLE="white-space:nowrap">90-1</FONT> (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE <FONT STYLE="white-space:nowrap">91-38</FONT> (a
class exemption for certain transactions involving bank collective investment funds) or PTE <FONT STYLE="white-space:nowrap">96-23</FONT> (a class exemption for certain transactions determined by <FONT STYLE="white-space:nowrap">in-house</FONT>
asset managers), is applicable with respect to such Bank&#146;s entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-67- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) such Bank is an investment fund managed by a &#147;Qualified Professional Asset Manager&#148; (within the
meaning of Part VI of PTE <FONT STYLE="white-space:nowrap">84-14),</FONT> (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Bank to enter into, participate in, administer and perform the Advances, the
Commitments and this Agreement, (C)&nbsp;the entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement satisfies the requirements of <FONT STYLE="white-space:nowrap">sub-sections</FONT>
(b)&nbsp;through (g) of Part I of PTE <FONT STYLE="white-space:nowrap">84-14</FONT> and (D)&nbsp;to the best knowledge of such Bank, the requirements of subsection (a)&nbsp;of Part I of PTE <FONT STYLE="white-space:nowrap">84-14</FONT> are satisfied
with respect to such Bank&#146;s entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent,
in its sole discretion, and such Bank. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition, unless either <FONT STYLE="white-space:nowrap">(1)&nbsp;sub-clause</FONT> (i)&nbsp;in the
immediately preceding clause (a)&nbsp;is true with respect to a Bank or (2)&nbsp;a Bank has provided another representation, warranty and covenant in accordance with <FONT STYLE="white-space:nowrap">sub-clause</FONT> (iv)&nbsp;in the immediately
preceding clause (a), such Bank further (x)&nbsp;represents and warrants, as of the date such Person became a Bank party hereto, to, and (y)&nbsp;covenants, from the date such Person became a Bank party hereto to the date such Person ceases being a
Bank party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Borrower, that the Administrative Agent is not a fiduciary with respect to the assets of such Bank involved in such
Bank&#146;s entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this
Agreement, any Loan Document or any documents related hereto or thereto). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Erroneous Payment</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Administrative Agent (x)&nbsp;notifies a Bank or any Person who has received funds on behalf of a Bank
(any such Bank or other recipient, a &#147;<B><U>Payment Recipient</U></B>&#148;) that the Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under immediately succeeding clause (b)) that any funds
received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Bank or other Payment
Recipient on its behalf) (any such funds, whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an &#147;<B><U>Erroneous Payment</U></B>&#148;) and
(y)&nbsp;demands in writing the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Administrative Agent and shall be segregated by the Payment Recipient pending its return or
repayment as contemplated below in this Section&nbsp;10.11 and held in trust for the benefit of the Administrative Agent, and such Bank shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment
Recipient to) promptly, but in no event later than two Banking Days thereafter (or such later date as the Administrative Agent may, in its sole discretion, specify in writing), return to the Administrative Agent the amount of any such Erroneous
Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon (except to the extent waived in writing by the Administrative Agent) in respect of each day from and
including the date such Erroneous Payment (or portion thereof) was received by such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-68- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the Federal Funds Effective Rate and a rate determined by the Administrative
Agent in accordance with banking industry rules on interbank compensation from time to time in effect. A notice of the Administrative Agent to any Payment Recipient under this clause (a)&nbsp;shall be conclusive, absent manifest error.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting immediately preceding clause (a), each Bank or any Person who has received funds on behalf of
a Bank hereby further agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its
Affiliates)&nbsp;(x) that is in a different amount than, or on a different date from, that specified in this Agreement or in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to
such payment, prepayment or repayment, (y)&nbsp;that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z)&nbsp;that such Bank, or other such recipient,
otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part), then in each case: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) it acknowledges and agrees that (A)&nbsp;in the case of immediately preceding clauses (x)&nbsp;or (y), an error and mistake shall be
presumed to have been made (absent written confirmation from the Administrative Agent to the contrary) or (B)&nbsp;an error and mistake has been made (in the case of immediately preceding clause (z)), in each case, with respect to such payment,
prepayment or repayment; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) such Bank shall (and shall cause any other recipient that receives funds on its respective behalf to)
promptly (and, in all events, within one Banking Day of its knowledge of the occurrence of any of the circumstances described in the immediately preceding clauses (x), (y) and (z)) notify the Administrative Agent of its receipt of such payment,
prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying the Administrative Agent pursuant to this Section&nbsp;10.11(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the failure to deliver a notice to the Administrative Agent pursuant to this Section&nbsp;10.11(b) shall not have
any effect on a Payment Recipient&#146;s obligations pursuant to Section&nbsp;10.11(a) or on whether or not an Erroneous Payment has been made. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Bank hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time
owing to such Bank under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Bank under any Loan Document with respect to any payment of principal, interest, fees or other amounts against any amount due to
the Administrative Agent under immediately preceding clause (a). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) In the event that an Erroneous Payment (or portion thereof) is not recovered by the Administrative Agent
for any reason, after demand therefor in accordance with immediately preceding clause (a), from any Bank that has received such Erroneous Payment (or portion thereof) (and/or from any Payment Recipient who received such Erroneous Payment (or portion
thereof) on its respective behalf) (such unrecovered amount, an &#147;<B><U>Erroneous Payment Return Deficiency</U></B>&#148;), upon the Administrative Agent&#146;s notice to such Bank at any time, then effective immediately (with the consideration
therefor being acknowledged by the parties hereto), (A) such Bank shall be deemed to have assigned its Loans (but not its Commitments) with respect to which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-69- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such Erroneous Payment was made (the &#147;<B><U>Erroneous Payment Impacted Class</U></B>&#148;) in an amount equal to the Erroneous Payment Return Deficiency (or such lesser amount as the
Administrative Agent may specify) (such assignment of the Loans (but not Commitments) of the Erroneous Payment Impacted Class, the &#147;<B><U>Erroneous Payment Deficiency Assignment</U></B>&#148;) (on a cashless basis and such amount calculated at
par plus any accrued and unpaid interest (with the assignment fee to be waived by the Administrative Agent in such instance)), and is hereby (together with the Borrower) deemed to execute and deliver an Assignment Agreement (or, to the extent
applicable, an agreement incorporating an Assignment Agreement by reference pursuant to a Platform as to which the Administrative Agent and such parties are participants) with respect to such Erroneous Payment Deficiency Assignment, and such Bank
shall deliver any Notes evidencing such Loans to the Borrower or the Administrative Agent (but the failure of such Person to deliver any such Notes shall not affect the effectiveness of the foregoing assignment), (B) the Administrative Agent as the
assignee Bank shall be deemed to acquire the Erroneous Payment Deficiency Assignment, (C)&nbsp;upon such deemed acquisition, the Administrative Agent as the assignee Bank shall become a Bank hereunder with respect to such Erroneous Payment
Deficiency Assignment and the assigning Bank shall cease to be a Bank hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for the avoidance of doubt, its obligations under the indemnification provisions of this
Agreement and its applicable Commitments which shall survive as to such assigning Bank, (D)&nbsp;the Administrative Agent and the Borrower shall each be deemed to have waived any consents required under this Agreement to any such Erroneous Payment
Deficiency Assignment, and (E)&nbsp;the Administrative Agent will reflect in the Register its ownership interest in the Loans subject to the Erroneous Payment Deficiency Assignment. For the avoidance of doubt, no Erroneous Payment Deficiency
Assignment will reduce the Commitments of any Bank and such Commitments shall remain available in accordance with the terms of this Agreement. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) Subject to Section&nbsp;11.9 (but excluding, in all events, any assignment consent or approval requirements (whether from the Borrower or
otherwise)), the Administrative Agent may, in its discretion, sell any Loans acquired pursuant to an Erroneous Payment Deficiency Assignment and upon receipt of the proceeds of such sale, the Erroneous Payment Return Deficiency owing by the
applicable Bank shall be reduced by the net proceeds of the sale of such Loan (or portion thereof), and the Administrative Agent shall retain all other rights, remedies and claims against such Bank (and/or against any recipient that receives funds
on its respective behalf). In addition, an Erroneous Payment Return Deficiency owing by the applicable Bank (x)&nbsp;shall be reduced by the proceeds of prepayments or repayments of principal and interest, or other distribution in respect of
principal and interest, received by the Administrative Agent on or with respect to any such Loans acquired from such Bank pursuant to an Erroneous Payment Deficiency Assignment (to the extent that any such Loans are then owned by the Administrative
Agent) and (y)&nbsp;may, in the sole discretion of the Administrative Agent, be reduced by any amount specified by the Administrative Agent in writing to the applicable Bank from time to time. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereto agree that (x)&nbsp;irrespective of whether the Administrative Agent may be equitably
subrogated, in the event that an Erroneous Payment (or portion thereof) is not recovered from any Payment Recipient that has received such Erroneous Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the
rights and interests of such Payment Recipient (and, in the case of any Payment Recipient who has received funds on behalf of a Bank, to the rights and interests of such Bank) under the Loan Documents with respect to such amount (the
&#147;<B><U>Erroneous </U></B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-70- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
<B><U>Payment Subrogation Rights</U></B>&#148;) (provided that the Obligations under the Loan Documents in respect of the Erroneous Payment Subrogation Rights shall not be duplicative of such
Obligations in respect of Loans that have been assigned to the Administrative Agent under an Erroneous Payment Deficiency Assignment) and (y)&nbsp;an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed
by the Borrower or any other guarantor; provided that this <U>Section</U><U></U><U>&nbsp;10.11</U> shall not be interpreted to increase (or accelerate the due date for), or have the effect of increasing (or accelerating the due date for), the
Obligations of the Borrower relative to the amount (and/or timing for payment) of the Obligations that would have been payable had such Erroneous Payment not been made by the Administrative Agent; provided, further, that for the avoidance of doubt,
immediately preceding clauses (x)&nbsp;and (y) shall not apply to the extent any such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the
Borrower for the purpose of making such Erroneous Payment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous
Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of <FONT STYLE="white-space:nowrap">set-off</FONT> or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the
return of any Erroneous Payment received, including, without limitation, any defense based on &#147;discharge for value&#148; or any similar doctrine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party&#146;s obligations, agreements and waivers under this <U>Section</U><U></U><U>&nbsp;10.11</U> shall
survive the resignation or replacement of the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Bank, the termination of the Commitments and/or the repayment, satisfaction or discharge of all Obligations (or
any portion thereof) under any Loan Document. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Miscellaneous </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Cumulative Remedies; No Waiver</U></B>. The rights, powers, privileges and remedies of the Administrative
Agent and the Banks provided herein or in any Note or other Loan Document are cumulative and not exclusive of any right, power, privilege or remedy provided by Law or equity. No failure or delay on the part of the Administrative Agent or any Bank in
exercising any right, power, privilege or remedy may be, or may be deemed to be, a waiver thereof; nor may any single or partial exercise of any right, power, privilege or remedy preclude any other or further exercise of the same or any other right,
power, privilege or remedy. The terms and conditions of <U>Article 8</U> hereof are inserted for the sole benefit of the Administrative Agent and the Banks; the same may be waived in whole or in part, with or without terms or conditions, in respect
of any Loan without prejudicing the Administrative Agent&#146;s or the Banks&#146; rights to assert them in whole or in part in respect of any other Loan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Amendments; Consents</U></B>. No amendment, modification, supplement, extension, termination or waiver of
any provision of this Agreement or any other Loan Document, no approval or consent thereunder, and no consent to any departure by the Borrower or any other party therefrom, may in any event be effective unless the same shall be in writing and signed
by the Majority Banks (or signed by the Administrative Agent at the direction of the Majority Banks) (and, in the case of amendments, modifications or supplements of or to any Loan Document to which a Borrower is a party, the approval in writing of
the Borrower), and then only in the specific instance and for the specific purpose given; and, without the approval in writing of all the Banks directly and adversely affected by such amendment, modification, supplement, termination, waiver or
consent, no amendment, modification, supplement, termination, waiver or consent may be effective: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-71- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To increase any Bank&#146;s Commitment, extend scheduled payment dates of any Loan or Note beyond the Maturity
Date, or reduce the rate of interest (other than any waiver of any increase in the interest rate applicable to any of the Loans pursuant to <U>Section</U><U></U><U>&nbsp;3.7</U>) or fees in respect of the Commitments or the Loans, or extend the time
of payment of principal, interest or fees, or reduce the principal amount of the Obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To amend or modify the provisions of the definitions of &#147;Maturity Date&#148;, or &#147;Majority
Banks&#148; or of this Section; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To amend or modify any provision of this Agreement that expressly requires the consent or approval of all the
Banks. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, no amendment, modification, supplement, termination, waiver or consent shall, unless in writing and
signed by the Administrative Agent in addition to the Banks required above to take such action, affect the rights or duties of the Administrative Agent acting in such capacity under this Agreement or any Note. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Costs, Expenses and Taxes</U></B>. The Borrower shall pay on demand the reasonable costs and expenses
(a)&nbsp;of each Arranger, the Administrative Agent and the Syndication Agent in connection with the negotiation, preparation, execution and delivery of the Loan Documents (including, without limitation, the reasonable legal fees and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses of Davis Polk&nbsp;&amp; Wardwell LLP and Mason Hayes&nbsp;&amp; Curran LLP), (b) if a Borrower requests the amendment, waiver, supplement or
modification the Loan Documents, of the Administrative Agent in connection with any such amendment, waiver, supplement or modification (including, without limitation, the reasonable legal fees and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses of counsel to the Administrative Agent), and (c)&nbsp;if any Event of Default has occurred and is continuing, of the Administrative Agent and the Banks in connection with any workout,
restructuring, reorganization (<U>including</U> a bankruptcy reorganization) and in any event enforcement or attempted enforcement of the Loan Documents, and any matter related thereto, <U>including</U>, without limitation, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and the reasonable fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses of any legal counsel,
independent public accountants and other outside experts retained by the Administrative Agent or any Bank, and <U>including</U>, without limitation, any costs, expenses or fees incurred or suffered by the Administrative Agent or any Bank in
connection with or during the course of any bankruptcy or insolvency proceedings of the Borrower or any Subsidiary thereof. The Borrower shall pay any and all costs, expenses, fees and charges payable or determined to be payable in connection with
the filing or recording of this Agreement, any other Loan Document or any other instrument or writing to be delivered hereunder or thereunder, or in connection with any transaction pursuant hereto or thereto, and shall reimburse, hold harmless and
indemnify the Arrangers, the Administrative Agent, the Syndication Agent and the Banks from and against any and all loss, liability or legal or other expense with respect to or resulting from any delay in paying or failure to pay any such tax, cost,
expense, fee or charge or that any of them may suffer or incur by reason of the failure of any party (other than any Arranger, the Administrative Agent, the Syndication Agent or any Bank) to perform any of its Obligations. This
<U>Section</U><U></U><U>&nbsp;11.3</U> shall not apply to the extent that any loss, liability or expense relates to any Taxes (including withholding Taxes and Other Taxes) for which there may be an indemnification, reimbursement or other payment
obligation imposed on the Borrower pursuant to any other provision of this Agreement (including, without limitation, <U>Section</U><U></U><U>&nbsp;3.10</U>). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-72- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Obligation to Make Payments in Dollars</U></B>. The obligation of the Borrower to make payments in
Dollars of the principal and interest becoming due and payable on each Loan, and to pay all other Obligations hereunder in Dollars, (i)&nbsp;shall not be discharged or satisfied by any tender, or any recovery pursuant to any judgment, which is
expressed in or converted into any currency other than Dollars, except to the extent that such tender or recovery shall result in the actual receipt by the Administrative Agent and the Banks of the full amount of Dollars, expressed to be payable in
respect of the principal and interest of each Loan and in respect of each other Obligation, (ii)&nbsp;shall be enforceable as an alternative or additional cause of action for the purpose of recovering in Dollars, the amount, if any, by which such
actual receipt shall fall short of the full amount of Dollars so expressed to be payable and (iii)&nbsp;shall not be affected by judgment being obtained for any other sum due under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Nature of Banks</U></B><B><U>&#146;</U></B><B><U> Obligations</U></B>. The obligations of the Banks
hereunder are several and not joint or joint and several. Nothing contained in this Agreement or any other Loan Document and no action taken by the Administrative Agent or the Banks or any of them pursuant hereto or thereto may, or may be deemed to,
make the Banks a partnership, an association, a joint venture or other entity, either among themselves or with the Borrower or any Affiliate of the Borrower. Each Bank&#146;s obligation to make any Advance pursuant hereto is several and not joint or
joint and several, and is not conditioned upon the performance by all other Banks of their obligations to make Advances. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Survival</U></B>. All representations and warranties contained herein or in any other Loan Document, or
in any certificate or other writing delivered by or on behalf of any one or more of the parties to any Loan Document, will survive the making of the Advances hereunder and the execution and delivery of the Notes, and have been or will be relied upon
by the Administrative Agent and each Bank, notwithstanding any investigation made by the Administrative Agent or any Bank or on their behalf. The obligations of the Borrower under <U>Sections 3.5</U> and <U>3.6</U> shall survive for thirty
(30)&nbsp;days following the termination of this Agreement and the repayment of the Notes. The obligations of the Borrower under <U>Sections 11.3</U> and <U>11.12</U> shall survive the termination of this Agreement and the repayment of the Notes,
<U>provided</U>, <U>however</U>, that such obligations shall not, from and after the termination of this Agreement, be deemed to be Obligations for any purpose under the Loan Documents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Notices and Other Communications; Facsimile Copies</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices General</U>. Except in the case of notices and other communications expressly permitted to be given
by telephone (and except as provided in paragraph (b)&nbsp;below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or
sent by facsimile or other electronic communication as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if to the Borrower, or the Administrative Agent, to the address, facsimile number, electronic mail address or
telephone number specified for such Person on <U>Schedule 13.7</U> or to such other address, facsimile number, electronic mail address or telephone number as shall be designated by such party in a notice to the other parties; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if to any other Bank, to the address, facsimile number, electronic mail address or telephone number specified
in its Administrative Questionnaire. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Notices sent by hand or overnight courier service, or mailed by certified or
registered mail, shall be deemed to have been given when received; notices sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given
at the opening of business on the next business day for the recipient). Notices delivered through electronic communications, to the extent provided in paragraph (b)below, shall be effective as provided in said paragraph (b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-73- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Electronic Communications</U>. Notices and other communications to the Banks hereunder may be delivered or
furnished by electronic communication (including <FONT STYLE="white-space:nowrap">e-mail</FONT> and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall not apply to notices to
any Bank pursuant to Article 2 if such Bank, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article 2 by electronic communication. The Administrative Agent or the Borrower may, in its
discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it; provided that approval of such procedures may be limited to particular notices or communications.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Unless the Agent otherwise prescribes, (i)&nbsp;notices and other communications sent to an <FONT
STYLE="white-space:nowrap">e-mail</FONT> address shall be deemed received upon the sender&#146;s receipt of an acknowledgement from the intended recipient (such as by the &#147;return receipt requested&#148; function, as available, return <FONT
STYLE="white-space:nowrap">e-mail</FONT> or other written acknowledgement), and (ii)&nbsp;notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its <FONT
STYLE="white-space:nowrap">e-mail</FONT> address as described in the foregoing clause (i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;11.7(b)</U>, of notification that such notice or communication is available and identifying the website address
therefor; provided that, for both clauses (i)&nbsp;and (ii) of this <U>Section</U><U></U><U>&nbsp;11.7(b)</U>, if such notice, email or other communication is not sent during the normal business hours of the recipient, such notice or communication
shall be deemed to have been sent at the opening of business on the next business day for the recipient. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Change of Address, etc</U>. Any party hereto may change its address or facsimile number for notices and
other communications hereunder by notice to the other parties hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of the Borrower agrees that the Administrative Agent may, but shall not be obligated to, make the
Communications available to the Banks by posting the Communications on DebtDomain, Intralinks, Syndtrak or a substantially similar electronic transmission systems (the &#147;<B><U>Platform</U></B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">THE PLATFORM IS PROVIDED &#147;AS IS&#148; AND &#147;AS AVAILABLE&#148;. THE AGENT PARTIES (AS DEFINED BELOW)
DO NOT WARRANT THE ACCURACY OF THE PLATFORM AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS OR OMISSIONS IN THE COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY THE AGENT PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE PLATFORM. IN NO
EVENT SHALL THE ADMINISTRATIVE AGENT OR ANY OF ITS AFFILIATES OR ANY OF THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, ADVISORS OR REPRESENTATIVES (COLLECTIVELY, &#147;<B><U>AGENT </U></B>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-74- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<B><U>PARTIES</U></B>&#148;) HAVE ANY LIABILITY TO THE BORROWER, ANY BANK OR ANY OTHER PERSON OR ENTITY FOR DAMAGES OF ANY KIND, INCLUDING, WITHOUT LIMITATION, DIRECT OR INDIRECT, SPECIAL,
INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF THE BORROWER&#146;S OR THE ADMINISTRATIVE AGENT&#146;S TRANSMISSION OF COMMUNICATIONS THROUGH THE PLATFORM. &#147;Communications&#148;
means, collectively, any notice, demand, communication, information, document or other material that the Borrower provides to the Administrative Agent pursuant to any Loan Document or the transactions contemplated therein which is distributed to the
Administrative Agent or any Bank by means of electronic communications pursuant to this Section, including through the Platform. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Execution of Loan Documents</U></B>. Unless the Administrative Agent otherwise specifies with respect to
any Loan Document, this Agreement and any other Loan Document may be executed in any number of counterparts and any party hereto or thereto may execute any counterpart, each of which when executed and delivered will be deemed to be an original and
all of which counterparts of this Agreement or any other Loan Document, as the case may be, when taken together will be deemed to be but one and the same instrument. The execution of this Agreement or any other Loan Document by any party hereto or
thereto will not become effective until counterparts hereof or thereof, as the case may be, have been executed by all the parties hereto or thereto. The words &#147;delivery,&#148; &#147;execution,&#148; &#147;execute,&#148; &#147;signed,&#148;
&#147;signature,&#148; and words of like import in or related to any document to be signed in connection with this Agreement, the other Loan Documents and the transactions contemplated hereby or thereby shall be deemed to include electronic
signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and
enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in
Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Binding Effect; Assignment; Entire Agreement</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement and the other Loan Documents shall be binding upon and shall inure to the benefit of the parties
hereto and thereto and their respective successors and assigns, except that the Borrower and/or its Affiliates may not assign their rights hereunder or thereunder or any interest herein or therein without the prior written consent of all the Banks.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignments by Banks</B>. Any Bank may at any time assign to one or more assignees all or a portion of its
rights and obligations under this Agreement (including all or a portion of its Commitments and Loans at the time owing to it); <U>provided</U> that any such assignment shall be subject to the following conditions: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Minimum Amounts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an assignment of the entire remaining amount of the assigning Bank&#146;s Commitments and/or the
Loans at the time owing to it or contemporaneous assignments to related Approved Funds that equal at least the amount specified in <U>Section</U><U></U><U>&nbsp;11.9(b)(i)(B)</U> in the aggregate or in the case of an assignment to a Bank, an
Affiliate of a Bank or an Approved Fund, no minimum amount need be assigned; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-75- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any case not described in <U>Section</U><U></U><U>&nbsp;11.9(b)(i)(A)</U>, the aggregate amount of the
Commitments (which for this purpose includes Loans outstanding thereunder) or, if the Commitments are not then in effect, the principal outstanding balance of the Advances of the assigning Bank subject to each such assignment (determined as of the
date the Assignment Agreement with respect to such assignment is delivered to the Administrative Agent or, if &#147;Trade Date&#148; is specified in the Assignment Agreement, as of the Trade Date) shall not be less than $5,000,000 and assigned
amounts must be in increments of $1,000,000 unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents in writing (each such consent not to be unreasonably withheld or
delayed). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Proportionate Amounts</U>. Each partial assignment shall be made as an assignment of a proportionate part of
all the assigning Bank&#146;s rights and obligations under this Agreement with respect to the Loan or the Commitments assigned. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Required Consents</U>. No consent shall be required for any assignment except to the extent required by
<U>Section</U><U></U><U>&nbsp;11.9(b)(i)(B)</U> and, in addition: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the written consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required
unless (x) (other than during the Certain Funds Period) an Event of Default under Section&nbsp;9.1(a), (b) or (i)&nbsp;has occurred and is continuing at the time of such assignment, (y) (during the Certain Funds Period), a Certain Funds Default has
occurred and is continuing at the time of such assignment, or (z) (other than during the Certain Funds Period) such assignment is to a Bank, an Affiliate of a Bank or an Approved Fund (provided in each case that reasonable notice thereof shall have
been given to the Borrower and Administrative Agent); <U>provided</U> that it is agreed that, notwithstanding the foregoing, during the Certain Funds Period, the Borrower may withhold such consent in its sole discretion unless such assignment is
from a Bank to one or more of its Affiliate(s) (in which case, provided that reasonable notice thereof shall have been given to the Borrower, such consent shall not be unreasonably withheld or delayed by the Borrower); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the written consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall
be required if such assignment is to a Person that is not a Bank, an Affiliate of such Bank or an Approved Fund. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignment and Assumption</U>. The parties to each assignment shall execute and deliver to the
Administrative Agent an Assignment Agreement, together with a processing and recordation fee of $3,500; <U>provided</U> that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any
assignment. The assignee, if it is not a Bank, shall deliver to the Administrative Agent an Administrative Questionnaire. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-76- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Assignment to Certain Persons</U>. No such assignment shall be made to (A)&nbsp;the Borrower or the
Borrower&#146;s Affiliates or Subsidiaries or (B)&nbsp;to any Defaulting Bank or Potential Defaulting Bank or any of their respective Subsidiaries, or any Person who, upon becoming a Bank hereunder, would constitute any of the foregoing Persons
described in this clause (B). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Assignment to Natural Persons</U>. No such assignment shall be made to a natural Person.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Provision of Tax Forms</U>. The documentation required by <U>Section</U><U></U><U>&nbsp;11.27</U> with
respect to such assignee shall have been provided to the Borrower and the Administrative Agent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Certain Additional Payments</U>. In connection with any assignment of rights and obligations of any
Defaulting Bank hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an
aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the
Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Bank, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x)&nbsp;pay and satisfy
in full all payment liabilities then owed by such Defaulting Bank to the Administrative Agent and each other Bank hereunder (and interest accrued thereon), and (y)&nbsp;acquire (and fund as appropriate) its full pro rata share of all Loans.
Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Bank hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of
such interest shall be deemed to be a Defaulting Bank for all purposes of this Agreement until such compliance occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Subject to acceptance and recording thereof by the Administrative Agent pursuant to Section&nbsp;11.9(g), from and after the effective date
specified in each Assignment Agreement, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment Agreement, have the rights and obligations of a Bank under this Agreement, and the
assigning Bank thereunder shall, to the extent of the interest assigned by such Assignment Agreement, be released from its obligations under this Agreement (and, in the case of an Assignment Agreement covering all of the assigning Bank&#146;s rights
and obligations under this Agreement, such Bank shall cease to be a party hereto) but shall continue to be entitled to the benefits of <U>Sections 3.5</U>, <U>3.6</U>, <U>3.10(d)</U>, <U>11.3</U>, and <U>11.12</U> with respect to facts and
circumstances occurring prior to the effective date of such assignment; <U>provided</U>, that except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Bank will constitute a waiver or release of any
claim of any party hereunder arising from that Bank&#146;s having been a Defaulting Bank. Any assignment or transfer by a Bank of rights or obligations under this Agreement that does not comply with this paragraph shall be treated for purposes of
this Agreement as a sale by such Bank of a participation in such rights and obligations in accordance with <U>Section</U><U></U><U>&nbsp;11.9(c)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-77- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Participations</B>. Any Bank may at any time, without the consent of, or notice to, the Borrower or the
Administrative Agent, sell participations to any Person (other than a natural Person or the Borrower or the Borrower&#146;s Affiliates or Subsidiaries) (each, a &#147;<B><U>Participant</U></B>&#148;) in all or a portion of such Bank&#146;s rights
and/or obligations under this Agreement (including all or a portion of its Commitments and/or the Loans owing to it); <U>provided</U> that (i)&nbsp;such Bank&#146;s obligations under this Agreement shall remain unchanged, (ii)&nbsp;such Bank shall
remain solely responsible to the other parties hereto for the performance of such obligations, and (iii)&nbsp;the Borrower, the Administrative Agent and Banks shall continue to deal solely and directly with such Bank in connection with such
Bank&#146;s rights and obligations under this Agreement. For the avoidance of doubt, each Bank shall be responsible for the indemnity under <U>Section</U><U></U><U>&nbsp;10.8</U> with respect to any payments made by such Bank to its Participant(s).
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Any agreement or instrument pursuant to which a Bank sells such a participation shall provide that such Bank shall
retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; <U>provided</U> that such agreement or instrument may provide that such Bank will not, without the consent of
the Participant, agree to any amendment, modification or waiver described in clauses (a)&nbsp;and (b) (in the case of such clause (b), solely with respect to amendments or modifications of the provisions of the definition of &#147;Maturity
Date&#148;) of <U>Section</U><U></U><U>&nbsp;11.2</U> that directly and adversely affects such Participant. The Borrower agrees that each Participant shall be entitled to the benefits of <U>Sections 3.5</U>, <U>3.6</U> and <U>3.10(d)</U> to the same
extent as if it were a Bank and had acquired its interest by assignment pursuant to <U>Section</U><U></U><U>&nbsp;11.9(b)</U>; <U>provided</U> that such Participant agrees to be subject to the provisions of <U>Section</U><U></U><U>&nbsp;11.27</U> as
if it were an assignee under <U>Section</U><U></U><U>&nbsp;11.9(b)</U>. To the extent permitted by Law, each Participant also shall be entitled to the benefits of <U>Section</U><U></U><U>&nbsp;11.10</U> as though it were a Bank; <U>provided</U> that
such Participant agrees to be subject to <U>Section</U><U></U><U>&nbsp;11.11</U> as though it were a Bank. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitations upon Participant Rights</B>. Unless the Borrower otherwise agrees in writing, a Participant
shall not be entitled to receive any greater payment under <U>Sections 3.5</U>, <U>3.6</U> and <U>3.10(d)</U> than the applicable Bank would have been entitled to receive with respect to the participation sold to such Participant. A Participant
shall not be entitled to the benefits of <U>Section</U><U></U><U>&nbsp;3.10(d)</U> with respect to United States withholding tax unless the Borrower is notified of the participation sold to such Participant and such Participant agrees, for the
benefit of the Borrower, to comply with <U>Section</U><U></U><U>&nbsp;11.27</U> as though it were a Bank. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Participant Register</B>. Each Bank that sells a participation, acting solely for this purpose as a <FONT
STYLE="white-space:nowrap">non-fiduciary</FONT> agent of the Borrower (and such agency being solely for tax purposes), shall maintain a register for the recordation of the name and address of each Participant and the principal amounts (and stated
interest) of each Participant&#146;s interest in its rights and other obligations under this Agreement (the &#147;<B><U>Participant Register</U></B>&#148;); <U>provided</U> that no Bank shall have any obligation to disclose all or any portion of the
Participant Register to any Person (including the identity of any participant or any information relating to a participant&#146;s interest in any commitments, loans, letters of credit or its other obligations under this Agreement) except to the
extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under <FONT STYLE="white-space:nowrap">Section&nbsp;5f.103-1(c)</FONT> of the United States Treasury
Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Bank shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this
Agreement notwithstanding any notice to the contrary. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-78- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Certain Pledges</B>. Any Bank may at any time pledge or assign a security interest in all or any portion of
its rights under this Agreement to secure obligations of such Bank, including any pledge or assignment to secure obligations to a Federal Reserve Bank or any central bank having jurisdiction over such Bank; <U>provided</U> that no such pledge or
assignment shall release such Bank from any of its obligations hereunder or substitute any such pledgee or assignee for such Bank as a party hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Register</B>. The Administrative Agent, acting solely for this purpose as a <FONT
STYLE="white-space:nowrap">non-fiduciary</FONT> agent of the Borrower, shall maintain at one of its offices in the address referred to in <U>Section</U><U></U><U>&nbsp;11.7</U> a copy of each Assignment Agreement delivered to it and a register for
the recordation of the names and addresses of the Banks, and the Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Bank pursuant to the terms hereof from time to time (the &#147;<B><U>Register</U></B>&#148;).
The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Banks shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Bank hereunder for all
purposes of this Agreement. The Register shall be available for inspection by the Borrower and any Bank, at any reasonable time and from time to time upon reasonable prior notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Debt Syndication during the Certain Funds Period. </B>Each of the Banks and the Administrative Agent
confirms that it is aware of, and agrees to comply in all respects with, the terms and requirements of the Takeover Panel and Takeover Rules in relation to debt syndication during an offer period under the Takeover Rules. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Setoff Rights</U></B>. Subject in all respects to Section&nbsp;8.3, if an Event of Default has occurred
and is continuing, the Administrative Agent and each Bank and each of its Affiliates (but only with the consent of the Majority Banks) is hereby authorized to the fullest extent permitted by law to setoff and apply any funds in any deposit account
maintained with it by the Borrower and/or any Property of the Borrower in its possession against the Obligations; <U>provided</U> that in the event that any Defaulting Bank shall exercise any such right of setoff, (a)&nbsp;all amounts so set off
shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section&nbsp;2.9 and, pending such payment, shall be segregated by such Defaulting Bank from its other funds and deemed held in
trust for the benefit of the Administrative Agent and the Banks, and (b)&nbsp;the Defaulting Bank shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Bank as to
which it exercised such right of setoff. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Sharing of Setoffs</U></B>. Each Bank severally agrees that if it, through the exercise of any right of
setoff, banker&#146;s lien or counterclaim against the Borrower, or otherwise, receives payment, through any means, of the Obligations held by it that is in excess of that Bank&#146;s proportionate share of the Total Outstandings as applied to such
payment, then: (a)&nbsp;the Bank exercising the right of setoff, banker&#146;s lien or counterclaim or otherwise receiving such payment shall purchase, and shall be deemed to have simultaneously purchased, from the other Bank a participation in the
Obligations held by the other Bank and shall pay to the other Bank a purchase price in an amount so that the share of the Obligations held by each Bank after the exercise of the right of setoff, banker&#146;s lien or counterclaim or receipt of
payment shall be in the same proportion that existed prior to the exercise of the right of setoff, banker&#146;s lien or counterclaim or receipt of payment; and (b)&nbsp;such other adjustments and purchases of participations shall be made from time
to time as shall be equitable to ensure that all of the Banks share any payment obtained in respect of the Obligations ratably in accordance with each Bank&#146;s share of the Obligations immediately prior to, and without taking into account, the
payment; <U>provided</U> that, if all or any portion of a disproportionate payment obtained as a result of the exercise of the right of setoff, banker&#146;s lien, counterclaim or otherwise is thereafter
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-79- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
recovered from the purchasing Bank by the Borrower or any Person claiming through or succeeding to the rights of the Borrower, the purchase of a participation shall be rescinded and the purchase
price thereof shall be restored to the extent of the recovery, but without interest. Each Bank that purchases a participation in the Obligations pursuant to this Section shall from and after the purchase have the right to give all notices, requests,
demands, directions and other communications under this Agreement with respect to the portion of the Obligations purchased to the same extent as though the purchasing Bank were the original owner of the Obligations purchased. The Borrower expressly
consents to the foregoing arrangements and agrees that any Bank holding a participation in an Obligation so purchased may exercise any and all rights of setoff, banker&#146;s lien or counterclaim with respect to the participation as fully as if the
Bank were the original owner of the Obligation purchased; <U>provided</U>, <U>however</U>, that each Bank agrees that it shall not exercise any right of setoff, banker&#146;s lien or counterclaim without first obtaining the consent of the Majority
Banks. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnity by the Borrower</U></B>. The Borrower agrees to indemnify, save and hold harmless each
Arranger, the Administrative Agent, the Syndication Agent and each Bank and their respective Related Parties (collectively the &#147;<B><U>Indemnitees</U></B>&#148;) from and against: (a)&nbsp;any and all claims, demands, actions or causes of action
asserted by any third party or by the Borrower if the claim, demand, action or cause of action arises out of or relates to the Commitments, the use or contemplated use of proceeds of any Advance, any transaction contemplated by this Agreement, or
any relationship or relationship alleged to exist by the Borrower, its Affiliates or any other third party of any Indemnitee to the Borrower related to this Agreement; (b)&nbsp;any administrative or investigative proceeding by any Governmental
Agency arising out of or related to a claim, demand, action or cause of action described in clause (a)&nbsp;of this <U>Section</U><U></U><U>&nbsp;11.12</U>; and (c)&nbsp;any and all liabilities, losses, costs or expenses (<U>including</U> reasonable
attorneys&#146; fees and disbursements and other professional services) that any Indemnitee suffers or incurs as a result of the assertion of any foregoing claim, demand, action or cause of action; <U>provided</U> that no Indemnitee shall be
entitled to indemnification for any loss caused by its own gross negligence or willful misconduct as determined by final, nonappealable judgment of a court of competent jurisdiction. If any claim, demand, action or cause of action is asserted
against any Indemnitee, such Indemnitee shall promptly notify the Borrower, but the failure to so promptly notify the Borrower shall not affect the Borrower&#146;s obligations under this <U>Section</U><U></U><U>&nbsp;11.12</U> unless such failure
materially prejudices the Borrower&#146;s right to participate in the contest of such claim, demand, action or cause of action, as hereinafter provided. If requested by the Borrower in writing, such Indemnitee shall in good faith contest the
validity, applicability and amount of such claim, demand, action or cause of action and shall permit the Borrower to participate in such contest. Any Indemnitee that proposes to settle or compromise any claim or proceeding for which the Borrower may
be liable for payment of indemnity hereunder shall give the Borrower written notice of the terms of such proposed settlement or compromise reasonably in advance of settling or compromising such claim or proceeding and shall obtain the
Borrower&#146;s prior written consent. In connection with any claim, demand, action or cause of action covered by this <U>Section</U><U></U><U>&nbsp;11.12</U> against more than one Indemnitee, all such Indemnitees shall be represented by the same
legal counsel selected by the Indemnitees and reasonably acceptable to the Borrower; <U>provided</U> that, if such legal counsel determines in good faith that representing all such Indemnitees would or could result in a conflict of interest under
Laws or ethical principles applicable to such legal counsel or that a defense or counterclaim is available to an Indemnitee that is not available to all such Indemnitees, then to the extent reasonably necessary to avoid such a conflict of interest
or to permit unqualified assertion of such a defense or counterclaim, each Indemnitee shall be entitled to separate representation by legal counsel selected by that Indemnitee and reasonably acceptable to the Borrower, with all such legal counsel
using reasonable efforts to avoid unnecessary duplication of effort by counsel for all Indemnitees; <U>provided</U> further that the amount of the legal fees to be reimbursed by the Borrower shall be limited to an amount reasonably determined
following consultation among </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-80- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Borrower, the Administrative Agent, the Banks and their respective legal counsel, to be equal to the amount that would have been expended if the Indemnitees have been represented by one
counsel. Any obligation or liability of the Borrower to any Indemnitee under this <U>Section</U><U></U><U>&nbsp;11.12</U> shall survive the expiration or termination of this Agreement and the repayment of all Advances and the payment and performance
of all other Obligations owed to the Banks. In the case of an investigation, litigation or other proceeding to which the indemnity in this <U>Section</U><U></U><U>&nbsp;11.12</U> applies, such indemnity shall be effective whether or not such
investigation, litigation or proceeding is brought by the Borrower, its directors, equityholders or creditors or an Indemnitee or any other Person, whether or not any Indemnitee is otherwise a party thereto and whether or not the transactions
contemplated hereby are consummated. This <U>Section</U><U></U><U>&nbsp;11.12</U> shall not apply to the extent that the losses, claims, demands, actions, causes of action, damages, liabilities or expenses relate to any Taxes (including withholding
Taxes and Other Taxes) for which there may be an indemnification, reimbursement or other payment obligation imposed on the Borrower pursuant to any other provision of this Agreement (including, without limitation, Sections <U>3.6</U> and
<U>3.10</U>). No party hereto or any Indemnitee shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information
transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Third Parties Benefited</U></B>. This Agreement is made for the purpose of defining and setting forth
certain obligations, rights and duties of the Borrower, the Administrative Agent and the Banks in connection with the Loans and Advances, and is made for the sole benefit of the Borrower, the Administrative Agent and the Banks, and the
Administrative Agent&#146;s and the Banks&#146; successors and assigns. <U>Except</U> as provided in <U>Sections 11.9</U>, <U>11.11</U> and <U>11.12</U>, no other Person shall have any rights of any nature hereunder or by reason hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Confidentiality</U></B>. Each of the Administrative Agent and each Bank agrees to hold any confidential
information that it may receive from the Borrower pursuant to this Agreement in confidence: except for disclosure: (a)&nbsp;to other Banks; (b)&nbsp;to legal counsel, accountants and other professional advisors to the Borrower or the Administrative
Agent or any Bank or agents involved in administration of this Agreement; (c)&nbsp;to regulatory officials having jurisdiction over the Administrative Agent or a Bank or its Affiliates; (d)&nbsp;as required by Law or legal process or in connection
with any legal proceeding to which the Administrative Agent or a Bank and that Borrower are adverse parties; (e)&nbsp;to Affiliates of the Administrative Agent by the Administrative Agent, (f)&nbsp;to Affiliates of a Bank or to another financial
institution, in each case, in connection with a disposition or proposed disposition to that financial institution of all or part of that Bank&#146;s interests hereunder or a participation interest in its Advances; (g)(i) any assignee of or
Participant in, or any prospective assignee of or Participant in, any of its rights and obligations under this Agreement, (ii)&nbsp;to any direct, indirect, actual or prospective counterparty (and its advisor) to any swap, derivative or
securitization transaction related to the obligations under this Agreement or (iii)&nbsp;or to any credit insurance provider relating to a Borrower and its Obligations, <U>provided</U> that such disclosure in this
<U>Section</U><U></U><U>&nbsp;11.14(g)</U> is made subject to an appropriate confidentiality agreement on terms substantially similar to this Section; (h)&nbsp;in connection with the exercise of any remedies hereunder or any other Loan Document or
the enforcement of rights hereunder or thereunder; or (i)&nbsp;with the consent of the Borrower. For purposes of the foregoing, &#147;confidential information&#148; shall mean any information respecting the Borrower or its Subsidiaries reasonably
considered by the Borrower to be confidential, other than (i)&nbsp;information previously filed with or furnished to any Governmental Agency and available to the public, (ii)&nbsp;information previously published in any public medium from a source
other than, directly or indirectly, that Bank, and (iii)&nbsp;information previously disclosed by a Borrower to any Person not associated with that Borrower without a written confidentiality agreement substantially similar to this
<U>Section</U><U></U><U>&nbsp;11.14</U>. Nothing in this <U>Section</U><U></U><U>&nbsp;11.14</U> shall be construed to create or give rise to any fiduciary duty on the part of the Administrative Agent or the Banks to the Borrower.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-81- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Further Assurances</U></B>. The Borrower and its Subsidiaries shall, at their expense and without expense
to the Banks or the Administrative Agent, do, execute and deliver such further acts and documents as any Bank or the Administrative Agent from time to time reasonably requires for the assuring and confirming unto the Banks or the Administrative
Agent of the rights hereby created or intended now or hereafter so to be, or for carrying out the intention or facilitating the performance of the terms of any Loan Document. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Fiduciary Duties</U></B>. The Borrower agrees that in connection with all aspects of the transactions
contemplated hereby and any communications in connection therewith, the Borrower and its Subsidiaries, on the one hand, and the Administrative Agent, Joint Lead Arrangers, Joint Book Runners, <FONT STYLE="white-space:nowrap">Co-Documentation</FONT>
Agents, Syndication Agents, Banks and their respective Affiliates, on the other hand, will have a business relationship that does not create, by implication or otherwise, any fiduciary duty on the part of the Administrative Agent, the Joint Lead
Arrangers, the Joint Book Runners, the <FONT STYLE="white-space:nowrap">Co-Documentation</FONT> Agents, the Syndication Agent, the Banks or their respective Affiliates and no such duty will be deemed to have arisen in connection with any such
transactions or communications. Accordingly, there may be situations where the Administrative Agent, a Joint Lead Arranger, a Joint Book Runner, a <FONT STYLE="white-space:nowrap">Co-Documentation</FONT> Agent, the Syndication Agent, a Bank or their
Affiliates and/or their clients either now have or may in the future have interests, or take actions, that may conflict with the Borrower&#146;s and its Subsidiaries&#146; interests. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Integration</U></B>. This Agreement, together with the other Loan Documents, comprises the complete and
integrated agreement of the parties on the subject matter hereof and supersedes all prior agreements, written or oral, on the subject matter hereof. In the event of any conflict between the provisions of this Agreement and those of any other Loan
Document, the provisions of this Agreement shall control and govern; <U>provided</U> that the inclusion of supplemental rights or remedies in favor of the Administrative Agent or the Banks in any other Loan Document shall not be deemed a conflict
with this Agreement. Each Loan Document was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor in favor of any party, but rather in accordance with the fair meaning thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Severability of Provisions</U></B>. Any provision in any Loan Document that is held to be inoperative,
unenforceable or invalid as to any party or in any jurisdiction shall, as to that party or jurisdiction, be inoperative, unenforceable or invalid without affecting the remaining provisions or the operation, enforceability or validity of that
provision as to any other party or in any other jurisdiction, and to this end the provisions of all Loan Documents are declared to be severable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Independent Covenants</U></B>. Each covenant in <U>Articles 5</U>, <U>6</U> and <U>7</U> is independent
of the other covenants in those Articles; the breach of any such covenant shall not be excused by the fact that the circumstances underlying such breach would be permitted by another such covenant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Headings</U></B>. Article and Section headings in this Agreement and the other Loan Documents are
included for convenience of reference only and are not part of this Agreement or the other Loan Documents for any other purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Time of the Essence</U></B>. Time is of the essence of the Loan Documents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-82- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Applicable Law</U></B>. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE
GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING SECTION <FONT STYLE="white-space:nowrap">5-1401</FONT> OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK) WITHOUT REGARD
TO CONFLICTS OF LAWS PRINCIPLES, EXCEPT THAT, AS APPLICABLE, WHETHER THE TARGET ACQUISITION HAS BEEN CONSUMMATED AND BECOME EFFECTIVE IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THE SCHEME DOCUMENTS OR THE TAKEOVER OFFER HAS BEEN CONSUMMATED AND
BECOME UNCONDITIONAL IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THE TAKEOVER OFFER DOCUMENTS SHALL, TO THE EXTENT REQUIRED BY THE LAWS OF IRELAND, BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF IRELAND. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Consent to Jurisdiction and Service of Process</U></B>. (a)&nbsp;Each of the parties hereto hereby
irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against the Borrower, the Administrative Agent,
any Bank or any Related Party of the foregoing in any way relating to this Agreement or any other Loan Document or the transactions relating hereto, in any forum other than the courts of the State of New York sitting in New York County and of the
United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of such courts and agrees that all
claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State or, to the fullest extent permitted by applicable Law, in such federal court. Notwithstanding the foregoing sentence, each of the
parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By executing and delivering this Agreement, each party hereto, for itself and in connection with its
properties, irrevocably </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">accepts generally and unconditionally the exclusive jurisdiction and venue of the courts of the State of New
York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waives any defense of <I>forum non conveniens</I>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agrees that service of all process in any such proceeding in any such court may be made by registered or
certified mail, return receipt requested, to such party at its address as provided in accordance with <U>Section</U><U></U><U>&nbsp;11.7</U> (<U>provided</U> that, with respect to the Borrower, service of process may be made to the Borrower at its
address provided in accordance with <U>Section</U><U></U><U>&nbsp;11.7</U>) or on the signature pages hereto; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agrees that service as provided in clause (iii)&nbsp;above is sufficient to confer personal jurisdiction over
such party in any such proceeding in any such court, and otherwise constitutes effective and binding service in every respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agrees that each party hereto retains the right to serve process in any other manner permitted by law; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agrees that the provisions of this <U>Section</U><U></U><U>&nbsp;11.23</U> relating to jurisdiction and venue
shall be binding and enforceable to the fullest extent permissible under New York General Obligations Law section <FONT STYLE="white-space:nowrap">5-1402</FONT> or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-83- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Waiver of Jury Trial</U></B>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY AGREES TO WAIVE ITS RESPECTIVE
RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE OTHER LOAN DOCUMENTS OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER OF THIS LOAN TRANSACTION OR THE BANK/BORROWER
RELATIONSHIP THAT IS BEING ESTABLISHED. The scope of this waiver is intended to be <FONT STYLE="white-space:nowrap">all-encompassing</FONT> of any and all disputes that may be filed in any court and that relate to the subject matter of this
transaction, including contract claims, tort claims, breach of duty claims and all other common law and statutory claims. Each party hereto acknowledges that this waiver is a material inducement to enter into a business relationship, that each has
already relied on this waiver in entering into this Agreement, and that each will continue to rely on this waiver in their related future dealings. Each party hereto further warrants and represents that it has reviewed this waiver with its legal
counsel and that it knowingly and voluntarily waives its jury trial rights following consultation with legal counsel. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING (OTHER THAN BY A MUTUAL WRITTEN WAIVER
SPECIFICALLY REFERRING TO THIS <U>SECTION 11.24</U> AND EXECUTED BY EACH OF THE PARTIES HERETO), AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR ANY OF THE OTHER LOAN DOCUMENTS OR
TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE LOANS MADE HEREUNDER. In the event of litigation, this Agreement may be filed as a written consent to a trial by the court. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Acknowledgement and Consent to <FONT STYLE="white-space:nowrap">Bail-In</FONT> of Certain Financial
Institutions</U></B>. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges and accepts that, to the extent any Bank party to any
Loan Document is subject to the Write-Down and Conversion Powers of a Resolution Authority, any liability of such Bank under or in connection with any Loan Document may be subject to <FONT STYLE="white-space:nowrap">Bail-In</FONT> Action by the
relevant Resolution Authority and acknowledges and accepts to be bound by the effect of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the application of any Write-Down and Conversion Powers by a Resolution Authority to any such liabilities
arising hereunder which may be payable to it by any Bank party hereto that is subject to the Write-Down and Conversion Powers of any Resolution Authority; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the effects of any <FONT STYLE="white-space:nowrap">Bail-In</FONT> Action on any such liability, including, if
applicable: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reduction in full or in part or cancellation of any such liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a conversion of all, or a portion of, such liability into shares or other instruments of ownership that may be
issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion
Powers of any Resolution Authority. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As used in this Section, the following terms shall have the meanings set forth
below: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-84- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Article 55 BRRD</B>&#148; means Article 55 of Directive 2014/59/EU establishing a
framework for the recovery and resolution of credit institutions and investment firms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Bail-In</FONT> Action</B>&#148; means the exercise of any Write-Down and Conversion Powers by the
applicable Resolution Authority with respect to any liability of any Bank party hereto that is subject to the Write-Down and Conversion Powers of such Resolution Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation</B>&#148; means: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to an EEA Member Country which has implemented, or which at any time implements, Article 55 BRRD,
the relevant implementing law or regulation as described in the EU <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation Schedule from time to time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to any state other than such an EEA Member Country or (to the extent that the United Kingdom is
not such an EEA Member Country) the United Kingdom, any analogous law or regulation from time to time which requires contractual recognition of any Write-Down and Conversion Powers contained in that law or regulation. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EEA Financial Institution</B>&#148; means (a)&nbsp;any credit institution or investment firm established in any EEA Member Country
which is subject to the supervision of an EEA Resolution Authority, (b)&nbsp;any entity established in an EEA Member Country which is a parent of an institution described in clause (a)&nbsp;of this definition, or (c)&nbsp;any financial institution
established in an EEA Member Country which is a subsidiary of an institution described in clauses (a)&nbsp;or (b) of this definition and is subject to consolidated supervision with its parent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EEA Member Country</B>&#148; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EEA Resolution Authority</B>&#148; means any public administrative authority or any Person entrusted with public administrative
authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EU <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation Schedule</B>&#148; means the EU
<FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Resolution Authority</B>&#148; means an EEA Resolution Authority or any other body which has authority to exercise any Write-down and
Conversion Powers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>UK <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation</B>&#148; means (to the extent that the United
Kingdom is not an EEA Member Country which has implemented, or implements, Article 55 BRRD) Part I of the United Kingdom Banking Act 2009 and any other law or regulation applicable in the United Kingdom relating to the resolution of unsound or
failing banks, investment firms or other financial institutions or their affiliates (otherwise than through liquidation, administration or other insolvency proceedings). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Write-Down and Conversion Powers</B>&#148; means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to any <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation described in the EU <FONT
STYLE="white-space:nowrap">Bail-In</FONT> Legislation Schedule from time to time, the powers described as such in relation to that <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation in the EU <FONT STYLE="white-space:nowrap">Bail-In</FONT>
Legislation Schedule; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in relation to any UK <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation or any other applicable <FONT
STYLE="white-space:nowrap">Bail-In</FONT> Legislation: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-85- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any powers under such <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation to cancel, transfer or dilute
shares issued by a Person that is a bank or investment firm or other financial institution or affiliate of a bank, investment firm or other financial institution, to cancel, reduce, modify or change the form of a liability of such a Person or any
contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that Person or any other Person, to provide that any such contract or instrument is to have effect as if a
right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under such <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation that are related to or ancillary to any of those powers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any similar or analogous powers under such <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>[Reserved]</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Tax Forms</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) Each Bank that is not a &#147;United States person&#148; within the meaning of Section&nbsp;7701(a)(30) of
the Code (a &#147;<B><U>Foreign Bank</U></B>&#148;) shall, to the extent it is legally entitled to do so, deliver to the Administrative Agent and the Borrower, prior to receipt of any payment (or upon accepting an assignment of an interest herein),
two duly signed completed copies of either IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or any successor thereto (relating to such Foreign Bank
and establishing any exemption to which it is entitled from, or reduction of, withholding tax on all applicable payments to be made to such Foreign Bank by the Borrower or the Administrative Agent, as applicable, pursuant to this Agreement) or IRS
Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> or any successor thereto (relating to all payments to be made to such Foreign Bank by the Borrower pursuant to this Agreement) or such other evidence satisfactory to the Borrower and the
Administrative Agent that such Foreign Bank is entitled to an exemption from, or reduction of, United States withholding tax, including any exemption pursuant to Section&nbsp;881(c) of the Code. Thereafter and from time to time, each such Foreign
Bank shall (A)&nbsp;promptly submit to the Administrative Agent and the Borrower such additional duly completed and signed copies of one of such forms (or such successor forms as shall be adopted from time to time by the relevant United States
taxing authorities) as may then be available under then current United States laws and regulations to avoid, or such evidence as is satisfactory to the Borrower and the Administrative Agent of any available exemption from or reduction of, United
States withholding Taxes in respect of all payments to be made to such Foreign Bank by the Borrower pursuant to this Agreement and (B)&nbsp;promptly notify the Administrative Agent and the Borrower of any change in circumstances which would modify
or render invalid any claimed exemption or reduction. (ii)&nbsp;Each Foreign Bank, to the extent it is not the beneficial owner of any portion of any sums paid or payable to such Bank under any of the Loan Documents (for example, in the case of a
typical participation by such Bank) and is legally entitled to do so, shall deliver to the Administrative Agent and the Borrower on the date when such Foreign Bank ceases to be the beneficial owner of any portion of any such sums paid or payable,
and at such other times as may be necessary in the determination of the Administrative Agent or the Borrower (in the reasonable exercise of their discretion), (A) two duly signed completed copies of the forms or statements required to be provided by
such Bank as set forth above, to establish the portion of any such sums paid or payable with respect to which such Bank is the beneficial owner that is not subject to U.S. withholding Tax, and (B)&nbsp;with respect to the remaining portion of any
such sums, two duly signed completed copies of IRS Form <FONT STYLE="white-space:nowrap">W-8IMY</FONT> (or any successor thereto) accompanied by IRS Forms <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> <FONT STYLE="white-space:nowrap">W-8ECI</FONT> and/or any other certificate or statement of exemption from each beneficial owner required under applicable Law, to establish any available exemption
from or reduction of withholding Taxes to which the beneficial owner is entitled. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-86- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the request of the Administrative Agent or the Borrower, each Bank that is a &#147;United States
person&#148; within the meaning of Section&nbsp;7701(a)(30) of the Code shall deliver to the Administrative Agent and the Borrower two duly signed completed copies of IRS Form <FONT STYLE="white-space:nowrap">W-9.</FONT> If such Bank fails to
deliver such forms, then the Administrative Agent or the Borrower, as applicable, may withhold from any interest payment to such Bank an amount equivalent to the applicable <FONT STYLE="white-space:nowrap">back-up</FONT> withholding imposed by the
Code or otherwise withhold any Taxes as required by applicable Law. Upon the request of the Borrower, the Administrative Agent shall provide the Borrower two duly signed completed copies of IRS Form <FONT STYLE="white-space:nowrap">W-9.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a payment made to a Bank under any Loan Document would be subject to withholding Tax imposed by FATCA if
such Bank were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section&nbsp;1471(b) or 1472(b) of the Code, as applicable), such Bank shall deliver to the Administrative Agent and the Borrower, at
the time or times prescribed by Law and at such time or times reasonably requested in writing by the Borrower or the Administrative Agent, such documentation prescribed by applicable Law (including as prescribed by Section&nbsp;1471(b)(3)(C)(i) of
the Code) and such additional documentation reasonably requested in writing by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA, to determine that
such Bank has complied with such Bank&#146;s obligations under FATCA or to determine the amount to deduct and withhold from such payment. For purposes of this clause (c), FATCA shall include any amendments made to FATCA after the date of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Bank agrees that if any form or certification it previously delivered becomes inaccurate in any respect,
it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so. In addition, each Bank agrees that if any form or certification it previously delivered expires or
becomes obsolete, upon written request by the Borrower or the Administrative Agent, the Bank shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Waiver of Damages</U></B>. To the extent permitted by applicable law, no party to this Agreement shall
assert, and each party to this Agreement hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection
with, or as a result of, this Agreement or any agreement or instrument contemplated hereby, the transactions contemplated hereby, any Loan or the use of the proceeds thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-87- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Patriot Act Notice</U></B>. Each Bank and the Administrative Agent (for itself and not on behalf of any
Bank) hereby notifies the Borrower that pursuant to the requirements of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L.
<FONT STYLE="white-space:nowrap">107-56,</FONT> signed into law October&nbsp;26, 2001 (the &#147;<B><U>Patriot Act</U></B>&#148;) and the Beneficial Ownership Regulation, it is required to obtain, verify and record information that identifies the
Borrower, which information includes the name and address of the Borrower and other information that will allow such Bank or the Administrative Agent, as applicable, to identify the Borrower in accordance with the Patriot Act and the Beneficial
Ownership Regulation. The Borrower shall provide such information and take such actions as are reasonably requested by the Administrative Agent or any Banks in order to assist the Administrative Agent and the Banks in maintaining compliance with the
Patriot Act and the Beneficial Ownership Regulation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Pages Begin On Following Page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-88- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be duly executed as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THE BORROWER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMGEN INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Justin G. Claeys</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Justin G. Claeys</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President, Finance and Treasurer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Amgen Center
Drive</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Thousand Oaks, California 91320-1799</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Treasurer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">cc: Corporate
Secretary</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telecopier: (805) <FONT STYLE="white-space:nowrap">499-6751</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telephone: (805) <FONT STYLE="white-space:nowrap">447-1000</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITIBANK, N.A., </B>as Administrative Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Rivera</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Richard Rivera</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BANK OF AMERICA, N.A.,</B> as Bank</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph L. Corah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joseph L. Corah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITIBANK, N.A.,</B> as Bank</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Rivera</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Richard Rivera</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITICORP NORTH AMERICA, INC.,</B> as Bank</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Rivera</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Richard Rivera</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-89- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[RESERVED] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF NOTE] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[NOTE]
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[DATE]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the undersigned promises to pay to the order of ________________ (the
&#147;<B>Bank</B>&#148;), the principal amount of _______ Dollars ($______), or such lesser aggregate amount of Advances as may be made pursuant to the Bank&#146;s Pro Rata Share of the Commitment under the Credit Agreement hereinafter described,
payable as hereinafter set forth. The undersigned promises to pay interest on the principal amount of each Advance made hereunder and remaining unpaid from time to time from the date of each such Advance until the date of payment in full, payable as
hereinafter set forth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Reference is made to the Bridge Credit Agreement dated as of [&#149;] (as amended from time to time, the
&#147;<B>Credit Agreement</B>&#148;), among Amgen Inc., the Banks from time to time party thereto, Citibank, N.A., as Administrative Agent, and [______], as Syndication Agent. Terms defined in the Credit Agreement and not otherwise defined herein
are used herein with the meanings defined for those terms in the Credit Agreement. This is one of the Notes (&#147;<B>Note</B>&#148;) referred to in the Credit Agreement, and any holder hereof is entitled to all of the rights, remedies, benefits and
privileges provided for in the Credit Agreement as originally executed or as it may from time to time be supplemented, modified, amended, renewed, extended or supplanted. The Credit Agreement, among other things, contains provisions for acceleration
of the maturity hereof upon the happening of certain stated events upon the terms and conditions therein specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The principal
indebtedness evidenced by this Note shall be payable as provided in the Credit Agreement and in any event on the Maturity Date applicable to the Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Interest shall be payable on the outstanding daily unpaid principal amount of each Advance hereunder from the date thereof until payment in
full and shall accrue and be payable at the rates and on the dates set forth in the Credit Agreement both before and after default, before and after maturity and judgment, and before and after the commencement of any proceeding under any Debtor
Relief Law with interest on overdue interest to bear interest at the rate set forth in Section&nbsp;3.7 of the Credit Agreement, to the extent permitted by applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned shall have the right to prepay any amounts outstanding under this Note in accordance with Section&nbsp;3.1(e) of the Credit
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The amount of each payment hereunto with respect to Advances made in Dollars shall be made to the Administrative Agent at the
Administrative Agent&#146;s Office, for the account of the Bank in lawful money of the United States of America and in immediately available funds not later than 2:00 p.m., New York City time, on the day of payment (which must be a Banking Day). All
payment received after 2:00 p.m., New York City time or local time, as the case may be, on any particular Banking Day shall be deemed received on the next succeeding Banking Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Note is a registered obligation, transferrable only upon notation in the Register, and
no assignment hereof shall be effective until recorded therein. A record of Advances made by and payments received by Bank with respect to this Note shall be maintained by the Administrative Agent in the Register pursuant to and in accordance with
Section&nbsp;11.9(g) of the Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As set forth in Section&nbsp;11.3 of the Credit Agreement, the undersigned hereby promises
to pay the reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses of any holder hereof incurred in collecting the undersigned&#146;s obligations hereunder or in enforcing any
holder&#146;s rights hereunder, including attorneys&#146; fees and disbursements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned hereby waives presentation, demand for
payment, dishonor, notice of dishonor, protest, notice of protest and any other notice of formality, to the fullest extent permitted by applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE SHALL BE DEEMED DELIVERED TO AND ACCEPTED BY THE ADMINISTRATIVE AGENT ON BEHALF OF THE BANK IN THE STATE OF NEW YORK, AND SHALL
BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[BORROWER]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ADVANCES AND PAYMENTS OF PRINCIPAL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UNDER COMMITMENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of Loan<BR>Made This Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Maturity Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Amount of<BR>Advance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Amount of<BR>Principal Paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Unpaid Principal<BR>Balance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Principal Balance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Notation Made By</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF COMPLIANCE CERTIFICATE] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPLIANCE CERTIFICATE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. This
Compliance Certificate (&#147;<B>Compliance Certificate</B>&#148;) is executed and delivered by AMGEN INC., a Delaware corporation (the &#147;<B>Company</B>&#148;), to CITIBANK, N.A. (the &#147;<B>Administrative Agent</B>&#148;) pursuant to
<B>Section</B><B></B><B>&nbsp;7.2</B> of the Bridge Credit Agreement dated as of [&#149;], among the Company, the Bank from time to time party thereto, Citibank, N.A., as Administrative Agent, and [______], as Syndication Agent (as amended from time
to time, the &#147;<B>Credit Agreement</B>&#148;). Any terms used herein and not defined herein shall have the meanings defined in the Credit Agreement. This Compliance Certificate covers the Company&#146;s: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">[Fiscal Quarter ended __________, _____] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">[Fiscal Year ended December&nbsp;31, _____] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The following paragraphs set forth calculations showing whether the Company is in compliance with its obligations pursuant to
<B>Section</B><B></B><B>&nbsp;6.6</B> of the Credit Agreement, as of the end of the fiscal period set forth in paragraph 1 hereof. Each calculation set forth below identified as &#147;Actual&#148; is derived from the books and records of the Company
in accordance with the relevant definitions of financial terms set forth in <B>Section</B><B></B><B>&nbsp;1.1</B> of the Credit Agreement, and correctly reflects whether the Company is in compliance with the obligations contained in the applicable
Sections of the Credit Agreement parenthetically noted, which obligations are set forth below identified under the column marked &#147;Required/Permitted&#148;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="13"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>I.&#8195;&#8201;&#8202;Consolidated Interest Coverage Ratio (Section
6.6)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consolidated EBITDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="5" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consolidated Interest Expense</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="5" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Not less than 3.50 to 1.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Y&nbsp;or&nbsp;N)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. To the best knowledge of the undersigned, during the fiscal period covered by this Compliance Certificate,
no Default has occurred and is continuing, with the exceptions set forth below in response to which the Company has taken or proposes to take the following actions (if none, so state): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This Compliance Certificate is executed on _________, ____, by a Senior Officer of the
Company. The undersigned hereby certifies that each and every matter contained herein is derived from the Company&#146;s books and records and is, to the best knowledge of the undersigned, true and correct. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMGEN INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[RESERVED] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF REQUEST FOR LOAN] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REQUEST FOR LOAN </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Request
for Loan is by ________ (the &#147;<B>Borrower</B>&#148;) to Citibank, N. A. (the &#147;<B>Administrative Agent</B>&#148;) pursuant to that certain Bridge Credit Agreement dated as of [&#149;] (as it may be amended, supplemented or otherwise
modified from time to time, the &#147;<B>Credit Agreement</B>&#148;) among Amgen Inc., the Banks from time to time party thereto, the Administrative Agent, and [_______], as Syndication Agent. Capitalized terms used herein and not defined herein
shall have the meanings defined in the Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Borrower hereby requests a Loan for the account of Borrower pursuant to the
Credit Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) DATE OF LOAN: ___________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) TYPE OF LOAN (Check one box only): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">__ BASE RATE ADVANCE </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">__ TERM RATE ADVANCE WITH A __-MONTH INTEREST PERIOD </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) AMOUNT OF REQUESTED LOAN: $______ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) INTEREST PERIOD OF LOAN ENDS: _______ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. In connection with the request pursuant to Section&nbsp;2 above, Borrower certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to giving effect to the Loans requested hereby, the aggregate outstanding principal amount of Advances is $________.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As of the date of the requested Loan, (i)&nbsp;each Certain Funds Representation will be true and correct in all
material respects (except that to the extent any representation or warranty is qualified by materiality, it shall be true and correct in all respects), as though such representations and warranties were made on and as of that date (except to the
extent such representations and warranties specifically relate to an earlier date in which case they shall be true and correct in all material respects as of such earlier date), (ii) no Certain Funds Default is continuing, and (iii)&nbsp;after
giving effect to the requested Loan, the Total Outstandings will not exceed the Commitments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. [Borrower instructs the Administrative Agent to deduct from the requested Loan all fees
due and payable by Borrower to (or for the account of) the Administrative Agent, Banks and/or Arrangers (as applicable) as of the date of the requested Loan, to the extent invoiced (if applicable) by the relevant person at least three Banking Days
prior to the Funding Date, in satisfaction of the same.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. This Request for Loan
is executed on ___________, __ by a Senior Officer of Borrower on behalf of Borrower. The undersigned in such capacity, hereby certifies each and every matter contained herein to be true and correct <B>except</B> as previously disclosed by Borrower
in writing to the Banks and waived by the Majority Banks or all Banks, as applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[BORROWER]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included to the extent the fees are netted at closing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF ASSIGNMENT AGREEMENT] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This
Assignment Agreement (the &#147;<B>Assignment Agreement</B>&#148;) is dated as of the Effective Date set forth below and is entered into by and between [the][each]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> Assignor identified in item 1
below ([the][each, an] &#147;<B>Assignor</B>&#148;) and [the][each]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> Assignee identified in item 2 below ([the][each, an] &#147;<B>Assignee</B>&#148;). [It is understood and agreed that the rights
and obligations of [the Assignors][the Assignees]<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> hereunder are several and not joint.]<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> Capitalized terms used but not defined herein shall
have the meanings given to them in the Credit Agreement identified below (as amended, supplemented or otherwise modified from time to time, the &#147;<B>Credit Agreement</B>&#148;), receipt of a copy of which is hereby acknowledged by [the][each]
Assignee. The Standard Terms and Conditions set forth in Annex I attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment Agreement as if set forth herein in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For an agreed consideration, [the][each] Assignor hereby irrevocably sells and assigns to [the Assignee][the respective Assignees], and
[the][each] Assignee hereby irrevocably purchases and assumes from [the Assignor][the respective Assignors], subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the
Administrative Agent as contemplated below (i)&nbsp;all of [the Assignor&#146;s][the respective Assignors&#146;] rights and obligations in [its capacity as a Bank][their respective capacities as Banks] under the Credit Agreement and any other
documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of [the Assignor][the respective Assignors] under the respective
facilities identified below, and (ii)&nbsp;to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of [the Assignor (in its capacity as a Bank)][the respective Assignors (in their
respective capacities as Banks)] against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in
</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For bracketed language here and elsewhere in this form relating to the Assignor(s) if the assignment is from a
single Assignor, choose the first bracketed language. If the assignment is from multiple Assignors, choose the second bracketed language. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For bracketed language here and elsewhere in this form relating.to the Assignee(s), if the assignment is to a
single Assignee, choose the first bracketed language. If the assignment is to multiple Assignees, choose the second bracketed language. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Select as appropriate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include bracketed language if there are either multiple Assignors or multiple Assignees.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity
related to the rights and obligations sold and assigned pursuant to clause (i)&nbsp;above (the rights and obligations sold and assigned by [the][any] Assignor to [the][any] Assignee pursuant to clauses (i)&nbsp;and (ii) above being referred to
herein collectively as [the][an] &#147;<B>Assigned Interest</B>&#148;). Each such sale and assignment is without recourse to [the][any] Assignor and, except as expressly provided in this Assignment Agreement, without representation or warranty by
[the][ any] Assignor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Assignor[s]: _______________________ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; _______________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Assignor [is][is not] a
Defaulting Bank] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Assignee[s]: _______________________ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; _______________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[for each Assignee, indicate [Affiliate][Approved Fund] of [<I>identify
Bank]</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Borrower: [Amgen Inc.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Administrative Agent: Citibank, N.A. (&#147;<B>Citibank</B>&#148;), as the administrative agent under the Credit Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Credit Agreement: The Bridge Credit Agreement dated as of [&#149;] among Amgen Inc., the Banks parties thereto, Citibank, as Administrative
Agent, and the other agents parties thereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Assigned Interest[s]: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Assignor[s]<SUP STYLE="font-size:75%; vertical-align:top">6</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Assignee[s]<SUP STYLE="font-size:75%; vertical-align:top">7</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<BR>Amount of<BR>Commitment/<BR>Advances<BR>for all<BR>Banks<SUP STYLE="font-size:75%; vertical-align:top">8</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount of<BR>Commitment<BR>/Advances<BR>Assigned<SUP STYLE="font-size:75%; vertical-align:top">9</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Percentage<BR>Assigned of<BR>Commitment/<BR>Advances<SUP STYLE="font-size:75%; vertical-align:top">10</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">CUSIP<BR>Number</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.45 Trade Date: __________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Page break] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">List each Assignor, as appropriate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">List each Assignee, as appropriate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount to be adjusted by the counterparties to take into account any payments or prepayments made between the
Trade Date and the Effective Date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Set forth, to at least 9 decimals, as a percentage of the Commitment/Advances of all Banks thereunder.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">10</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be completed if the Assignor(s) and the Assignee(s) intend that the minimum assignment amount is to be
determined as of the Trade Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Effective Date: _________, 20__ [TO BE INSERTED BY AGENT AND WHICH SHALL BE THE EFFECTIVE
DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">The terms set forth in this Assignment Agreement are hereby agreed to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ASSIGNOR[S]<SUP STYLE="font-size:75%; vertical-align:top">11</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME OF ASSIGNOR]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASSIGNEE[S]<SUP STYLE="font-size:75%; vertical-align:top">12</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NAME OF ASSIGNEE</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">NAME OF ASSIGNEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Consented to and]<SUP STYLE="font-size:75%; vertical-align:top">13</SUP> Accepted: </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CITIBANK, N.A., as</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Administrative Agent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">11</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Add additional signature blocks as needed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">12</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Add additional signature blocks as needed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">13</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be added only if the consent of the Administrative Agent is required by the terms of the Credit Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Consented to and]<SUP STYLE="font-size:75%; vertical-align:top">14</SUP> Accepted: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[NAME OF ISSUING BANK],<BR>as Issuing Bank</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Consented to:]<SUP STYLE="font-size:75%; vertical-align:top">15</SUP> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AMGEN INC.,<BR>as the Borrower</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">14</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be added only if the consent of the Issuing Bank is required by the terms of the Credit Agreement.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">15</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be added only if the consent of the Borrower is required by the terms of the Credit Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMGEN INC. BRIDGE CREDIT AGREEMENT DATED AS OF DECEMBER&nbsp;[&#149;],&nbsp;2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">STANDARD TERMS AND CONDITIONS FOR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
Representations and Warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1. <B>Assignor[s]</B>. [The][Each] Assignor (a)&nbsp;represents and warrants that (i)&nbsp;it is the
legal and beneficial owner of [the] [the relevant] Assigned Interest, (ii) [the] [such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim, (iii)&nbsp;it has full power and authority, and has taken all action
necessary, to execute and deliver this Assignment Agreement and to consummate the transactions contemplated hereby and (iv)&nbsp;it is [not] a Defaulting Bank; and (b)&nbsp;assumes no responsibility with respect to (i)&nbsp;any statements,
warranties or representations made in or in connection with the Credit Agreement or any other Loan Document, (ii)&nbsp;the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral
thereunder, (iii)&nbsp;the financial condition of the Borrowers, any of their Subsidiaries or Affiliates or any other Person obligated in respect of any Loan Document, or (iv)&nbsp;the performance or observance by the Borrowers, any of their
Subsidiaries or Affiliates or any other Person of any of their respective obligations under any Loan Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2. <B>Assignee[s]</B>.
[The] [Each] Assignee (a)&nbsp;represents and warrants that (i)&nbsp;it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment Agreement and to consummate the transactions contemplated hereby and to
become a Bank under the Credit Agreement, (ii)&nbsp;it meets all the requirements to be an assignee under Section&nbsp;11.9(b)(iii), (v) and (vi)&nbsp;of the Credit Agreement (subject to such consents, if any, as may be required under
Section&nbsp;11.9(b)(iii) of the Credit Agreement), (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Bank thereunder and, to the extent of [the] [the relevant] Assigned Interest, shall have
the obligations of a Bank thereunder, (iv)&nbsp;it is sophisticated with respect to decisions to acquire assets of the type represented by the Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire the
Assigned Interest, is experienced in acquiring assets of such type, (v)&nbsp;it has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered
pursuant to Section&nbsp;7.1 thereof, as applicable, and such other documents and information as it deems appropriate to make its own credit analysis and decision to enter into this Assignment Agreement and to purchase [the][such] Assigned Interest,
(vi)&nbsp;it has, independently and without reliance upon the Administrative Agent or any other Bank and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment
Agreement and to purchase [the] [such] Assigned Interest, and (vii)&nbsp;attached to the Assignment Agreement is any documentation required to be delivered by it pursuant to Section&nbsp;11.27 of the Credit Agreement, duly completed and executed by
[the] [such] Assignee; and (b)&nbsp;agrees that (i)&nbsp;it will, independently and without reliance on the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administrative Agent, [the][any] Assignor or any other Bank, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in
taking or not taking action under the Loan Documents, and (ii)&nbsp;it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Payments</B>. From and after the Effective Date, the Agent shall make all payments in respect of [the] [each] Assigned Interest
(including payments of principal interest, fees and other amounts) to [the][the relevant] Assignee whether such amounts have accrued prior to, on or after the Effective Date. The Assignor[s] and the Assignee[s] shall make all appropriate adjustments
in payments by the Administrative Agent for periods prior to the Effective Date or with respect to the making of this assignment directly between themselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>General Provisions</B>. This Assignment Agreement shall be binding upon, and inure to the benefit of, the parties hereto and then
respective successors and assigns. This Assignment Agreement may be executed m any number of counterparts, which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Assignment Agreement by
telecopy shall be effective as delivery of a manually executed counterpart of this Assignment Agreement. This Assignment Agreement shall be governed by, and construed in accordance with, the law of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BANKS&#146; COMMITMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Bank</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Commitment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citibank, N.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,550,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citicorp North America, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,125,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America, N.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,825,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28,500,000,000.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCLOSURE OF SUBSIDIARIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen (Europe) GmbH</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Canada Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Fremont Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Global Finance B.V.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen GmbH Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Ilac Ticaret Limited Sirketi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen <FONT STYLE="white-space:nowrap">K-A,</FONT> Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Manufacturing, Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Research (Munich) GmbH</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Rockville, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen S.A.S.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen S.r.l.<SUP STYLE="font-size:75%; vertical-align:top">17</SUP></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen SF, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Singapore Manufacturing Pte. Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Technology (Ireland) Unlimited Company</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Technology, Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen USA Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen Worldwide Holdings B.V.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amgen, S.A.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BioVex, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">deCODE Genetics ehf</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Five Prime Therapeutics Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gensenta Ilac Sanayi ve Ticaret Anomim Sirketi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Immunex Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Immunex Rhode Island Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KAI Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ilypsa, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Onyx Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Onyx Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Saga Investments Co&ouml;peratief U.A.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TeneoBio, Inc.</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">17</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Formerly named Amgen S.p.A. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LITIGATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4.11(c) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ERISA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen Inc. Retiree Medical Savings
Account Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENVIRONMENTAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 6.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIENS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 13.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE COMPANY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Amgen Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thousand Oaks, California 91320-1799 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Corporate
Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telecopier: (805) <FONT STYLE="white-space:nowrap">499-6751</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (805) <FONT STYLE="white-space:nowrap">447-1000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: <U>to.treasury@amgen.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Website: www.amgen.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE ADMINISTRATIVE AGENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citibank, N.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Penns Way OPS II, Floor 2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Castle, DE 19720 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agency Operations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile No. (646) <FONT
STYLE="white-space:nowrap">274-5080</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone No. (302) <FONT STYLE="white-space:nowrap">894-6160</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> AgencyABTFSupport@citi.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With copies to: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agency Operations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: GLAgentOfficeOps@citi.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d346985dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B><I>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION
OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B><I>THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER
RULES </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B><I>FOR IMMEDIATE RELEASE </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B><I>December&nbsp;12, 2022 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RECOMMENDED
CASH OFFER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>for </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>HORIZON
THERAPEUTICS PLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>by </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Pillartree
Limited, a newly formed private limited company wholly owned by Amgen Inc. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>to be implemented by way of a scheme of arrangement under Chapter
1 of Part 9 of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Companies Act 2014 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The board of directors of Horizon Therapeutics plc (the &#147;<B>Company</B>&#148; or &#147;<B>Horizon</B>&#148;) and
the board of directors of Amgen Inc. (&#147;<B>Amgen</B>&#148;) are pleased to announce that they have reached agreement on the terms of a cash offer for the Company by Pillartree Limited (&#147;<B>Acquirer Sub</B>&#148;), a newly formed private
limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company. Under the terms of the
Acquisition, each Company Shareholder at the Scheme Record Time will be entitled to receive: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>$116.50 for each
Company Share in cash </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Acquisition represents: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a premium of approximately 47.9% to the closing price of $78.76 per Company Share on November&nbsp;29, 2022 (being the
last closing price per Company Share prior to the Company&#146;s issuance of an announcement of a possible offer under Rule 2.4 of the Irish Takeover Rules); and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a premium of approximately 19.7% to the closing price of $97.29 per Company Share on December&nbsp;9, 2022.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Acquisition values the entire issued and to be issued ordinary share capital of the Company at approximately
$27.8&nbsp;billion on a fully diluted basis and implies an enterprise value of approximately $28.3&nbsp;billion. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amgen has entered into a Bridge Credit Agreement, dated December&nbsp;12, 2022, for an aggregate amount of
$28.5&nbsp;billion, by and among Amgen, Citibank N.A., as administrative agent, Bank of America, N.A., as syndication agent, and Citibank, N.A. and Bank of America, N.A. as lead arrangers and book runners, and the other banks from time to time party
thereto to finance, together with Amgen&#146;s own cash resources, the Acquisition. Further information on the financing of the Acquisition will be set out in the Proxy Statement (which will include the Scheme Document). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Commenting on today&#146;s announcement, Tim Walbert, chairman, president and chief executive officer of the Company
said: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<I>In nearly 15 years, we have built one of the fastest growing and most respected companies in the
biotechnology industry from the ground up. We have accomplished a tremendous amount for patients, their families and our customers, and created significant value for shareholders. These accomplishments are all rooted in our employees&#146; deep
commitment, dedication and personal passion for those impacted by rare, autoimmune and severe inflammatory diseases. Amgen is aligned with that commitment and passion and will continue to maximise the value of the current portfolio and pipeline and
accelerate the ability to reach more patients globally.&#148; </I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Commenting on today&#146;s announcement, Robert A. Bradway, chairman and chief executive officer of Amgen said:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<I>The acquisition of Horizon is a compelling opportunity for Amgen and one that is consistent with our
strategy of delivering long-term growth by providing innovative medicines that address the needs of patients who suffer from serious diseases. Amgen&#146;s decades of leadership in inflammation and nephrology, combined with our global presence and
world-class biologics capabilities, will enable us to reach many more patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines like TEPEZZA, KRYSTEXXA and UPLIZNA. Additionally, the
potential new medicines in Horizon&#146;s pipeline strongly complement our own R&amp;D portfolio. The acquisition of Horizon will drive growth in Amgen&#146;s revenue and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS and is expected to be
accretive from 2024.&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Amgen Background to and Reasons for the Acquisition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen believes that there is a compelling strategic and financial rationale for undertaking the Acquisition, which is expected to deliver the following
benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Strengthens Amgen&#146;s portfolio of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> / <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> innovative therapeutics by adding a complementary
portfolio of medicines from Horizon that address the needs of patients suffering from rare diseases; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Capitalises on Amgen&#146;s <FONT STYLE="white-space:nowrap">20-year</FONT> commercial and medical legacy in
inflammation and nephrology and its global scale to enhance the growth potential of Horizon&#146;s portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Utilises Amgen&#146;s industry-leading research and development, process development and global manufacturing expertise
in biologic medicines for the benefit of Horizon&#146;s approved medicines and potential new medicines; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Generates robust cash flow (approximately $10&nbsp;billion combined over twelve months through Q3 2022)<SUP
STYLE="font-size:75%; vertical-align:top">[1]</SUP> to support capital allocation priorities, including ongoing investment in innovation and continued dividend growth while sustaining a commitment to an investment grade credit rating;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Accelerates revenue growth and is expected to be accretive to <FONT STYLE="white-space:nowrap">non-GAAP</FONT> earnings
per share from 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Increases efficiency for the Combined Group, leading to an estimated annual
<FONT STYLE="white-space:nowrap">pre-tax</FONT> cost reduction of at least $500&nbsp;million by the end of the third fiscal year following Completion. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Company Board Recommendation </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Having taken into account the relevant factors and applicable risks, the Company Board, which has been so advised by
Morgan Stanley, which as financial advisor to the Company Board has rendered a fairness opinion, considers the terms of the Acquisition as set out in this Announcement to be fair and reasonable. In providing its advice to the Company Board, Morgan
Stanley has taken into account the commercial assessments of the Company Directors. The Company Board has unanimously determined that the Transaction Agreement and the Transactions, including the Scheme, are advisable for, fair to and in the best
interests of, the Company Shareholders. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Accordingly, the Company Board unanimously recommends that Company Shareholders vote in favour of the Scheme Meeting
Resolution and the Required EGM Resolutions, or, if the Acquisition is implemented by a Takeover Offer, accept or procure acceptance of such Takeover Offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Timeline and Conditions </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">It is agreed that the Acquisition will be implemented by way of an Irish High Court-sanctioned scheme of arrangement
under Chapter 1 of Part 9 of the Irish Companies Act (although Acquirer </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top">[1]</SUP> For the twelve months through Q3 2022, Amgen GAAP operating cash flow of $9.88&nbsp;billion less Amgen capital
expenditures of $883&nbsp;million plus Horizon GAAP operating cash flow of $1.37&nbsp;billion less Horizon capital expenditures of $56&nbsp;million = ~$10&nbsp;billion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
Sub reserves the right to effect the Acquisition by way of a Takeover Offer, subject to the provisions of the Transaction Agreement and the Irish Takeover Rules and with the consent of the Irish
Takeover Panel). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Acquisition will be subject to the satisfaction or waiver (as applicable) of the Conditions, which are set out in
full in Appendix 3 (<I>Conditions of the Acquisition and the Scheme</I>) to this Announcement, including, in summary: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the requisite approval by Company Shareholders of the Scheme Meeting Resolution and the Required EGM Resolutions;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the sanction of the Scheme by the Irish High Court; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the receipt of required antitrust clearances in the United States, Austria and Germany and the receipt of required
foreign investment clearances in France, Germany, Denmark and Italy. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">It is expected that the Scheme Document, containing further information about the Acquisition and notices of the Scheme
Meeting and the EGM, the expected timetable for Completion and action to be taken by Company Shareholders, will be published as soon as practicable. It is anticipated that the Scheme will, subject to obtaining the necessary regulatory approvals, be
declared effective in the first half of 2023. An expected timetable of key events relating to the Acquisition will be provided in the Scheme Document. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Advisors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Company&#146;s financial advisors in respect of the Acquisition are Morgan Stanley and J.P. Morgan. The
Company&#146;s legal advisors are Cooley LLP and Matheson LLP. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amgen&#146;s lead financial advisor in respect of the Acquisition is PJT Partners and its financial advisor is
Citigroup. Amgen&#146;s legal advisors are Sullivan&nbsp;&amp; Cromwell LLP and William Fry LLP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About the Company Group </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Company is a public limited company registered in Ireland whose shares are admitted to trading on Nasdaq under the
ticker &#147;HZNP&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Company is a global biotechnology company headquartered in Dublin, Ireland and is focused on the discovery,
development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. The Company has 12 marketed medicines and a pipeline with more than 20 development programs. The
Company has offices or a presence across four continents and more than 2,000 employees. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">For more information about the Company Group, see <FONT COLOR="#0000ff"><U>www.horizontherapeutics.com</U></FONT>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Amgen and Acquirer Sub </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Acquirer Sub is a private limited company incorporated in Ireland established for the sole purpose of implementing the
Acquisition and is a wholly owned subsidiary of Amgen. As of the date of this Announcement, the entire issued ordinary share capital of Acquirer Sub is owned by Amgen. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amgen is a highly focused biotechnology company committed to unlocking the potential of biology for patients suffering
from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of
human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people&#146;s lives. A biotechnology pioneer since 1980, Amgen has grown to be
one of the world&#146;s leading independent biotechnology companies. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the <FONT STYLE="white-space:nowrap">Nasdaq-100</FONT> index.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">For more information about Amgen, see <FONT COLOR="#0000ff"><U>www.amgen.com</U></FONT>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Enquiries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors: Tina Ventura</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 224 383 3344</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Media: Geoff Curtis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 224 383 3333</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Morgan Stanley (Joint Financial Advisor to the Company)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Julie Rozenblyum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 761 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joe Modisett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tedd Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Kitterick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7425 8000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>J.P. Morgan (Joint Financial Advisor to the Company)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dwayne Lysaght</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+44&nbsp;(0)&nbsp;20&nbsp;7742&nbsp;4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jeremy Meilman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Tel:&nbsp;+1&nbsp;(212)&nbsp;270-6000</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ben Carpenter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Tel:&nbsp;+1&nbsp;(212)&nbsp;270-6000</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Steve Frank</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Tel:&nbsp;+1&nbsp;(212)&nbsp;270-6000</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Amgen</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors: Arvind Sood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 805 447 1060</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Media: Jessica Akopyan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 805 440 5721</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>PJT Partners (Lead Financial Advisor to Amgen)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Taubman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 364 7800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tom Davidson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 364 7800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basil Geoghegan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+44&nbsp;(0)20&nbsp;3650&nbsp;1100</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Daniel Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 364 7800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kush Nanjee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+44&nbsp;(0)20&nbsp;3650&nbsp;1100</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Citigroup (Financial Advisor to Amgen)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Torrey Browder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sumit Khedekar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+44&nbsp;20&nbsp;7986&nbsp;4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Rob Way</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sian Evans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Marc Banziger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Edelman (PR Advisor to Amgen)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lex Suvanto</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: + 1 212 768 0550</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shannon Susko</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+&nbsp;1&nbsp;212&nbsp;768&nbsp;0550</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jamaal Mobley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+&nbsp;1&nbsp;212&nbsp;768&nbsp;0550</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joe Carmody</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +353 1 592 1330</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Piaras Kelly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +353 1 592 1330</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Feargal Purcell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +353 1 592 1330</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>WEBCAST INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen
will host a webcast call for the investment community at 5:00 a.m. Pacific Standard Time on December&nbsp;12, 2022. Robert A. Bradway, chairman and chief executive officer, along with other members of Amgen&#146;s management team, will present an
overview of Amgen&#146;s acquisition of Horizon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The webcast will be broadcast over the internet simultaneously and will be available to members of
the news media, investors and the general public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The webcast, as with other selected presentations regarding developments in Amgen&#146;s business
given by Amgen management at certain investor and medical conferences, can be found on Amgen&#146;s website, <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.amgen.com</U></FONT><FONT STYLE="font-family:ARIAL">, under
&#147;Investors&#148;. Information regarding presentation times, webcast availability and webcast links are noted on Amgen&#146;s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after
the event. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NO OFFER OR SOLICITATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This
Announcement is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise
dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition will be implemented by means of an Irish High Court-sanctioned scheme of arrangement on the terms provided for in the Scheme
Document (or, if the Acquisition is implemented by way of a Takeover Offer, the Takeover Offer Document), which will contain the full terms and conditions of the Acquisition, including details of how Company Shareholders may vote in respect of the
Acquisition. Any decision in respect of, or other response to, the Acquisition, should be made only on the basis of the information contained in the Scheme Document (or if the Acquisition is implemented by way of a Takeover Offer, the Takeover Offer
Document). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In connection with the Acquisition, the Company will file with the SEC a Proxy Statement (which will include the Scheme Document). The Proxy Statement
will be mailed to Company Shareholders as of the record date to be established for voting at the Scheme Meeting or EGM. This Announcement is not a substitute for the Proxy Statement or any other document that the Company may file with the SEC or
send to its shareholders in connection with the Acquisition. BEFORE MAKING ANY VOTING DECISION, HOLDERS OF COMPANY SHARES ARE URGED TO READ THE PROXY STATEMENT (INCLUDING THE SCHEME DOCUMENT) ANY AMENDMENTS OR SUPPLEMENTS THERETO AND OTHER RELEVANT
DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE ACQUISITION, INCLUDING ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT THE ACQUISITION, THE PARTIES TO THE SCHEME AND RELATED MATTERS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any vote in respect of the Scheme Meeting Resolution and the EGM Resolutions to approve the
Acquisition, the Scheme or related matters, or other responses in relation to the Acquisition, should be made only on the basis of the information contained in the Proxy Statement (including the Scheme Document). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Proxy Statement, if and when filed, as well as the Company&#146;s other public filings with the SEC, may be obtained without charge at the
SEC&#146;s website at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.sec.gov</U></FONT><FONT STYLE="font-family:ARIAL"> and at the Company&#146;s website at
</FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.horizontherapeutics.com</U></FONT><FONT STYLE="font-family:ARIAL">. Company Shareholders and investors will also be able to obtain, without charge, a copy of the Proxy
Statement (including the Scheme Document) and other relevant documents (when available) by directing a written request to the Company, Attn: Investor Relations, 70 St. Stephen&#146;s Green, Dublin 2, D02 E2X4, Ireland, or by contacting Tina Ventura,
Investor Relations, by email to </FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>ir@horizontherapeutics.com</U></FONT><FONT STYLE="font-family:ARIAL">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PARTICIPANTS IN THE SOLICITATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company and certain of
its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from Company Shareholders in connection with the Acquisition and any other matters to be voted on at the Scheme Meeting or the EGM.
Information about the directors and executive officers of the Company, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company&#146;s definitive proxy statement on Schedule 14A
for its 2022 annual general meeting of shareholders, dated and filed with the SEC on March&nbsp;17, 2022. Other information regarding the persons who may, under the rules of the SEC, be deemed to be participants in the solicitation of Company
Shareholders, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement (which will contain the Scheme Document) and other relevant materials to be filed with the SEC
in connection with the Acquisition. You may obtain free copies of these documents using the sources indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CAUTIONARY STATEMENT REGARDING
FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This Announcement contains certain statements about the Company and Amgen that are or may be forward-looking
statements which include, but are not limited to, statements regarding expected timing, completion and effects of the Acquisition. These forward-looking statements are subject to the safe harbor provisions under the U.S. Private Securities
Litigation Reform Act of 1995. All statements other than statements of historical facts included in this Announcement may be forward-looking statements. Without limitation, forward-looking statements often include words such as &#147;expect,&#148;
&#147;anticipate,&#148; &#147;outlook,&#148; &#147;could,&#148; &#147;target,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;estimate,&#148; &#147;should,&#148; &#147;may,&#148;
&#147;assume&#148; and &#147;continue&#148; as well as variations of such words and similar expressions are intended to identify such forward-looking statements. The Company&#146;s and Amgen&#146;s expectations and beliefs regarding these matters
may not materialise. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and
uncertainties related to: the ability of the Parties to consummate the Acquisition in a timely manner or at all; the satisfaction (or waiver) of conditions to the consummation of the Acquisition, including with respect to the approval of Company
Shareholders and required regulatory approvals; potential delays in consummating the Acquisition; the ability of the Company and Amgen to timely and successfully achieve the anticipated strategic benefits, synergies or opportunities expected as a
result of the Acquisition; the successful integration of the Company into Amgen subsequent to Completion and the timing of such integration; the impact of changes in global, political, economic, business, competitive, market and regulatory forces;
the impact of health pandemics, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on the Company&#146;s or Amgen&#146;s respective businesses; the occurrence of any event, change or other circumstance or condition that could
give rise to the termination of the Transaction Agreement; adverse effects on the market price of the Company&#146;s or Amgen&#146;s securities and on the Company&#146;s or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen&#146;s operating results because of a failure to complete the Acquisition; the effect of the
announcement or pendency of the Acquisition on the Company&#146;s or Amgen&#146;s business relationships, operating results and business generally; costs related to the Acquisition; and the outcome of any legal proceedings that may be instituted
against the Company, Amgen, Acquirer Sub or any of their respective directors or officers related to the Transaction Agreement or the Acquisition. Additional risks and uncertainties that could cause actual outcomes and results to differ materially
from those contemplated by the forward-looking statements are included under the caption &#147;Risk Factors&#148; and elsewhere in the Company&#146;s most recent filings with the SEC, including its Quarterly Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarter ended September&nbsp;30, 2022, and Amgen&#146;s most recent filings with the SEC, including its Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT>
for the quarter ended September&nbsp;30, 2022, and any subsequent reports on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;Form&nbsp;10-Q&nbsp;or</FONT></FONT>
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;filed</FONT> with the SEC by the Company or Amgen from time to time and available at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.sec.gov</U></FONT><FONT
STYLE="font-family:ARIAL">. These documents can be accessed on the Company&#146;s web page at
</FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U><FONT STYLE="white-space:nowrap">https://ir.horizontherapeutics.com/financial-information/sec-filings</FONT></U></FONT><FONT STYLE="font-family:ARIAL"> or on Amgen&#146;s web
page at </FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U><FONT STYLE="white-space:nowrap">https://investors.amgen.com/financials/sec-filings</FONT></U></FONT><FONT STYLE="font-family:ARIAL">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The forward-looking statements included in this Announcement are made only as of the date hereof. Neither the Company nor Amgen assumes any obligation
to, and neither the Company nor Amgen intends to, update these forward-looking statements, except as required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RESPONSIBILITY STATEMENT
REQUIRED BY THE IRISH TAKEOVER RULES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company Directors accept responsibility for the information contained in this Announcement relating to
the Company, the Company Group and the Company Directors and members of their immediate families, related trusts and persons connected with them and for the Company Amgen Statements (as defined below), except for the statements made by Amgen in
respect of the Company (the &#147;<B>Amgen Company Statements</B>&#148;). To the best of the knowledge and belief of the Company Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this
Announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Amgen Directors and Acquirer Sub Directors accept responsibility for the information contained in this Announcement other than that relating to the
Company, the Company Group and the Company Directors and members of their immediate families, related trusts and persons connected with them but including the Amgen Company Statements (for which the Amgen Directors and the Acquirer Sub Directors
accept responsibility), and other than the statements made by the Company in respect of Amgen (the &#147;<B>Company Amgen Statements</B>&#148;). To the best of the knowledge and belief of the Amgen Directors (who have taken all reasonable care to
ensure such is the case), the information contained in this Announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>IMPORTANT NOTICES RELATING TO FINANCIAL ADVISORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Morgan
Stanley&nbsp;&amp; Co. LLC, acting through its affiliate Morgan Stanley&nbsp;&amp; Co. International plc (together, &#147;<B>Morgan Stanley</B>&#148;), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct
Authority in the United Kingdom, is acting exclusively for the Company as financial advisor and for no one else in relation to the matters referred to in this Announcement. In connection with such matters, Morgan Stanley and its directors, officers,
employees and agents will not regard any other person as its client, nor will it be responsible to anyone other than the Company for providing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">protections afforded to their clients or for providing advice in connection with the matters described
in this Announcement or any matter referred to herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">J.P. Morgan Securities LLC (&#147;<B>J.P. Morgan</B>&#148;), which is a registered broker
dealer with the SEC, is acting as financial advisor to the Company in connection with the Acquisition. In connection with the Acquisition, J.P. Morgan and its directors, officers, employees and agents will not regard any other person as its client,
nor will it be responsible to anyone other than the Company for providing the protections afforded to clients of J.P. Morgan or for giving advice in connection with the Acquisition or any matter referred to herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">PJT Partners, which is a registered broker dealer with the SEC, is acting exclusively for Amgen and for <FONT STYLE="white-space:nowrap">no-one</FONT>
else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than Amgen for providing the protections afforded to clients of PJT Partners nor for providing advice in relation to the matters
referred to in this Announcement. Neither PJT Partners nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or
otherwise) to any person who is not a client of PJT Partners in connection with this Announcement, any statement contained herein or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Citigroup, which is a registered broker-dealer regulated by the SEC, is acting exclusively for Amgen and for no one else in connection with the
Acquisition and other matters described in this announcement, and will not be responsible to anyone other than Amgen for providing the protections afforded to clients of Citigroup nor for providing advice in connection with the Acquisition or any
other matters referred to in this announcement. Neither Citigroup nor any of its affiliates, directors or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, consequential, whether in contract, in
tort, under statute or otherwise) to any person who is not a client of Citigroup in connection with this announcement, any statement contained herein, the Acquisition or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>DISCLOSURE REQUIREMENTS OF THE IRISH TAKEOVER RULES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under
the provisions of Rule 8.3(a) of the Irish Takeover Rules, any person who is &#145;interested&#146; in 1% or more of any class of &#145;relevant securities&#146; of the Company must make an &#145;opening position disclosure&#146; following the
commencement of the &#145;offer period&#146;. An &#145;opening position disclosure&#146; must contain the details contained in Rule 8.6(a) of the Irish Takeover Rules, including, among other things, details of the person&#146;s &#145;interests&#146;
and &#145;short positions&#146; in any &#145;relevant securities&#146; of the Company. An &#145;opening position disclosure&#146; by a person to whom Rule 8.3(a) applies must be made by no later than 3:30 p.m. (E.T.) on the day falling ten
&#145;business days&#146; following the commencement of the &#145;offer period&#146;. Relevant persons who deal in any &#145;relevant securities&#146; prior to the deadline for making an &#145;opening position disclosure&#146; must instead make a
&#145;dealing&#146; disclosure as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under the provisions of Rule 8.3(b) of the Irish Takeover Rules, if any person is, or becomes,
&#145;interested&#146; in 1% or more of any class of &#145;relevant securities&#146; of the Company, that person must publicly disclose all &#145;dealings&#146; in any &#145;relevant securities&#146; of the Company during the &#145;offer
period&#146;, by not later than 3:30 p.m. (E.T.) on the &#145;business day&#146; following the date of the relevant transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If two or more
persons <FONT STYLE="white-space:nowrap">co-operate</FONT> on the basis of any agreement either express or tacit, either oral or written, to acquire an &#145;interest&#146; in &#145;relevant securities&#146; of the Company or any securities exchange
offeror, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition, each of the Company and
any offeror must make an &#145;opening position disclosure&#146; by no later 12:00 noon (E.T.) on the date falling ten &#145;business days&#146; following the commencement of the &#145;offer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">period&#146; or the announcement that first identifies a securities exchange offeror, as applicable,
and disclose details of any &#145;dealings&#146; by it or any person &#145;acting in concert&#146; with it in &#145;relevant securities&#146; during the &#145;offer period&#146;, by no later than 12:00 noon (E.T.) on the business day following the
date of the transaction (see Rules 8.1, 8.2 and 8.4). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">A disclosure table, giving details of the companies in whose &#145;relevant securities&#146;
&#145;opening position&#146; and &#145;dealings&#146; should be disclosed can be found on the Irish Takeover Panel&#146;s website at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.irishtakeoverpanel.ie</U></FONT><FONT
STYLE="font-family:ARIAL">. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#145;Interests&#146; in securities arise, in summary, when a person has long economic exposure, whether
conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an &#145;interest&#146; by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative
referenced to, securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel&#146;s
website. If you are in any doubt as to whether or not you are required to disclose an &#145;opening position&#146; or &#145;dealing&#146; under Rule 8, please consult the Irish Takeover Panel&#146;s website at <FONT
STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.irishtakeoverpanel.ie</U></FONT><FONT STYLE="font-family:ARIAL"> or contact the Irish Takeover Panel on telephone number +353 1 678 9020. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NO PROFIT FORECAST / QUANTIFIED FINANCIAL BENEFIT STATEMENT / ASSET VALUATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">No statement in this Announcement is intended to constitute a profit forecast or quantified financial benefit statement for any period, nor should any
statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Amgen or the Company. No statement in this Announcement constitutes an asset
valuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PUBLICATION ON WEBSITE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In accordance with
Rule 26.1 of the Irish Takeover Rules, a copy of this Announcement will be available on the Company&#146;s website at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.horizontherapeutics.com</U></FONT><FONT
STYLE="font-family:ARIAL"> and Amgen&#146;s website at </FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.amgen.com</U></FONT><FONT STYLE="font-family:ARIAL"> by no later than 12:00 noon (E.T.) on the business day
following this Announcement. Neither the content of any such website nor the content of any other website accessible from hyperlinks on such website is incorporated into, or forms part of, this Announcement. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>REQUESTING HARD COPY INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any Company Shareholder
may request a copy of this Announcement and / or any information incorporated by reference into this Announcement in hard copy form by writing to the Company, Attn: Investor Relations, 70 St. Stephen&#146;s Green, Dublin 2, D02 E2X4, Ireland or by
contacting Tina Ventura, Investor Relations, via email at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>ir@horizontherapeutics.com</U></FONT><FONT STYLE="font-family:ARIAL">. Any written requests must include the identity of the
Company Shareholder and any hard copy documents will be posted to the address of the Company Shareholder provided in the written request. If you have received this Announcement in electronic form, a hard copy of this Announcement and / or any
document or information incorporated by reference into this Announcement will not be provided unless such a request is made. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RIGHT TO SWITCH TO A
TAKEOVER OFFER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen reserves the right to elect to implement the Acquisition by way of a Takeover Offer for the entire issued and to be issued
ordinary share capital of the Company as an alternative to the Scheme, subject to the provisions of the Irish Takeover Rules and the Transaction Agreement and with the Irish Takeover Panel&#146;s consent whether or not the Scheme Document has been
posted. In such event, the Acquisition would be implemented on the same terms (subject to appropriate amendments), so far as are applicable, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">as those which would apply to the Scheme and subject to the amendments referred to in Appendix 3
(<I>Conditions of the Acquisition and the Scheme</I>) to this Announcement and in the Transaction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If Amgen exercises its right to
implement the Acquisition by way of a Takeover Offer as an alternative to the Scheme, subject to the provisions of the Irish Takeover Rules and the Transaction Agreement and with the Irish Takeover Panel&#146;s consent, such offer would be made in
compliance with applicable U.S. Laws and regulations, including the registration requirements of the U.S. Securities Act and the tender offer rules under the U.S. Exchange Act and any applicable exemptions provided thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>ROUNDING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Certain figures included in this Announcement have
been subjected to rounding adjustments. Accordingly, any figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that
precede them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>OVERSEAS JURISDICTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The release,
publication or distribution of this Announcement in or into jurisdictions other than Ireland and the United States may be restricted by Law and therefore any persons who are subject to the Law of any jurisdiction other than Ireland and the United
States should inform themselves about, and observe, any applicable legal or regulatory requirements. In particular the ability of persons who are not resident in Ireland or the United States, to vote their Company Shares with respect to the Scheme
at the Scheme Meeting, or to appoint another person as proxy to vote at the Scheme Meeting on their behalf, may be affected by the Laws of the relevant jurisdictions in which they are located. Any failure to comply with the applicable legal or
regulatory requirements may constitute a violation of the Laws of any such jurisdiction. To the fullest extent permitted by applicable Law, the Company and Amgen and persons involved in the Acquisition disclaim any responsibility or liability for
the violation of such restrictions by any person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This Announcement has been prepared for the purpose of complying with the Laws of Ireland and the
Irish Takeover Rules and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the Laws of jurisdictions outside of Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Unless otherwise determined by Amgen or required by the Irish Takeover Rules, and permitted by applicable Law and regulation, the Acquisition will not
be made available directly or indirectly, in, into or from any Restricted Jurisdiction and no person may vote in favour of the Acquisition by any use, means, instrumentality or facilities from within a Restricted Jurisdiction or any other
jurisdiction if to do so would constitute a violation of the Laws of that jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Copies of this Announcement and any formal documentation
relating to the Acquisition will not be and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from any Restricted Jurisdiction or any jurisdiction where to do so would violate the Laws of that
jurisdiction and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in or into or from any Restricted Jurisdiction. Doing so may render invalid any related
purported vote in respect of the Acquisition. If the Acquisition is implemented by way of a Takeover Offer (unless otherwise permitted by applicable Law or regulation), the Takeover Offer may not be made, directly or indirectly, in or into or by use
of the mails or any other means or instrumentality or facilities (including, without limitation, facsimile, email or other electronic transmission, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">telex or telephone) of interstate or foreign commerce of, or any facility of a national, state or
other securities exchange of any Restricted Jurisdiction and the Takeover Offer will not be capable of acceptance by any such use, means, instrumentality or facilities from within any Restricted Jurisdiction or any other jurisdiction if to do so
would constitute a violation of the Laws of that jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Further details in relation to overseas shareholders will be contained in the Proxy
Statement (which will include the Scheme Document). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>GENERAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This summary should be read in conjunction with, and is subject to, the full text of this Announcement (including its Appendices). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition is subject to, <I>inter alia</I>, the terms and conditions of the Transaction Agreement and the terms and the satisfaction or waiver (as
applicable) of the Conditions set out in Appendix 3 (<I>Conditions of the Acquisition and the Scheme</I>) to this Announcement. The Acquisition is also subject to the full terms and conditions which will be set out in the Scheme Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Appendix 1 (<I>Sources and Bases of Information</I>) contains further details of the sources of information and bases of calculations set out in this
Announcement; Appendix 2 (<I>Definitions</I>) contains definitions of certain expressions used in this Announcement; Appendix 3 (<I>Conditions of the Acquisition and the Scheme</I>) contains the Conditions of the Acquisition and the Scheme; and
Appendix 4 (<I>Transaction Agreement</I>) appends the Transaction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The financial information included in this Announcement and to be
included in the Scheme Document has or will be prepared in accordance with generally accepted accounting principles in the United States. The following <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures have been included in this
Announcement in relation to Amgen and the Combined Group: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;free cash flow&#148;, which is computed by subtracting capital expenditures from operating cash flow, each as
determined in accordance with GAAP; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> EPS&#148;, which is computed by taking <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> net income and dividing it by the number of weighted-average shares of Amgen. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">These <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Be aware that addresses, electronic addresses and certain other information provided by Company Shareholders, holders of shares in Amgen, persons with
information rights and other relevant persons for the receipt of communications from the Company, and / or Amgen may be exchanged between the Parties as required by the Irish Takeover Rules and applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any response in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Document and the Proxy Statement
or any document by which the Acquisition and the Scheme are made. Company Shareholders are advised to read carefully the formal documentation in relation to the Acquisition, including the Scheme Document once the Proxy Statement has been sent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Transaction Agreement contains representations and warranties made by and to the parties thereto as of specific dates. The statements embodied in
those representations and warranties were made for purposes of the contract between the parties and may be subject to qualifications and limitations agreed by the parties in connection with negotiating the terms of that contract. In addition,
certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">representations and warranties were made as of a specified date, may be subject to a contractual
standard of materiality different from those generally applicable to investors, or may have been used for the purpose of allocating risk between the parties rather than establishing matters as facts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent
financial advice immediately from your appropriately authorised independent financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B><I>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY
JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B><I>THIS ANNOUNCEMENT
IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B><I>FOR IMMEDIATE RELEASE </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B><I>December&nbsp;12, 2022 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RECOMMENDED
CASH OFFER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>for </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>HORIZON
THERAPEUTICS PLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>by </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Pillartree
Limited, a newly formed private limited company wholly owned by Amgen Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>to be implemented by way of a scheme of arrangement under Chapter
1 of Part 9 of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Companies Act 2014 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Introduction </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board of directors of Horizon Therapeutics plc (the &#147;<B>Company</B>&#148; or &#147;<B>Horizon</B>&#148;) and the board of directors of Amgen
Inc. (&#147;<B>Amgen</B>&#148;) are pleased to announce that they have reached agreement on the terms of a cash offer for the Company by Pillartree Limited (&#147;<B>Acquirer Sub</B>&#148;), a newly formed private limited company wholly owned by
Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>The Acquisition </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">It is agreed that the Acquisition will be implemented by way of an Irish High Court-sanctioned scheme of arrangement under Chapter 1 of Part 9 of the
Irish Companies Act (although Amgen reserves the right to effect the Acquisition by way of a Takeover Offer, subject to the terms of the Transaction Agreement, compliance with the Irish Takeover Rules and with the consent of the Irish Takeover
Panel). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under the terms of the Acquisition, which will be subject to the Conditions and other terms set out in this Announcement and to further
terms to be set out in the Scheme Document, each Company Shareholder at the Scheme Record Time will be entitled to receive: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>$116.50 for each Company Share in cash </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition represents: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a premium of approximately 47.9% to the closing price of $78.76 per Company Share on November&nbsp;29, 2022 (being the
last closing price per Company Share prior to the Company&#146;s issuance of an announcement of a possible offer under Rule 2.4 of the Irish Takeover Rules); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a premium of approximately 19.7% to the closing price of $97.29 per Company Share on December&nbsp;9, 2022.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition values the entire issued and to be issued ordinary share capital of the Company at approximately
$27.8&nbsp;billion on a fully diluted basis and implies an enterprise value of approximately $28.3&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>The sources and bases of information contained
in this Announcement to calculate the implied value of the Acquisition are set out in Appendix 1 (</B><B><I>Sources and Bases of Information</I></B><B>). </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Company Background to and Reasons for Recommending the Acquisition </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company is a biotechnology company focused on the discovery, development and commercialisation of medicines that address critical needs for people
impacted by rare, autoimmune and severe inflammatory diseases. The Company Board, together with the Company&#146;s senior management, and with the assistance of its financial and legal advisors, regularly reviews the Company&#146;s strategic and
financial prospects on a standalone basis in light of developments in the Company&#146;s business, the sectors in which it operates and the economy and financial markets generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Following receipt of an unsolicited proposal from Sanofi to acquire the entire issued and to be issued ordinary share capital of the Company for cash
(the &#147;<B>Unsolicited Proposal</B>&#148;), the Company Board, together with the Company&#146;s senior management, and with the assistance of its outside advisors, met to discuss the Unsolicited Proposal and determined that the offer price was
insufficient to warrant any substantive discussions or allow access to any due diligence and rejected the proposal. During the next 28 days, Sanofi made two subsequent proposals at higher prices before the Company Board determined that the proposed
price was sufficient to permit Sanofi to receive a management presentation and access to limited additional information in order to support Sanofi making a further enhanced offer. The Company Board also determined that the best way to maximise
shareholder value would be to approach other potential bidders and authorised the Company&#146;s senior management and its financial advisors to contact three additional global biopharmaceutical companies that it believed may be interested in a
potential acquisition of the Company and would have the financial means to complete an acquisition of this size, with the outreach subject to obtaining the relevant consents of the Irish Takeover Panel. After obtaining the consents, the
Company&#146;s financial advisors contacted the three parties, comprised of Amgen and two other global pharmaceutical companies (one such company being referred to herein as Company A and the other being Janssen Global Services, LLC
(&#147;<B>JNJ</B>&#148;)), and conveyed that the Company had received an unsolicited proposal to be acquired on an expeditious timetable. All three parties expressed an interest in receiving a management presentation and engaging in due diligence to
determine whether they would submit a proposal. The Company entered into confidentiality agreements with all four parties and gave each of the parties management presentations in a two day period and responded to preliminary due diligence questions.
Subsequently, Amgen submitted an initial bid and Sanofi increased its proposed price. Company A declined to submit a proposal. JNJ indicated that it would continue to evaluate the information shared in the management presentation and would make a
determination after a board meeting as to whether to submit a bid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">On November&nbsp;29, 2022, the Company released an announcement of a possible
offer under Rule 2.4 of the Irish Takeover Rules, confirming that it was in highly preliminary discussions with Amgen, Sanofi and JNJ. On December&nbsp;2, 2022, Sanofi and Amgen each released a statement as required by Rule 2.12 of the Irish
Takeover Rules confirming that any offer, if made, would be in cash. Subsequently, JNJ conveyed to the Company&#146;s financial advisors that it had decided not to submit a proposal and issued a statement on December&nbsp;3, 2022 under Rule 2.8 of
the Irish Takeover Rules that it did not intend to make an offer for the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">After considering the initial proposal from Amgen and the revised proposal from Sanofi, the Company
Board authorised the Company to provide both parties with access to a due diligence data room and to provide both parties with a draft transaction agreement. After Amgen and Sanofi submitted proposed changes to the draft transaction agreement and
identified required regulatory approvals, the Company Board authorised its financial advisors to send a process letter to both parties indicating that final offers with confirmation of funds certain should be submitted with a negotiated transaction
agreement by no later than December&nbsp;9, 2022. At the instruction of the Company and its financial advisors, each of Amgen and Sanofi submitted its revised offer to acquire the Company on December&nbsp;9, 2022. On December&nbsp;10, 2022, the
Company continued to discuss the offers from Sanofi and Amgen and received additional offers from Amgen and Sanofi at higher prices. Following the discussions with Amgen and Sanofi, the Company Board met on December&nbsp;10, 2022, together with the
Company&#146;s senior management and financial and legal advisors, to consider proposed terms of the best and final proposals from each of Amgen and Sanofi. The Company Board, together with the Company&#146;s senior management, and with the
assistance of its financial and legal advisors, reviewed the key legal and financial terms of each of the proposals from each of Amgen and Sanofi. Following discussions, the Company Board determined that the final proposal from Amgen was superior to
the proposal from Sanofi and the near final drafts of the transaction agreements submitted by each party were substantially comparable. Following discussions, the Company Board unanimously determined to accept the terms of the offer received from
Amgen of $116.50 per Company Share, resolving that such offer was in the best interests of the Company and the Company Shareholders, and thereby approved the Acquisition and resolved to recommend to the Company Shareholders that they approve the
Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company Board carefully considered the terms of the Acquisition and the other Transactions, consulted with Company senior
management and its financial and legal advisors, and considered a number of factors, each of which is supportive of its unanimous decision to approve the Acquisition and the other Transactions and recommend the Transactions to the Company
Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company believes Amgen has the capacity to maximise the value of the Company&#146;s current portfolio and accelerate the ability
for Horizon&#146;s medicines to reach more patients globally with increased global commercial scale as well as enhanced R&amp;D and technology capabilities to rapidly advance the pipeline to find more therapies for patients who are underserved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Further detail in respect of the background and reasons for recommending the Acquisition will be included in the Proxy Statement (which will include the
Scheme Document). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Amgen Background to and Reasons for the Acquisition </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen believes there is a compelling strategic and financial rationale for undertaking the acquisition, which is expected to deliver the following
benefits: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The Acquisition adds <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> / <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> innovative medicines that fit well with Amgen&#146;s portfolio and strategic vision </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Since its founding in 2005, the Company has successfully built a robust business with continued growth potential.
TEPEZZA, KRYSTEXXA and UPLIZNA are innovative biologic medicines with impressive benefits that are reaching a growing number of patients suffering from serious diseases. These three early life cycle products collectively generated $2.0&nbsp;billion
of sales through the first nine months of 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amgen&#146;s long-term strategy includes a focus on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> innovative therapeutics that treat grievous illness, and
on delivering those medicines to more patients around the world. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Company&#146;s focus and products align well with Amgen&#146;s long-term growth strategy: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Amgen&#146;s growth reflects contributions from therapies with large addressable patient populations (such as
cardiovascular disease, osteoporosis, psoriasis, and asthma), as well as therapies that address diseases with lower prevalence (such as ANCA-associated vasculitis, immune thrombocytopenic purpura and acute lymphoblastic leukemia) that are adjacent
to Amgen&#146;s core therapeutic areas. TEPEZZA and KRYSTEXXA are a strong fit with the latter category and help to further diversify the Combined Group&#146;s revenue outlook. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">TEPEZZA has significant growth potential in key <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> markets such as Europe
and Japan, which complements Amgen&#146;s international growth strategy. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Company&#146;s R&amp;D efforts include significant lifecycle management expansion for currently marketed products,
along with an innovative <FONT STYLE="white-space:nowrap">mid-</FONT> to late-stage pipeline with opportunities for advancement of novel programs in disease areas such as myasthenia gravis, IgG4-related disease, systemic lupus erythematosus, lupus
nephritis and Sjogren&#146;s Syndrome. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amgen&#146;s global scale and <FONT STYLE="white-space:nowrap">20-year</FONT> history in
commercializing inflammation therapies can accelerate growth of the Company&#146;s portfolio </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">TEPEZZA is mechanistically rooted in inflammation and KRYSTEXXA is commercially aligned with Enbrel and TAVNEOS, given
the shared rheumatology prescriber base. UPLIZNA targets an autoimmune disorder (neuromyelitis optica spectrum disorder), which is also consistent with Amgen&#146;s expertise in inflammation. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Company also has recent product approvals in Europe and Japan, where Amgen has existing commercial platforms that
could be quickly leveraged and augmented with specialised sales force where needed. Globally, including the U.S., the Combined Group will benefit from Amgen&#146;s experience in commercial operations such as access, medical, patient support, and
overall scale/expertise in marketing and sales. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The Company&#146;s platform strategies in R&amp;D and manufacturing can be strengthened by
Amgen&#146;s <FONT STYLE="white-space:nowrap">40-year</FONT> history in biologics, development and manufacturing </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amgen has the scale, expertise, and resources to advance the Company&#146;s pipeline molecules with speed, and to
support global registration and commercialisation. Given the Company&#146;s focus on biologics, Amgen also has the process development expertise to assist the Company in delivering lifecycle management programs focused on new formulations and new
routes of administration. Amgen is also an industry leader in biologics manufacturing, which provides opportunities for manufacturing cost efficiencies while helping to ensure the Combined Group&#146;s products will reach &#147;every patient, every
time&#148;. Further, Amgen has considerable expertise in drug delivery systems that benefit the patient experience. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Strong financial
profile with <FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS accretion from 2024 and significant cash flow generation enabling continued attractive shareholder payouts and investment in innovation </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The robust free cash flow generated by the Combined Group (approximately $10&nbsp;billion over the twelve months through
Q3 2022)<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> will enable <FONT STYLE="white-space:nowrap">de-levering</FONT> following Completion, while continuing to support investment in the Combined Group&#146;s pipeline and commercial brands.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Acquisition is expected to be accretive to Amgen&#146;s revenue and <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
earnings per share from 2024. Amgen is not providing or updating 2022 or 2030 guidance as a result of the Acquisition. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amgen&#146;s goal is to maintain a strong investment grade credit profile with debt leverage that is <FONT
STYLE="white-space:nowrap">in-line</FONT> with current levels by the end of 2025. Amgen expects to support this goal with over $10&nbsp;billion of debt retirement through that period. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amgen remains committed to growing its annual dividend over time. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Acquisition is expected to deliver annual <FONT STYLE="white-space:nowrap">pre-tax</FONT> cost synergies of at least
$500&nbsp;million by the end of the third fiscal year following Completion. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Company Board Recommendation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company Board, which has been so advised as to the financial terms of the Acquisition by Morgan Stanley, which has rendered a fairness opinion,
considers the terms of the Acquisition to be fair and reasonable. In providing its financial advice, Morgan Stanley has taken into account the commercial assessments of the Company Directors. Morgan Stanley is providing independent financial advice
to the Company Board for the purposes of Rule 3 of the Irish Takeover Rules. The Company Board has unanimously determined that the Transaction Agreement and the Transactions, including the Scheme, are advisable for, fair to and in the best interests
of, the Company Shareholders. Accordingly, the Company Board unanimously recommends that Company Shareholders vote in favour of the Scheme Resolutions and the Required EGM Resolutions or, if the Acquisition is implemented by a Takeover Offer, to
accept or procure acceptance of such Takeover Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>6. The Scheme Process </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">It is agreed that the Acquisition will be implemented by means of an Irish High Court-sanctioned scheme of arrangement between the Company and Company
Shareholders under Chapter 1 of Part 9 of the Irish Companies Act, pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company and each Company Shareholder will receive the Consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company Shares will be acquired pursuant to the Acquisition fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all
liens, charges, equities, encumbrances, rights of <FONT STYLE="white-space:nowrap">pre-emption</FONT> and any other third party rights of any nature whatsoever and together with all rights attaching thereto, including without limitation voting
rights and the right to receive and retain in full all dividends and other distributions (if any) announced, declared, made or paid with a record date on or after the Scheme Record Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">To become effective, the Scheme will require, among other things, the approval of: </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> For the twelve months through Q3 2022, Amgen GAAP operating cash flow of $9.88&nbsp;billion less
Amgen capital expenditures of $883&nbsp;million plus Horizon GAAP operating cash flow of $1.37&nbsp;billion less Horizon capital expenditures of $56&nbsp;million = ~$10&nbsp;billion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Scheme Meeting Resolution by a majority in number of members of each class of Company Shareholders (including as may
be directed by the Irish High Court pursuant to Section&nbsp;450(5) of the Irish Companies Act) present and voting either in person or by proxy at the Scheme Meeting (or at any adjournment or postponement of such meeting) representing, at the Voting
Record Time, at least 75% in value of Company Shares of that class held by such Company Shareholders present and voting either in person or by proxy at the Scheme Meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Required EGM Resolutions being duly passed by the Company Shareholders at the EGM (or any adjournment or
postponement thereof). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Scheme Document will include full details of the Scheme, together with notices of the Scheme Meeting
and the EGM and the expected timetable, and will specify the action to be taken by Company Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Following the passing of the approvals
noted above being obtained and the satisfaction or (where applicable) waiver of the other conditions to the consummation of the Scheme, the sanction of the Irish High Court will also be required in order for the Scheme to become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Assuming the above requirements are satisfied, and the other Conditions, as described in more detail in paragraph 7 (<I>The Conditions</I>) below, have
been satisfied or waived (where applicable), the Scheme will become effective upon delivery to the Irish Registrar of Companies of a copy of the Court Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Upon the Scheme becoming effective, the Scheme will be binding on all Company Shareholders, irrespective of whether or not they attended or voted at the
Scheme Meeting or the EGM and share certificates, if any, in respect of Company Shares will cease to be valid and entitlements to Company Shares held within DTC will be cancelled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any Company Shares issued before the Scheme Record Time will be subject to the terms of the Scheme. One of the EGM Resolutions to be proposed at the EGM
will, amongst other matters, provide that the Company&#146;s memorandum and articles of association be amended to incorporate provisions requiring any Company Shares issued after the Scheme Record Time (other than to Amgen or its affiliates), for
example, due to the crystallisation of Company Options or Company Share Awards, to either be subject to the terms of the Scheme or acquired by Amgen and / or its affiliates on the same terms as the Acquisition (other than terms as to timings and
certain formalities). The inclusion of these provisions in the Company&#146;s memorandum and articles of association will prevent any person (other than Amgen or its affiliates) holding Company Shares immediately after the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to satisfaction or waiver (as applicable) of the Conditions, the Acquisition is expected to be completed in the first half of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If the Scheme does not become effective on or before the End Date (as may be extended pursuant to the Transaction Agreement), it will lapse and the
Acquisition will not proceed (unless the Company, Amgen and Acquirer Sub otherwise agree and the Irish Takeover Panel otherwise consents). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>7.
The Conditions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As well as being conditional upon the Company Shareholder Approval and the Scheme becoming effective, as described in paragraph
6 (<I>The Scheme Process</I>) above, the Acquisition is also subject to receipt of certain other conditions as summarised below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition is subject to the satisfaction or waiver (as applicable) of the Conditions, which are <FONT
STYLE="white-space:nowrap">set-out</FONT> in full in Appendix 3 (<I>Conditions of the Acquisition and the Scheme</I>) to this Announcement, including, in summary: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approval by the Company Shareholders of the Scheme; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the sanction of the Scheme by the Irish High Court; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt of required antitrust clearances in the United States, Austria and Germany and the receipt of required
foreign investment clearances in France, Germany, Denmark and Italy; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a copy of the Court Order having been delivered to the Irish Registrar of Companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Transaction Agreement not having been terminated in accordance with its terms; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the accuracy of each of the Parties&#146; representations and warranties, subject to certain materiality and material
adverse effect exceptions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the performance by each Party, in all material respects, with all of such Party&#146;s covenants and agreements under
the Transaction Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the absence of a Company Material Adverse Effect that is continuing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">It is expected that the Proxy Statement (which will contain the Scheme Document), containing further information relating to the implementation of the
Acquisition, the full terms and conditions of the Scheme, notices of the Scheme Meeting and the EGM, will be made available to Company Shareholders as promptly as reasonably practicable after securing approval of the Irish High Court to send the
Scheme Document to Company Shareholders and, for information only, to Company Equity Award Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Proxy Statement will contain important
information about the Acquisition (including the Scheme), the Transaction Agreement, the Scheme Meeting and the EGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>8. About the Company Group
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company is a public limited company registered in Ireland and whose shares are admitted to trading on Nasdaq under the ticker
&#147;HZNP&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company is a global biotechnology company headquartered in Dublin, Ireland and focused on the discovery, development and
commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. The Company has 12 marketed medicines and a pipeline with more than 20 development programs. The Company has offices
or a presence across four continents and more than 2,000 employees. For more information about the Company Group, see <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.horizontherapeutics.com</U></FONT><FONT
STYLE="font-family:ARIAL">. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>9. About Amgen and Acquirer Sub </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Acquirer Sub is a private limited company incorporated in Ireland established for the sole purpose of implementing the Acquisition and is a wholly owned
subsidiary of Amgen. As of the date of this Announcement, the entire issued ordinary share capital of Acquirer Sub is owned by Amgen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen is a highly focused biotechnology company committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand
the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people&#146;s lives. A biotechnology pioneer since 1980,
Amgen has grown to be one of the world&#146;s leading independent biotechnology companies. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the <FONT STYLE="white-space:nowrap">Nasdaq-100</FONT>
index. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">For more information about Amgen, see <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.amgen.com</U></FONT><FONT
STYLE="font-family:ARIAL">. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>10. Effect of the Scheme on Company Share Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In accordance with Rule 15 of the Irish Takeover Rules, Amgen will make appropriate proposals to participants of the Company Share Plans in relation to
the options and awards under the Company Share Plans. Participants will be contacted separately, at or as soon as possible after the time of publication of the Scheme Document, regarding the effect of the Acquisition on their options and awards
under the Company Share Plans and the relevant details will be summarised in the Scheme Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Scheme will extend to any Company Shares
which are unconditionally allotted or issued at or before the Scheme Record Time, including those allotted or issued to satisfy the exercise of options or vesting of awards under the Company Share Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>11. Management, Employees and Locations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As
described in paragraph 4 (<I>Amgen Background to and Reasons for the Acquisition</I>) above, Amgen believes there is a compelling strategic rationale for undertaking the Acquisition, which would enable the Combined Group to deliver <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines to many more patients suffering from serious illness. Amgen recognises the skills, knowledge and experience of the Company&#146;s employees and is
excited to work with them to further enhance the therapeutic offerings, and grow the value, of the Combined Group in the longer term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Following
this Announcement, to the extent permitted by applicable antitrust rules, Amgen intends to engage with the Company&#146;s senior management in integration planning, involving a review of the Company&#146;s business. While the parameters of the
review have not yet been finalised, Amgen expects that it will involve evaluating the best way in which to further develop, as part of the Combined Group following Completion, the three existing strategic goals of the Company, which are to
(i)&nbsp;maximise the value of its <FONT STYLE="white-space:nowrap">on-market</FONT> rare disease medicines through commercial execution and clinical investment; (ii)&nbsp;expand its R&amp;D pipeline through significant internal investment and
external business development; and (iii)&nbsp;build a global presence in targeted international markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition, the review will also involve
assessing how best to combine the operations of Amgen and the Company in order to achieve some of the expected benefits of the Acquisition (including the cost synergies identified in paragraph 4 (<I>Amgen Background to and Reasons for the
Acquisition</I>) above. The review would aim to identify and assess integration benefit opportunities, and to ascertain those areas in which a reduction in the number of employees of the Combined Group may be appropriate. Amgen has not yet carried
out the review referred to above and, except as described below, has not reached any conclusions as to its likely outcome nor made any decisions in relation to specific actions that may be taken in relation to the integration of Amgen and the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen understands the importance of innovation to the Company&#146;s business, and intends to continue to invest in and develop its
R&amp;D capabilities as part of the Combined Group following Completion, with a view to ensuring in particular that the Company&#146;s existing pipeline of preclinical and clinical development programmes can continue to expand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Management and employees </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen attributes significant value to the Company Group&#146;s management and employees, whose ongoing contribution will be key to growing the value of
the enlarged business of Amgen in the longer term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen will safeguard the existing employment rights, including pension rights, of the Company
Group&#146;s management and employees in accordance with applicable Law. Amgen does not envisage any material change in the conditions of employment of the management and employees of the Combined Group as a result of the Acquisition. Under the
Transaction Agreement, Amgen has given certain assurances in relation to the continuation of certain existing compensation and employment benefit arrangements of the Company Group&#146;s employees following the Acquisition. Further details in this
regard will be included in the Scheme Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">While Amgen has not yet begun to carry out the review of the Company&#146;s business referred to
above and has not reached any conclusions as to its likely outcome or made any decisions in relation to any specific actions that may be taken as a result of this evaluation in relation to employees of the Combined Group, Amgen currently anticipates
that there will be some operational and administrative restructuring of the Company Group required following Completion. This will also facilitate the integration of the two businesses as part of the Combined Group. In particular, certain central
corporate and support functions, including those relating to the Company&#146;s status as a listed company, may no longer be required on a standalone basis or may be reduced in scope. No decisions have been made as to the number of employees or the
roles and locations that may be affected. Amgen also currently anticipates that there may be opportunities for the Combined Group to realise cost efficiencies from leveraging Amgen&#146;s global scale, systems and processes across various functions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The <FONT STYLE="white-space:nowrap">non-executive</FONT> directors of the Company intend to resign as directors of the Company with effect from
Completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Headquarters, locations of business and fixed assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Following Completion, the global headquarters of the Combined Group will be located at Amgen&#146;s current global headquarters in Thousand Oaks,
California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen will, as part of its review of the Company&#146;s business referred to above, evaluate the consolidation of some or all of the
Company&#146;s locations of business into Amgen&#146;s global headquarters in Thousand Oaks, California and other locations of Amgen across the United States and worldwide, including functions currently undertaken at the Company&#146;s current
global headquarters in Dublin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">No material changes are envisaged by Amgen with respect to the redeployment of the Company&#146;s fixed asset base.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Trading facilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company Shares are
currently listed on the Nasdaq Global Select Market and, as set out in paragraph 12 (<I>Delisting of Company Shares</I>) below, the Company Shares will be delisted from the Nasdaq Global Select Market and deregistered, as promptly as practicable
after the Effective Time, and in any event no more than ten days after the Completion Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>12. Delisting of Company Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Prior to the Completion Date, the Company will cooperate with Amgen and use its reasonable best efforts to take, or cause to be taken, all actions, and
do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Laws and rules and policies of Nasdaq to enable the delisting of the Company Shares from Nasdaq and the deregistration of the Company Shares
under the Exchange Act as promptly as practicable after the Effective Time. After the cancellation of the listing and trading of Company Shares on the Nasdaq Global Select Market, the Company will be
<FONT STYLE="white-space:nowrap">re-registered</FONT> as a private limited company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>13. Transaction Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company, Amgen and Acquirer Sub have entered into the Transaction Agreement, dated December&nbsp;11,&nbsp;2022, which contains certain assurances,
obligations and commitments in relation to the implementation of the Acquisition, including provisions in relation to the conduct of the Company&#146;s business between the date of this Announcement and the Effective Date. A copy of the Transaction
Agreement is appended to this Announcement at Appendix 4 (<I>Transaction Agreement</I>) and a summary of the principal terms of the Transaction Agreement will be set out in the Proxy Statement (which will include the Scheme Document). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Transaction Agreement provides that neither the Company Directors nor the Company shall make a Company Change of Recommendation for a Company
Superior Proposal or a Company Intervening Event or terminate the Transaction Agreement in order to substantially concurrently enter into a definitive agreement providing for a Company Superior Proposal, unless, among other things, prior to taking
such action, the Company has notified Amgen in writing at least four Business Days before taking such action, that the Company intends to take such action, and has negotiated in good faith with Amgen regarding any proposal by Amgen to amend the
Transaction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Transaction Agreement includes provisions pursuant to which the Company has agreed to reimburse to Amgen in certain
circumstances set out below for an amount equal to all documented, specific, quantifiable third party costs and expenses incurred, directly or indirectly, by Amgen and / or any member of the Amgen Group, or on its behalf, for the purposes of, in
preparation for, or in connection with the Acquisition, including third party costs and expenses incurred in connection with exploratory work carried out in contemplation of and in connection with the Acquisition, legal, financial and commercial due
diligence, the arrangement of financing and the engagement of third party representatives to assist in the process (the &#147;<B>Expenses</B> <B>Reimbursement</B> <B>Provisions</B>&#148;). The gross amount payable by the Company to Amgen for such
reimbursement shall not, in any event, exceed $278,404,301 (being 1% of the total value of the issued and to be issued ordinary share capital of the Company that is the subject of the Acquisition (excluding, for the avoidance of doubt, any interest
in such share capital held by Amgen or any person Acting in Concert with Amgen)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If the Transaction Agreement is terminated pursuant to its terms,
Amgen&#146;s receipt of such reimbursement payment (to the extent owed by the Company pursuant to the Transaction Agreement) and Amgen&#146;s right to seek specific performance will be the sole and exclusive remedies of the Amgen Parties and the
Amgen Related Parties against any of the Company and its Affiliates and Company Related Parties, including for any failure to consummate the Transactions or any claims or actions under applicable Laws arising out of any breach, termination or
failure by the Company and its Affiliates to perform any covenant or agreement in the Transaction Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The amount payable by the Company to Amgen under the Expenses Reimbursement Provisions will exclude
any amounts in respect of VAT incurred by Amgen or any member of the Amgen Group attributable to such third party costs other than irrevocable VAT incurred by Amgen or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The circumstances in which such payment will be made by the Company are, if the Transaction Agreement is terminated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by Amgen pursuant to a Change of Recommendation Termination; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by the Company pursuant to a Superior Proposal Termination; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">all of the following occur: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Transaction Agreement is terminated (x)&nbsp;by Amgen pursuant to a Company Breach Termination as a result of a
material breach or failure to perform any covenant or agreement in the Transaction Agreement described in Section&nbsp;9.1(a)(iii)(A) of the Transaction Agreement that first occurred following the making of a Company Alternative Proposal of the type
referred to in Section&nbsp;9.2(b)(iii)(B) of the Transaction Agreement or (y)&nbsp;by Amgen or the Company pursuant to a Non Approval Termination but if such termination is by the Company at such time Amgen would be permitted to terminate the
Transaction Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">prior to the Scheme Meeting, a Company Alternative Proposal was publicly disclosed or announced and not withdrawn (or,
in the case of a Company Breach Termination as a result of a material breach or failure to perform any covenant or agreement in the Transaction Agreement, was made publicly or privately to the Company Board), or any Person shall have publicly
announced an intention (whether or not conditional) to make a Company Alternative Proposal that has not been withdrawn (it being understood that, for purposes of Section&nbsp;9.2(b)(iii)(B) of the Transaction Agreement, references to
&#147;<I>20%</I>&#148; in the definition of Company Alternative Proposal shall be deemed to refer to &#147;<I>50%</I>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">(x) a Company Alternative Proposal is consummated within 12 months after such termination, or (y)&nbsp;a definitive
agreement providing for a Company Alternative Proposal is entered into within 12 months after such termination and is subsequently consummated. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Morgan Stanley as Rule 3 Advisor to the Company and the Company have confirmed in writing to the Panel that, in the opinion of Morgan Stanley and the
Company (respectively), in the context of the note to Rule 21.2 of the Irish Takeover Rules and the Acquisition, the Expenses Reimbursement Provisions are in the best interests of the Company Shareholders. The Irish Takeover Panel has consented to
the Company entering into the Expenses Reimbursement Provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Transaction Agreement provides that, upon termination of the Transaction
Agreement under certain circumstances relating to the failure to obtain applicable Antitrust Laws or Foreign Investment Laws Clearances prior to the End Date, Amgen will pay the Company a reverse termination fee of $974,415,054. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>14. Financing of the Acquisition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen has
entered into a Bridge Credit Agreement, dated December&nbsp;12, 2022, for an aggregate amount of $28.5&nbsp;billion, by and among Amgen, Citibank N.A., as administrative agent, Bank of America, N.A., as syndication agent, and Citibank, N.A. and Bank
of America, N.A. as lead arrangers and book runners, and the other banks from time to time party thereto to finance, together with Amgen&#146;s own cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
resources, the Acquisition. Further information on the financing of the Acquisition will be set out in the Scheme Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">PJT Partners, lead financial advisor to Amgen, is satisfied that sufficient resources are available to Acquirer Sub to satisfy in full the consideration
payable to Company Shareholders under the terms of the Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>15. Other Acquisition-related Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company and Amgen entered into a confidentiality agreement on November&nbsp;18,&nbsp;2022, pursuant to which the Company and Amgen have undertaken,
amongst other things, to: (a)&nbsp;keep confidential information relating to the Acquisition and not to disclose it to third parties (other than certain permitted parties) unless required by Law or regulation; and (b)&nbsp;use the confidential
information for the sole purpose of evaluating and participating in discussions regarding the Acquisition. The agreement also includes standstill provisions, pursuant to which Amgen has agreed to certain restrictions in respect of dealings in
Company Shares, solicitation or engagement in respect of competing transactions, subject to customary standstill termination provisions, for a period of 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>16. Tax </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Each holder of Company Shares is
urged to consult his, her or its independent professional advisor regarding the tax consequences of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>17. Disclosure of
Interests in Relevant Securities of the Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As of the close of business on December&nbsp;9, 2022 (being the last Business Day prior to the
date of this Announcement), the Robert A. Eckert Living Trust (a related trust of Robert A. Eckert, an Amgen Director) was interested in 86 Company Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Save as described above, as of the close of business on December 9, 2022 (being the last Business Day prior to the date of this Announcement), none of
Amgen or, so far as Amgen is aware, any person Acting in Concert with Amgen: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">had an interest in relevant securities of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">had any short position in relevant securities of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">had received an irrevocable commitment or letter of intent to accept the terms of the Acquisition in respect of
relevant securities of the Company; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">had borrowed or lent any Company Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Furthermore, no arrangement to which Rule 8.7 of the Irish Takeover Rules applies exists between Amgen or the Company or a person Acting in Concert with
Amgen or the Company in relation to Company Shares. For these purposes, an &#147;arrangement to which Rule 8.7 of the Irish Takeover Rules applies&#148; includes any indemnity or option arrangement, and any agreement or understanding, formal or
informal, of whatever nature, between two or more persons relating to relevant securities which is or may be an inducement to one or more of such persons to deal or refrain from dealing in such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>18. Section&nbsp;3(7) of Appendix 4 Derogation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Section&nbsp;3(7) of Appendix 4 of the Irish Takeover Rules requires that, except with the consent of the Panel, and subject to Rule 2.11 of the Irish
Takeover Rules, the Company must send the Scheme Document to Company Shareholders within 28 days of the announcement of a firm intention to make an offer, being this Announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">On December&nbsp;9, 2022 the Panel agreed to grant a waiver of Section&nbsp;3 (7) of Appendix 4 of the Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">There is a requirement to file the Proxy Statement (which will also include the Scheme Document) with the SEC in connection with the Scheme. The
preparation of the Proxy Statement may take more than 28 days. Also, the SEC may elect to review the Proxy Statement. This review process will take no fewer than 10 days and may take a longer time to complete. Under SEC rules, the Proxy Statement
may not be mailed to Company Shareholders until such review is complete. The Panel granted the derogation on the basis that the Scheme Document cannot be sent until the SEC&#146;s review of the Proxy Statement is completed. The Proxy Statement
(which will also contain the Scheme Document) will be mailed to Company Shareholders as soon as practicable after a definitive Proxy Statement is filed with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>19. Documents on display </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Copies of the
following documents will, by no later than 12:00 noon (E.T.) on the business day following the date of this Announcement, be made available the Company&#146;s website
<FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.horizontherapeutics.com</U></FONT><FONT STYLE="font-family:ARIAL"> and on Amgen&#146;s website
</FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.amgen.com</U></FONT><FONT STYLE="font-family:ARIAL">: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Leak Announcement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">this Announcement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Confidentiality Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Transaction Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Neither the contents of the Company&#146;s website or the contents of Amgen&#146;s website, nor the contents of any other website accessible from
hyperlinks on either such website, is incorporated into or forms part of, this Announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>20. Rule 2.7(b)(xv) Statement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the Transaction Agreement, Amgen will have the right to reduce the Consideration by the amount of any dividend (or other distribution) which
is paid or becomes payable by the Company to Company Shareholders in addition to the Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><B>21. General </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Transaction Agreement is governed by the Laws of the State of Delaware. However, the Acquisition and the Scheme, and matters related thereto
(including matters related to the Irish Takeover Rules), shall, to the extent required by the Laws of Ireland, be governed by, and construed in accordance with, the Laws of Ireland. The interpretation of the duties of the Company Directors shall
also be governed by, and construed in accordance with, the Laws of Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition is subject to, <I>inter alia</I>, the terms and
conditions of the Transaction Agreement and the terms and the satisfaction or waiver (as applicable) of the Conditions set out in Appendix 3 (<I>Conditions </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
<I>of the Acquisition and the Scheme</I>) to this Announcement. The Acquisition is also subject to the full terms and conditions which will be set out in the Scheme Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Appendix 1 (<I>Sources and Bases of Information</I>) contains further details of the sources of information and bases of calculations set out in this
Announcement; Appendix 2 (<I>Definitions</I>) contains definitions of certain expressions used in this Announcement; Appendix 3 (<I>Conditions of the Acquisition and the Scheme</I>) contains the Conditions of the Acquisition and the Scheme; and
Appendix 4 (<I>Transaction Agreement</I>) appends the Transaction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The financial information included in this Announcement and to be
included in the Scheme Document has or will be prepared in accordance with generally accepted accounting principles in the United States. The following <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures have been included in this
Announcement in relation to Amgen and the Combined Group: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;free cash flow&#148;, which is computed by subtracting capital expenditures from operating cash flow, each as
determined in accordance with GAAP; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> EPS&#148;, which is computed by taking <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> net income and dividing it by the number of weighted-average shares of Amgen. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">These <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Be aware that addresses, electronic addresses and certain other information provided by Company Shareholders, holders of shares in Amgen, persons with
information rights and other relevant persons for the receipt of communications from the Company, and / or Amgen may be exchanged between the Parties as required by the Irish Takeover Rules and applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This Announcement does not constitute a prospectus or prospectus equivalent document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any response in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Document and the Proxy Statement
or any document by which the Acquisition and the Scheme are made. Company Shareholders are advised to read carefully the formal documentation in relation to the Acquisition, including the Scheme Document once the Proxy Statement has been sent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Transaction Agreement contains representations and warranties made by and to the parties thereto as of specific dates. The statements embodied in
those representations and warranties were made for purposes of the contract between the parties and may be subject to qualifications and limitations agreed by the parties in connection with negotiating the terms of that contract. In addition,
certain representations and warranties were made as of a specified date, may be subject to a contractual standard of materiality different from those generally applicable to investors, or may have been used for the purpose of allocating risk between
the parties rather than establishing matters as facts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If you are in any doubt about the contents of this Announcement or the action you should
take, you are recommended to seek your own independent financial advice immediately from your appropriately authorised independent financial advisor. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Enquiries
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Company</B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors: Tina Ventura</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 224 383 3344</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Media: Geoff Curtis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 224 383 3333</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Morgan Stanley (Joint Financial Advisor to the Company)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Julie Rozenblyum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 761 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joe Modisett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tedd Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Kitterick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7425 8000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>J.P. Morgan (Joint Financial Advisor to the Company)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dwayne Lysaght</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+44&nbsp;(0)&nbsp;20&nbsp;7742&nbsp;4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jeremy Meilman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 (212) <FONT STYLE="white-space:nowrap">270-6000</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ben Carpenter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 (212) <FONT STYLE="white-space:nowrap">270-6000</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Steve Frank</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 (212) <FONT STYLE="white-space:nowrap">270-6000</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Amgen</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors: Arvind Sood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 805 447 1060</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Media: Jessica Akopyan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 805 440 5721</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>PJT Partners (Lead Financial Advisor to Amgen)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Taubman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 364 7800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tom Davidson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 364 7800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basil Geoghegan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel:&nbsp;+44&nbsp;(0)20&nbsp;3650&nbsp;1100</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Daniel Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +1 212 364 7800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kush Nanjee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 (0)20 3650 1100</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Citigroup (Financial Advisor to Amgen)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Torrey Browder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sumit Khedekar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Rob Way</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sian Evans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Marc Banziger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +44 20 7986 4000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Edelman (PR Advisor to Amgen)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lex Suvanto</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: + 1 212 768 0550</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shannon Susko</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: + 1 212 768 0550</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jamaal Mobley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: + 1 212 768 0550</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joe Carmody</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +353 1 592 1330</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Piaras Kelly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +353 1 592 1330</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Feargal Purcell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tel: +353 1 592 1330</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NO OFFER OR SOLICITATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This Announcement is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the
solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise, nor shall
there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition will be implemented
by means of an Irish High Court-sanctioned scheme of arrangement on the terms provided for in the Scheme Document (or, if the Acquisition is implemented by way of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
Takeover Offer, the Takeover Offer Document), which will contain the full terms and conditions of the Acquisition, including details of how Company Shareholders may vote in respect of the
Acquisition. Any decision in respect of, or other response to, the Acquisition, should be made only on the basis of the information contained in the Scheme Document (or if the Acquisition is implemented by way of a Takeover Offer, the Takeover Offer
Document). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In connection with the Acquisition, the Company will file with the SEC a Proxy Statement (which will include the Scheme Document). The Proxy Statement
will be mailed to Company Shareholders as of the record date to be established for voting at the Scheme Meeting or EGM. This Announcement is not a substitute for the Proxy Statement or any other document that the Company may file with the SEC or
send to its shareholders in connection with the Acquisition. BEFORE MAKING ANY VOTING DECISION, HOLDERS OF COMPANY SHARES ARE URGED TO READ THE PROXY STATEMENT (INCLUDING THE SCHEME DOCUMENT) ANY AMENDMENTS OR SUPPLEMENTS THERETO AND OTHER RELEVANT
DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE ACQUISITION, INCLUDING ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT THE ACQUISITION, THE PARTIES TO THE SCHEME AND RELATED MATTERS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any vote in respect of the Scheme Meeting Resolution and the EGM Resolutions
to approve the Acquisition, the Scheme or related matters, or other responses in relation to the Acquisition, should be made only on the basis of the information contained in the Proxy Statement (including the Scheme
Document).&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Proxy Statement, if and when filed, as well as the Company&#146;s other public filings with the SEC, may be
obtained without charge at the SEC&#146;s website at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.sec.gov</U></FONT><FONT STYLE="font-family:ARIAL"> and at the Company&#146;s website at </FONT><FONT
STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U><FONT STYLE="white-space:nowrap">https://ir.horizontherapeutics.com/financial-information/sec-filings</FONT></U></FONT><FONT STYLE="font-family:ARIAL">. Company Shareholders and investors
will also be able to obtain, without charge, a copy of the Proxy Statement (including the Scheme Document) and other relevant documents (when available) by directing a written request to the Company, Attn: Investor Relations, 70 St. Stephen&#146;s
Green, Dublin 2, D02 E2X4, Ireland or by contacting Tina Ventura, Investor Relations, by email to </FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>ir@horizontherapeutics.com</U></FONT><FONT STYLE="font-family:ARIAL">.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PARTICIPANTS IN THE SOLICITATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company
and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from Company Shareholders in connection with the Acquisition and any other matters to be voted on at the Scheme Meeting or
the EGM. Information about the directors and executive officers of the Company, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company&#146;s definitive proxy statement on
Schedule 14A for its 2022 annual general meeting of shareholders, dated and filed with the SEC on March&nbsp;17, 2022. Other information regarding the persons who may, under the rules of the SEC, be deemed to be participants in the solicitation of
Company Shareholders, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement (which will contain the Scheme Document) and other relevant materials to be filed with
the SEC in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
connection with the Acquisition. You may obtain free copies of these documents using the sources indicated above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This Announcement contains certain statements about the Company and Amgen that are or may be forward-looking statements which include, but are not
limited to, statements regarding expected timing, completion and effects of the Acquisition. These forward-looking statements are subject to the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. All statements
other than statements of historical facts included in this Announcement may be forward-looking statements. Without limitation, forward-looking statements often include words such as &#147;expect,&#148; &#147;anticipate,&#148; &#147;outlook,&#148;
&#147;could,&#148; &#147;target,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;estimate,&#148; &#147;should,&#148; &#147;may,&#148; &#147;assume&#148; and &#147;continue&#148; as well
as variations of such words and similar expressions are intended to identify such forward-looking statements. The Company&#146;s and Amgen&#146;s expectations and beliefs regarding these matters may not materialise. Actual outcomes and results may
differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the Parties to
consummate the Acquisition in a timely manner or at all; the satisfaction (or waiver) of conditions to the consummation of the Acquisition, including with respect to the approval of Company Shareholders and required regulatory approvals; potential
delays in consummating the Acquisition; the ability of the Company and Amgen to timely and successfully achieve the anticipated strategic benefits, synergies or opportunities expected as a result of the Acquisition; the successful integration of the
Company into Amgen subsequent to Completion and the timing of such integration; the impact of changes in global, political, economic, business, competitive, market and regulatory forces; the impact of health pandemics, including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on the Company&#146;s or Amgen&#146;s respective businesses; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Transaction
Agreement; adverse effects on the market price of the Company&#146;s or Amgen&#146;s securities and on the Company&#146;s or Amgen&#146;s operating results because of a failure to complete the Acquisition; the effect of the announcement or pendency
of the Acquisition on the Company&#146;s or Amgen&#146;s business relationships, operating results and business generally; costs related to the Acquisition; and the outcome of any legal proceedings that may be instituted against the Company, Amgen
Acquirer Sub or any of their respective directors or officers related to the Transaction Agreement or the Acquisition. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by
the forward-looking statements are included under the caption &#147;Risk Factors&#148; and elsewhere in the Company&#146;s most recent filings with the SEC, including its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the
quarter ended September&nbsp;30, 2022, and Amgen&#146;s most recent filings with the SEC, including its Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarter ended September&nbsp;30,&nbsp;2022, and any subsequent
reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC by the Company or Amgen from time to time and available at <FONT
STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.sec.gov</U></FONT><FONT STYLE="font-family:ARIAL">. These documents can be accessed on the Company&#146;s web page at </FONT><FONT
STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U><FONT STYLE="white-space:nowrap">https://ir.horizontherapeutics/financial-information.com/sec-filings</FONT></U></FONT><FONT STYLE="font-family:ARIAL"> or on Amgen&#146;s web page at
</FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U><FONT STYLE="white-space:nowrap">https://investorsamgen.com/financials/sec-filings</FONT></U></FONT><FONT STYLE="font-family:ARIAL">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The forward-looking statements included in this Announcement are made only as of the date hereof. Neither the Company nor Amgen assumes any obligation
to, and neither the Company nor Amgen intends to, update these forward-looking statements, except as required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RESPONSIBILITY STATEMENT
REQUIRED BY THE IRISH TAKEOVER RULES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company Directors accept responsibility for the information contained in this Announcement relating to
the Company, the Company Group and the Company Directors and members of their immediate families, related trusts and persons connected with them and for the Company Amgen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
Statements (as defined below), except for the statements made by Amgen in respect of the Company (the &#147;<B>Amgen Company Statements</B>&#148;). To the best of the knowledge and belief of the
Company Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this Announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect
the import of such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Amgen Directors and Acquirer Sub Directors accept responsibility for the information contained in this
Announcement other than that relating to the Company, the Company Group and the Company Directors and members of their immediate families, related trusts and persons connected with them but including the Amgen Company Statements (for which the Amgen
Directors and the Acquirer Sub Directors accept responsibility), and other than the statements made by the Company in respect of Amgen (the &#147;<B>Company Amgen Statements</B>&#148;). To the best of the knowledge and belief of the Amgen Directors
(who have taken all reasonable care to ensure such is the case), the information contained in this Announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>IMPORTANT NOTICES RELATING TO FINANCIAL ADVISORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Morgan Stanley&nbsp;&amp; Co. LLC, acting through its affiliate Morgan Stanley&nbsp;&amp; Co. International plc (together, &#147;<B>Morgan
Stanley</B>&#148;), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for the Company as financial advisor and for no one else in relation to the
matters referred to in this Announcement. In connection with such matters, Morgan Stanley and its directors, officers, employees and agents will not regard any other person as its client, nor will it be responsible to anyone other than the Company
for providing the protections afforded to their clients or for providing advice in connection with the matters described in this Announcement or any matter referred to herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">J.P. Morgan Securities LLC (&#147;<B>J.P. Morgan</B>&#148;), which is a registered broker dealer with the SEC, is acting as financial advisor to the
Company in connection with the Acquisition. In connection with the Acquisition, J.P. Morgan and its directors, officers, employees and agents will not regard any other person as its client, nor will it be responsible to anyone other than the Company
for providing the protections afforded to clients of J.P. Morgan or for giving advice in connection with the Acquisition or any matter referred to herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">PJT Partners, which is a registered broker dealer with the SEC, is acting exclusively for Amgen and for <FONT STYLE="white-space:nowrap">no-one</FONT>
else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than Amgen for providing the protections afforded to clients of PJT Partners nor for providing advice in relation to the matters
referred to in this Announcement. Neither PJT Partners nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or
otherwise) to any person who is not a client of PJT Partners in connection with this Announcement, any statement contained herein or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Citigroup, which is a registered broker-dealer regulated by the SEC, is acting exclusively for Amgen and for no one else in connection with the
Acquisition and other matters described in this announcement, and will not be responsible to anyone other than Amgen for providing the protections afforded to clients of Citigroup nor for providing advice in connection with the Acquisition or any
other matters referred to in this announcement. Neither Citigroup nor any of its affiliates, directors or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, consequential, whether in contract, in
tort, under statute or otherwise) to any person who is not a client of Citigroup in connection with this announcement, any statement contained herein, the Acquisition or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>DISCLOSURE REQUIREMENTS OF THE IRISH TAKEOVER RULES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under the provisions of Rule 8.3(a) of the Irish Takeover Rules, any person who is &#145;interested&#146; in 1% or more of any class of &#145;relevant
securities&#146; of the Company must make an &#145;opening position disclosure&#146; following the commencement of the &#145;offer period&#146;. An &#145;opening position disclosure&#146; must contain the details contained in Rule 8.6(a) of the
Irish Takeover Rules, including, among other things, details of the person&#146;s &#145;interests&#146; and &#145;short positions&#146; in any &#145;relevant securities&#146; of the Company. An &#145;opening position disclosure&#146; by a person to
whom Rule 8.3(a) applies must be made by no later than 3:30 pm (E.T.) on the day falling ten &#145;business days&#146; following the commencement of the &#145;offer period&#146;. Relevant persons who deal in any &#145;relevant securities&#146; prior
to the deadline for making an &#145;opening position disclosure&#146; must instead make a &#145;dealing&#146; disclosure as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under
the provisions of Rule 8.3(b) of the Irish Takeover Rules, if any person is, or becomes, &#145;interested&#146; in 1% or more of any class of &#145;relevant securities&#146; of the Company, that person must publicly disclose all &#145;dealings&#146;
in any &#145;relevant securities&#146; of the Company during the &#145;offer period&#146;, by not later than 3:30 p.m. (E.T.) on the &#145;business day&#146; following the date of the relevant transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If two or more persons <FONT STYLE="white-space:nowrap">co-operate</FONT> on the basis of any agreement either express or tacit, either oral or written,
to acquire an &#145;interest&#146; in &#145;relevant securities&#146; of the Company or any securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition, each of the Company and any offeror must make an &#145;opening position disclosure&#146; by no later 12:00 noon (E.T.) on the date falling
ten &#145;business days&#146; following the commencement of the &#145;offer period&#146; or the announcement that first identifies a securities exchange offeror, as applicable, and disclose details of any &#145;dealings&#146; by it or any person
&#145;acting in concert&#146; with it in &#145;relevant securities&#146; during the &#145;offer period&#146;, by no later than 12:00 noon (E.T.) on the business day following the date of the transaction (see Rules 8.1, 8.2 and 8.4). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">A disclosure table, giving details of the companies in whose &#145;relevant securities&#146; &#145;opening position&#146; and &#145;dealings&#146;
should be disclosed can be found on the Irish Takeover Panel&#146;s website at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.irishtakeoverpanel.ie</U></FONT><FONT STYLE="font-family:ARIAL">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#145;Interests&#146; in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the
price of securities. In particular, a person will be treated as having an &#145;interest&#146; by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel&#146;s website. If you are in any doubt
as to whether or not you are required to disclose an &#145;opening position&#146; or &#145;dealing&#146; under Rule 8, please consult the Irish Takeover Panel&#146;s website at
<FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.irishtakeoverpanel.ie</U></FONT><FONT STYLE="font-family:ARIAL"> or contact the Irish Takeover Panel on telephone number +353 1 678 9020. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NO PROFIT FORECAST / QUANTIFIED FINANCIAL BENEFIT STATEMENT / ASSET VALUATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">No statement in this Announcement is intended to constitute a profit forecast or quantified financial benefit statement for any period, nor should any
statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Amgen or the Company. No statement in this Announcement constitutes an asset
valuation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PUBLICATION ON WEBSITE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this Announcement will be available on the Company&#146;s website at <FONT
STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.horizon.therapeutics.com</U></FONT><FONT STYLE="font-family:ARIAL"> and Amgen&#146;s website at
</FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>www.amgen.com</U></FONT><FONT STYLE="font-family:ARIAL"> by no later than 12 noon (E.T.) on the business day following this Announcement. Neither the content of any such
website nor the content of any other website accessible from hyperlinks on such website is incorporated into, or forms part of, this Announcement. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>REQUESTING HARD COPY INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any Company Shareholder
may request a copy of this Announcement and / or any information incorporated by reference into this Announcement in hard copy form by writing to the Company, Attn: Investor Relations, 70 St. Stephen&#146;s Green, Dublin 2, D02 E2X4, Ireland, or by
contacting Tina Ventura, Investor Relations, via email at <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0000ff"><U>ir@horizontherapeutics.com</U></FONT><FONT STYLE="font-family:ARIAL">. Any written requests must include the identity of the
Company Shareholder and any hard copy documents will be posted to the address of the Company Shareholder provided in the written request. If you have received this Announcement in electronic form, a hard copy of this Announcement and / or any
document or information incorporated by reference into this Announcement will not be provided unless such a request is made. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RIGHT TO SWITCH TO A
TAKEOVER OFFER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Amgen reserves the right to elect to implement the Acquisition by way of a Takeover Offer for the entire issued and to be issued
ordinary share capital of the Company as an alternative to the Scheme, subject to the provisions of the Irish Takeover Rules and the Transaction Agreement and with the Irish Takeover Panel&#146;s consent, whether or not the Scheme Document has been
posted. In such event, the Acquisition would be implemented on the same terms (subject to appropriate amendments), so far as are applicable, as those which would apply to the Scheme and subject to the amendments referred to in Appendix 3
(<I>Conditions of the Acquisition and the Scheme</I>) to this Announcement and in the Transaction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">If Amgen exercises its right to
implement the Acquisition by way of a Takeover Offer as an alternative to the Scheme, subject to the provisions of the Irish Takeover Rules and the Transaction Agreement and with the Irish Takeover Panel&#146;s consent, such offer would be made in
compliance with applicable U.S. Laws and regulations, including the registration requirements of the U.S. Securities Act and the tender offer rules under the U.S. Exchange Act and any applicable exemptions provided thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>ROUNDING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Certain figures included in this Announcement have
been subjected to rounding adjustments. Accordingly, any figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that
precede them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>OVERSEAS JURISDICTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The release,
publication or distribution of this Announcement in or into jurisdictions other than Ireland and the United States may be restricted by Law and therefore any persons who are subject to the Law of any jurisdiction other than Ireland and the United
States should inform themselves about, and observe, any applicable legal or regulatory requirements. In particular the ability of persons who are not resident in Ireland or the United States, to vote their Company Shares with respect to the Scheme
at the Scheme Meeting, or to appoint another person as proxy to vote at the Scheme Meeting on their behalf, may be affected by the Laws of the relevant jurisdictions in which they are located. Any failure
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
to comply with the applicable legal or regulatory requirements may constitute a violation of the Laws of any such jurisdiction. To the fullest extent permitted by applicable Law, the Company and
Amgen and persons involved in the Acquisition disclaim any responsibility or liability for the violation of such restrictions by any person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This
Announcement has been prepared for the purpose of complying with the Laws of Ireland and the Irish Takeover Rules and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in
accordance with the Laws of jurisdictions outside of Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Unless otherwise determined by Amgen or required by the Irish Takeover Rules, and
permitted by applicable Law and regulation, the Acquisition will not be made available directly or indirectly, in, into or from any Restricted Jurisdiction and no person may vote in favour of the Acquisition by any use, means, instrumentality or
facilities from within a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of the Laws of that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Copies of this Announcement and any formal documentation relating to the Acquisition will not be and must not be, directly or indirectly, mailed or
otherwise forwarded, distributed or sent in, into or from any Restricted Jurisdiction or any jurisdiction where to do so would violate the Laws of that jurisdiction and persons receiving such documents (including custodians, nominees and trustees)
must not mail or otherwise forward, distribute or send them in or into or from any Restricted Jurisdiction. Doing so may render invalid any related purported vote in respect of the Acquisition. If the Acquisition is implemented by way of a Takeover
Offer (unless otherwise permitted by applicable Law or regulation), the Takeover Offer may not be made, directly or indirectly, in or into or by use of the mails or any other means, instrumentality or facilities (including, without limitation,
facsimile, email or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or any facility of a national, state or other securities exchange of any Restricted Jurisdiction and the Takeover Offer will not be capable
of acceptance by any such use, means, instrumentality or facilities from within any Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of the Laws of that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Further details in relation to overseas shareholders will be contained in the Proxy Statement (which will include the Scheme Document). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RULE 2.12 &#150; RELEVANT SECURITIES IN ISSUE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In accordance
with Rule 2.12 of the Irish Takeover Rules, the Company confirms that, as of December&nbsp;9, 2022 (being the latest practicable date prior to the publication of this Announcement), its issued ordinary share capital is comprised of 227,346,959
ordinary shares, nominal value $0.0001 per share (the &#147;<B>Ordinary Shares</B>&#148;) and 40,000 deferred ordinary shares of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>1.00 each. The Company has 384,366 Ordinary Shares which are held
as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol &#147;HZNP&#148;. The International Securities Identification Number for these securities is IE00BQPVQZ61. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Company confirms that as of December&nbsp;9, 2022, there were outstanding options to purchase up to 4,997,294 Ordinary Shares and outstanding
restricted stock units and performance stock units conferring on their holders vested or unvested rights to convert into, or receive, up to an aggregate of 5,491,118 Ordinary Shares and incremental restricted stock units to be issued of 2,550,000
Ordinary Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>APPENDIX 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SOURCES AND BASES OF INFORMATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The historical share price for the Company has been sourced from the Nasdaq website. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The value of the Acquisition is based upon the Consideration due under the terms of the Acquisition and on the basis
of the issued and to be issued ordinary share capital of the Company referred to in paragraph 3 below. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The entire issued and to be issued ordinary share capital (fully diluted share capital) of the Company as of the close
of business on December&nbsp;9, 2022 (being the last practicable date prior to the release of this Announcement), calculated on the basis of: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the number of issued Shares, being 227,346,959 Company shares, with 384,366 Ordinary Shares which are held as treasury
shares; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">1,909,313 issued Company PSUs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">3,581,805 issued Company RSUs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">2,550,000 incremental ordinary course grants to be issued by the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">3,969,938 Company Shares which may be issued on or after the date of this Announcement to satisfy the exercise of
Company Options under the treasury stock method, based on a weighted average price of $23.95. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Save where otherwise stated, financial and other information concerning the Company has been extracted from audited
financial results of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">As of 30&nbsp;September, 2022 the Company has gross, financial debt of $2.6&nbsp;billion, cash and cash equivalents of
$2.1&nbsp;billion, and net financial debt of $0.5&nbsp;billion. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>APPENDIX 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The following definitions apply
throughout this Announcement unless the context otherwise requires: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Acquirer Sub</B>&#148; means Pillartree Limited, a
private limited company incorporated in Ireland with registered number 730855. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Acquirer Sub Board</B>&#148; means the
board of directors of Acquirer Sub. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Acquirer Sub Directors</B>&#148; means the members of the Acquirer Sub Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Acquisition</B>&#148; means the proposed offer by Acquirer Sub to acquire the entire issued, and to be issued ordinary share
capital of the Company in accordance with the terms of the Transaction Agreement, to be effected by means of the Scheme or, should Amgen elect, and subject to the provisions of the Transaction Agreement and Irish Takeover Rules and the consent of
the Irish Takeover Panel, by means of a Takeover Offer, and, where the context admits any subsequent revision, variation, extension or renewal thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Acting in Concert</B>&#148; has the meaning given to that term in the Irish Takeover Panel Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Affiliate</B>&#148; means, in relation to any Person, any other Person that, directly or indirectly, controls, is controlled
by, or is under common control with, such first person (as used in this definition, &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of management or policies of a Person, whether
through the ownership of securities or partnership or other ownership interests, by Contract or otherwise and the terms &#147;controlled&#148; and &#147;controlling&#148; shall have correlative meanings). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Amgen</B>&#148; means Amgen Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Amgen Board</B>&#148; means the board of directors of Amgen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Amgen Common Stock</B>&#148; means shares of common stock, $0.0001 par value, of Amgen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Amgen Directors</B>&#148; means the members of the Amgen Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Amgen Group</B>&#148; means Amgen and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Amgen Parties</B>&#148; means Amgen and Acquirer Sub and &#147;<B>Amgen Party</B>&#148; means either Amgen or Acquirer Sub (as
the context requires). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Amgen Related Parties</B>&#148; has the meaning ascribed to it in the Transaction Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Announcement</B>&#148; means this Announcement issued pursuant to Rule 2.7 of the Irish Takeover Rules for the purposes of the
Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Antitrust Laws</B>&#148; means the Sherman Act of 1890, the Clayton Act of 1914, the Federal Trade
Commission Act of 1914, the HSR Act and all other federal, state and foreign applicable Laws in effect from time to time that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or
restraint of trade. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Burdensome Condition</B>&#148; has the meaning ascribed to it in the Transaction Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Business Day</B>&#148; means any day, other than a Saturday, Sunday or a day
on which banks in Ireland or in New York are authorised or required by applicable Laws to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Change of
Recommendation Termination</B>&#148; has the meaning ascribed to it in the Transaction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Citigroup</B>&#148;
means Citigroup Global Markets Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Combined Group</B>&#148; means the enlarged group following Completion comprising the
Amgen Group and the Company Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Clearances</B>&#148; means all consents, clearances, approvals, permissions, licenses,
variances, exemptions, authorizations, acknowledgements, permits, nonactions, Orders and waivers to be obtained from, and all registrations, applications, notices and filings to be made with or provided to, any Governmental Entity in connection with
the implementation of the Scheme or the Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company</B>&#148; means Horizon Therapeutics plc, an Irish public
limited company with registered number 507678. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Alternative Proposal</B>&#148; means any bona fide proposal or
offer (including <FONT STYLE="white-space:nowrap">non-binding</FONT> proposals or offers) from any Person or Group, other than Amgen, its controlled Affiliates or any of its Concert Parties, relating to any (i)&nbsp;direct or indirect acquisition
(whether in a single transaction or a series of related transactions) of assets of the Company or any of its Subsidiaries (including equity securities of Subsidiaries) equal to 20% or more of the consolidated assets of the Company, or to which 20%
or more of the revenues or earnings of the Company on a consolidated basis are attributable for the most recent fiscal year for which audited financial statements are then available, (ii)&nbsp;direct or indirect acquisition (including by scheme of
arrangement or takeover offer) or issuance (whether in a single transaction or a series of related transactions) of 20% or more of any class of equity or voting securities of the Company, (iii)&nbsp;scheme of arrangement, tender offer, takeover
offer or exchange offer that, if consummated, would result in a Person or Group beneficially owning 20% or more of any class of equity or voting securities of the Company, or (iv)&nbsp;scheme of arrangement, merger, consolidation, share exchange,
business combination, joint venture, reorganization, recapitalization or similar transaction involving the Company or any of its Subsidiaries, under which a Person or Group, or, in the case of clause (B)&nbsp;below, the shareholders or equityholders
of any Person or Group would, directly or indirectly, (A)&nbsp;acquire assets equal to 20% or more of the consolidated assets of the Company, or to which 20% or more of the revenues or earnings of the Company on a consolidated basis are attributable
for the most recent fiscal year for which audited financial statements are then available, or (B)&nbsp;immediately after giving effect to such transactions, beneficially own 20% or more of any class of equity or voting securities of the Company or
the surviving or resulting Person (including any parent Person) in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Approval Time</B>&#148;
means the time of the receipt of the Company Shareholder Approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Board</B>&#148; means the board of directors
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Board Recommendation</B>&#148; means the unanimous recommendation of the Company Board that the
Company Shareholders vote to approve the Scheme Meeting Resolution and the Required EGM Resolutions (or if Acquirer Sub effects the Acquisition as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
a Takeover Offer, the unanimous recommendation of the Company Board that Company Shareholders accept the Takeover Offer). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Breach Termination</B>&#148; means termination of the Transaction Agreement and the Acquisition (and any transactions
contemplated by the Transaction Agreement) by Amgen if the Company shall have breached or failed to perform in any material respect any of its covenants or other agreements contained in the Transaction Agreement or if any of its representations or
warranties set out in the Transaction Agreement are inaccurate, which breach, failure to perform or inaccuracy (1)&nbsp;would result in a failure of Condition 4.2 or Condition 4.3 and (2)&nbsp;is not reasonably capable of being cured by the End Date
or, if curable, is not cured by the earlier of (x)&nbsp;the End Date and (y) 30 days following written notice by Amgen thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Change of Recommendation</B>&#148; means the Company&#146;s (i)&nbsp;withholding, withdrawal or qualification,
amendment or modification in any manner adverse to Amgen, the Company Board Recommendation, if applicable, (ii)&nbsp;failure to include the Company Board Recommendation in the Scheme Document or the Proxy Statement, (iii)&nbsp;recommending, adopting
or approving or publicly proposing to recommend, adopt or approve any Company Alternative Proposal or (iv)&nbsp;failure to reaffirm the Company Board Recommendation in a statement complying with Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or
Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> under the Exchange Act with regard to a Company Alternative Proposal or in connection with such action by the close of business on the 10th Business Day after the commencement of such Company
Alternative Proposal under Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or Rule <FONT STYLE="white-space:nowrap">14e-2(a).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Directors</B>&#148; means the members of the Company Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Disclosure Schedule</B>&#148; has the meaning ascribed to that term in the Transaction Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Equity Awards</B>&#148; means the Company Options, the Company RSU Awards and the Company PSU Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Equity Award Holders</B>&#148; means the holders of the Company Equity Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Group</B>&#148; means the Company and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Intervening Event</B>&#148; means any material event, fact, change, effect, development or occurrence arising or
occurring after the date of the Transaction Agreement and prior to the Company Approval Time that (i)&nbsp;was not known or reasonably foreseeable, or the material consequences of which were not known or reasonably foreseeable, in each case to the
Company Board as of or prior to the date of the Transaction Agreement, and (ii)&nbsp;does not relate to (a)&nbsp;any Company Alternative Proposal or consequence thereof, (b)&nbsp;Amgen or any of its Subsidiaries, or (c)&nbsp;any change in the market
price or trading volume of the Company Shares or the fact that the Company meets or exceeds any internal or analysts&#146; expectations or projections of the results of operations of the Company Group (it being understood that the underlying causes
of such change or fact shall not be excluded by this clause (c)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Material Adverse Effect</B>&#148; means any
event, change, effect, development or occurrence that, individually or together with any other event, change, effect, development or occurrence, (a)&nbsp;would prevent, materially delay or materially impair the ability of the Company to consummate
the Acquisition or (b)&nbsp;has had or would reasonably be expected to have a material adverse effect on the condition (financial or otherwise), business, assets, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
liabilities or results of operations of the Company Group, taken as a whole; <I>provided</I> that, solely for the purposes of <U>clause (b)</U>, no event, change, effect, development or
occurrence to the extent resulting from or arising out of any of the following shall be deemed to constitute a Company Material Adverse Effect or shall be taken into account in determining whether there has been, or would reasonably be expected to
be, a Company Material Adverse Effect: (i)&nbsp;any decline in the market price or change in trading volume of the Company Shares; (ii)&nbsp;any event, change, effect, development or occurrence directly resulting from the announcement or pendency of
the Transactions (other than for purposes of any representation or warranty contained in Section&nbsp;6.1(u)(ii) and Section&nbsp;6.1(v) of the Transaction Agreement but subject to corresponding disclosures in the Company Disclosure Schedule); (iii)
any event, change, effect, development or occurrence in the industries and jurisdictions in which the Company Group operates or in the U.S. or global economy generally or other general business, financial or market conditions in the U.S. or
globally, except in each case to the extent that the Company Group, taken as a whole, is adversely affected disproportionately relative to the other participants in such industries or the U.S. or the global economy generally, as applicable, and then
only to the extent of such disproportionate impact; (iv)&nbsp;any event, change, effect, development or occurrence arising directly or indirectly from or otherwise relating to fluctuations in the value of any currency, except to the extent that the
Company Group, taken as a whole, is adversely affected disproportionately relative to the other participants in such industries or the economy generally, as applicable, and then only to the extent of such disproportionate impact; (v)&nbsp;any event,
change, effect, development or occurrence arising directly or indirectly from or otherwise relating to any act of terrorism, war, national or international calamity or any other similar event (other than cyberattacks), except to the extent that such
event, circumstance, change or effect disproportionately affects the Company Group, taken as a whole, relative to other participants in the industries in which the Company Group operates or in the U.S. or global economy generally, as applicable, and
then only to the extent of such disproportionate impact; (vi)&nbsp;any epidemic, pandemic (including <FONT STYLE="white-space:nowrap">COVID-19),</FONT> disease outbreak or other public health-related event, hurricane, tornado, flood, earthquake,
tsunamis, tornadoes, mudslides, fires or other natural disaster or other force majeure event, or the escalation or worsening thereof, except to the extent that the Company Group, taken as a whole, is adversely affected disproportionately relative to
other participants in the industries in which the Company Group operates or in the U.S. or global economy generally, as applicable, and then only to the extent of such disproportionate impact; (vii)&nbsp;the failure of any member of the Company
Group to meet internal or analysts&#146; expectations or projections of the results of operations of the Company Group; (viii)&nbsp;any adverse effect arising directly from or otherwise directly relating to any action taken by the Company Group at
the written direction of Amgen or any action specifically required pursuant to the terms of the Transaction Agreement to be taken by the Company (except for any obligation to operate in the ordinary course of business); (ix) any event, change,
effect, development or occurrence arising directly or indirectly from or otherwise relating to any change in, or any compliance with, any applicable Laws or GAAP (or interpretations of any applicable Laws or GAAP), except to the extent that the
Company Group, taken as a whole, is adversely affected disproportionately relative to the other participants in such industries or the U.S. or global economy generally, as applicable, and then only to the extent of such disproportionate impact; or
(x)&nbsp;any FDA or similar (in the U.S. or globally) regulatory, manufacturing, safety or clinical event, change, effect, development or occurrence relating to any Company Product (but excluding the loss of any manufacturing license or the loss of
marketing authorisation for any Company Product); it being understood that the exceptions in <U>clauses (i)</U>&nbsp;and (<U>vii)</U> shall not prevent or otherwise affect a determination that the underlying cause of any such decline or failure
referred to therein (if not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
otherwise expressly excluded under any of the exceptions provided by <U>clauses (ii)</U>&nbsp;through (<U>vi)</U> or <U>(viii)</U>&nbsp;through (x) hereof) is a Company Material Adverse Effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Options</B>&#148; means all options to purchase Company Shares granted pursuant to Company Share Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Products</B>&#148; means all products or product candidates that are being researched, tested, developed,
commercialized, manufactured, sold or distributed by any member of the Company Group and all products or product candidates, if any, with respect to which any member of the Company Group has royalty rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company PSU Awards</B>&#148; means all restricted stock units payable in Company Shares or whose value is determined with
reference to the value of Company Shares with performance-based vesting or delivery requirements granted pursuant to the Company Share Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Related Parties</B>&#148; has the meaning ascribed to it in the Transaction Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company RSU Awards</B>&#148; means all restricted stock units payable in Company Shares or whose value is determined with
reference to the value of Company Shares granted pursuant to the Company Share Plans other than any Company PSU Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Share Award</B>&#148; means the Company PSU Awards and the Company RSU Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Share Plans</B>&#148; means, collectively, the 2011 Equity Incentive Plan, as amended, the Amended and Restated 2014
Equity Incentive Plan, the 2014 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Equity Plan, as amended, the Amended and Restated 2018 Equity Incentive Plan, the 2020 Employee Share Purchase Plan, and the Amended and Restated 2020 Equity
Incentive Plan, as amended, including any <FONT STYLE="white-space:nowrap">sub-plans</FONT> thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Shareholder
Approval</B>&#148; means (i)&nbsp;the approval of the Scheme by a majority in number of members of each class of the Company Shareholders (including as may be directed by the Irish High Court pursuant to Section&nbsp;450(5) of the Irish Companies
Act) representing, at the Voting Record Time, at least 75% in value of the Company Shares of that class held by the Company Shareholders who are members of that class and that are present and voting either in person or by proxy, at the Scheme
Meeting (or at any adjournment or postponement of such meeting) and (ii)&nbsp;the Required EGM Resolutions being duly passed by the requisite majorities of the Company Shareholders at the EGM (or at any adjournment or postponement of such meeting).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Shareholders</B>&#148; means the registered holders of Company Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Shares</B>&#148; means the ordinary shares of the Company, nominal value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Company Superior Proposal</B>&#148; means any bona fide, written Company Alternative Proposal (with all references to
&#147;20%&#148; in the definition of the Company Alternative Proposal being deemed to be references to &#147;50%&#148;) on terms that the Company Board determines in good faith, after consultation with its financial advisor and outside legal
counsel, (a)&nbsp;is more favorable to the Company Shareholders (in their capacity as such) from a financial point of view than the Acquisition and (b)&nbsp;is reasonably expected to be consummated in accordance with its terms, in the case of each
of clauses (a)&nbsp;and (b), taking into account all the financial, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
legal, regulatory and other terms and conditions of the Company Alternative Proposal that the Company Board considers to be appropriate (including the expected timing of consummation, any
governmental or other approval requirements, and availability of necessary financing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Completion</B>&#148; means the
completion of the Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Completion Date</B>&#148; means the date of the completion of the Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Concert Parties</B>&#148; means such Persons as are deemed to be Acting in Concert with Amgen pursuant to Rule 3.3 of Part A
of the Irish Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Conditions</B>&#148; means the conditions to the Scheme and the Acquisition set out in
Appendix 3 (<I>Conditions of the Acquisition</I> <I>and the Scheme</I>) of this Announcement and to be set out in the Scheme Document, and &#147;<B>Condition</B>&#148; means any one of the Conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Confidentiality Agreement</B>&#148; means the confidentiality agreement between the Company and Amgen dated November&nbsp;18,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Consideration</B>&#148; means $116.50 in cash per Company Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Court Order</B>&#148; means the Order or Orders of the Irish High Court sanctioning the Scheme under Section&nbsp;453 of the
Irish Companies Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>DTC</B>&#148; means the relevant system to facilitate the transfer of title to shares in
uncertificated form in respect of which the Depository Trust&nbsp;&amp; Clearing Corporation is the operator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Effective
Date</B>&#148;<B> </B>means the date on which the Scheme becomes effective in accordance with its terms or, if the Acquisition is implemented by way of a Takeover Offer, the date on which the Takeover Offer has become (or has been declared)
unconditional in all respects in accordance with the provisions of the Takeover Offer Document and the Irish Takeover Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Effective Time</B>&#148; means the time on the Effective Date at which the Court Order is delivered to the Registrar of
Companies or, if the Acquisition is implemented by way of a Takeover Offer, the time on the Effective Date at which the Takeover Offer becomes (or is declared) unconditional in all respects in accordance with the provisions of the Takeover Offer
Documents and the Irish Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>EGM</B>&#148; means the extraordinary general meeting of the Company Shareholders
(and any adjournment or postponement thereof) to be convened in connection with the Scheme, expected to be held as soon as the preceding Scheme Meeting shall have been concluded (it being understood that if the Scheme Meeting is adjourned or
postponed, the EGM shall be correspondingly adjourned or postponed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>EGM Resolutions</B>&#148; means, collectively, the
following resolutions to be proposed at the EGM: (i)&nbsp;an ordinary resolution to approve the Scheme and to authorise the Company Board to take all such action as it considers necessary or appropriate to implement the Scheme and (ii)&nbsp;a
special resolution amending the Company Memorandum and Articles of Association in accordance with Section&nbsp;4.3 of the Transaction Agreement (the resolutions described in the foregoing clauses (i)&nbsp;and (ii), the &#147;<B><I>Required EGM
Resolutions</I></B>&#148;); (iii) an ordinary resolution that any motion by the chairperson of the Company Board to adjourn or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
postpone the EGM, or any adjournments or postponements thereof, to another time and place if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of
the EGM to approve the Scheme or any of the Required EGM Resolutions to be approved; and (iv)&nbsp;any other resolutions as the Company reasonably determines to be (A)&nbsp;required under applicable Laws or (B)&nbsp;otherwise necessary or desirable
for the purposes of implementing the Acquisition as have been approved by Amgen (such approval not to be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>End Date</B>&#148; means June&nbsp;12, 2023; <I>provided, however</I>, that in the event that on the original End Date, one or
more of paragraphs 3.1, 3.2 or 3.3 of the Conditions (with respect to paragraph 3.3, only if the failure of such Condition to have been satisfied as of such date is an Order or Law under any Antitrust Law or Foreign Investment Law in connection with
or in respect of any matter involving Antitrust Law or Foreign Investment Law) have not been satisfied, and on such date, all of the other Conditions (other than (a)&nbsp;the paragraphs 2.3 and 2.4 of the Conditions or (b)&nbsp;any other Condition
that by its nature can only be satisfied on the Sanction Date or, in the alternative to (a)&nbsp;and (b) where the Acquisition is implemented by Takeover Offer, any other condition that by its nature can only be satisfied by no later than the latest
date upon which the Takeover Offer may be declared unconditional in all respects) have been satisfied or waived (or remain capable of being satisfied or waived), then the End Date shall be automatically extended without further action by the Parties
until September&nbsp;12, 2023 (the &#147;<B>First Extended End Date</B>&#148;) (and in the case of such extension, any reference to the End Date in the Transaction Agreement shall be a reference to the First Extended End Date); provided, further,
that in the event that on the First Extended End Date, one or more of the paragraphs 3.1, 3.2 or 3.3 of the Conditions (with respect to paragraph 3.3, only if the failure of such Condition to have been satisfied as of such date is an Order or Law
under any Antitrust Law or Foreign Investment Law in connection with or in respect of any matter involving Antitrust Law or Foreign Investment Law) have not been satisfied, and on such date, all of the other Conditions (other than (a)&nbsp;the
Conditions set out in paragraphs 2.3 and 2.4 of the Conditions or (b)&nbsp;any other Condition that by its nature can only be satisfied on the Sanction Date or, in the alternative to (a)&nbsp;and (b) where the Acquisition is implemented by Takeover
Offer, any other condition that by its nature can only be satisfied by no later than the latest date upon which the Takeover Offer may be declared unconditional in all respects) have been satisfied or waived (or remain capable of being satisfied or
waived), then the First Extended End Date shall be automatically extended without further action by the Parties until December&nbsp;12, 2023 (the &#147;<B>Second Extended End Date</B>&#148;) (and in the case of such extension, any reference to the
End Date in the Transaction Agreement shall be a reference to the Second Extended End Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Foreign Investment
Laws</B>&#148; means all applicable Laws (other than Antitrust Laws) in effect from time to time that are designed or intended to prohibit, restrict or regulate actions by foreigners to acquire interests in or control over domestic equities,
securities, entities, assets, land or other holdings for reasons of national security or other public policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>GAAP</B>&#148; means U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Government Official</B>&#148; means (i)&nbsp;any official, officer, employee, or representative of, or any Person acting in an
official capacity for or on behalf of, any Governmental Entity, (ii)&nbsp;any political party, party official or candidate for political office or (iii)&nbsp;any company, business, enterprise or other entity owned or controlled by any Person
described in the foregoing <U>clause (i)</U>&nbsp;or <U>(ii)</U> of this definition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Governmental Entity</B>&#148; means any United States, Irish or other
foreign or supranational, federal, state or local governmental commission, board, body, division, ministry, political subdivision, bureau or other regulatory authority or agency, including courts and other judicial bodies, or any competition,
antitrust, foreign investment or supervisory body, central bank, public international organization or other governmental, trade or regulatory agency or body, securities exchange or any self-regulatory body or authority, including any instrumentality
or entity designed to act for or on behalf of the foregoing, in each case, in any jurisdiction, including, the Irish Takeover Panel, the Irish High Court and the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>HSR</B> <B>Act</B>&#148; means the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Irish Companies</B> <B>Act</B>&#148; means the Companies Act 2014 of Ireland, all enactments which are to be read as one with,
or construed or read together as one with, the Companies Act 2014 and every statutory modification and <FONT STYLE="white-space:nowrap">re-enactment</FONT> thereof for the time being in force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Irish High Court</B>&#148; means the High Court of Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Irish Registrar of Companies</B>&#148; means the Registrar of Companies in Dublin, Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Irish Takeover Panel Act</B>&#148; means the Irish Takeover Panel Act 1997. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Irish Takeover Rules</B>&#148; means the Irish Takeover Panel Act 1997, Takeover Rules, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Law</B>&#148; means any federal, state, local, foreign or supranational law, statute, ordinance, rule, regulation, judgment,
order, injunction, decree, executive order or agency requirement of any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Nasdaq</B>&#148; means the
Nasdaq Global Select Market, or any successor stock market or exchange operated by Nasdaq, Inc., or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Non Approval Termination</B>&#148; means has the meaning ascribed to it in the Transaction Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Order</B>&#148; means any order, writ, decree, judgment, award, injunction, ruling, settlement or stipulation issued,
promulgated, made, rendered or entered into by or with any Governmental Entity or arbitrator (in each case, whether temporary, preliminary or permanent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Parties</B>&#148; means the Company and the Amgen Parties and &#147;<B><I>Party</I></B>&#148; means either the Company, on the
one hand, or Amgen or the Amgen Parties (whether individually or collectively), on the other hand (as the context requires). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Person</B>&#148; means any individual, corporation, partnership, limited liability company, association, trust or other entity
or organization, including a government or political subdivision or an agency or instrumentality of such government or political subdivision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>PJT Partners</B>&#148; means PJT Partners LP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Proxy Statement</B>&#148; means the proxy statement to be sent to the Company Shareholders in connection with the matters to
be submitted at the Scheme Meeting and the EGM (such proxy statement, as amended or supplemented). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Required <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Jurisdiction</B>&#148; means (a)&nbsp;with respect to filings and notices under applicable Antitrust Laws, Germany and Austria and (b)&nbsp;with respect to filings and notices under applicable Foreign Investment Laws, France, Germany, Denmark and
Italy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Restricted Jurisdiction</B>&#148; means any jurisdiction where it would be unlawful to send or make available
information concerning the Acquisition to Company Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Sanction Date</B>&#148; means the date on which the
Condition in paragraph 2.3 of Appendix 3 (<I>Conditions of the Acquisition</I> <I>and the Scheme</I>) of this Announcement is satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Scheme</B>&#148; means the proposed scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act to effect the
Acquisition pursuant to the Transaction Agreement, on such terms and in such form as is consistent with the terms agreed to by the Parties as set out in this Announcement and to be set out in the Scheme Document, including any revision thereof as
may be agreed between the Parties in writing, and, if required, by the Irish High Court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Scheme Document</B>&#148; means
a document (or relevant sections of the Proxy Statement) (including any amendments or supplements thereto) to be distributed to Company Shareholders and, for information only, to the Company Equity Award Holders containing (i)&nbsp;the Scheme,
(ii)&nbsp;the notice or notices of the Scheme Meeting and EGM, (iii)&nbsp;an explanatory statement as required by Section&nbsp;452 of the Irish Companies Act with respect to the Scheme, (iv)&nbsp;such other information as may be required or
necessary pursuant to the Irish Companies Act, the U.S. Exchange Act or the Irish Takeover Rules and (v)&nbsp;such other information as the Company and Amgen shall agree. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Scheme Meeting</B>&#148; means the meeting or meetings of the Company Shareholders or, if applicable, the meeting or meetings
of any class or classes of Company Shareholders (and, in each case, any adjournment or postponement thereof) convened by order of the Irish High Court pursuant to Section&nbsp;450 of the Irish Companies Act to consider and, if thought fit, approve
the Scheme (with or without amendment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Scheme Meeting Resolution</B>&#148; means the resolution to be proposed at the
Scheme Meeting for the purposes of approving and implementing the Scheme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Scheme Record Time</B>&#148; means time
specified as the scheme record time in the Scheme Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>SEC</B>&#148; means the United States Securities and Exchange
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any entity of which securities or other ownership
interests having ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are directly or indirectly owned by such Person. For purposes of the Transaction Agreement, a Subsidiary shall be
considered a &#147;wholly owned Subsidiary&#148; of a Person if such Person directly or indirectly owns all of the securities or other ownership interests (excluding any securities or other ownership interests held by an individual director or
officer required to hold such securities or other ownership interests pursuant to applicable Laws) of such Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Superior Proposal Termination</B>&#148; has the meaning ascribed to it in the Transaction Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Takeover Offer</B>&#148; means an offer in accordance with Section&nbsp;3.6
of the Transaction Agreement for the entire issued share capital of the Company (other than any Company Shares beneficially owned by Amgen or Acquirer Sub and any Company Shares held by any member of the Company Group) including any amendment or
revision thereto pursuant to the Transaction Agreement, the full terms of which would be set out in the Takeover Offer Document or (as the case may be) any revised offer documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Takeover Offer Document</B>&#148; means, if, following the date of the Transaction Agreement, Amgen elects to implement the
Acquisition by way of the Takeover Offer in accordance with Section&nbsp;3.6 of the Transaction Agreement, the document to be sent to the Company Shareholders and others jointly by Amgen and Acquirer Sub containing, among other things, the Takeover
Offer, the Conditions (except as Amgen determines pursuant to and in accordance with Section&nbsp;3.6 of the Transaction Agreement not to be appropriate in the case of a Takeover Offer) and certain information about Amgen, Acquirer Sub and the
Company and, where the context so requires, includes any form of acceptance, election, notice or other document reasonably required in connection with the Takeover Offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Transaction Agreement</B>&#148; means the Transaction Agreement dated December&nbsp;11, 2022 by and among Amgen, Acquirer Sub
and the Company, as the same may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Transactions</B>&#148; means the transactions contemplated
by the Transaction Agreement, including the Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>U.S. Exchange Act</B>&#148; means the United States Securities
Exchange Act of 1934, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>U.S. Securities Act</B>&#148; means the
United States Securities Act of 1933. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Voting Record Time</B>&#148; means the date and time specified in the Scheme
Document by which entitlement to vote at the Scheme Meeting will be determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">References to &#147;dollars&#148; and &#147;$&#148; means U.S.
dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">References to any applicable Law shall be deemed to refer to such applicable Law as amended from time to time and to any rules or
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any singular term in this Announcement shall be deemed to include the plural, and any plural term the singular,
and references to any gender shall include all genders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>APPENDIX 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDITIONS OF THE ACQUISITION AND THE SCHEME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition and the Scheme will comply with the Irish Takeover Rules and, where relevant, the rules and regulations of the U.S. Exchange Act, the
Irish Companies Act and the Nasdaq, and are subject to the terms and conditions set out in this Announcement and to be set out in the Scheme Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition and the Scheme are, to the extent required by the Laws of Ireland, governed by the Laws of Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Acquisition and the Scheme will be subject to the conditions set out in this Appendix 3 (<I>Conditions of the Acquisition</I> <I>and the
Scheme</I>). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Acquisition will be conditional upon the Scheme becoming effective and unconditional by not later than the End
Date (or such earlier date as may be specified by the Irish Takeover Panel, or such later date as the Amgen Parties and the Company may, subject to receiving the consent of the Irish Takeover Panel and the Irish High Court, in each case if required,
agree). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Scheme will be conditional upon: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Scheme having been approved by a majority in number of the Company Shareholders (including as may be directed by
the Irish High Court pursuant to Section&nbsp;450(5) of the Irish Companies Act) present and voting either in person or by proxy at the Scheme Meeting (or at any adjournment or postponement of such meeting) representing, at the Voting Record Time,
at least 75% in value of the Company Shares held by such Company Shareholders present and voting either in person or by proxy at the Scheme Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">each of the Required EGM Resolutions having been duly passed by the requisite majority of Company Shareholders at the
EGM (or at any adjournment or postponement of such meeting); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Irish High Court having sanctioned (without material modification) the Scheme pursuant to Sections 449 to 455 of
the Irish Companies Act (the date on which the condition in this paragraph 2.3 is satisfied, the &#147;<B>Sanction Date</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a copy of the Court Order having been delivered for registration to the Irish Registrar of Companies within 21 days of
the Sanction Date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Amgen Parties and the Company have agreed that, subject to paragraph 6, the Scheme and the Acquisition<B> </B>will
also be conditional upon the following matters having been satisfied or waived on or before the Sanction Date: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the waiting period (and any extension thereof) applicable to the Acquisition under the HSR Act shall have expired or
been earlier terminated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">all applicable waiting periods having expired, lapsed or been terminated or Clearances obtained (as appropriate), in
each case in connection with the Acquisition, under (a)&nbsp;the applicable Antitrust Laws of each of Germany and Austria and (b)&nbsp;the applicable Foreign Investment Laws of France, Germany, Denmark and Italy; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">there shall not have been issued by any court of competent jurisdiction and remain in effect any temporary restraining
order, preliminary or permanent injunction or other Order preventing the consummation of the Acquisition, nor shall any Law or Order (other than any Antitrust Laws or Foreign Investment Laws of any jurisdiction that is not (a)&nbsp;a Required <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdiction or (b)&nbsp;under the HSR Act) promulgated, entered, enforced, enacted, issued or deemed applicable to the Acquisition by any Governmental Entity which (i)&nbsp;directly or indirectly prohibits
the consummation of the Acquisition or (ii)&nbsp;imposes any Burdensome Condition; <I>provided however</I>, that Amgen and Acquirer Sub shall not be permitted to invoke this paragraph<I> </I>3.3<I> </I>unless they shall have otherwise taken all
actions required under the Transaction<I> </I>Agreement to have any such Order lifted; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Transaction Agreement not having been terminated in accordance with its terms by the applicable Party or Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Amgen Parties and the Company have agreed that, subject to paragraph 6, the Amgen Parties&#146; obligation to
effect the Scheme and the Acquisition<B> </B>will also be conditional upon the following matters having been satisfied (or, to the extent permitted by applicable Laws, waived by the Amgen Parties) on or before the Sanction Date:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">from the date of the Rule 2.7 Announcement to the Sanction Date, there having not been any event, change, effect,
development or occurrence that has had, or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect and that is continuing; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">(a) each of the representations and warranties of the Company set out in Sections 6.1(a) (<I>Qualification,
Organization, Subsidiaries, etc.</I>), 6.1(b) (<I>Subsidiaries</I>), 6.1(u) (<I>Corporate Authority Relative to the Transaction Agreement</I>) and 6.1(y) (<I>Brokers and Other Advisors</I>) of the Transaction Agreement having been true and correct
in all material respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date (in each case except to extent that any such representation and warranty speaks as of a
particular date, in which case such representation and warranty shall have been true and correct in all material respects as of such particular date), (b) the representations and warranties of the Company set out in Section&nbsp;6.1(c)
(<I>Capitalization</I>) of the Transaction Agreement having been true and correct in all respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date except for de
minimis inaccuracies, (c)&nbsp;the representations and warranties of the Company set out in Section&nbsp;6.1(e)(i) (<I>Absence of Changes</I>) of the Transaction Agreement having been true and correct in all respects at and as of the date of the
Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date and (d)&nbsp;each of the other representations and warranties of the Company having been true and correct (without any qualification as to
materiality or the Company Material Adverse Effect therein) in all respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the Sanction Date (in each case except to the extent that
any such representation and warranty speaks as of a particular date, in which case such representation and warranty shall have been true and correct as of such particular date), except for such failures to be true and correct as have not had and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Company having performed and complied, in all material respects, with all of the covenants and agreements that the
Transaction Agreement requires the Company to perform or comply with prior to the Sanction Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Amgen having received a certificate from an executive officer of the Company confirming the satisfaction of the
conditions set out in paragraphs 4.2 and 4.3. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Amgen Parties and the Company have agreed that, subject to paragraph 6, the Company&#146;s obligation to effect
the Scheme and the Acquisition will also be conditional upon the following matters having been satisfied (or, to the extent permitted by applicable Laws, waived by the Company) on or before the Sanction Date: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">(a) each of the representations and warranties of the Amgen Parties set out in Sections 6.2(a) (<I>Qualification and
Organization</I>) and 6.2(b) (<I>Corporate Authority Relative to the Transaction Agreement</I>) of the Transaction Agreement having been true and correct in all material respects at and as of the date of the Transaction Agreement and at and as of
the Sanction Date as though made at and as of the Sanction Date (in each case except to the extent that any such representation and warranty speaks as of a particular date, in which case such representation and warranty shall have been true and
correct in all material respects as of such particular date), and (b)&nbsp;each of the other representations and warranties of the Amgen Parties set out in Section&nbsp;6.2 of the Transaction Agreement having been true and correct (read for purposes
of this paragraph 5.1(b) without any qualification as to materiality or Amgen Material Adverse Effect therein) in all respects at and as of the date of the Transaction Agreement and at and as of the Sanction Date as though made at and as of the
Sanction Date (in each case except to the extent that any such representation and warranty speaks as of a particular date, in which case such representation and warranty shall have been true and correct in all respects as of such particular date),
except for such failures to be true and correct as have not had and would not reasonably be expected to have, individually or in the aggregate, an Amgen Material Adverse Effect; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Amgen Parties having performed and complied, in all material respects, with all of the covenants and agreements
that the Transaction Agreement requires either of the Amgen Parties to perform or comply with prior to the Sanction Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Company having received a certificate from an executive officer of Amgen confirming the satisfaction of the
conditions set out in paragraphs 5.1 and 5.2. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Subject to the requirements of the Irish Takeover Panel: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Amgen Parties, on one hand, and the Company, on the other hand, reserve the right (but in no event shall any Party
be under any obligation) to waive (to the extent permitted by applicable Laws), in whole or in part, all or any of the conditions in paragraph 3 (provided that no such waiver shall be effective unless agreed to by both Parties);
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Amgen reserves the right (but shall be under no obligation) to waive (to the extent permitted by applicable Laws), in
whole or in part, all or any of the conditions in paragraph 4; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Company reserves the right (but shall be under no obligation) to waive (to the extent permitted by applicable
Laws), in whole or in part, all or any of the conditions in paragraph 5. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Scheme will lapse unless it is effective on or prior to the End Date (or such later date as the Amgen Parties and
the Company may, subject to receiving the consent of the Irish Takeover Panel and the Irish High Court, in each case if required, agree). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If Amgen is required to make an offer for the Company Shares under the provisions of Rule 9 of the Irish Takeover
Rules, Amgen may make such alterations to any of the Conditions set out in paragraphs 1, 2, 3, 4 and 5 above as are necessary to comply with the provisions of that rule. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Amgen reserves the right, subject to the prior written consent of the Irish Takeover Panel, to effect the
Acquisition<B> </B>by way of a Takeover Offer in the circumstances described in and subject to the terms of Section&nbsp;3.6 of the Transaction Agreement. Without limiting Section&nbsp;3.6 of the Transaction Agreement, in the event the
Acquisition<B> </B>is structured as a Takeover Offer, such Takeover Offer will be implemented on terms and conditions that are at least as favorable to the Company Shareholders and the Company Equity Award Holders as those which would apply in
relation to the Scheme (except for an acceptance condition set at 80% of the nominal value of the Company Shares to which such an offer relates (and which are not already in the beneficial ownership of Amgen)). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>APPENDIX 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRANSACTION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">See Exhibit 2.1 of the
Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as filed with the SEC on December&nbsp;12,&nbsp;2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">50 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>amgn-20221211.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/12/2022 5:02:13 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:amgn="http://www.amgen.com/20221211"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amgen.com/20221211"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221211_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221211_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221211_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amgn_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>amgn-20221211_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/12/2022 5:02:16 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20221211.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="amgn-20221211.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="amgn-20221211.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeniorNotesMember" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>amgn-20221211_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/12/2022 5:02:13 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="amgn-20221211.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="amgn-20221211.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Notes [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>amgn-20221211_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/12/2022 5:02:14 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20221211.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="amgn-20221211.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="amgn_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20221211.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeniorNotesMember" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140694221641104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMGEN INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 11,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.000% Senior Notes Due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d346985d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20221211.xsd" xlink:type="simple"/>
    <context id="duration_2022-12-11_to_2022-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-12-11</startDate>
            <endDate>2022-12-11</endDate>
        </period>
    </context>
    <context id="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-11</startDate>
            <endDate>2022-12-11</endDate>
        </period>
    </context>
    <context id="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-11</startDate>
            <endDate>2022-12-11</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-12-11_to_2022-12-11"
      id="Hidden_dei_EntityRegistrantName">AMGEN INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2022-12-11_to_2022-12-11">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-12-11_to_2022-12-11"
      id="Hidden_dei_EntityCentralIndexKey">0000318154</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-12-11_to_2022-12-11">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-12-11_to_2022-12-11">2022-12-11</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-12-11_to_2022-12-11">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-12-11_to_2022-12-11">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-12-11_to_2022-12-11">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-12-11_to_2022-12-11">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-12-11_to_2022-12-11">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-12-11_to_2022-12-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-12-11_to_2022-12-11">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-12-11_to_2022-12-11">(805)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-12-11_to_2022-12-11">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-12-11_to_2022-12-11">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-12-11_to_2022-12-11">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-12-11_to_2022-12-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-12-11_to_2022-12-11">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">2.000% Senior Notes Due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-11_to_2022-12-11_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-12-11_to_2022-12-11">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_
M[/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*$IY"
M&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X2O2Q
MS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y"M-2
MD&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y
M>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0HGQ,
MC$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ
M/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q
M3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7=\%@
M\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#NDI &
M$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A%W+C
M[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#
M>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->YA,L
M0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_2P=\
M'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E
M/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04    "  2
M/(Q5(?U*O;T$   W%0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;+68
M;6_B.!2%_XJ5?=&N-"UQ @6Z@,30=A;-E+*%W9%VM!],8L!J$F=MI[3_?J\3
MFM"=<(,J=3Y,$X@/3WQ]SW$RV$GUH+><&_(41XD>.EMCTLM62P=;'C-]+E.>
MP#=KJ6)FX%1M6CI5G(7YH#AJ>:Y[T8J92)S1(/]LKD8#F9E()'RNB,[BF*GG
MCSR2NZ%#G9</[L5F:^P'K=$@91N^X.;/=*[@K%6JA"+FB18R(8JOA\Z87G[T
M\P'Y%7\)OM,'Q\3>RDK*!WLR#8>.:XEXQ -C)1C\>>03'D56"3C^W8LZY6_:
M@8?'+^HW^<W#S:R8YA,9?16AV0Z=GD-"OF999.[E[G>^OZ&.U0MDI//_R:ZX
MMMUQ2)!I(^/]8""(15+\94_[B3@8 #=:/\#;#_!R[N*'<LHK9MAHH.2.*'LU
MJ-F#_%;ST0 G$EN5A5'PK8!Q9G0E@PPFV1"6A.0Z,<(\DVE25!MF;= R\"/V
MTE:P%_Q8"'K'!'EP3BC]0#S7\UX/;P%;">B5@%ZNYS<!CFL!R;<O,(!,#8_U
M/W6TA7J[7MVN^4N=LH /'5C4FJM'[HQ^_H%>N+\A['[)[F/JHSWN/=\(;12#
MFYBQF-=1XCKCVT_7,S*=31"F=LG4QK5@,L-\0F\BMJECP<>O6:0YPM$I.3JG
MS,T$2!2+H*0A?R*?^7,=$:[DPC^?]FBGC6!=E%@7J%BYW);/:6VE\.&]L\\(
M1+>$Z)X&,>=*2+OL0P+=7<O3H/32C4WMV"O1>J>4;9H$4J52%3VX, !')C*#
M6D))95A+B@M?72-T_9*N?PK=C8@XF67QBJLZ$%S#=>F9W^VZV&Q1M[)7]Q2B
M)7LBTQ!**M8B*";M.%^#9+]SYG?:;K=[@1$>!  ]A7 <AF" ^L/+ <E]]2ZI
M+66#)(PBXWC#D[R]N2)7"J(7HZW2@**&_1WMQ)Y)199R5Q]6N-QR*S-MH^^.
M/6@,L+)\>I+GEX!%;P#A7,E'D03U\XEK3L886N7\%+?N_Z/-I39@O7^+]&C/
M-BCVJ>^Y9[3;[V. 5210W,GS8HYA<WF<!Q?XI>=V?L50JAB@N)%_D0%,S7PK
M$\Q)&D3:[>X9A73"B*I,H+B5?U7"&-M2,HZS9.\BNI8*%VI*<%IE <4]>R$C
M$0@CD@VYA56N!(MJ>7"51I[*_2ENW7/%\^GAT&9%B,->!^SG;KT^4C]<KXG,
MJV+ PSW[.[*IUAF0-0$VR#8"5BG@G90"US%7&UO/3Z!@MI8Y94GMIJQ!L!'M
MX $ ]V@[;_DF0P8/Y-LMM\U8O]5_C[V^5SF_Y[_ODPH: F_%K]+!P[U\P8-,
M66;JK<A2F*C6@!M$7M7J1_<<S(^2E"GRR*(,70Y52'BXQR\5"^T*73S'*UGK
M-PT"\#0UPTBJC/!P>R]G[/HIV+)DPX\^WC4(S<:+J_$?&%.5$AYN[@N>"-AL
MS*3A&F\65.>MJZV*#J_WOLV"9LI;\:ND\?!D.+%9<!'/ML=/Y%7)KC)N']6P
MK;U?I8Z/QT-SJS0(V%;!6:J \?$\.+U9&H2.-TOKX#68?:5XRVR6:1+Q-2BY
MYUWP!56\I2M.C$SS-V,K:8R,\\,M9Q#(]@+X?BVA)OL3^[*M?%<Z^@]02P,$
M%     @ $CR,59^@&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M:]LP
M$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')
MW3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG
M;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],
M;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]
MN/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^
MR=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KX
MK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_O
MC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;
M2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<
MT:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M
M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<
MGB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8
MGKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U]
M;4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\
MQQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73
M>RHY_U=3_ 102P,$%     @ $CR,59>*NQS     $P(   L   !?<F5L<R\N
M<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9
M>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:
M+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU
M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*
MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  2/(Q5'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ $CR,520>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( !(\C%5ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  2/(Q50=WBE>P    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  2/(Q5
MF5R<(Q &  "<)P  $P              @ '* 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( !(\C%4A_4J]O00  #<5   8              "
M@0L(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  2/(Q5
MGZ ;\+$"  #B#   #0              @ '^#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( !(\C%67BKL<P    !,"   +              "  =H/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( !(\C%4<.&7J/P$  #P"   /
M      "  <,0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  2/(Q5)!Z;
MHJT   #X 0  &@              @ $O$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  2/(Q599!YDAD!  #/ P  $P
M    @ $4$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !>
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d346985d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d346985d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d346985d8k.htm">d346985d8k.htm</File>
    <File>amgn-20221211.xsd</File>
    <File>amgn-20221211_def.xml</File>
    <File>amgn-20221211_lab.xml</File>
    <File>amgn-20221211_pre.xml</File>
    <File>d346985dex101.htm</File>
    <File>d346985dex21.htm</File>
    <File>d346985dex22.htm</File>
    <File>d346985dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d346985d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "amgn-20221211_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d346985d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20221211_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20221211_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20221211.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20221211",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d346985d8k.htm",
      "contextRef": "duration_2022-12-11_to_2022-12-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d346985d8k.htm",
      "contextRef": "duration_2022-12-11_to_2022-12-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "amgn_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.amgen.com/20221211",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.amgen.com/20221211",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com//20221211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-22-302256-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-302256-xbrl.zip
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M8O&J"V7;'_67CM;_-?@<9L\-'B%"B<.A#U<ZSP[<^YB@!O&+;^/1GE?"ZIE
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M/P%L'HIC<I\#Y:/D$N^]+%=.Z]D.QN=/#L;U(^J+T R$_4CZGP58K<*;@!(
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M ,CMR&\AJ'D!DV( 6"VB<!RB#J%5LU7/5<U4.]F1%\"*/=!A^'@-'<"J<#=
M^V-:M"=\#Y:38.R5]!.]=M" /H51Y*4YO"K>\SH1'T%;B::DWJ$.DH;7J"]5
M]W$S2B)X*KE!S1N&8MBLC+7^GP5 .!47Q:"V11>9V*GJ/@[:580*%'W#>ADH
M4O"GP7E*X!R8+T L@=X%_#$;$;%Y$V0\""(-D<VL@$DPJ31!-8U UA)KH""M
MDS7#VJ[P"/[1ZSWO['718J'# >VQNKQU,/\X(6')/]0FCI,Q3!"Q;]1Z2[&K
M&\[8*D$",0MQ83UL%1<C*MXNK:!#S4D<T)"./0"+512@#X=C3K$%>J,(>,!X
MA6 @<JQ1HUGK&I#2[[[!D6OK? 3"XQ13,^-8Q7G)D,C+T%-2I%4F"I<YD=I(
M=C'I XUBLR6PW4F 9C2 M-;FA/]8FQ4W3KD$G5>VRJ0.E"R!(LDB \082QA;
M,;BD2 ':8%/ATYBM3VT*Z<<T1=MH;:E'O9ZKF*PR"IC/@^SN*.X'$D2FUW"V
M)$Y03VN)K!C\ 6O&O978,GZ8<2+P*%F>^ <UAJ755V$"( ";@P&0:V''7'X3
M&Z,@*\/9T'_B>$@:)#%)R"T!FV?OB\=/\=9A;QG, %LKHMRX..BGEL$T=3Y
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MV&MI(??J[P(T8%AGN.#C>8N=D=?Y-12GRT6 1873H3@?7H3!0/_SS7Z=0G%
M!,#2*Z'5%?@J:]GRSFNVT*W2B62BZ9?0'U@""DM^1]L ]7>LWOLST!- NTC7
MLPCHS1IK=.L^W07P/!_1(TY45]'$&[7.+<MH=4"*N!H'ZC"N"&^_1?<2B(#3
M5$8HM\C=08L J3W)N5,B&8;X6Q[F*9P#L K@I"CN,KV"7V-RZU ,&H!X5*"D
M\VBXG\!ZH!#KG*$Q^@'H :.AZD:&2GF.=_1G2P_6 ALSII ;CGH*E#!EOX!?
M(H:%U(O]!8 !Y*@?XS3# M@0_'LTF2"3N!4[>IA&O^6Z[A6]1#U-S77 K%?>
MHE:>D6^Q9@)R#;$Z=&!6-U[(IAMI* X<<'L 7T %=58-"VC-M)45^"RN#<,T
MP[AF-,2YP*;?^?HL\%Q.T&B.<U79@$CQ&]GL&#\_A!U?RQ@^9(^, 3:'(#"
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M.@.<]JJ$JNN;PQ6KNW]TRE)3):@-@@4RIVXU\-0HN6GNQ(B6#^%MN1-LW1-
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M&N0J=*AVHE"/_6F#3KO4*HU7DI-(@'# >D<KO;9ZS[W675TW$4T/5:_>2M>
M+\ S3'$UZP@:L?B*-=5'P#9X4;INJ$.OF B*ADMN78!-C7KFM%9R<DXI7 *H
MD];VW=R21GD0[QTHV$W .(-F*1T.(3'Z>7-T+7(#K*9J+;*9C$UBS2+?8W^/
M4G7/L7?9.X^ ZVK",LKD#3=JK6/R&-".ND8 ?'5K'[=CCPLVK%3Z[P*T*YG"
M=E8U?WO=]G^[B3HXP9\\FF"5NG)QR4Y7)SO7U>5O9MD<I3%25_<47&7Z7UIZ
M_M57# M>/8NJUN_0;;NM69]"9VR&H'0IWJ_MLL$.*F#YG:OD6GL&=&@TTRXZ
MC]07V2@,;N2 4H5PK(4[&.7Y)#O8W@[3SHC'0='H360!2D/6 2+=AK6T%;8X
M $(N44*N]:8UO?4\'(SF,[=49N[4ID?NHW!HS64\-4?(/?B^O%*32]NVDL)V
MW/"O ZOF,!:C6NQT[F1+/V/Y8JO(=&EE//-%MMSY"N1BHOJNS+=PW6QO]S;
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M#?&^AC%68(SUA?NVSYO?,, *#+"^&-_58*PFROL,XTES'X&?&R;8$2988RW
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M_0+&5&1-//9.@1(AR@I^@6+C)8JTJY$5*3A3\":M@YEXY[98A3<^B'1!6KV
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MJN-0<++/]IT*2/:S_F=CCI0Y4D\)2MO\]>JS6?8;A%\9^-$CLE9><7GQK[_
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MBENWJ2R>>UI=.7U*04F>K1XBH$>^#]LMID@;W\T[U,"H!&*)22>Y_T5*/;0
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MADN +R<X&Z?DHB2O9E\ZL&]TH:@H+QV)&Z2@,4=+D,JJ42W!OZM.G\M)G?)
M2WAD9/1HBZ*/[W(G(<2D^98>:4,<,#OC[V%I,F04R"K%87<</GN,;X%_G]C9
M@Q1W9D^\&.:%6[9"^Y6T85)J&83+78\ZGCU\<N0*P#))C&R1JCG'+F>P!@YP
M<HVNB+@)>I,8[0C'QV=G'&3+WSZLI2Q'6:7*-P$VTW5<XA)3M&LT<ZNT,S,+
M%W"+2#<Q=<WP&+LJU0#A$B9:L%N>'>VQ@($_7Y8BL7V#*%E&&3*%;>4G'1FY
MI;? 36F3?_L68*1/+"Q5N8!HI)2VZSQR;^$)"HQZ=/B8Y?C1X5,SR'V[O4IR
MBG<$@UTR=@#A'B4H-^#%[=;L_C#\IXM$[SE)^%XDU*(AZ5K;,#/(+?F"U3UZ
M8N?:,?76H:YOKNPYJ8XV7QC4QQE9UV.&X1VQL^[3[F'C/UV75MQN.;M^G@2[
MG]""[R6V[X3S<_^K3CZ(B$4'8_1(:I%]//:G&+5D5=G:,FF]2'^)OSP]1,%%
M]?AL#446'>[)X?.N%8H.-%J-3L*P@4YU%QB1J3ES3: >+9UP4@(Z@U,'#E[%
MOPB8'2?]9/N>/_+Q )VKCTGMKT0_.ER&R[<LHW:[59:R523'6D4!\?]DEEK4
M&;\NN;YCBJJ#9"K0L<-&J95NLBQ:BZS3[?;T4(E"M;E355<X.Q=#D_=666?4
M"$L:=;L%]XE'<K5;.E7]5T;.L2Y8L@D>.7@RU<[)>=V0?:V"F<>T\[_RL5HS
ME*<S0Z'B4 O"2 YUBSZ"CR^K#;[W(51QK3!_?/AX[XNC*7/E_]B_46QR352^
MU##8K 4.W!TK#!5?,"A1?<YQNZ65 DG4),:A@W!9CN3A01<7P ).;<M,L1@>
M,\@P"8!S66?GCYE"Y:3KV?F7&(*G&^QOV53/)E-_@.+^.(()+,XK!_OZF]8X
MV,8UOE1YD<;.4C\,?V_EW*^*?IHP3HQ'R2@U"P^"?"%SKS)YM063KZ#W52;J
MB.728AO$G%7! S<[2?(UPFBO48F[1W'(LG3ZQP?=PZU@X7D8[W-C8IG"D]ND
M1'%HF.&IVJTJ>A0Y^0+)3SH!W0O]W\+(1QWOZ+#[LE-.L/+<_*I:J-&9B"?G
MK47XA#2SX;5CT"808-0[/^@=T%LJ?CJ"4C$ 4:BA91E!%?49VP&^_.^+CP0P
MBEIZI@3TP3PONP,5AKT+(,%'IDYD0VOYKG=]7!_+-#X%N+CK:8P9^/"DDJL^
MDT=6 5O4>FXY(6XP4%D&O^C(O)-5CPYJ)'3$&<M^2H$$)"TZF+6! ;^22Q"D
M:8KBM QBMB\Q'/*1D5=,<NS<2 (Y7=W<KBEP@?QF# T:ND4V(].4\9Z3^2X)
MI!F6G'3+RC6W5R! -NK702\=N8A%=A>47E1CM8C5R6Q?AM Q2^<:ASK,/ PS
MC!W8Q/8DO8.-, JS2'*"3>;[%!&/0DH9"))I.;%0BG16FDNVV8(VG0#[CIR>
M-HUF+FIKM;4,([=R2X6XF& X"?,T,TKF9/2> >:(=SQRK*)Y-N6L$2\<MENP
M;'"QG^+#.$H4JZ^Y-X:S'A[9_:5[2#&7[L_[%N_%O!67%6E*/ER=!#JDF>0V
M=4CP9B3#4:^[GO@E0_Y[5W=9KB8T9KMNXL"K7LL +$.BZ;^2](MQ:UB /IX&
M;67%D27!N'A-)]DL$)N)$X9#<RWN>=S6OOOD<N)RW;K-Z>NC.QDI@QU3(I+,
M@<;-\)4:QDI/"25TXE#'O<.9:6FL.GQM)Q<GSDC"V4=RX&_1,[]Q_G1: ;L@
M(!"]G/U&I"G686AU-)[4P ?+@]*=,EF*C@._<U=/3NX]4.UL5/>>.<A\X7#Y
M1,W<""N5'$G_!HG?<2A<W]8)KS(1C)GF7I4RS=WT['8;S^[#'!C8% Q+M>9H
MM,"Z Y5B2:&KSTF>OI(F0QVCR!(JOM&0M&+15_FMDK9E/8:N3V=!.3>K'4HC
MD@^8-EM'"U:1RRE;OJ=KPUC=N9".*BP?;%X0W(E;&J.%K/LQ%/]8H[UCV5H:
ML"6@$TMT9Q1Z@X988A+V_8B;$(TQ\8$(;M]%O3RD>4XU+>&]0?;M46LTN$JP
M^E :7S#X6;3IRLMWK+;];^&G\_E2:>WN3[YLIET+)2.S\<;QVC%(0>ZZHF^%
MM0J3 -1/7:*)I2/MUD<_'8S%#NUVO/\N8J5]JQU0.(%LUDQ[?$ALK&TW[W%W
MPUQ,$_N7\I?2[4[YFFCMUGRJW:KH9A6R;0\)I,%8#81_C4>"$I96P:OH=@^.
MGF,:2KAYK\1,#[7Y5?7S^QFAGXWM4.D18D(MY"[ AB#$ 67T6QOB(I1U"?V$
M0Y!Y N!>URM%1UI.4%<*.=AVG$3%I!_Z&Y8U,.5E<!%N8,_W8NS4Q+L@P]Y'
MFHI[5$U/RAD8-_'('[$,GOA?J)15*ICH;ZQO8K1W."_QX;<AU6I@78'DZSB]
MY:B](D/62O,60EW/M-TK7J7YS=)0Z]4YFIME7(T77H,EPV0G45)NV8HK(9B;
M2&="(78Z"]BL?(Y7SN*_;73*YLAMMQ:?N;7DL%#\OK[9MS=/S<UZ\2N[SC0H
M.O"N);?)JQW<$GV@UGG-?5\# PU "8K4RRW3ULXM,".HA.XKY8 !Y1@GQ9GP
ME<</DRBBMF\A; %"JXXD*X<P_CI&?M/6(SNPEB8ZS][G;#IY+>E%462C]Q((
MS2AU%NNTT)#BWL!4>65[$582@#2(/();314A7$D' DX(A1%AT>,^.SDP%]>,
M"&WR$"$ #%XX^:!"QON&TW6S^[0&6;P^&]JW:>QTDN*QU-&^&ZGI16@&( 5A
MDV,I,^/K6O<9Z<*(G4$P7N@5Q5HK\92* 6$@?%$8E#QO<"]H@%GXJ.*/XP98
M?@&$QSH4L$$2/PW@GP+8J.AP'XLL(R]@@!JSP>DMH\HGIB%'/PG@,:8TBO/F
MBS2G%,&*WYPR-V,>GBE+J@^[VRQ\/^V'N63ANP_0Y51Q>8IZ:MQZ -FK=%2[
M-L'8-RV=5;#9 _>W<#2&LQ_H-E=!M9>@!#O#O*!XPZ-V.QJN:AS:S1%%E6ZS
M0YV$D^KVWN56EQT7L]H'#L,:@]#F;;KM-BH/8Q6N9,UFIH)&8#:BNXK%64I#
M]1_>OG2V4;FKIK9'W&K%<C-2Y^2GC")#B2HAM%ZFJ&YSH-'E$3L@Q'#,'?IB
MG5;:6K>R @!+SABC@,MJK=KE:%TZ.J!7O5(C4+NV@2-"2A.@:%&)+\B5,J]1
M\- Z'-"=P)E9()6!86E.&K(!-5?V1.J*'6E$R&N38?LOG_MQSU,AM?J(M;AJ
M?PGIA4M)4U9U14$9P:%Q"DZ'/.C [Q8VC3LGX#CQ$X>!W0HB$T##(D.]L)01
M1;X6[IPQ7+@N5>D(=Q7H3^4F]\[,TNJ=U2M@'"L5[U;;_R+2$25ZF=;8I?'V
M"ZR&CNZ\N@W"WB3C\QCZ@RKT?'D*DN6&/5G2+["E;_RH,-:;$"Q+7)@O_ $I
M"LL]U,F3\X6.#^<.[A&IRZ6]SQA6N^MP/FH<SNM+)2ZWA6<V<;XSDB[,!J;M
M@A9.MOOVS";9&\V3I.6C !O@A),^";-<<!Z4*4-B'[9K27/9G8S**/,S1^W4
ML5&#NMWJ>UC,8.O=R':EKA%CTX.=KA\(PMALW@96BU=V7LG-*?FEM_[4QGG
M>#A/<CR1S2%:*LK*X,#/R)9$<=HIG["F510B/E!ZCR!* (T$*48\$C2;:E$$
ME8BY7B<J.ZFXHDA3XC-HA4O+,8+>/7J*5(BE#;;2?"M:>;NUUY6UJ1#5FKVE
MT#4NT/=#,Y%@#A";B45T!9V)!?8>QEL11 !,C'VS:0SI*9:/8'^4&%$9?.Y_
M43%K>PBQJ224>U0CW,N=U;6R4@J\2K^]LJ)HB5XY(Q$^P\9.$R[^B0D67QZ3
MA=GWZ9/5;:%1'HZ=][1;93@ZT1&#3;N(D!TG,2>[WS>1KH+'R6ESF[>5)NB'
MNM]$EKK?NT>;;Q%<YUZ<:\>6W9CL*$^S?+XS<]-SDYY\%^2!6F3FDK_O&KV)
ME+=@&@O3*</1(?)?P_:TV*=$#ML=>Z::3EL_FCQN M:R;FM=L1]HWTM@JMOQ
MJ)+U&4>OLI(+$9-?JD-Q\&3<'F25GZKMR.KS/5[-+*5=EV?3;^U]L]XF-DYW
MG&H3G6J3'5?[U T)2$_U_N'-:T!@6@K(S4]^KD//EQ^?@E;KMA[0*BYKJV0J
MVGO<W[ZO8<$]-LMKKS*H:[.A*6N(=9+*)K(Z0RGIZ[5GNA(0RK_&^&_X94W\
MTM]"?NG5L <I(+>4!F+C@"H6)0GY2OLZ9A(''77TJZV<TQE\DG<\F_57[<VN
MOQ_"PU@'$\5\X&/*N)^R]*3L.>F+C;8*W5_/[#+\Q=F'KQD4O]D%#[D+!ENX
M"\Z3>6S#G<3[ZBZ1O+ AP<=]1"\BNJ9M*'<QR_Q0G8F#$[4JH/S6\2PBSSDJ
MNRJ-[6\Z!PXCI1*:/4O#;%R-M!*D15I(_!?]LZ/H;K.YYC1.Z=2,]E1O,#^D
M4[H*ZUJ>;$UH9QZR/X8(HXC3<[&C/"[$G @GK2+!&#M ^SDBR%.%.Q49=-QR
MC!(,/P+P!H)R7 DC)JE!<N/8-DI2[A[-ZD9-H':CINP'!<2JY0+Z16PYF++S
M\:CC_OBX].D)DL#Y_-04*M$IQ"U2.E4-G+X8@_Y^(S$0R<!>H2&MVWQ6<$(H
MTXG&X 4AHIX2$HU.:=US 0+X*N=0[Y=,AU";.'S=K:+HB'&,2&MU0FG1K['U
M$:5J2+CFZN_^9/KZPMO#WTL1UKLIGN <3==7U2P,0X_OW=UG_-XW#;_=JAG_
MQR0)[K1';O$D2I?6S@0N98V#G\$<H[-)3/7 W/QYO%-J5,21-)^(1F0O&:(X
MV/JS_(0H3WR)QGJJX:OU#**S#LI,PB"(-'.L-CY,AUYQ@.2I$\8JO2E(%*N]
M"HLPUS*32#P-[K3,:F3?0_MVJX8#]L1%FSE%&:X<A!?BKA#.H_S"LEQ4^>!@
M?Y>K-AXW0;0'/V;YJ_(G8;"Y-1W.2=AN+8BC?$CBT2-R])VH/L(6I^0Z5V'N
MR$K.UT-.9C&?S31^_C$J2$]72:1Z2U%]M-Z\FU$R>T?UHW+%Q885X-68Z6@5
M9EH4DQN %8<9E_BS*P7AK( CD%(KX.J,/+):Q.X(_RT-[PDO/&+:252OW9KA
MSQ^_9Q[K(W0GF?+Q.IDR9K8J&2==8,R2!7)$Z<0[RZE,X[=OW_X_[KH+"V[(
MG?#6][L[S85/ULJ%7%A3YL).F07++/GX+\*2&N!J\U(1./)HISGRZ0_FR+(+
MI\*?3\K\N5D'5:CFMVD%6SP?4;-&L!P)-)RP #O8!$8%^/V83;Z!;BEH0-K8
M!)6F%QWSE^E)!;9</"@F_90#Y1$EJZ:"6:#7XTN(+F&=;WJ31%A!DL*<L,B)
MJU PQ4>2+?MW'B;_FHRW#_ZM2>W%.%('>PF@_U)Z NE<8?*.F:HIB9H[P"]H
M+X^P71=;!T9.I&J44/4:5SX(/"&UHHR<I.*<>L"FBI!U,8REG]N19#NG+9%D
M"%.=80W)I)T,QP(BJ4DE-$QWJ(131&@OZ% 5V/=< 'ET*K1G<J!]<J/Z!%Z-
M"69UMV'RD6E/R2EM/&XW&K?*'/:=DLK/<8B@DM313RK[-)2I@_U#J\CL4"KG
MJ"T>D17=L$A*%G0^-OTX)*M#4EZD\0,*%H*OTLD@?OPEJR9^]-(\' !EMB#]
M!Z?JG20#*@]8*6I0!N!@V7J><(" X$ T_()MCE--,"DWWVVWY/Q&,9Z&(XR1
M@8!07X'U<A$0@D3F3]A#/H,2QO Q;I_&21)0*DQ'0U=U#&I9Q\:7-?R8O_DR
M(M1MO"MXU>(4+.6G(&I)V7$]^Y*W@6TV$93+J8XN=QYC#[GCPA7?XRFZ=O$"
M>:'DO7-C(J>/-]Y1V_5LLV=@22^L[S>IXA 1T(M8:BS@#(SP-E04'F'VK-/P
MKII\N<L.RR>-P_(A6.ZC_P?7*I*$GYM:N%@OY=,!4[2EV0.&3LAK_O3P9U/-
M8OJL72<8%/UD*\DR CNX)4&&<&5U5_A2X$-B$M56!F#B5W.5I7T#GN1ASOG5
M>.V(FH:G,V-RKZ,HANE=-A\L"NE P&0V@PQ$#F.)ZER:TF@[G-_HI@4).*<!
M\R[1$P=77I;RY$EVS1*(Z*>+WA:-1Q-YSG/F$+I*+DDF;[=JYJM;J5%P<J,2
M]2.V&2)TP6-4<B+I9#2_C125:,VT-:F:Y)@98%# $6,<GS=KH#<Y4G^QS-);
MVLBT<7QJSMIS.KV:KI%][*O,B:?2IO75^K.C7MYW6^Q)>RYI'/M1*0838AOH
M]/W'&41ZW0?&.JXJ]UZJ+)&.]?*82]V="I]G?\XJ,@&4%E/-Y+P0+@"):_.^
MJ=<54!>U99*'H-.\_DYQ\@UT$\(YU>\\^$ -(NPE03"F0ZS)0?$+<D;*_#6]
M.IR?B3B% X9/X+HSZL?)N724<[E*L2J02/D1TE '*S9 #R"(V#H.4T3^-.,J
M0FZ:HSL&Q;#8DMM:*BM &B@TR/C8X@:YN?M$,N\K?8UK:I$JA3;/M+2NU>]?
M?Z]Q] WTNBEMO.,P'114S\[>BB"$5<X'B,HIC96.7F""<0VDL7G&!35,Z\5Q
M4@ 9#,(Q'<$1:3K<I"X36<4D;+<N_%A%9'I.4=_(]W_\;@)B^+*+/J5@G.UE
M^]1BB2L[L;B:JO/#2.@A8F5$N7>I(5'7ID%K6F%5F>[_2U'='[[2-R(IB/@&
MVJ'[E(=(!2[N*I9-6D8>K*P@+U-N1:+9#K24L]S<J!Q_L>*$^ZL<98FY+:H'
M<79%F/.1T;%MT*0YNST[-K./]8E?&:[V+XK(6BR\K3Q.$%155]\MV=#[%:'?
M;I%@U-_R.&:E_XP8;\3 7ZPZ U>?+?)<(QN !CKE]BWBNT]2R:BD3^BE/A:
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MU=HM'$QH$$S-\2?I)6D8C)2A?L<K=U"L@4L/J53,-$C#)-Q4.2VP-\Y3IB5
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MY]&/GD-2@S3><[$(O)[K+$+/BKBXN%':P+%O=-L]UR&K$<J)<ZTC=Z;EF8D
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M/64$2UHU7!1(J2[Y W+!J4Y3+=7LA>33YO(NCOVK2!F\$OS,L];OV;!$@@U
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M%MYG'RWP:]>LG#XD+!P>-+#\];OD!)0CXVN=IL7P%'%C-Z>-%=A;#N,+DGC
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M+<KRVA8RCG7*[[=.*4E7&[5*IH=!1-H?F6<@;\MBK3'<.*9*L!/2IU3C'"'
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M5\R(;%]'>OC]RWAVK "2#R+6SZ ]IUTO'<89OPK_C4_F)0WV<S\"//CGCKM
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MZAK]@U4#C<$LJ>H[ 8'<5507<;%NS'->;=U.5-Z7+6Z.^!O0G+7H2)\$&$N
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M">9.$3OH/N<QW5CE7WO['7 %!X+0&T=?T['T;YL80%B,1X&*E=>@F &,"Z)
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MD,UG/R5.\Y<IF7FL-9 #4A49*0O,1%N\BZ)!-B.-G[FDK>L_ALQ?BV@-9G&
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M5:5WW+A:EXT0S4@:L$66+754-UCC*3TU-A0(Y$V-.X X0IG/A35V\ ,35WQ
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MLCDU5E0Z? %-'G>5*-, .8OD>8\Z!%,9+WI,!'__:_IY*HB^0?U?H5THFJ@
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M2N0_@%VE>=MD>8@F'*()/8KLFT45B-_T^L"-?H@J#"FY;[S=#D&%AU>8\DY
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MR<Z?U5EUF1D],R_!NDXX1I.XRK>@^7%+CZ"ZRS=8:YI4BMZ4A["?+H])597
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M/5-%R6FT)T=CH@O\]A&KMS>.^2 @.R#M0FXNRFFJ3V)7.#$#ZF<ZC8/K C+
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M^K):<?VGM.JUB$.%HQ.ICW$WXVA9UC5^F"8K>!JZ^ADH4[Y0K//8X;MJC"W
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M.:6$QJKD#Z[9Q(M-U69@51I<VV1'SKOQNLOL'$0=69?$U47Y_O%H(.._$Q(
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MR7 #5XS.Z<U\Z_C16%(02I^GN$. PCB@%*K'O#D]"@8G!X^#8^UKLGO6=%O
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MWA_H8YM*#J )-1.)/LT2AT1TH1(6EJ#(74<]AM4'#88S 8<3Q[>C9DJ7%VL
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M;K$PI;_WV.\>)-0->0D-P?8'MG:;ICX.NE<Y4\F$KYS_^@UEX\/OWZD.C6K
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M$:DPPE!>COWQYK8H(\R"OI9((&ZD7NLSWX<[=B]"K&A^N\\UJ(0ES6<8 [+
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M%#SR-[BMC,O]"DO_J)K1%/9L.M58LU1R6D\&X4T4(.\"YD"X#VMKH%E5#C6
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M+&AZYD0(>NV<6)YS8F^UG1.X];9C'\D%08QZ?G@U0L6%XL2ABEXB;^D3K:J
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M/=9\EDP*MC?<&4>#*)R>$9+:_&CAD+VK"=%HS.X:+9QX'#&4&SMD)64]/7C
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M4WSJMS\O0<ER*RI^Z'=]97TLJ0TGL>S#Q<MMQ*=>U/9[XH1BOE(<;?^UQ+:
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M_[Q<^WI7CP\>V3![VJ7RL1Y*=;IFF1/',3K#GQABZF/K.AHEZ*^M^S^2DJB
M0,,Z"@-??-A]L[>SM?ONPX>G[GIYB(@/010>&J^Q) 2+6 []>'P?[)3%QH#K
ML0(9'XJ-]SO[FW?G-[S]\&'KX-W^KLYQ>/)I@B8.KD'YS]_"M^^V0+'M/%<+
MO;X?] [%'Q<?A]'V$%1R,HK'_^.C1&]WHOX?OUU\?/*)_"+;"8S$H;B]O=TV
MK[Y7=>5]%%/Y^*Q:JS9;C7*K^A=\_,3X;$^O&-/5"$\^U:BJSF48)N*+/Q;U
M\Z:H5DOBI!=%L=A[:F6!?U;\9(@Y*\>P]WUXM[?SY#T&#07*"2N$.]!ACA!@
M??H3]_7$[R0!_"1%+=H6&P=O#_3"!_4X?>GOO7N[M;_S/K7TG["51C=Q*]_L
M[,VAGMY_>+MUL'OP;.KIS@9Y6Z3 ='MXKLM'K9/FB !K_J<#B^QYU,D7+"Q7
M>#C#Z/#)M]]<L7Z&O>+3*=7<UQ&Y3M8'27J(7^0!Y_T=!QS8#>K'7^'+SZVS
MTX__'U!+ P04    "  2/(Q5'ND= 8!] 0 >5 @ $    &0S-#8Y.#5D97@R
M,2YH=&WLO6ESVTBR+OR=$?P/B+YW3H@1D%J+UW9/1\B2;&N.%UU)GIXYWT "
M)&&# !N+9)U?_^96&PA0E$V9Y+R\<>ZT18) 52$K*Y<GG_S]W?6']W_\_N[L
M^/2/;N?WZ_/K]V=_G/UK]W#OX/=?^2_X^%?YWOO]]:?3?WNOWYY\>O_I\N^_
M_/GN_/KLES^\;@<N.HG2,LK_^/WT_)_>U?6_WY_]_9?;."S'O[W8>QJGOWA!
M$H_2O_^21,/R%[K7A;IL$N2C.-TML^EO^]/RE2=_][.RS";\T3!+R]TB_M_H
MMP/S]S"8Q,G=;]?Q)"J\C]&M=YE- GC2\?OSMQ___DL>C\;PJ-]?_W'V;1SW
MX]*#67F___KZC]]_O<!I-0W@X'")(QC0DM 0KB^//UX=GUR??_KH';^]/#O[
M</;Q>E6#"8,R"KV@\+*A=QH-HDD_RKV# ]\[W#\\7-6@@DF6CO3#F\7CL9Y]
M_.'MV4?O_./)'DK[*D9P<?[^_?'E-0B&]_[\ VRKTY6]AS1<T5MX]^GR_'\^
M?>QVKM^=71Y?G'V^/C^Y\B[>GS2-QWK6"VLX[4KDES_^*^T7TU>RI+^"GH)[
MBM8"?43_]_O4*\J[)'+G&TUF[H<?38-1M-O/H^#K;C\:9GGT6Y#<!G<%JK??
MWUUZ5^?_ P,]^D7=DK3F;__G)?V_7[P_ST^OW_W]EX/]_;_IU3@!K7!VN;8J
MU59HQZ_?GWF?WG@GGV#('Z^O&N75>@@*36U8<]\1O@U^R,G9^_=7%\<GYQ_?
M_OV7_5_H[XOCTU/UM[.0KS]=GIY=TN<R!OYD%U;__?'%U=EOZA]SIUQ?GYDE
MP!=$0[S\0_YQ:@;R-UBB7Z]/S3?_E%_S5,V0U87N#5X\^\X;S/\W_,\E?W"I
MUL82X3@MXA!$^":+0V_AM7F!+ZUYC/I=FOD]WA7W7@=RBD($'QPVZE]8"!;@
MA<9"2VE$8&G+2:)6?SYLEU]LU5?3=5[C]I:/4#?\=K"W3PJKC+Z5,+ 0IOW;
MKOKP(7K@CZLS,F%X)0[V<)_^T-OS/G[Z$U3]'^>H]BXNSZZ/\?;?\[KY1@N,
MH/G"FM%X\+!;-^PL:UFM5_KN[/SMNVO8X>Z^-Q_;8GKO)4]^>;R-_3B2>+0T
M280]>X!."I\Y2Q%"N.5I-(S3N(RSM%A,&VP%<2N(((B'RQ;$$Y# ,J\&*(KK
M(8F'6U'<J-/Y<'FG\^5GL,(/]YY[QQ\_?OK\\82#%\<?3[VKDW?PAW?ZZ>0S
M?K8&4GJXE=+U5YB'RS^Y+ZLD8AE-TZQ*!]$$1K@FFG,KDQLADTL_Q*_'D7<U
M&(,H;@5Q*XB+"^+1TJW)<9".(B].O:MQD$=KXML<'FW%<1/$\<GRG9O)-$CO
MO+._JKB\\XYO@SSTWF5)&.7>19Y-LR)(MB+Z'RVBC^3T'"TQ)/GAXCTY.A22
MQ$S'];LS<7C60#"?; 5S_77GT2/X.5$QS6"]^G$2EW%$.?P2[$RE4^&,QTNB
M0:F^62L+="NV&R&V2W>%FL3V DS1M/00<' \ %,@A^/_JNJONP@_WXKP)HCP
MTIVH#U59!8G7IH!!FO'/-1'2%ULAW00A7;IK=1H%29R."N\V+L<DE^=Y7(R]
MZ^!KE-V@?Q6DT;HX5R^W0KH)0OITV4+Z,9,3W3N>1&F(D7JO?V>;L>LAH$?;
ME.=&".BS90OH%6C/P1CTJ%=F7F"4YZ?A,,JWLOD?+9N/%)EZLKS(U-G_^WQ^
M_6_O^,_CR].K-9#$;8QT [3DD^6'HJZML),=RE\3'V@KEYLAETN/-;VI<C E
M<^]XL$9 SJ-MY',CI''I82/CXF1#[S@OXT&R+E&BK4QNE@WY='DV).8R3SY]
M@/7]-U9PG7X^60/PYM'3K3RNOXY\NGQ+\B1+PXK3/:^K(DZCHEC/@-!60#="
M0)=N4O[^YM/':UV#.X[+:+>8!H/HMS2[S0.8_,<LW;W*DG@0EP'7;. O_J#D
MIO*1!(4'0GX9#;()V@7!^M1W'&VC\1ME##Q;8GW'V<7EV96".EU19<>?QY>7
MQQ^OS\_6(,+T9.O);X#:??88=@%KSLMHFD<%C([T94%:]<\@SX-T?5+N6R'=
M#"%=NFT@,*9-D-%GVP*0C3KCGR_OC$>^%+SQ\7O#/[4&1_NS+9IN [3F\^4?
M[<># 7KY9>:=I\,LGY#6? 6^4CJ,<;!QD,3EW2OO8U;& T;9G41Y&<2I=W8#
MWZ^+1MW*[T;([Z,0-* 8TCE_&8VJ)"BS_,X[GD[S["9(UD4^MT#0C9#/I:>=
M3N,\&H!$%O_U?PZ>/'M%8OII. 1=JC\ZAU%/TA@^(^5+EYRG104FZV!-P/;/
MMP;K1HCOTG',9Y-IDMU-5'W(ZRB-AG'I?0C*$@1X381SFS[=".%<.GZ9A3.*
MN)K>NZCRP3@HX!])L";!_.?/OD,TX7^0;Q-_Y?T^;:$2G7EUGOU*7M0X/'\:
M(^ENO.L):VCW/Y+<=2WI71]Y'#L#N#A.JRCL\<M=CE0*:^=F<LL>_"BW[-/'
MXY9=.AWJEEWV_W^G]=*+.=[$*3@T<3K:X*-Y:S7^=#E\OO2BHHCPR/R3@V=K
MYLMLXY@;(94O'DT[>B=9-HWR-4(D/=_&+C=")E\NO; (5JQ4D'F=]?D6%R7*
M*88M^V44(DIT/03UQ39*N1&">K"_?$D-TB*@<]U['Y?Q:(W4YXLM(&DSI'+I
MN?6K,B@C4[6.?U;ENF"07FRCYILAEDM/F=LD7UM9W,KB V1QZ>GQZ^#;>CG@
M6U'<$%%<>JK[JLP&7\&]&7!YT&F4L*/S"OZ91R/X8YV<\JV<;HB<+CWK_29&
M9CETR=]D^<2[MR3N:O?%*U4&]UY\=RR!#T-JL!4D:T5&OY7KS8+&OU@>-![K
MX-^?*9;OXY/_]_G\ZIP[-7\\]3Z<7;X]NUP# =W6'F^ XGWQ.$5P2;1&%L!6
M$#="$!^AT.U.!^4S6K>U,DRW8KD18KET5_[/N!R/LR1<&X3'BRW"8Z-,R9=+
MI%4ZN_QP_G%-FEAOY7 3-.++1R#FC/))G*[3V;R5Q(V0Q.5722KPQG 8#4JJ
MXET_X=S"C#;JN#[87]YY_?;LX]GE\?O5"^'++5AC S0DB-[RB1"L?M5K$@O?
M"N.&"./2SVMAV]B*X58,'R"&R^?,+HIXE*)&7!-)W,86-T,2'Z%5=855?-,@
M7YO#>2N+FR&+2P=@Z$X"6T'<"N(#!''I%;5G:1GGD7<\RJ-HC>1Q&V3<#'E<
M>F7M>1J$T5]5,+C# .-I,(%U7)?3>BN4FR&42R^L/8V+09(55<[MR\,JB;S+
M:!CE48I\ELAJ=75VXIUF@VK"_,'JNZWD;B7W 9*[]/+;J^@FR@/J;[XF?5=>
M;MD)-D,6EU]A^S'S+L#Y3J.\&,=34IOPT?$(-.56.+?"^2#A? 1H;B$,P&??
MIE%:K,W9O17)#1')I6=PWF+)=XJU-N^#6Q+-?U1Y7(3Q8'T0%UOQW!3Q7'[=
M[3C.0SK1[X34=Q '^=HT2'FY;8*V(9*Y]$S/GT&,9!E8W) $\:0 &S. %2P]
MPY!UE57Y^OCG6U'=$%%=>B)HL6Z457X3WP2)*L&EMI-.BRK?,_VI?.\$# <0
M=+%G=6Q_DZ4=+MY@2NLX_L]FM/ZY?-:7QQ^OCD^XJE?UO[J/T_K@L&4PMFIX
M\K>':X7KWZ\^'+]__\>[\ZO??^5_>NHS,U#]U;%\I<:MOJ#ARS]?\U^_ZC]I
M<COE."ZZ'6SX\?P57G/^AY6U.Z??X)<O7O5\+PS**/0"0FF?1H-HTH?S\.#
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MOMLY;0GZT#QM5>JE&,^#C32((FU$(V3!JZ9:0W(BN<2(Q&!0Y;GT'-B)>[P
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M1/QQ@9H5K[S-\J^%9@,!T>(;C&%K^8IAI2 ?.2!@9I4JT)Z78$;9X/LR00B
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M64:NC.MP?_^EV@ZG)\<B86S<\C/@=0LI"?SDE7>JJ/'QIP>_OCCZ]>Q$@;U
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M5#7SL)(:JZ[D:V,ZQ<5P@1T^HSH,H+R.I\<X@:\0:&CNA4S6 *)/!!RYQK^
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M(H>/!E$\+34=!U<D2.R-2S&0#&5$N7TIR<=_ELP&XM=.D" ,IHH$L8QR??[
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M&=F*EKC.<P[J4^Y8:\MI'J=,;%?>357!(!N7;+61@N)0+P%V>%#U^%>>I?$
M?A'&08\VAX?Z5&*<DU<60_VL2+@(CZ;5UZ-EN\V]'A4\1JI0N5(K!*PAP&V(
M_R5WD!\CQUZN^.Q([UE]>7F+T4$$XYT=+K7-8QP X\*4$I4*&?6A'HZ",G+0
MSL3/&@?:D*(K=>FT*G!.0Q5ZPQ$VJW@KZF5O7%@Y1)EG$M*=ZGXNR*$U4B=
MH B1X<R&!S0\@24,QU_?9N4XQR(Y+75WG.1%*?+GG":^=4LK"62V:_T![D5*
M\B4]0)UU:'%:3D"^50B;+L@+LT.4B?)_'8^%4E!R+=WTQC8$4.7QK_C<N0G
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M3M00?7Q#G =K3%;P IO.AJV)B]7P-1R:+.:UWNIL4ETM*DQ21O#;:HPPQWC
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M$;@:%+:U-\6:%K%/V%"8$V+:Z5<<"@6+A ,&%NS)Q30=[3.FJ8>\5QAQ% V
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M+J/E,7)CSSD.V8_6W74[;85W7GO=W?W%=K8 KZ+B;C51NO%,=543"8J]-H_
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M24B4 4)=,PD&7H> Q9NPPEG9??QO[CRC';U&#/O(AJ%2P5'IF>5P&SOIGZ^
M&O2TT^%PC\/CSH %=_O18W/Q=;6$/JXW!4AI6",WI_F%ZD0?$8-R/#=O?P.O
MW;V?;/>.X\*Z\4W>S//?,;-%)/<^)O<J;R! ,GDUUP"@&R@<R7_!2G_8N G:
M3/X3ZCSR)9)O<M]NXL"DAV%(NR[.L6$*HT*W3J?4)0$DH6UB#;2\"T06N5\<
M/9-/KZE/TAP*3;B0G$?=%+!Q@EJ4<(F]QKQW /!N&:'Q*#"CWGTN,^H.\8:'
M-*"\9+N[U<%*.F5\>*OC;+C5 5P^*"*P1=IF([5=B] (\4O$=:=$KW1>.$$8
MJ:X/OT D^[(LKO%1L:Z, A _'-@H>2?CHQ_!1.F-$N!$^*_3<0%%&Y?$)(<G
M8E+-UH1TUDE&\]8\+ZI.5]L8L_Y0=[-JI,72%>)LBK0YW1L9HL!RS!  -:N,
M/K-00 .,R" 1"]O\(&TSGL+"4B#V)SZ>9S,3\7S7]\GM&3IB*8W?YZ:+NJ-P
M?IIFE@\W5)6ZU0'LM"+C0V?UW3*'B@+:(13&!]:H&7<L\!H=O)MYM=;\1>UK
MY#)NERM_XMHBQ"/)&C0! "KKYAW K]]R$G*RL83Y,2X0M/RN)@1//3;PLR^Z
M=B'U_#)NQY]1&QM>>AN8URX[,U_[2T8>]1;D^<:#'+?[2,.V"8&(Q9EX/>V!
MB)GCG]J.!\6\C _'VC25>SN_E? YX(14$ZU,CD2U^X(*,73>_F0 UWOL_B,*
MRWTH5^R?%_&Y#400WXT5TC.?<6.#:$>:,=SK>6,E].U.U+M/N I8?5ZLV8S9
MKEFS;LHK;L)+1<3P_9B^&PKC-TD^\BR^V+CBTZ]QQ;O-I'MXJY)_S].IL@-Q
M(WPFEM;4!.I4BA[X/@E&)$\[X '(HS@7.U*S"L9(X^3=>.0>)WY?54>&6BI$
MVFJD&?FL3FR!9@\,@H0PD:;G82+>8F$03H':B7I_Y#.HT'5V[47!YCSZPUA$
MY@YG- ?:]_$< @SR%BNDQB,:5I^>^2RIYV=.H?SCU>3EVW^^.WOS/^Z_;W[\
MY>7'@R6@G_D$]$OF5'$3ICY?BFSM()GHGY0J&>R.=B\DHD+!_9_7SBL((K0<
MUD7(Z>?IJ,10%(W;Y@&;)((H!M&6)!$K[G:.*-0$;]>0[(+KB2QMR<2SEHB5
M!D;D*FJ,A7PU5VL&#@>=Y /"EV4U<Z;.S@C]R[?_^_6/CTZ_D^C\/YTQZ4PF
M&.RMGQ-#S]"FUZTGWQP_!:#/;J)=XD+ZPS A*0Y&)]I=47R"LM%F>9NT4VTT
M2E#L :S,/U3H/]RX@2H$5NHH1>UZ%USV-,$'F-G4*4:F"VZ=!\6Q'[;GSJ@J
M\YJ0\!DV8 GZ+AA(H32]\9$RSZ:$)&5*I\01*K?[W8&I8<[<Z<"SIY=@D/VQ
MX7Z&JMSZ&J( FYP>:.B9ZHM\5?Z1ZUF4>L/FLEPS5SS \3!>ZJ9PMG6Z\ J)
M"A%F7N(_W3YT;FKE_PF4]? TBGM]O"R=TM%.Z.[WV-S,$.I@9 NS.8T2LW$U
ML?O9O5NJ*27!Y.;*1F]\]1J"M6CWNITT*]CI8CYK./ 7=7ZUAY4I$2$ZGVTN
MN=9BQSE]XJUN8*.[R2FQ$2C2 _$V1] !2"8:/=6G0,AQ1_G6*32N8#X8X<P%
MDIA/UT(3(US:7+XZ :-0FCL"X1AH0R=##X 4/)]._A6A^P@"?%&LG"."[9F4
M85,YJ!;_)OIF6']%43=GN]2-.]X/H6]^&"C"!PKNEP\GN.6D!GUC$%&4X#-E
MF?VPLAH>M(>\)@:I0_7JB1@U[<>@".P8-=<!X>_?&K'N+(,?M1S! ].SEJ#"
M!^L3;S/C76$=0^=#HRY@ZDU!AA]F L)N5^MB7N@JA65]OL3579;//,\I(LDM
MSX4):QVL)P_0(4:1%\.Y4*Z<'L%,UL :9:=,+Z3U4E,M2Y1MBB_F&@1$1U /
M6PKFC$='08P1GU)GYB&EO<$CV<F5K9"BI-@ GRF1IRQ)F:WDIXSAS92 $%)Q
MJ9K&AT-RQ$EKL!2DXB%M5[ !#)D^X?'7"SGBJNUY<530.D4+0YFJMJ#FF_D&
M/STX(11!ZKUS&A _+A$8G?OZ%$C9V>+!=\J%N6O@0:U'$'95!\ M".SM_*J*
M0LEH(:UP\9'0C0\U)-UA.6Y KMD3CJ$"-=6['BLP<5I)5F'\0^>CLX #$R/6
M@,I9YBN&.H#^Q)%BO8N;LF7I]I7L,R ZY# KQ*AG^;K<."WNUQ^A&,Z<1::9
MD$W2/HG[QFK(EF,K$)%/?&%YI0O8^6%?<*GBLZ]QP8<M:T/)[<RL#<C)J_.2
MCI[;KDM@-UK<3MA>J-4+F?!.9K%YY/>MVY#!83]]Z,..!_+QP+/>^90I&H9L
M&6 M"\ Y0*Y!#0@Y1Y",;OQ1PV'9)#T!/L8C7ZR?>?-P#K-70U%R >":<LY"
MXE8EYQQ>C22J0IV/D^B.^:8NS^F<:[@5$I6(OV-8E4I^%L6T;H8D"$C7VVUF
M&*-B1VQ$CHRJ87&CXV@(C.AMH%CRQ%%FU"+IR;^-;3=8SQ]YUIP)[8QC$)7.
MVYA=(D4F@08BRXBT/?X2Z\,0,]"^-WF36<[6?,A\)OZ ,^A6N^M#@JE4)>='
M@\]&([U:SCG'$P?'TW5./5%RR8CO%2BWR"I($[EMTRP$X,']B!"!$-!<.'<,
M0.P0?"&_0AP.3FQ%GMIT)R(@ %L$540)+$R/>WN4?E%9$V!?<6,[GS2ET@6"
M76H=P7C4]=ZHR-8&+^[@7C(,]-:#G;P838O-G7)R?[EX&._A>DIYH4R*)&@?
M0RRQ4GC8'Q0/0_ .-J_G:U&"8'(*K,[=4BY "LG3 H;T<"_>=UVS2?2B9-7L
M>G=&;-"#$B*$Y-V"(!O,X(PE*,B!-RN8OS+XCE<?WKW+]I<L"IOOEW. >D6A
M<SOYF'\*.+9 JS'V0X_7_:5?)%UJ%&<RA. E")$,6,!"N=8.#Z3&% !/P%?
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M""+P2/Q324?)>+GI2G,QP_U'22XJD I8BQQ_62"?@XCQ-"%A0:3M]4S\>);
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MVT=XY7@4FO%=-+V+NN#MZ\1S+5&75B^@L!,0BVKT?PQLO[RBP!0@+L/9H<_
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M3F&P,J]7T-F^F"<ZHHY'W/ 0IU(:4EU7&VH9YHS":P@T4@D]4\L7S$6&4[0
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M=A_R^CQWQM^CMY^6Q2U=F^*>P?? \DUB'GAYH?L4 *UNEQ=^"5J!_E:M@9T
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MZ06PJ%PBB\HT/&<TSYU&QIPP$SO%>=/R3/#T!K.130QKN:&;%+;(.]! (B'
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MA+T'=Q@FU[PK/:\@+@EK0[:YACK182.<%Q4,8+D;)1$W=$3'(Z(Q@UBZ^R]
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MOQY6$+0&^/N0 4XGW*+$Q^-RKTITE#$?>)N:\R=A^]#=%.H'6][IV<[BK[5
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M.98</GMV<O(B@$L&US3;JRM8 IK3 DRS-5>P4T%,FOI)IQA(L5]U/'L%6<G
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MFF.;+JVM8ZHZ4?E*Q5/0KEZ[ (Q"D<DR?JETJH@3S(F7%94R5U/4>R6X\;'
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M0FD>*%3,SI$>-21,NT[27AUM>GX9P>%\'NH :[VQ?1I_URGLUXY^GAT&$F(
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M&3O$!T'ZU(<2[$P%11/QU:C#K'G2)&::%S25D20R2%TX?KF$9D3(EC'2%W\
MDT6&3,O9:TS+\>B3VY9@%AL^XYVB&+X*K$%B8@S9V-F-3>R)4^3[CB#;45L3
M5.R)FE O)66-">'N#<?M_8*3%0^:Q8-5,WM?KCEB)X$[8326AFZ8HY4N%,P(
M]<D&@ZG7W+>\0*/8A-W,K8#OM&L[:FQ*XIP/TY=BAK%C?BH#(%C%8 .360OV
M!_QXHN9V8++&(L"@7D">&XN6PIG>F*6L2VBUAA7^34VPQ.6$RBLPT<Q2W+^G
ME+?DI-"'GE]*XC,T@_W%B4T.\*Q]E.+FW*B/N4]8#(%@)*-U/@IRMG PN\W1
M$,T^>,V_X-CJHZ^QU7MD//Q(H<?QZ- P5[+#%/&'8:(-,6MD6T 9*@QM45PW
M+:79(Q,ENAMY<#. A-?*1=N*KZDU>H&*R]-N4PJ$";FI<U(;,Y/><;;[XS,D
M@,Q2>&0*R+0KZ+T]!P$-TK"<AXX_\B?#S5]$>UVLD>-HO7^;131R_TR?1,<6
M%&YEP!,L/+N4^&F&4'D1R-:>0,HS3>YM><1&OL$$)<.W@\>5DJ3NK2%1_'X"
MV(GSA@)8DUCFS4IM0NV&BK:+,^%2QDO8X1 0>H)9H6Z0*X)[0( Y!*J ]KJJ
M-BCB)]"<:Y\5X/;L >R9:'[4?DX!DYGDKLZ2S2'?A7/5N#EO 4>$IXG^Y18#
M#J2PR%/QOZ 8G0%XS??9&M#!X8%I=&Z'D(*[==(T".=QM8+Z5REN 6)\;LO$
M!>=%'KB.!UZNQ+ZFOLJ6D$3NH945OY7_8M_-'_46%TP*^*]*6LFSZN[,O=MY
MW= +@YL:F"&=NJWX$W; AMTP7%)FLD=JFCTVM]-30USPYF"2[P!G2Z;KY1!4
M3;A7/7:*4,%E=0UL7704,F+5AX HGM/(=QEL-,@A.%EFJE7E1Y+)& ?*?RG^
MK*[<@'^C@??*Q5\%IV8\4OR!H?T+)KECX2+]9Y]0V&<DN@RZ#WJ$5S=9\(CL
M@-<?'A M0/_=N-M]1ATAFK'OF[E-I)<IA0( _JD!BO\(B7=@9[=DQ,L<(#;Z
MY\QP2D5CB]>/"7SLQ(2BM<NN"'0M4J;K#2,U O<DY8L:CZ+7!_A;>QRM.:.(
M52\_*0AEW^NIE,QC)EI!4)EJ9Q3^$'SFMB&<ID3;'G"SJ!N<G"0,JET?^)*M
M"H[/8C_S"U4232T< 7&AO=?/1Z)D7:37;1> V\<\\5L==,CI;&6W8$99 &-4
M#1&EG4GY<#C+1@8CQ.^TE-@01(NUP!LT(M6O,R\#.)#@$U]6*Q_8%^SL0@H%
M(B K(5P9 \@C7U;NS,^)"H?8.:^)UV^O*>#.P[Q[L%GE8@N@>>+[B[;<J:BC
MD$1K <'++7U(L9JH 3VC@WFQ)( *]E4NB"J?TJ<J:.:T5E/5TT!@&4W7>#EG
M=I)?AEO9#!R*'FK._6!SQ<7E_E"/1X%M?FA<^P@78$Z-$XQ5+Y;_02-&BPE2
MH355]$#.0"-S8L[Y")U%M ,$&M-?)4$<MUP].!P5/('L2/1"NB)0+K_B<GEX
MUTQ:P]YD+I,\NZ3 (]P>S&X0/,-_J!F-J$S1*3.=E.%#(_MU]P'+N7!BET@U
M!_ 4M\NIL\URY4/%<3A&:ZP6A)R_P88&PL?WOT' ^FRYZ6!4-DH\'OE\&+?G
MVQW8E?Q:'F(C(R?*C5M;R.&E]>VYW;?Y;@8V4=IM_8)C3(^_QICN$[_W1/![
M+[')F28^?V3I] MQ%QVQ@\U/,;S)PLH-M&GA)!.,O09"?*2Z3^*<@ T-">VZ
MRZ9=$[:U-!Y@Z=>AD;9NU/@>X.-J<;SDGG 38NH-B#1IZ;J,OT["YS=\0P\-
M%-C84A;>M(&5&U2?K;4_51[4R*"62 P06DU!C*,KEERX<=EL6JA()/Y_:D^?
M<.\AGH:9I*(CWNW$SVW5*J$2$@.HKIRTK B2L--?\P;7X&36 !]:B_OJ'N5<
M"-C%);A#W26 .#94N%@J:P+$AKCC)PIKC>:#X>KL+,R>E+48@&33C4>[TCQU
M^6#MAJQYI@^%4[6>YP?2:9FP^FCZU?X9P8->ND]V!EID)_YE)G^_QX:Q796O
M+R;+H/=(AA%>8-?63+HZBB%&D1FH7"Z5=<T4J^W8E_Z3@@E63K85;I.<U ,V
M<_>I-I0T%G4JRC+0!C#N&2<X'^H$0 XPL03W!I8^81(J-]-%ADDL.L0<'?G2
MDNOF6AC,><NC885J<.C)L)D+,[$]@WC8*JBOO"R+)3E\'\KE D;EGX/-VVT)
MPZXO$V>;.<%,#T^I?R@#%: ;.:5P6,,8O?/'&"S@J?^.X'),L0V*U&GGR9)C
MD?MQ\.$ /1%)U/%([QFX#YAPKH@D("X?L1K1@(]W:3G 0%Z73$ECGX9^#MV'
M\-KM$WTW>EYCX13I.6.9&I)43$NW]XINVZP:'R,<7 9&T[DKHD_\;8DC)6U:
M^/'B)<DY/H4^^$5;0/PH:/%LFC/@E-A-[O.6/X%S<@!O>0A8)MX0:Z.\U?&=
M&Q!\9)U(("&YFG[J $@IG15;L1MB\_:4/SM0E)]BRG-(LB'VK+($GH=D\I]P
M+X"<TT[H)C+^/^B+F%X1ZA8L?=P"&9$KZMKFQ)3R;>!Y>MA]6["]0$3(G-EE
M<P<Y,FEQ)"T'<@3G2A)"TRI"?AJ23DYTAO.J(S)10'0>(^08;SZB1 !^0H<+
M$\"8VPL.&#;!\J?$F>K4;UK%@2\,B=4AWLTHJ@7[J:0!+$$1KFND"P*>4^;%
MKGA%WT^ Z8/8Z)<(# MKC:?,G&Y%EA2\"R880]DK"&\R7#%FN^7J%;$W5NY!
MI<1BF%8Q&6UI?#J1L[;";:&?\^YA7[N=TD*#'3M?.![1+'VZ1>;D]W36M(8G
M)13'E2UC3HW%'*2Y0.N&)-G!YNA@MDX[EQGSHU@I?8YM$>+;1=;;W>87'UFQ
MJS#'>0/SR1"4QV!&46:+MOEG60NVD!/4'OI%:"O#V5-@\[+YHL 4QMR-9[59
M%LI.8-\'7LL##(F3J?E@BOCNP&WI$PDIMV6((6"BD,ZRP"C%A*^-G6_\7ZV8
MP%"\>6^*,Y0.N4\6TVDD19!*(O;S>/842W14,FMZI<-Y!?>8!95;<?TV7@[Q
M,;*TC[&F@FWX*=U^?X%4"IV&]B?,233)#M;@X&#G'AL]Z,%S_X%I>*,&;IUG
M38;C(LP=:[QGC'L1.*?.(UH^34IRH0%L@'R7,"ONM,\T;T1V9_0C]\T!R3(H
MYBX+&%9;%O.MKYS///-FH@5?((WLX@P*24ZYHQJ+.SW%VN:UNP=I;8/^LZ"A
M8]\2]U'7R^M#&-T,P@=SA/7G7S ?X9.O$>5;\Q&NH$"WF)4;8#_ F!3G%@^P
MEZ+@YR$DX6>22J;LO_O5W@RLLV\>B,7OH=@,<(+FN)B^D88==X> %WP#'Q3K
M!Q^:]GV$ C>%9YTFH?5^44K)R89K$>Q!&"?*NZ&4PE@+U.B0@C0\'+%Z+ TE
M4PZD1PF#IL2VE!S]4I%*A<BF"$Y2YP(3L_:8"E&5."QB'B75-E)X!2RN4E;
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M-*S,E\U%DS1CHHQ6$CV,JTQ/@"@>6N50K[?<]C&^5<?EB[XO+@ZK8]RO2@&
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MS2<[_U"T\XY2N6::IS3 I(D$\QZRD88.%TU(CY@FY*Y+YOGLA=BB=<_Y$<(
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M0A1^F^76*EMB14<H"15!B(L,N2#8",H?6?++ IBL5LY><C\_"<EHW;.!0=M
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M#;F0" QHB4Z21W!I' 8[>^A^$%02>JS:+&IO'5@(R?'0K&ZW(B<!<"HKQJ-
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M;F SUO('ES\^U7WRU]<P]_"56<O^\W4UMPC.%FE5'/)!K@._M$-XPV6YS3[
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M%G03HF)R#J"[;>YEG P"+>!&TSICH/)T:F1\]35\Y U_TG,[X\[?K)QAX/\
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MWV4]V>:RFSFOW?ZNE!;#4P$UW@'9K<2"T4=YTWLI^SEG4*7(EFI[JBJ94]F
M<>.D5QFTO3'QAM,R>-A5)IM:AMPC1I%[+'@Q>F=#^1\N]U.L N15Y!"YA[&,
M!E6I[1:':)Z5";H5X<@R/2>BKCS+>I..Y$%OV:;S_GD,.O<?"8TYY'__]M:<
MQQ(]6U/LSGC+[OSF34*U/8997;2IBO,Y3][^WJG->/( -3GHGYTG=KY.98U"
MSI3G)$QE.0/\NE,794/V%!OJF0*/)K<2DN1$EMK"9K80C VJ,M9_&VGM%C/1
M%'6-?^%B&G+L9(D#72L='#=2T@#VL,(5+!GDPO5FK^WMNY4L);6\-FD(3IF
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M=>[8;SW[A;N]YAE<;*>=Z-/_ 5!+ P04    "  2/(Q5?R?UGFH/   J9P
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M%YC#I;@$[!^3_()RR=\2B#@\Z6;Y624F0'64&J*D&3T8BTD40CPR@\L8F,@
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M: 0 "+'U$E W]H\ <AO5"N&11Q+B9HOP9Z(F[5VIL&+1,215H5J!0$1.8-*
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MS>'; ,8 6AQS(G@H/ PL5#6;MM7O\F(]P,=$8*"B(JCR%#<D2&:99=;(Q*?
M4-!70XPG3!5-F!4W4!9GJ1K BY*)8X4#. PXP@ST@1#V"-VRK-7AT[+" YJU
MT<F>^<- >LC(RZV!V:1)DI,<HM<8N"29&Y,Q$:G F&FS@<[A,!>!9 I>CTYA
M>$42@^HZU6"GPY?LYTXRBICI@83+4G@=C'R6)^%D,H--P'LS \8Z.C"'D9X
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M$ B:"_22"*T (.N,?%(.*X%JPG/"<B/45)L)(6"#$\)#0.,G(@R^'.8AYD
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M0$ZQ Z'PR01+C8$H=1B[]6"D(ZG8'B3QT*2(BY0!M6+A-Y9FSV*"E"J]#::
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MR')?TBY.Q/).T38L&^!NMR"2!L:PV4OG7)3CT"8%P9G7(S1X2H9-R[9#*'6
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MQOM:/H9&[BI+;."RO!>RF)B:$\A/V1@=6G8N6;%7N,J?MBF?M$88_[)T _P
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M+6*=L//U$T]7LR''"[9NJ.;)3 HCV)&7S/J40DK6LA$ME/1\>Z5++J7Z#&N
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MHZK0N19L,&)LB\GK(7G67?.K %Y[+7GO#O01>U%0P_7%1.>OE[R$M=E5$1:
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MZ9QUY&%]Q.:&D'2=[Q&G!%\V&\!/<X:VT<$DC-VDVS)BJ[20Q1? ?J?(\G5
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ME#8;^ 9QU8!>R6=X0O ;"%DB/2RJ[;<*;&(XTK 1,^YZ@?T=!I$<%($A(=,
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MA6%9?9_%%!@-Y?_(+V5MM=FXT_+6I39[!LF1OK&RTA6WFQAQOD<LI5RB(+9
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MC6:4_%OT05K0@C)+9X-(AQ/^2WY88HZG(3=VFN7,".>J3Q'LEMM]1M%N-NP
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M)4,(-DZPY*'2$2#5LW8![KO"Y]%L&%Q&L^[3&:,8Y-I[N1^\>OTW,?$OTU%
M@8<\7:_I8YGM49X,,6=Q=1U?/8FHEGU5]5+W7A[(7SL[?Y/E/H[&23P,3N)X
M+<"/LZ*_S/+KX#0:__%$2[J_'Y#(!BBMP2)!7=L?]ZH$2:;)%;8*!1MKN^,Q
MS\@LBY%D.;WM/U$<1N+R;UZ__/ODUSJS43(-?KF.^_'G:+VLC[6L%VDW^%<T
M7Z_G8XEI$HV#UDTT?IK*D[_CDGZ,LAY2=?XGN?JZ^G1M7MS'O&CU8\P#!1OG
M%VNKXHL7]"3^,^C,L-DK?9(M$&C)SNM@^^#@[Z%8.M<(/CR&=<T_KU?UT=+
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M^Q.K?A%]OD=7P)7CJU!)GO6 C0<#^+XJ.$N1K'SAR' 8!4:6/!K$ 2CA+J,
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M34CN+/\R<FHD=.#-3P3V*KE9+JV%KN'5$$D78OC+9*RH126((ZIR:0!MG+Z
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MZ:^5-]0+0$4:5/8@2;P8[#PNN,VHTBW4\<OXY 4HLH?P+M@!5)?4+E71%:_
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M#$C'XNO!RQE33Y>I4#&L\7D9?*YZ^JQ[G+MFL; /1(*X"Z?]+9G$9 N S85
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M#'+SR"]'TX2,:$. 4;&+2(ZR+MAS:'A3OZ9C"1O8^7B$1=;DZL IA'UC4G0
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MJL!1N!OR'T14^"W1,1UL+]Z&\%;/CG^'#S]<?CSYX?\#4$L! A0#%     @
M$CR,56F89V#? P  30\  !$              ( !     &%M9VXM,C R,C$R
M,3$N>'-D4$L! A0#%     @ $CR,59V26DVW!0  ##0  !4
M ( !#@0  &%M9VXM,C R,C$R,3%?9&5F+GAM;%!+ 0(4 Q0    ( !(\C%6E
M[4 GL <  --5   5              "  ?@)  !A;6=N+3(P,C(Q,C$Q7VQA
M8BYX;6Q02P$"% ,4    "  2/(Q5*8R* 6T%  "5-P  %0
M@ ';$0  86UG;BTR,#(R,3(Q,5]P<F4N>&UL4$L! A0#%     @ $CR,5;-H
M_(<>,0  90T!  X              ( !>Q<  &0S-#8Y.#5D.&LN:'1M4$L!
M A0#%     @ $CR,54U:=5X$L@$ %O<+ !$              ( !Q4@  &0S
M-#8Y.#5D97@Q,#$N:'1M4$L! A0#%     @ $CR,51[I'0& ?0$ 'E0( !
M             ( !^/H! &0S-#8Y.#5D97@R,2YH=&U02P$"% ,4    "  2
M/(Q5?R?UGFH/   J9P  $               @ &F> , 9#,T-CDX-61E>#(R
M+FAT;5!+ 0(4 Q0    ( !(\C%6^$O/S6\P  %JT!  1              "
L 3Z( P!D,S0V.3@U9&5X.3DQ+FAT;5!+!08     "0 ) #X"  #(5 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
